{"47657978dd272aff0e0be8c8aa3877b8db673067": [["IntroductionViral myocarditis (VMC) is induced by viral infection and often progresses to chronic myocarditis with persisting myocardial inflammation [1, 2] .", [["VMC", "ANATOMY", 31, 34], ["myocardial", "ANATOMY", 126, 136], ["myocarditis", "DISEASE", 18, 29], ["VMC", "DISEASE", 31, 34], ["viral infection", "DISEASE", 50, 65], ["myocarditis", "DISEASE", 98, 109], ["myocardial inflammation", "DISEASE", 126, 149], ["VMC", "CANCER", 31, 34], ["myocardial", "MULTI-TISSUE_STRUCTURE", 126, 136], ["IntroductionViral myocarditis", "PROBLEM", 0, 29], ["viral infection", "PROBLEM", 50, 65], ["chronic myocarditis", "PROBLEM", 90, 109], ["persisting myocardial inflammation", "PROBLEM", 115, 149], ["myocarditis", "OBSERVATION", 18, 29], ["viral", "OBSERVATION_MODIFIER", 50, 55], ["infection", "OBSERVATION", 56, 65], ["chronic", "OBSERVATION_MODIFIER", 90, 97], ["myocarditis", "OBSERVATION", 98, 109], ["persisting", "OBSERVATION_MODIFIER", 115, 125], ["myocardial", "ANATOMY", 126, 136], ["inflammation", "OBSERVATION", 137, 149]]], ["Patients with severe cardiac dysfunction may also develop dilated cardiomyopathy [3] , which is one of the most frequent reasons for heart transplantation.", [["cardiac", "ANATOMY", 21, 28], ["heart", "ANATOMY", 133, 138], ["cardiac dysfunction", "DISEASE", 21, 40], ["dilated cardiomyopathy", "DISEASE", 58, 80], ["Patients", "ORGANISM", 0, 8], ["cardiac", "ORGAN", 21, 28], ["heart", "ORGAN", 133, 138], ["Patients", "SPECIES", 0, 8], ["severe cardiac dysfunction", "PROBLEM", 14, 40], ["dilated cardiomyopathy", "PROBLEM", 58, 80], ["heart transplantation", "TREATMENT", 133, 154], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["cardiac", "ANATOMY", 21, 28], ["dysfunction", "OBSERVATION", 29, 40], ["dilated", "OBSERVATION_MODIFIER", 58, 65], ["cardiomyopathy", "OBSERVATION", 66, 80], ["heart", "ANATOMY", 133, 138], ["transplantation", "OBSERVATION", 139, 154]]], ["Although many different infectious agents have been attributed as the cause of viral myocarditis, the enterovirus coxsackievirus B3 (CVB3) is considered to be the most common cause of heart disease in adults and children [4, 5] .IntroductionTo date, many potential vaccines to prevent acute infection of myocarditis have been tested in animal models, including inactivated virus vaccines, attenuated virus vaccines, recombinant protein vaccines, DNA vaccines, and virus-like particle (VLP) vaccines [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .", [["heart", "ANATOMY", 184, 189], ["viral myocarditis", "DISEASE", 79, 96], ["enterovirus coxsackievirus B3", "DISEASE", 102, 131], ["heart disease", "DISEASE", 184, 197], ["infection", "DISEASE", 291, 300], ["myocarditis", "DISEASE", 304, 315], ["enterovirus coxsackievirus B3", "ORGANISM", 102, 131], ["CVB3", "ORGANISM", 133, 137], ["heart", "ORGAN", 184, 189], ["children", "ORGANISM", 212, 220], ["DNA", "CELLULAR_COMPONENT", 446, 449], ["virus-like particle", "ORGANISM", 464, 483], ["VLP", "ORGANISM", 485, 488], ["[6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 499, 549], ["enterovirus coxsackievirus B3", "SPECIES", 102, 131], ["children", "SPECIES", 212, 220], ["enterovirus coxsackievirus B3", "SPECIES", 102, 131], ["CVB3", "SPECIES", 133, 137], ["viral myocarditis", "PROBLEM", 79, 96], ["the enterovirus coxsackievirus B3 (CVB3", "PROBLEM", 98, 137], ["heart disease", "PROBLEM", 184, 197], ["many potential vaccines", "TREATMENT", 250, 273], ["acute infection", "PROBLEM", 285, 300], ["myocarditis", "PROBLEM", 304, 315], ["inactivated virus vaccines", "TREATMENT", 361, 387], ["attenuated virus vaccines", "TREATMENT", 389, 414], ["recombinant protein vaccines", "TREATMENT", 416, 444], ["DNA vaccines", "TREATMENT", 446, 458], ["virus-like particle (VLP) vaccines", "TREATMENT", 464, 498], ["different", "OBSERVATION_MODIFIER", 14, 23], ["infectious", "OBSERVATION", 24, 34], ["viral myocarditis", "OBSERVATION", 79, 96], ["heart", "ANATOMY", 184, 189], ["disease", "OBSERVATION", 190, 197], ["acute", "OBSERVATION_MODIFIER", 285, 290], ["infection", "OBSERVATION", 291, 300], ["myocarditis", "OBSERVATION", 304, 315]]], ["Intramuscular immunization of mice with a DNA vaccine was reported to induce variable humoral and cellular immunities, resulting in the protection of mice against lethal CVB3 infection [6] [7] [8] .", [["Intramuscular", "ANATOMY", 0, 13], ["cellular", "ANATOMY", 98, 106], ["CVB3 infection", "DISEASE", 170, 184], ["Intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["mice", "ORGANISM", 30, 34], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["cellular", "CELL", 98, 106], ["mice", "ORGANISM", 150, 154], ["CVB3", "ORGANISM", 170, 174], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 150, 154], ["CVB3", "SPECIES", 170, 174], ["Intramuscular immunization of mice", "TREATMENT", 0, 34], ["a DNA vaccine", "TREATMENT", 40, 53], ["variable humoral and cellular immunities", "PROBLEM", 77, 117], ["lethal CVB3 infection", "PROBLEM", 163, 184]]], ["Although these studies are very promising, no effective clinical vaccine against CVB3 is currently available.", [["CVB3", "DISEASE", 81, 85], ["CVB3", "ORGANISM", 81, 85], ["CVB3", "SPECIES", 81, 85], ["these studies", "TEST", 9, 22], ["effective clinical vaccine", "TREATMENT", 46, 72], ["CVB3", "PROBLEM", 81, 85]]], ["Hence, there is still an urgent need to develop new vaccines to protect against CVB3 infection.IntroductionPrevious studies have demonstrated the importance of both humoral and cellular immune responses for protection from CVB3.", [["cellular", "ANATOMY", 177, 185], ["CVB3 infection", "DISEASE", 80, 94], ["CVB3", "ORGANISM", 80, 84], ["cellular", "CELL", 177, 185], ["CVB3", "ORGANISM", 223, 227], ["CVB3", "SPECIES", 80, 84], ["CVB3", "SPECIES", 80, 84], ["CVB3", "SPECIES", 223, 227], ["new vaccines", "TREATMENT", 48, 60], ["CVB3 infection", "PROBLEM", 80, 94], ["IntroductionPrevious studies", "TEST", 95, 123], ["CVB3", "PROBLEM", 223, 227], ["infection", "OBSERVATION", 85, 94], ["cellular immune", "OBSERVATION", 177, 192]]], ["Agammaglobulinemic individuals are particularly susceptible to CVB3-associated encephalitis, and mice lacking B cells develop a chronic infection and remain viremic for at least 2 months; viremia can be alleviated by the adoptive transfer of B cells from CVB3immune wild-type mice [17] [18] [19] .", [["B cells", "ANATOMY", 110, 117], ["B cells", "ANATOMY", 242, 249], ["encephalitis", "DISEASE", 79, 91], ["chronic infection", "DISEASE", 128, 145], ["viremia", "DISEASE", 188, 195], ["CVB3", "ORGANISM", 63, 67], ["mice", "ORGANISM", 97, 101], ["B cells", "CELL", 110, 117], ["B cells", "CELL", 242, 249], ["mice", "ORGANISM", 276, 280], ["B cells", "CELL_TYPE", 110, 117], ["B cells", "CELL_TYPE", 242, 249], ["mice", "SPECIES", 97, 101], ["mice", "SPECIES", 276, 280], ["CVB3", "SPECIES", 63, 67], ["mice", "SPECIES", 97, 101], ["Agammaglobulinemic individuals", "PROBLEM", 0, 30], ["CVB3", "PROBLEM", 63, 67], ["encephalitis", "PROBLEM", 79, 91], ["mice lacking B cells", "PROBLEM", 97, 117], ["a chronic infection", "PROBLEM", 126, 145], ["viremic", "PROBLEM", 157, 164], ["viremia", "PROBLEM", 188, 195], ["B cells", "PROBLEM", 242, 249], ["CVB3", "OBSERVATION", 63, 67], ["encephalitis", "OBSERVATION", 79, 91], ["chronic", "OBSERVATION_MODIFIER", 128, 135], ["infection", "OBSERVATION", 136, 145]]], ["Reports have also highlighted the importance of cellular immunity against CVB3-induced viral myocarditis.", [["cellular", "ANATOMY", 48, 56], ["viral myocarditis", "DISEASE", 87, 104], ["cellular", "CELL", 48, 56], ["CVB3", "ORGANISM", 74, 78], ["CVB3", "SPECIES", 74, 78], ["cellular immunity", "TREATMENT", 48, 65], ["CVB3", "PROBLEM", 74, 78], ["viral myocarditis", "PROBLEM", 87, 104], ["viral myocarditis", "OBSERVATION", 87, 104]]], ["Comparison of C57BL/6 mice (resistant to chronic CVB3 myocarditis) and A.BY/SnJ mice (susceptible to chronic CVB3 myocarditis) found that a failure to clear the virus may be attributed to defects in dendritic cell (DC) maturation/activation and MHC class I antigen processing [20] .", [["dendritic cell", "ANATOMY", 199, 213], ["DC", "ANATOMY", 215, 217], ["CVB3 myocarditis", "DISEASE", 49, 65], ["CVB3 myocarditis", "DISEASE", 109, 125], ["C57BL/6 mice", "ORGANISM", 14, 26], ["CVB3", "ORGANISM", 49, 53], ["A.BY/SnJ mice", "ORGANISM", 71, 84], ["CVB3", "ORGANISM", 109, 113], ["dendritic cell", "CELL", 199, 213], ["DC", "CELL", 215, 217], ["MHC class I antigen", "GENE_OR_GENE_PRODUCT", 245, 264], ["DC", "CELL_TYPE", 215, 217], ["MHC class I antigen", "PROTEIN", 245, 264], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 22, 26], ["CVB3", "SPECIES", 49, 53], ["A.BY/SnJ mice", "SPECIES", 71, 84], ["CVB3", "SPECIES", 109, 113], ["C57BL/6 mice", "TREATMENT", 14, 26], ["chronic CVB3 myocarditis", "PROBLEM", 41, 65], ["A.BY/SnJ mice", "TREATMENT", 71, 84], ["chronic CVB3 myocarditis", "PROBLEM", 101, 125], ["a failure", "PROBLEM", 138, 147], ["the virus", "PROBLEM", 157, 166], ["defects in dendritic cell", "PROBLEM", 188, 213], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["myocarditis", "OBSERVATION", 54, 65], ["chronic", "OBSERVATION_MODIFIER", 101, 108], ["myocarditis", "OBSERVATION", 114, 125], ["failure", "OBSERVATION", 140, 147], ["defects", "OBSERVATION", 188, 195], ["dendritic cell", "OBSERVATION", 199, 213]]], ["The neutralization of interleukin 17 (IL-17) increases both CD4 + and CD8 + T cells, which ameliorates the pathological cardiac changes and reduces viral replication [21] .IntroductionAs a member of enteroviruses, CVB3 invades host through gastrointestinal tract [5] .", [["CD4 + and CD8 + T cells", "ANATOMY", 60, 83], ["cardiac", "ANATOMY", 120, 127], ["gastrointestinal tract", "ANATOMY", 240, 262], ["enteroviruses", "DISEASE", 199, 212], ["interleukin 17", "GENE_OR_GENE_PRODUCT", 22, 36], ["IL-17", "GENE_OR_GENE_PRODUCT", 38, 43], ["CD4", "GENE_OR_GENE_PRODUCT", 60, 63], ["CD8", "GENE_OR_GENE_PRODUCT", 70, 73], ["cardiac", "ORGAN", 120, 127], ["enteroviruses", "ORGANISM", 199, 212], ["CVB3", "ORGANISM", 214, 218], ["gastrointestinal tract", "PATHOLOGICAL_FORMATION", 240, 262], ["interleukin 17", "PROTEIN", 22, 36], ["IL-17", "PROTEIN", 38, 43], ["CD4", "PROTEIN", 60, 63], ["CD8", "PROTEIN", 70, 73], ["T cells", "CELL_TYPE", 76, 83], ["CVB3", "SPECIES", 214, 218], ["The neutralization of interleukin", "TEST", 0, 33], ["IL", "TEST", 38, 40], ["CD4", "TEST", 60, 63], ["CD8 + T cells", "PROBLEM", 70, 83], ["the pathological cardiac changes", "PROBLEM", 103, 135], ["reduces viral replication", "PROBLEM", 140, 165], ["enteroviruses", "PROBLEM", 199, 212], ["cardiac", "ANATOMY", 120, 127], ["viral replication", "OBSERVATION", 148, 165], ["gastrointestinal tract", "ANATOMY", 240, 262]]], ["Thus, it is important for a CVB3 vaccine to produce mucosal immunity at the sites of viral transmission to block the initial infection as well as the induction of potent systemic immune responses.", [["mucosal", "ANATOMY", 52, 59], ["infection", "DISEASE", 125, 134], ["CVB3", "ORGANISM", 28, 32], ["mucosal", "ORGAN", 52, 59], ["CVB3", "SPECIES", 28, 32], ["a CVB3 vaccine", "TREATMENT", 26, 40], ["mucosal immunity", "PROBLEM", 52, 68], ["viral transmission", "TREATMENT", 85, 103], ["the initial infection", "PROBLEM", 113, 134], ["infection", "OBSERVATION", 125, 134]]], ["All rights reserved. microparticles, liposomes, and attenuated pathogens, have been developed as alternative platforms for mucosal delivery.", [["mucosal", "ANATOMY", 123, 130], ["liposomes", "SIMPLE_CHEMICAL", 37, 46], ["mucosal", "MULTI-TISSUE_STRUCTURE", 123, 130], ["microparticles", "TEST", 21, 35], ["attenuated pathogens", "PROBLEM", 52, 72], ["mucosal delivery", "TREATMENT", 123, 139], ["liposomes", "ANATOMY", 37, 46], ["attenuated", "OBSERVATION_MODIFIER", 52, 62], ["pathogens", "OBSERVATION", 63, 72]]], ["Vesicular stomatitis virus (VSV), a viral vaccine vector, has been shown to be an excellent vector to deliver foreign antigens [22, 23] .", [["Vesicular stomatitis", "DISEASE", 0, 20], ["Vesicular stomatitis virus", "ORGANISM", 0, 26], ["VSV", "ORGANISM", 28, 31], ["foreign antigens", "PROTEIN", 110, 126], ["Vesicular stomatitis virus", "SPECIES", 0, 26], ["Vesicular stomatitis virus", "SPECIES", 0, 26], ["VSV", "SPECIES", 28, 31], ["Vesicular stomatitis virus (VSV", "PROBLEM", 0, 31], ["a viral vaccine vector", "TREATMENT", 34, 56], ["stomatitis virus", "OBSERVATION", 10, 26]]], ["Using reverse genetics, an exogenous gene can be inserted into the VSV genome and recombinant VSV can be recovered entirely from an infectious cDNA clone [24, 25] .", [["VSV", "ORGANISM", 67, 70], ["recombinant VSV", "ORGANISM", 82, 97], ["exogenous gene", "DNA", 27, 41], ["VSV genome", "DNA", 67, 77], ["infectious cDNA clone", "DNA", 132, 153], ["VSV", "SPECIES", 67, 70], ["VSV", "SPECIES", 94, 97], ["an exogenous gene", "TREATMENT", 24, 41], ["the VSV genome", "TREATMENT", 63, 77], ["an infectious cDNA clone", "PROBLEM", 129, 153], ["infectious", "OBSERVATION", 132, 142]]], ["The exogenous antigen is expressed continuously in vivo once the recombinant viruses are inoculated into animals, and thus it triggers specific immune responses.", [["exogenous antigen", "PROTEIN", 4, 21], ["the recombinant viruses", "PROBLEM", 61, 84]]], ["Recombinant VSV has been successfully developed for a number of vaccine candidates, such as human immunodeficiency virus [26] [27] [28] [29] , severe acute respiratory syndrome virus [30, 31] , hepatitis C virus [32, 33] , hepatitis B virus [34] , influenza virus [35] , papillomavirus [36] , human respiratory syncytial virus [37] , poxvirus [38] , Ebola virus, and Marburg virus [39, 40] .", [["human immunodeficiency virus", "DISEASE", 92, 120], ["acute respiratory syndrome virus", "DISEASE", 150, 182], ["hepatitis C", "DISEASE", 194, 205], ["hepatitis B", "DISEASE", 223, 234], ["influenza virus", "DISEASE", 248, 263], ["respiratory syncytial virus", "DISEASE", 299, 326], ["Ebola virus", "DISEASE", 350, 361], ["VSV", "ORGANISM", 12, 15], ["human immunodeficiency virus [26] [27] [28] [29", "ORGANISM", 92, 139], ["severe acute respiratory syndrome virus", "ORGANISM", 143, 182], ["hepatitis C virus", "ORGANISM", 194, 211], ["hepatitis B virus", "ORGANISM", 223, 240], ["influenza virus", "ORGANISM", 248, 263], ["papillomavirus", "ORGANISM", 271, 285], ["human", "ORGANISM", 293, 298], ["respiratory syncytial virus", "ORGANISM", 299, 326], ["poxvirus [38]", "ORGANISM", 334, 347], ["Ebola virus", "ORGANISM", 350, 361], ["Marburg virus", "ORGANISM", 367, 380], ["human immunodeficiency virus", "SPECIES", 92, 120], ["hepatitis C virus", "SPECIES", 194, 211], ["hepatitis B virus", "SPECIES", 223, 240], ["influenza virus", "SPECIES", 248, 263], ["human", "SPECIES", 293, 298], ["respiratory syncytial virus", "SPECIES", 299, 326], ["Ebola virus", "SPECIES", 350, 361], ["Marburg virus", "SPECIES", 367, 380], ["VSV", "SPECIES", 12, 15], ["human immunodeficiency virus", "SPECIES", 92, 120], ["severe acute respiratory syndrome virus", "SPECIES", 143, 182], ["hepatitis C virus", "SPECIES", 194, 211], ["hepatitis B virus", "SPECIES", 223, 240], ["human respiratory syncytial virus", "SPECIES", 293, 326], ["Ebola virus", "SPECIES", 350, 361], ["Marburg virus", "SPECIES", 367, 380], ["Recombinant VSV", "PROBLEM", 0, 15], ["vaccine candidates", "TREATMENT", 64, 82], ["human immunodeficiency virus", "PROBLEM", 92, 120], ["severe acute respiratory syndrome virus", "PROBLEM", 143, 182], ["hepatitis C virus", "PROBLEM", 194, 211], ["hepatitis B virus", "TEST", 223, 240], ["influenza virus", "PROBLEM", 248, 263], ["papillomavirus", "TEST", 271, 285], ["human respiratory syncytial virus", "TEST", 293, 326], ["poxvirus", "TEST", 334, 342], ["Ebola virus", "PROBLEM", 350, 361], ["Marburg virus", "PROBLEM", 367, 380], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["respiratory syndrome", "OBSERVATION", 156, 176]]], ["The VSV-based HIV vaccine candidate has been so successful in early studies that it has recently been moved to clinical study through the HIV Vaccine Design and Development Teams program [41] .", [["VSV", "ORGANISM", 4, 7], ["HIV", "ORGANISM", 14, 17], ["HIV", "SPECIES", 14, 17], ["VSV", "SPECIES", 4, 7], ["HIV", "SPECIES", 14, 17], ["HIV", "SPECIES", 138, 141], ["The VSV", "TREATMENT", 0, 7], ["based HIV vaccine", "TREATMENT", 8, 25], ["clinical study", "TEST", 111, 125], ["the HIV Vaccine", "TREATMENT", 134, 149]]], ["Collectively, these studies have demonstrated the great potential of VSV-based vaccines to trigger strong immunity even after a single immunizing dose.", [["VSV", "ORGANISM", 69, 72], ["VSV", "SPECIES", 69, 72], ["these studies", "TEST", 14, 27], ["VSV-based vaccines", "TREATMENT", 69, 87], ["a single immunizing dose", "TREATMENT", 126, 150]]], ["In spite of this, the capacity of VSV-based vaccines to induce mucosal immunity has not yet been fully characterized.IntroductionWe previously reported that a mucosal vaccine chito-pcDNA3.1-VP1, a DNA plasmid pcDNA3.1-VP1 encapsulated in a chitosan particle, protected mice against CVB3-induced viral myocarditis [14] .", [["mucosal", "ANATOMY", 63, 70], ["mucosal", "ANATOMY", 159, 166], ["chitosan particle", "CHEMICAL", 240, 257], ["myocarditis", "DISEASE", 301, 312], ["VSV", "ORGANISM", 34, 37], ["mucosal", "MULTI-TISSUE_STRUCTURE", 63, 70], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 181, 189], ["VP1", "GENE_OR_GENE_PRODUCT", 190, 193], ["DNA", "CELLULAR_COMPONENT", 197, 200], ["pcDNA3.1-VP1", "GENE_OR_GENE_PRODUCT", 209, 221], ["chitosan particle", "SIMPLE_CHEMICAL", 240, 257], ["mice", "ORGANISM", 269, 273], ["CVB3", "ORGANISM", 282, 286], ["pcDNA3.1", "DNA", 181, 189], ["VP1", "DNA", 190, 193], ["DNA plasmid pcDNA3.1", "DNA", 197, 217], ["VP1", "DNA", 218, 221], ["mice", "SPECIES", 269, 273], ["VSV", "SPECIES", 34, 37], ["mice", "SPECIES", 269, 273], ["CVB3", "SPECIES", 282, 286], ["VSV-based vaccines", "TREATMENT", 34, 52], ["mucosal immunity", "PROBLEM", 63, 79], ["a mucosal vaccine chito", "TREATMENT", 157, 180], ["VP1", "TEST", 190, 193], ["a DNA plasmid pcDNA3.1", "TREATMENT", 195, 217], ["VP1", "PROBLEM", 218, 221], ["a chitosan particle", "TREATMENT", 238, 257], ["CVB3", "PROBLEM", 282, 286], ["viral myocarditis", "PROBLEM", 295, 312], ["mucosal", "ANATOMY", 63, 70], ["immunity", "OBSERVATION", 71, 79], ["mucosal", "ANATOMY", 159, 166], ["viral myocarditis", "OBSERVATION", 295, 312]]], ["A moderate level of mucosal IgA and an IFN-\u2425 + T cell immune response were induced by intranasal immunization with chito-pcDNA3.1-VP1.", [["mucosal", "ANATOMY", 20, 27], ["-\u2425 + T cell", "ANATOMY", 42, 53], ["IgA", "GENE_OR_GENE_PRODUCT", 28, 31], ["IFN", "GENE_OR_GENE_PRODUCT", 39, 42], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 121, 129], ["mucosal IgA", "PROTEIN", 20, 31], ["IFN", "PROTEIN", 39, 42], ["pcDNA3.1", "DNA", 121, 129], ["VP1", "DNA", 130, 133], ["A moderate level of mucosal IgA", "PROBLEM", 0, 31], ["an IFN", "TEST", 36, 42], ["T cell immune response", "PROBLEM", 47, 69], ["intranasal immunization", "TREATMENT", 86, 109], ["chito", "TEST", 115, 120], ["VP1", "PROBLEM", 130, 133], ["moderate", "OBSERVATION_MODIFIER", 2, 10], ["mucosal IgA", "ANATOMY", 20, 31]]], ["To develop a more efficient vaccine, in the present study we have applied a VSV viral vector as a mucosal delivery system to express the main antigenic protein for CVB3 VP1.", [["mucosal", "ANATOMY", 98, 105], ["VSV", "ORGANISM", 76, 79], ["CVB3", "ORGANISM", 164, 168], ["VP1", "ORGANISM", 169, 172], ["antigenic protein", "PROTEIN", 142, 159], ["CVB3 VP1", "PROTEIN", 164, 172], ["VSV", "SPECIES", 76, 79], ["CVB3", "SPECIES", 164, 168], ["a VSV viral vector", "TREATMENT", 74, 92], ["a mucosal delivery system", "TREATMENT", 96, 121], ["CVB3 VP1", "TREATMENT", 164, 172]]], ["We evaluated the potential of this VSV-based vaccine to induce antigen-specific mucosal and systemic immunity in a viral myocarditis mouse model.Materials and methodsThe coding region of CVB3 (Nancy strain) major capsid protein VP1 was amplified by PCR from pcDNA3.1-VP1 [14] and cloned into the G-L junction of the pVSVXN 2 plasmid.", [["mucosal", "ANATOMY", 80, 87], ["viral myocarditis", "DISEASE", 115, 132], ["VSV", "ORGANISM", 35, 38], ["mucosal", "MULTI-TISSUE_STRUCTURE", 80, 87], ["mouse", "ORGANISM", 133, 138], ["CVB3 (Nancy strain", "ORGANISM", 187, 205], ["VP1", "GENE_OR_GENE_PRODUCT", 228, 231], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 258, 266], ["pVSVXN 2", "GENE_OR_GENE_PRODUCT", 316, 324], ["CVB3 (Nancy strain) major capsid protein VP1", "PROTEIN", 187, 231], ["pcDNA3.1", "DNA", 258, 266], ["VP1 [14]", "DNA", 267, 275], ["G-L junction", "DNA", 296, 308], ["pVSVXN 2 plasmid", "DNA", 316, 332], ["mouse", "SPECIES", 133, 138], ["VSV", "SPECIES", 35, 38], ["mouse", "SPECIES", 133, 138], ["this VSV", "TREATMENT", 30, 38], ["based vaccine", "TREATMENT", 39, 52], ["antigen", "TEST", 63, 70], ["a viral myocarditis mouse model", "PROBLEM", 113, 144], ["CVB3 (Nancy strain", "TREATMENT", 187, 205], ["major capsid protein VP1", "TEST", 207, 231], ["PCR", "TEST", 249, 252], ["VP1", "TEST", 267, 270], ["mucosal", "ANATOMY", 80, 87], ["viral myocarditis", "OBSERVATION", 115, 132], ["CVB3", "OBSERVATION", 187, 191], ["L", "ANATOMY_MODIFIER", 298, 299], ["junction", "ANATOMY_MODIFIER", 300, 308]]], ["Recombinant VSV containing VP1 (VSV-VP1) was recovered as previously described [22] .", [["VSV", "ORGANISM", 12, 15], ["VP1", "GENE_OR_GENE_PRODUCT", 27, 30], ["VSV-VP1", "ORGANISM", 32, 39], ["VP1", "PROTEIN", 27, 30], ["VSV", "PROTEIN", 32, 35], ["VP1", "PROTEIN", 36, 39], ["VSV", "SPECIES", 12, 15], ["Recombinant VSV", "TREATMENT", 0, 15], ["VP1 (VSV-VP1", "TEST", 27, 39]]], ["Six-week-old male BALB/c mice were purchased from the experimental animal center of Chinese Academy of Science (Shanghai, China) and remained in pathogen-free conditions and housed at the Soochow University School of Medicine animal facilities.", [["BALB/c mice", "ORGANISM", 18, 29], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29]]], ["All animal experiments were performed according to the guidelines for the Care and Use of Laboratory Animals (Ministry of Health, China, 1998) and the guidelines of the Laboratory Animal Ethical Commission of Soochow University.", [["All animal experiments", "TEST", 0, 22]]], ["Mice were lightly anesthetized by injecting 0.75% pentobarbital sodium into cavum abdominis (30 mg/kg) prior to all immunizations.", [["pentobarbital sodium", "CHEMICAL", 50, 70], ["pentobarbital", "CHEMICAL", 50, 63], ["sodium", "CHEMICAL", 64, 70], ["Mice", "ORGANISM", 0, 4], ["pentobarbital", "SIMPLE_CHEMICAL", 50, 63], ["sodium", "SIMPLE_CHEMICAL", 64, 70], ["cavum abdominis", "ORGANISM", 76, 91], ["Mice", "SPECIES", 0, 4], ["0.75% pentobarbital sodium into cavum abdominis", "TREATMENT", 44, 91], ["all immunizations", "TREATMENT", 112, 129], ["cavum abdominis", "ANATOMY", 76, 91]]], ["Each group contained 6 mice.", [["mice", "ORGANISM", 23, 27], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27]]], ["For VSV-VP1 or VSV-GFP immunization, single dose of 10 6 plaqueforming units (PFU) viruses in a 25 l volume was intranasally administered.", [["VSV-VP1", "ORGANISM", 4, 11], ["VSV-GFP", "ORGANISM", 15, 22], ["VSV", "SPECIES", 4, 7], ["VSV", "SPECIES", 15, 18], ["VSV", "TEST", 4, 7], ["VP1", "TEST", 8, 11], ["VSV", "TEST", 15, 18], ["GFP immunization", "TREATMENT", 19, 35], ["PFU) viruses", "TREATMENT", 78, 90], ["a 25 l volume", "TREATMENT", 94, 107]]], ["The group of mice receiving PBS alone was used as control.", [["mice", "ORGANISM", 13, 17], ["mice", "SPECIES", 13, 17], ["mice", "SPECIES", 13, 17], ["PBS alone", "TREATMENT", 28, 37]]], ["For chitosan-DNA immunization, each group of mice were mildly intranasally immunized with chitosan encapsulated 50 g pcDNA3.1-VP1 (chito-pcDNA3.1-VP1) or 50 g pcDNA3.1 (chito-pcDNA3.1) for 4 times biweekly.", [["chitosan", "CHEMICAL", 4, 12], ["chitosan", "CHEMICAL", 90, 98], ["chito-pcDNA3.", "CHEMICAL", 169, 182], ["chitosan", "SIMPLE_CHEMICAL", 4, 12], ["DNA", "CELLULAR_COMPONENT", 13, 16], ["mice", "ORGANISM", 45, 49], ["chitosan", "SIMPLE_CHEMICAL", 90, 98], ["pcDNA3", "ORGANISM", 117, 123], ["VP1", "ORGANISM", 126, 129], ["pcDNA3.1", "ORGANISM", 137, 145], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 159, 167], ["VP1", "PROTEIN", 126, 129], ["chito", "PROTEIN", 131, 136], ["pcDNA3.1", "PROTEIN", 137, 145], ["VP1", "PROTEIN", 146, 149], ["chito-pcDNA3.", "DNA", 169, 182], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["chitosan", "TREATMENT", 4, 12], ["DNA immunization", "TREATMENT", 13, 29], ["mildly intranasally", "PROBLEM", 55, 74], ["chitosan", "TEST", 90, 98], ["pcDNA3", "TEST", 117, 123], ["VP1", "TEST", 126, 129], ["chito", "TEST", 131, 136], ["VP1", "TEST", 146, 149], ["chito", "TEST", 169, 174]]], ["The detection of antibody response, lymphocyte proliferation assay, CTL activity assay, measurement of dendirtic cell maturation et al. as described previously [42] .", [["lymphocyte", "ANATOMY", 36, 46], ["dendirtic cell", "ANATOMY", 103, 117], ["lymphocyte", "CELL", 36, 46], ["dendirtic cell", "CELL", 103, 117], ["The detection", "TEST", 0, 13], ["antibody response", "TEST", 17, 34], ["lymphocyte proliferation assay", "TEST", 36, 66], ["CTL activity assay", "TEST", 68, 86], ["dendirtic cell maturation", "PROBLEM", 103, 128], ["antibody response", "OBSERVATION", 17, 34], ["lymphocyte proliferation", "OBSERVATION", 36, 60], ["dendirtic cell maturation", "OBSERVATION", 103, 128]]], ["Statistical analysis of the data was performed with the two-tailed independent Student's t-test using GraphPad Prism version 4.01 (GraphPad Software Incorporated).", [["the data", "TEST", 24, 32], ["GraphPad Prism version", "TEST", 102, 124]]], ["Full detailed methods are provided in Supplemental materials and methods.Construction and identification of the recombinant VSV based vaccinesThe coding region of CVB3 main antigenic protein VP1 was amplified by PCR and cloned into pVSVXN2 plasmid at the G-L junction in the VSV genome by XhoI and NheI restriction enzymes as indicated in Fig. 1A .", [["plasmid", "ANATOMY", 240, 247], ["VSV", "ORGANISM", 124, 127], ["CVB3", "ORGANISM", 163, 167], ["VP1", "GENE_OR_GENE_PRODUCT", 191, 194], ["pVSVXN2", "GENE_OR_GENE_PRODUCT", 232, 239], ["VSV", "ORGANISM", 275, 278], ["XhoI", "GENE_OR_GENE_PRODUCT", 289, 293], ["NheI restriction enzymes", "GENE_OR_GENE_PRODUCT", 298, 322], ["CVB3 main antigenic protein VP1", "PROTEIN", 163, 194], ["pVSVXN2 plasmid", "DNA", 232, 247], ["VSV genome", "DNA", 275, 285], ["NheI restriction enzymes", "PROTEIN", 298, 322], ["VSV", "SPECIES", 124, 127], ["CVB3", "SPECIES", 163, 167], ["VSV", "SPECIES", 275, 278], ["the recombinant VSV based vaccines", "TREATMENT", 108, 142], ["CVB3 main antigenic protein VP1", "PROBLEM", 163, 194], ["PCR", "TEST", 212, 215], ["pVSVXN2 plasmid", "TREATMENT", 232, 247], ["NheI restriction enzymes", "TEST", 298, 322], ["protein VP1", "OBSERVATION", 183, 194], ["L junction", "ANATOMY_MODIFIER", 257, 267], ["VSV genome", "OBSERVATION", 275, 285]]], ["A VSV-GFP recombinant virus was generated as a control.", [["VSV", "ORGANISM", 2, 5], ["GFP", "GENE_OR_GENE_PRODUCT", 6, 9], ["VSV", "SPECIES", 2, 5], ["A VSV", "TEST", 0, 5], ["GFP recombinant virus", "PROBLEM", 6, 27]]], ["We then recovered the recombinant viruses in BHK-21 cells as previously reported [24] and the recombinant viruses were purified by plaque assay.", [["BHK-21 cells", "ANATOMY", 45, 57], ["plaque", "ANATOMY", 131, 137], ["BHK-21 cells", "CELL", 45, 57], ["BHK-21 cells", "CELL_LINE", 45, 57], ["BHK-21", "SPECIES", 45, 51], ["the recombinant viruses in BHK", "PROBLEM", 18, 48], ["the recombinant viruses", "PROBLEM", 90, 113], ["plaque assay", "TEST", 131, 143], ["recombinant", "OBSERVATION_MODIFIER", 22, 33], ["viruses", "OBSERVATION", 34, 41], ["plaque", "OBSERVATION", 131, 137]]], ["Immunofluorescence staining of VP1 indicated that VP1 was efficiently expressed in the cytoplasmic region of VSV-VP1-infected BHK-21 cells (Fig. 1B) .", [["cytoplasmic region", "ANATOMY", 87, 105], ["BHK-21 cells", "ANATOMY", 126, 138], ["VP1", "GENE_OR_GENE_PRODUCT", 31, 34], ["VP1", "GENE_OR_GENE_PRODUCT", 50, 53], ["cytoplasmic", "ORGANISM_SUBSTANCE", 87, 98], ["VSV-VP1", "ORGANISM", 109, 116], ["BHK-21 cells", "CELL", 126, 138], ["Fig. 1B", "CELL", 140, 147], ["VP1", "PROTEIN", 31, 34], ["VP1", "PROTEIN", 50, 53], ["cytoplasmic region", "PROTEIN", 87, 105], ["VSV-VP1-infected BHK-21 cells", "CELL_LINE", 109, 138], ["BHK-21", "SPECIES", 126, 132], ["Immunofluorescence staining", "TEST", 0, 27], ["VP1", "TEST", 31, 34], ["VP1", "PROBLEM", 50, 53], ["VSV", "TEST", 109, 112], ["VP1", "TEST", 113, 116], ["infected BHK", "PROBLEM", 117, 129], ["VSV", "ANATOMY", 109, 112]]], ["We also detected the expected green fluorescence in VSV-GFP infected cells.", [["cells", "ANATOMY", 69, 74], ["VSV", "ORGANISM", 52, 55], ["GFP", "GENE_OR_GENE_PRODUCT", 56, 59], ["cells", "CELL", 69, 74], ["VSV-GFP infected cells", "CELL_LINE", 52, 74], ["VSV", "SPECIES", 52, 55], ["GFP infected cells", "PROBLEM", 56, 74], ["green fluorescence", "OBSERVATION", 30, 48], ["GFP infected cells", "OBSERVATION", 56, 74]]], ["A western blot further confirmed the expression of VP1 as well as the expression of VSV glycoprotein VSVG in infected cells (Fig. 1C) .", [["cells", "ANATOMY", 118, 123], ["VP1", "GENE_OR_GENE_PRODUCT", 51, 54], ["VSV", "ORGANISM", 84, 87], ["VSVG", "GENE_OR_GENE_PRODUCT", 101, 105], ["cells", "CELL", 118, 123], ["VP1", "PROTEIN", 51, 54], ["VSV glycoprotein VSVG", "PROTEIN", 84, 105], ["infected cells", "CELL_TYPE", 109, 123], ["VSV", "SPECIES", 84, 87], ["A western blot", "TEST", 0, 14], ["VP1", "PROBLEM", 51, 54], ["VSV glycoprotein VSVG", "TREATMENT", 84, 105], ["VSV glycoprotein", "OBSERVATION", 84, 100], ["infected cells", "OBSERVATION", 109, 123]]], ["These results demonstrate the successful generation of recombinant virus VSV-VP1 expressing CVB3 antigen VP1.The humoral response generated by VSV-VP1 vaccinationAdministration of vaccines at mucosal surfaces has been shown to elicit an adequate local immune response at the administration site and at distant mucosal sites, as well as a systemic immune response [43] .", [["mucosal surfaces", "ANATOMY", 192, 208], ["mucosal sites", "ANATOMY", 310, 323], ["recombinant virus VSV", "ORGANISM", 55, 76], ["-VP1", "ORGANISM", 76, 80], ["CVB3", "ORGANISM", 92, 96], ["VSV-VP1", "ORGANISM", 143, 150], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 192, 208], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 310, 323], ["recombinant virus VSV-VP1 expressing CVB3 antigen VP1", "PROTEIN", 55, 108], ["CVB3", "SPECIES", 92, 96], ["VSV", "SPECIES", 143, 146], ["recombinant virus VSV", "TREATMENT", 55, 76], ["VSV", "TEST", 143, 146], ["VP1 vaccination", "TREATMENT", 147, 162], ["vaccines at mucosal surfaces", "TREATMENT", 180, 208], ["a systemic immune response", "TEST", 336, 362], ["humoral response", "OBSERVATION", 113, 129]]], ["Thus, groups of mice were intranasally immunized with VSV-VP1, VSV-GFP, chito-pcDNA3.1-VP1, chito-pcDNA3.1 and PBS described in Section 2.", [["mice", "ORGANISM", 16, 20], ["VSV-VP1", "ORGANISM", 54, 61], ["VSV", "ORGANISM", 63, 66], ["GFP", "GENE_OR_GENE_PRODUCT", 67, 70], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 78, 86], ["VP1", "GENE_OR_GENE_PRODUCT", 87, 90], ["chito-pcDNA3.1", "GENE_OR_GENE_PRODUCT", 92, 106], ["VSV-VP1, VSV-GFP, chito-pcDNA3.1-VP1, chito-pcDNA3.1", "DNA", 54, 106], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["VSV", "SPECIES", 54, 57], ["VSV", "TEST", 54, 57], ["VP1", "TEST", 58, 61], ["VSV", "TEST", 63, 66], ["GFP", "TEST", 67, 70], ["chito", "TEST", 72, 77], ["VP1", "TEST", 87, 90], ["chito", "TEST", 92, 97], ["PBS", "TREATMENT", 111, 114]]], ["We monitored the weight change of immunized mice to assess the effects of viral infection.", [["viral infection", "DISEASE", 74, 89], ["mice", "ORGANISM", 44, 48], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 44, 48], ["immunized mice", "TREATMENT", 34, 48], ["viral infection", "PROBLEM", 74, 89], ["viral", "OBSERVATION_MODIFIER", 74, 79], ["infection", "OBSERVATION", 80, 89]]], ["As previously reported [44] , mice inoculated with 10 6 PFU of either VSV-VP1 or VSV-GFP demonstrated severe weight loss as well as other clinical symptoms such as tremors, paralysis, and circling within the 6 days post inoculation but recovery was noted thereafter (data not shown).", [["weight loss", "DISEASE", 109, 120], ["tremors", "DISEASE", 164, 171], ["paralysis", "DISEASE", 173, 182], ["mice", "ORGANISM", 30, 34], ["VSV-VP1", "ORGANISM", 70, 77], ["VSV-GFP", "ORGANISM", 81, 88], ["GFP", "PROTEIN", 85, 88], ["mice", "SPECIES", 30, 34], ["mice", "SPECIES", 30, 34], ["VSV", "SPECIES", 70, 73], ["VSV", "SPECIES", 81, 84], ["VSV", "TEST", 70, 73], ["VP1", "TEST", 74, 77], ["VSV", "TEST", 81, 84], ["severe weight loss", "PROBLEM", 102, 120], ["other clinical symptoms", "PROBLEM", 132, 155], ["tremors", "PROBLEM", 164, 171], ["paralysis", "PROBLEM", 173, 182], ["circling", "PROBLEM", 188, 196], ["inoculation", "PROBLEM", 220, 231], ["severe", "OBSERVATION_MODIFIER", 102, 108], ["weight loss", "OBSERVATION", 109, 120], ["paralysis", "OBSERVATION", 173, 182]]], ["Meanwhile, the weight of mice immunized with chito-pcDNA3.1-VP1, chito-pcDNA3.1 and PBS steadily increased, and were not significantly different from those of VSV-VP1 and VSV-GFP groups 2 weeks post inoculation.The humoral response generated by VSV-VP1 vaccinationTo analyze the antibody response in the immunized mice, blood samples were collected from each mouse and the serum IgG antibody response was determined by ELISA at indicated time points.", [["blood samples", "ANATOMY", 320, 333], ["serum", "ANATOMY", 373, 378], ["mice", "ORGANISM", 25, 29], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 51, 59], ["VP1", "GENE_OR_GENE_PRODUCT", 60, 63], ["chito-pcDNA3.1", "GENE_OR_GENE_PRODUCT", 65, 79], ["VSV-VP1", "ORGANISM", 159, 166], ["VSV-GFP", "ORGANISM", 171, 178], ["VSV-VP1", "ORGANISM", 245, 252], ["mice", "ORGANISM", 314, 318], ["blood samples", "ORGANISM_SUBSTANCE", 320, 333], ["mouse", "ORGANISM", 359, 364], ["serum", "ORGANISM_SUBSTANCE", 373, 378], ["IgG", "GENE_OR_GENE_PRODUCT", 379, 382], ["pcDNA3.1", "DNA", 51, 59], ["serum IgG antibody", "PROTEIN", 373, 391], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 314, 318], ["mouse", "SPECIES", 359, 364], ["mice", "SPECIES", 25, 29], ["VSV", "SPECIES", 159, 162], ["VSV", "SPECIES", 171, 174], ["VSV", "SPECIES", 245, 248], ["mice", "SPECIES", 314, 318], ["mouse", "SPECIES", 359, 364], ["the weight", "TEST", 11, 21], ["chito", "TEST", 45, 50], ["VP1", "TEST", 60, 63], ["chito-pcDNA3.1", "TEST", 65, 79], ["PBS", "TEST", 84, 87], ["VSV", "TEST", 159, 162], ["VP1", "TEST", 163, 166], ["VSV", "TEST", 171, 174], ["inoculation", "PROBLEM", 199, 210], ["VSV", "TEST", 245, 248], ["VP1 vaccination", "TREATMENT", 249, 264], ["the antibody response", "TEST", 275, 296], ["blood samples", "TEST", 320, 333], ["the serum IgG antibody response", "TEST", 369, 400], ["ELISA", "TEST", 419, 424], ["steadily", "OBSERVATION_MODIFIER", 88, 96], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["significantly different", "OBSERVATION_MODIFIER", 121, 144]]], ["As shown in Fig. 2A mice immunized with a single dose of VSV-VP1 exhibited a high serum IgG response compared with that of mice immunized with VSV-GFP and it peaked at week 4 post inoculation with a drop in the following weeks.", [["serum", "ANATOMY", 82, 87], ["Fig. 2A mice", "ORGANISM", 12, 24], ["VSV-VP1", "ORGANISM", 57, 64], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["IgG", "ORGANISM_SUBSTANCE", 88, 91], ["mice", "ORGANISM", 123, 127], ["VSV-GFP", "ORGANISM", 143, 150], ["VP1", "PROTEIN", 61, 64], ["serum IgG", "PROTEIN", 82, 91], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 20, 24], ["VSV", "SPECIES", 57, 60], ["mice", "SPECIES", 123, 127], ["VSV", "SPECIES", 143, 146], ["VSV", "TREATMENT", 57, 60], ["VP1", "PROBLEM", 61, 64], ["a high serum IgG response", "PROBLEM", 75, 100], ["VSV-GFP", "TEST", 143, 150], ["inoculation", "PROBLEM", 180, 191]]], ["The serum IgG level in mice receiving chito-pcDNA3.1-VP1 gradually increased with three additional boosts and reached a peak at week 8.", [["serum", "ANATOMY", 4, 9], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["IgG", "GENE_OR_GENE_PRODUCT", 10, 13], ["mice", "ORGANISM", 23, 27], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 44, 52], ["VP1", "ORGANISM", 53, 56], ["serum IgG", "PROTEIN", 4, 13], ["pcDNA3.1", "DNA", 44, 52], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["The serum IgG level", "TEST", 0, 19], ["chito", "TEST", 38, 43], ["VP1", "PROBLEM", 53, 56]]], ["Interestingly, although the trend of fecal secretory IgA (sIgA) generated by VSV-VP1 was similar to that for serum IgG, its production was faster and higher than that in chito-pcDNA3.1-VP1 immunized mice (Fig. 2B) .", [["serum", "ANATOMY", 109, 114], ["fecal secretory IgA", "GENE_OR_GENE_PRODUCT", 37, 56], ["sIgA", "GENE_OR_GENE_PRODUCT", 58, 62], ["VSV-VP1", "ORGANISM", 77, 84], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["IgG", "GENE_OR_GENE_PRODUCT", 115, 118], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 176, 184], ["VP1", "ORGANISM", 185, 188], ["mice", "ORGANISM", 199, 203], ["Fig. 2B", "ORGANISM", 205, 212], ["fecal secretory IgA", "PROTEIN", 37, 56], ["sIgA", "PROTEIN", 58, 62], ["VP1", "PROTEIN", 81, 84], ["serum IgG", "PROTEIN", 109, 118], ["mice", "SPECIES", 199, 203], ["VSV", "SPECIES", 77, 80], ["mice", "SPECIES", 199, 203], ["VSV", "TEST", 77, 80], ["VP1", "TEST", 81, 84], ["serum IgG", "TEST", 109, 118], ["chito", "TEST", 170, 175], ["VP1 immunized mice", "TREATMENT", 185, 203], ["fecal", "ANATOMY", 37, 42]]], ["These results indicate that intranasal immunization with VSV-VP1 can efficiently induce both mucosal and systemic antibody responses.Vaccination of mice with VSV-VP1 elicits strong cellular immunityWe next investigated the CVB3-specific T cell immune responses in the spleen and mesenteric lymph node (MLN) induced by VSV-VP1 immunization.", [["mucosal", "ANATOMY", 93, 100], ["cellular", "ANATOMY", 181, 189], ["T cell", "ANATOMY", 237, 243], ["spleen", "ANATOMY", 268, 274], ["mesenteric lymph node", "ANATOMY", 279, 300], ["MLN", "ANATOMY", 302, 305], ["VSV-VP1", "CHEMICAL", 57, 64], ["VSV-VP1", "ORGANISM", 57, 64], ["mucosal", "MULTI-TISSUE_STRUCTURE", 93, 100], ["mice", "ORGANISM", 148, 152], ["VSV-VP1", "ORGANISM", 158, 165], ["cellular", "CELL", 181, 189], ["CVB3", "ORGANISM", 223, 227], ["T cell", "CELL", 237, 243], ["spleen", "ORGAN", 268, 274], ["mesenteric lymph node", "MULTI-TISSUE_STRUCTURE", 279, 300], ["MLN", "MULTI-TISSUE_STRUCTURE", 302, 305], ["VSV", "ORGANISM", 318, 321], ["-VP1", "ORGANISM", 321, 325], ["mice", "SPECIES", 148, 152], ["VSV", "SPECIES", 57, 60], ["mice", "SPECIES", 148, 152], ["VSV", "SPECIES", 158, 161], ["CVB3", "SPECIES", 223, 227], ["VSV", "SPECIES", 318, 321], ["intranasal immunization", "TREATMENT", 28, 51], ["VSV", "TREATMENT", 57, 60], ["VP1", "TREATMENT", 61, 64], ["Vaccination of mice with VSV", "TREATMENT", 133, 161], ["the CVB3", "TEST", 219, 227], ["mesenteric lymph node", "PROBLEM", 279, 300], ["VP1 immunization", "TREATMENT", 322, 338], ["systemic antibody", "OBSERVATION", 105, 122], ["spleen", "ANATOMY", 268, 274], ["mesenteric", "ANATOMY", 279, 289], ["lymph node", "OBSERVATION", 290, 300], ["MLN", "ANATOMY", 302, 305]]], ["As shown in Fig. 3A , compared with mice given PBS or VSV-GFP, mice immunized with VSV-VP1 displayed a significant increase in specific T cell proliferation in both the spleen and MLN as measured by BrdU assay (P < 0.001).", [["T cell", "ANATOMY", 136, 142], ["spleen", "ANATOMY", 169, 175], ["MLN", "ANATOMY", 180, 183], ["BrdU", "CHEMICAL", 199, 203], ["mice", "ORGANISM", 36, 40], ["PBS", "SIMPLE_CHEMICAL", 47, 50], ["VSV-GFP", "ORGANISM", 54, 61], ["mice", "ORGANISM", 63, 67], ["VSV-VP1", "ORGANISM", 83, 90], ["T cell", "CELL", 136, 142], ["spleen", "ORGAN", 169, 175], ["MLN", "ORGAN", 180, 183], ["BrdU", "SIMPLE_CHEMICAL", 199, 203], ["VP1", "PROTEIN", 87, 90], ["MLN", "CELL_TYPE", 180, 183], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 36, 40], ["VSV", "SPECIES", 54, 57], ["mice", "SPECIES", 63, 67], ["VSV", "SPECIES", 83, 86], ["PBS", "TEST", 47, 50], ["VSV", "TEST", 54, 57], ["GFP", "TEST", 58, 61], ["VSV", "TEST", 83, 86], ["VP1", "PROBLEM", 87, 90], ["specific T cell proliferation", "PROBLEM", 127, 156], ["BrdU assay", "TEST", 199, 209], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["increase", "OBSERVATION_MODIFIER", 115, 123], ["specific T cell proliferation", "OBSERVATION", 127, 156], ["both", "ANATOMY_MODIFIER", 160, 164], ["spleen", "ANATOMY", 169, 175], ["MLN", "ANATOMY", 180, 183]]], ["This proliferation level was even higher than that of mice immunized with chito-pcDNA3.1-VP1 (P < 0.05).Vaccination of mice with VSV-VP1 elicits strong cellular immunityAn IFN-\u2425 ELISPOT analysis indicated that mice immunized with VSV-VP1 developed the most IFN-\u2425-secreting T cells in the spleen -specific cytokine-secreting lymphocytes were quantified by ELISPOT assay in response to CVB3 VP1237-249 peptide or inactivated CVB3 for 48 h.", [["cellular", "ANATOMY", 152, 160], ["T cells", "ANATOMY", 273, 280], ["spleen", "ANATOMY", 288, 294], ["lymphocytes", "ANATOMY", 324, 335], ["VP1237-249", "CHEMICAL", 389, 399], ["mice", "ORGANISM", 54, 58], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 80, 88], ["mice", "ORGANISM", 119, 123], ["VSV-VP1", "ORGANISM", 129, 136], ["cellular", "CELL", 152, 160], ["IFN", "GENE_OR_GENE_PRODUCT", 172, 175], ["mice", "ORGANISM", 210, 214], ["VSV-VP1", "ORGANISM", 230, 237], ["IFN", "GENE_OR_GENE_PRODUCT", 257, 260], ["T cells", "CELL", 273, 280], ["spleen", "ORGAN", 288, 294], ["lymphocytes", "CELL", 324, 335], ["CVB3", "ORGANISM", 384, 388], ["VP1237-249 peptide", "SIMPLE_CHEMICAL", 389, 407], ["CVB3", "ORGANISM", 423, 427], ["pcDNA3.1", "DNA", 80, 88], ["VP1", "DNA", 89, 92], ["IFN", "PROTEIN", 172, 175], ["IFN", "PROTEIN", 257, 260], ["T cells", "CELL_TYPE", 273, 280], ["cytokine", "PROTEIN", 305, 313], ["secreting lymphocytes", "CELL_TYPE", 314, 335], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 210, 214], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 119, 123], ["VSV", "SPECIES", 129, 132], ["mice", "SPECIES", 210, 214], ["VSV", "SPECIES", 230, 233], ["CVB3", "SPECIES", 384, 388], ["CVB3", "SPECIES", 423, 427], ["This proliferation level", "TEST", 0, 24], ["chito", "TEST", 74, 79], ["VP1", "TEST", 89, 92], ["Vaccination of mice with VSV", "TREATMENT", 104, 132], ["An IFN-\u2425 ELISPOT analysis", "TEST", 169, 194], ["VSV", "TEST", 230, 233], ["VP1", "PROBLEM", 234, 237], ["secreting T cells", "PROBLEM", 263, 280], ["secreting lymphocytes", "PROBLEM", 314, 335], ["ELISPOT assay", "TEST", 355, 368], ["CVB3 VP1237", "TEST", 384, 395], ["spleen", "ANATOMY", 288, 294], ["secreting lymphocytes", "OBSERVATION", 314, 335]]], ["(C) CVB3-specific CTL activity of splenic and mesenteric cells was evaluated by lactate dehydrogenase assays using pcDNA3.1-VP1 stable-transfected autologous SP2/0 cells as target cells.", [["splenic", "ANATOMY", 34, 41], ["mesenteric cells", "ANATOMY", 46, 62], ["SP2/0 cells", "ANATOMY", 158, 169], ["cells", "ANATOMY", 180, 185], ["lactate", "CHEMICAL", 80, 87], ["lactate", "CHEMICAL", 80, 87], ["(C) CVB3", "ORGANISM", 0, 8], ["CTL", "CELL", 18, 21], ["splenic", "CELL", 34, 41], ["mesenteric cells", "CELL", 46, 62], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 80, 101], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 115, 123], ["VP1", "GENE_OR_GENE_PRODUCT", 124, 127], ["SP2/0 cells", "CELL", 158, 169], ["cells", "CELL", 180, 185], ["splenic and mesenteric cells", "CELL_TYPE", 34, 62], ["lactate dehydrogenase", "PROTEIN", 80, 101], ["pcDNA3.1-VP1 stable-transfected autologous SP2/0 cells", "CELL_LINE", 115, 169], ["target cells", "CELL_TYPE", 173, 185], ["CVB3", "SPECIES", 4, 8], ["CVB3", "TEST", 4, 8], ["splenic and mesenteric cells", "PROBLEM", 34, 62], ["lactate dehydrogenase assays", "TEST", 80, 108], ["pcDNA3.1", "TEST", 115, 123], ["VP1", "TEST", 124, 127], ["splenic", "ANATOMY", 34, 41], ["mesenteric cells", "ANATOMY", 46, 62]]], ["The effector/target cell ratio was between 50:1 and 12.5:1.", [["cell", "ANATOMY", 20, 24], ["cell", "CELL", 20, 24], ["The effector/target cell ratio", "TEST", 0, 30]]], ["Results are represented as the mean \u00b1 SD (n = 6) of three separate experiments. * P < 0.05, ** P < 0.01, *** P < 0.001. and MLN, with frequencies reaching 351 and 255 spot-forming cells (SFC)/10 6 cells, respectively ( Fig. 3B ; P < 0.05).", [["MLN", "ANATOMY", 124, 127], ["cells", "ANATOMY", 180, 185], ["SFC", "ANATOMY", 187, 190], ["cells", "ANATOMY", 197, 202], ["MLN", "CELL", 124, 127], ["cells", "CELL", 180, 185], ["SFC", "CELL", 187, 190], ["cells", "CELL", 197, 202], ["MLN", "CELL_TYPE", 124, 127], ["forming cells", "CELL_TYPE", 172, 185], ["SFC", "CELL_TYPE", 187, 190], ["frequencies", "TEST", 134, 145], ["spot-forming cells", "TEST", 167, 185], ["SFC", "TEST", 187, 190], ["P", "TEST", 229, 230], ["MLN", "ANATOMY", 124, 127]]], ["Mice immunized with chito-pcDNA3.1-VP1 produced a modest amount of IFN-\u2425 secreting T cells compared with control groups.", [["T cells", "ANATOMY", 83, 90], ["Mice", "ORGANISM", 0, 4], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 26, 34], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 67, 72], ["T cells", "CELL", 83, 90], ["chito-pcDNA3.1-VP1", "DNA", 20, 38], ["IFN", "PROTEIN", 67, 70], ["T cells", "CELL_TYPE", 83, 90], ["Mice", "SPECIES", 0, 4], ["chito", "TEST", 20, 25], ["VP1", "PROBLEM", 35, 38], ["IFN", "TEST", 67, 70], ["secreting T cells", "PROBLEM", 73, 90], ["modest", "OBSERVATION_MODIFIER", 50, 56], ["amount", "OBSERVATION_MODIFIER", 57, 63]]], ["In agreement with the ELISPOT data, the strongest CVB3-specific cytotoxicity responses were also detected in the splenic (50.3%) and mesenteric lymphocytes (51.1%) derived from mice immunized with VSV-VP1 at an E:T ratio of 50:1 (Fig. 3C) .", [["splenic", "ANATOMY", 113, 120], ["mesenteric lymphocytes", "ANATOMY", 133, 155], ["CVB3", "ORGANISM", 50, 54], ["splenic", "CANCER", 113, 120], ["mesenteric lymphocytes", "CELL", 133, 155], ["mice", "ORGANISM", 177, 181], ["VSV-VP1", "ORGANISM", 197, 204], ["mesenteric lymphocytes", "CELL_TYPE", 133, 155], ["mice", "SPECIES", 177, 181], ["CVB3", "SPECIES", 50, 54], ["mice", "SPECIES", 177, 181], ["VSV", "SPECIES", 197, 200], ["the ELISPOT data", "TEST", 18, 34], ["the strongest CVB3", "TEST", 36, 54], ["mesenteric lymphocytes", "TEST", 133, 155], ["VSV", "TEST", 197, 200], ["VP1", "TEST", 201, 204], ["T ratio", "TEST", 213, 220], ["splenic", "ANATOMY", 113, 120], ["mesenteric lymphocytes", "ANATOMY", 133, 155]]], ["Taken together, these data indicate that in addition to the previously reported VSV-induced specific systemic T cell immune responses against other viral pathogens, VSV-based vaccines can also induce a strong mucosal antigenspecific T cell immune response.VSV-VP1 vaccination significantly alleviates CVB3-induced viral myocarditisTo determine if VSV-VP1 immunization has protective effects, 2 weeks after the final DNA vaccine immunization, all of groups mice were infected with a 50% lethal dose (LD 50 ) of 3 of CVB3 to induce acute myocarditis.", [["T cell", "ANATOMY", 110, 116], ["mucosal", "ANATOMY", 209, 216], ["T cell", "ANATOMY", 233, 239], ["myocarditis", "DISEASE", 320, 331], ["myocarditis", "DISEASE", 536, 547], ["VSV", "ORGANISM", 80, 83], ["T cell", "CELL", 110, 116], ["VSV", "ORGANISM", 165, 168], ["mucosal antigenspecific T cell", "CELL", 209, 239], ["VSV-VP1", "ORGANISM", 256, 263], ["CVB3", "ORGANISM", 301, 305], ["VSV-VP1", "ORGANISM", 347, 354], ["DNA", "CELLULAR_COMPONENT", 416, 419], ["mice", "ORGANISM", 456, 460], ["CVB3", "ORGANISM", 515, 519], ["mice", "SPECIES", 456, 460], ["VSV", "SPECIES", 80, 83], ["VSV", "SPECIES", 165, 168], ["VSV", "SPECIES", 256, 259], ["CVB3", "SPECIES", 301, 305], ["VSV", "SPECIES", 347, 350], ["mice", "SPECIES", 456, 460], ["CVB3", "SPECIES", 515, 519], ["systemic T cell immune responses", "TREATMENT", 101, 133], ["other viral pathogens", "PROBLEM", 142, 163], ["VSV-based vaccines", "TREATMENT", 165, 183], ["VSV", "TEST", 256, 259], ["VP1 vaccination", "TREATMENT", 260, 275], ["CVB3", "PROBLEM", 301, 305], ["viral myocarditis", "PROBLEM", 314, 331], ["VSV", "TEST", 347, 350], ["VP1 immunization", "TREATMENT", 351, 367], ["the final DNA vaccine immunization", "TREATMENT", 406, 440], ["CVB3", "TREATMENT", 515, 519], ["acute myocarditis", "PROBLEM", 530, 547], ["cell immune response", "OBSERVATION", 235, 255], ["viral myocarditis", "OBSERVATION", 314, 331], ["acute", "OBSERVATION_MODIFIER", 530, 535], ["myocarditis", "OBSERVATION", 536, 547]]], ["Seven days post-viral infection, mice in the groups vaccinated with PBS, VSV-GFP or chito-pcDNA3.1 suffered from loss of body weight, up to approximately 17.9% of total weight (Fig. 4A) , indicating the development of myocarditis in these mice.", [["body", "ANATOMY", 121, 125], ["post-viral infection", "DISEASE", 11, 31], ["loss of body weight", "DISEASE", 113, 132], ["myocarditis", "DISEASE", 218, 229], ["mice", "ORGANISM", 33, 37], ["VSV-GFP", "ORGANISM", 73, 80], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 90, 98], ["body", "ORGANISM_SUBDIVISION", 121, 125], ["mice", "ORGANISM", 239, 243], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 239, 243], ["mice", "SPECIES", 33, 37], ["VSV", "SPECIES", 73, 76], ["mice", "SPECIES", 239, 243], ["Seven days post-viral infection", "PROBLEM", 0, 31], ["PBS", "TEST", 68, 71], ["VSV", "TEST", 73, 76], ["chito", "TEST", 84, 89], ["loss of body weight", "PROBLEM", 113, 132], ["total weight", "TEST", 163, 175], ["myocarditis", "PROBLEM", 218, 229], ["infection", "OBSERVATION", 22, 31], ["myocarditis", "OBSERVATION", 218, 229]]], ["Detection of serum creatine kinase (CK) and CK-MB activity reflects the amount of cardiac damage.", [["serum", "ANATOMY", 13, 18], ["cardiac", "ANATOMY", 82, 89], ["creatine", "CHEMICAL", 19, 27], ["cardiac damage", "DISEASE", 82, 96], ["creatine", "CHEMICAL", 19, 27], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 19, 34], ["CK", "GENE_OR_GENE_PRODUCT", 36, 38], ["CK-MB", "GENE_OR_GENE_PRODUCT", 44, 49], ["cardiac", "ORGAN", 82, 89], ["serum creatine kinase", "PROTEIN", 13, 34], ["CK", "PROTEIN", 36, 38], ["CK", "PROTEIN", 44, 46], ["serum creatine kinase", "TEST", 13, 34], ["CK", "TEST", 36, 38], ["CK-MB activity", "TEST", 44, 58], ["cardiac damage", "PROBLEM", 82, 96], ["amount", "OBSERVATION_MODIFIER", 72, 78], ["cardiac", "ANATOMY", 82, 89], ["damage", "OBSERVATION", 90, 96]]], ["Immunization with VSV-VP1 significantly reduced the serum CK and CK-MB activity ( Fig. 4B and C) .", [["serum", "ANATOMY", 52, 57], ["VSV-VP1", "ORGANISM", 18, 25], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["CK", "GENE_OR_GENE_PRODUCT", 58, 60], ["CK-MB", "GENE_OR_GENE_PRODUCT", 65, 70], ["serum CK", "PROTEIN", 52, 60], ["CK", "PROTEIN", 65, 67], ["VSV", "SPECIES", 18, 21], ["Immunization", "TREATMENT", 0, 12], ["VSV", "TEST", 18, 21], ["VP1", "TEST", 22, 25], ["the serum CK", "TEST", 48, 60], ["CK", "TEST", 65, 67], ["MB activity", "TEST", 68, 79]]], ["For example, CK-MB in the VSV-VP1 immunized group was only 631.3 IU/L, while it was 1420.0 IU/L in the VSV-GFP immunized group.", [["CK-MB", "GENE_OR_GENE_PRODUCT", 13, 18], ["VSV-VP1", "ORGANISM", 26, 33], ["VSV-GFP immunized", "ORGANISM", 103, 120], ["CK", "PROTEIN", 13, 15], ["VSV", "SPECIES", 103, 106], ["CK-MB", "TEST", 13, 18], ["the VSV", "TEST", 22, 29], ["VP1", "TEST", 30, 33], ["the VSV", "TEST", 99, 106], ["VSV", "ANATOMY", 26, 29]]], ["Additionally, the viral titer of heart tissue in the VSV-VP1 immunized group was at least 250-fold lower than that of the VSV-GFP immunized group (Fig. 4D ).", [["heart tissue", "ANATOMY", 33, 45], ["heart tissue", "TISSUE", 33, 45], ["VSV-VP1", "ORGANISM", 53, 60], ["VSV-GFP", "ORGANISM", 122, 129], ["VSV", "SPECIES", 53, 56], ["VSV", "SPECIES", 122, 125], ["the viral titer of heart tissue", "PROBLEM", 14, 45], ["the VSV", "TEST", 49, 56], ["the VSV", "TEST", 118, 125], ["viral titer", "OBSERVATION", 18, 29], ["heart", "ANATOMY", 33, 38], ["tissue", "ANATOMY_MODIFIER", 39, 45], ["VSV", "ANATOMY", 53, 56]]], ["Histology analysis of hematoxylin and eosin (HE)-stained heart sections showed a large amount of myocyte necrosis and immune-infiltration in the control (PBS), VSV-GFP and chito-pcDNA3.1 immunized groups.", [["heart sections", "ANATOMY", 57, 71], ["myocyte", "ANATOMY", 97, 104], ["necrosis", "DISEASE", 105, 113], ["hematoxylin", "CHEMICAL", 22, 33], ["eosin", "CHEMICAL", 38, 43], ["hematoxylin", "SIMPLE_CHEMICAL", 22, 33], ["eosin", "SIMPLE_CHEMICAL", 38, 43], ["HE", "SIMPLE_CHEMICAL", 45, 47], ["heart sections", "MULTI-TISSUE_STRUCTURE", 57, 71], ["myocyte", "CELL", 97, 104], ["VSV", "ORGANISM", 160, 163], ["GFP", "GENE_OR_GENE_PRODUCT", 164, 167], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 178, 186], ["VSV", "SPECIES", 160, 163], ["Histology analysis", "TEST", 0, 18], ["hematoxylin", "TEST", 22, 33], ["eosin", "TEST", 38, 43], ["stained heart sections", "TEST", 49, 71], ["myocyte necrosis", "PROBLEM", 97, 113], ["infiltration", "PROBLEM", 125, 137], ["PBS", "TEST", 154, 157], ["VSV", "TEST", 160, 163], ["GFP", "TEST", 164, 167], ["chito", "TEST", 172, 177], ["heart", "ANATOMY", 57, 62], ["large", "OBSERVATION_MODIFIER", 81, 86], ["amount", "OBSERVATION_MODIFIER", 87, 93], ["myocyte", "ANATOMY", 97, 104], ["necrosis", "OBSERVATION", 105, 113], ["infiltration", "OBSERVATION", 125, 137]]], ["Only a tiny amount of inflammation was seen in the VSV-VP1 immunized group, suggesting that this vaccination prevented the development of myocarditis (Fig. 4E) .", [["inflammation", "DISEASE", 22, 34], ["myocarditis", "DISEASE", 138, 149], ["VSV-VP1", "ORGANISM", 51, 58], ["a tiny amount of inflammation", "PROBLEM", 5, 34], ["this vaccination", "TREATMENT", 92, 108], ["myocarditis", "PROBLEM", 138, 149], ["tiny", "OBSERVATION_MODIFIER", 7, 11], ["amount", "OBSERVATION_MODIFIER", 12, 18], ["inflammation", "OBSERVATION", 22, 34], ["VSV", "ANATOMY", 51, 54], ["myocarditis", "OBSERVATION", 138, 149]]], ["Similar results were also observed in HEstained pancreas sections (Fig. S2) .VSV-VP1 vaccination significantly alleviates CVB3-induced viral myocarditisIn vivo ventricular systolic function was measured by fractional shortening (FS) and ejection fraction (EF) using an Values were presented as mean \u00b1 SD; n = 6 for each group; ** P < 0.01.", [["pancreas sections", "ANATOMY", 48, 65], ["ventricular", "ANATOMY", 160, 171], ["pancreas sections", "MULTI-TISSUE_STRUCTURE", 48, 65], ["VSV-VP1", "ORGANISM", 77, 84], ["CVB3", "ORGANISM", 122, 126], ["ventricular systolic", "MULTI-TISSUE_STRUCTURE", 160, 180], ["S2", "PROTEIN", 72, 74], ["VSV", "SPECIES", 77, 80], ["CVB3", "SPECIES", 122, 126], ["VSV", "TEST", 77, 80], ["VP1 vaccination", "TREATMENT", 81, 96], ["CVB3", "PROBLEM", 122, 126], ["ventricular systolic function", "TEST", 160, 189], ["fractional shortening", "PROBLEM", 206, 227], ["FS", "TEST", 229, 231], ["ejection fraction", "TEST", 237, 254], ["EF", "TEST", 256, 258], ["an Values", "TEST", 266, 275], ["pancreas", "ANATOMY", 48, 56], ["ventricular systolic", "ANATOMY", 160, 180]]], ["(C) The survival rate of mice was observed for 14 days following 5LD50 infection.", [["infection", "DISEASE", 71, 80], ["mice", "ORGANISM", 25, 29], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["The survival rate of mice", "TREATMENT", 4, 29], ["5LD50 infection", "PROBLEM", 65, 80], ["infection", "OBSERVATION", 71, 80]]], ["Individual experiment was conducted three times with 12 mice per group and one representative data was shown. echocardiography assay (Fig. 5A) .", [["mice", "ORGANISM", 56, 60], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 56, 60], ["echocardiography assay", "TEST", 110, 132]]], ["The left ventricular FS (LVFS) in chito-pcDNA3.1-VP1 immunized mice was \u223c12% lower compared with that in the VSV-VP1 immunized group.", [["left ventricular", "ANATOMY", 4, 20], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 4, 20], ["chito-pcDNA3.1-VP1", "GENE_OR_GENE_PRODUCT", 34, 52], ["mice", "ORGANISM", 63, 67], ["VSV-VP1", "ORGANISM", 109, 116], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["VSV", "SPECIES", 109, 112], ["The left ventricular FS", "TEST", 0, 23], ["LVFS", "TEST", 25, 29], ["chito", "TEST", 34, 39], ["VP1 immunized mice", "TREATMENT", 49, 67], ["left ventricular", "ANATOMY", 4, 20]]], ["When left ventricular EF (LVEF) was calculated, it was \u223c10% lower in chito-pcDNA3.1-VP1 immunized mice compared with that in the VSV-VP1 immunized group (Fig. 5B) , indicating that in vivo ventricular function after infection was improved by prior immunization with VSV-VP1.VSV-VP1 vaccination significantly alleviates CVB3-induced viral myocarditisTo further evaluate the protective abilities of the vaccine candidates, mice were challenged with 5 LD 50 of CVB3 2 weeks after the final DNA immunization.", [["left ventricular", "ANATOMY", 5, 21], ["ventricular", "ANATOMY", 189, 200], ["infection", "DISEASE", 216, 225], ["myocarditis", "DISEASE", 338, 349], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 5, 21], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 75, 83], ["VP1", "GENE_OR_GENE_PRODUCT", 84, 87], ["mice", "ORGANISM", 98, 102], ["VSV-VP1", "ORGANISM", 129, 136], ["immunized", "ORGANISM", 137, 146], ["ventricular", "MULTI-TISSUE_STRUCTURE", 189, 200], ["VSV-VP1", "ORGANISM", 266, 273], ["VSV-VP1", "ORGANISM", 274, 281], ["CVB3", "ORGANISM", 319, 323], ["mice", "ORGANISM", 421, 425], ["CVB3", "ORGANISM", 458, 462], ["DNA", "CELLULAR_COMPONENT", 487, 490], ["VP1", "PROTEIN", 84, 87], ["VP1", "PROTEIN", 270, 273], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 421, 425], ["mice", "SPECIES", 98, 102], ["VSV", "SPECIES", 266, 269], ["VSV", "SPECIES", 274, 277], ["CVB3", "SPECIES", 319, 323], ["mice", "SPECIES", 421, 425], ["CVB3", "SPECIES", 458, 462], ["left ventricular EF", "TEST", 5, 24], ["LVEF", "TEST", 26, 30], ["chito", "TEST", 69, 74], ["VP1 immunized mice", "TREATMENT", 84, 102], ["the VSV", "TEST", 125, 132], ["infection", "PROBLEM", 216, 225], ["prior immunization", "TREATMENT", 242, 260], ["VSV", "TEST", 266, 269], ["VP1", "PROBLEM", 270, 273], ["VSV", "TEST", 274, 277], ["VP1 vaccination", "TREATMENT", 278, 293], ["CVB3", "PROBLEM", 319, 323], ["viral myocarditis", "PROBLEM", 332, 349], ["the vaccine candidates", "TREATMENT", 397, 419], ["CVB3", "TREATMENT", 458, 462], ["the final DNA immunization", "TREATMENT", 477, 503], ["left ventricular", "ANATOMY", 5, 21], ["ventricular", "ANATOMY", 189, 200], ["infection", "OBSERVATION", 216, 225], ["viral myocarditis", "OBSERVATION", 332, 349]]], ["All mock-immunized mice succumbed to severe illness and died within 8 days, while 41.67% (5/12) of the chito-pcDNA3.1-VP1 immunized mice and 66.67% (8/12) of the VSV-VP1 immunized mice survived to 14 days with no signs of illness (Fig. 5C) , indicating that nasal immunization with VSV-VP1 provides some protection against CVB3-induced myocarditis.", [["nasal", "ANATOMY", 258, 263], ["illness", "DISEASE", 44, 51], ["VSV-VP1", "CHEMICAL", 282, 289], ["myocarditis", "DISEASE", 336, 347], ["mice", "ORGANISM", 19, 23], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 109, 117], ["VP1", "GENE_OR_GENE_PRODUCT", 118, 121], ["mice", "ORGANISM", 132, 136], ["VSV-VP1", "ORGANISM", 162, 169], ["mice", "ORGANISM", 180, 184], ["nasal", "ORGANISM_SUBDIVISION", 258, 263], ["VSV-VP1", "ORGANISM", 282, 289], ["CVB3", "ORGANISM", 323, 327], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 180, 184], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 132, 136], ["VSV", "SPECIES", 162, 165], ["mice", "SPECIES", 180, 184], ["VSV", "SPECIES", 282, 285], ["CVB3", "SPECIES", 323, 327], ["the chito", "TEST", 99, 108], ["the VSV", "TEST", 158, 165], ["illness", "PROBLEM", 222, 229], ["nasal immunization", "TREATMENT", 258, 276], ["VSV", "TREATMENT", 282, 285], ["VP1", "TREATMENT", 286, 289], ["CVB3", "PROBLEM", 323, 327], ["myocarditis", "PROBLEM", 336, 347], ["no signs of", "UNCERTAINTY", 210, 221], ["nasal", "ANATOMY", 258, 263], ["myocarditis", "OBSERVATION", 336, 347]]], ["MLN.", [["MLN", "ANATOMY", 0, 3], ["MLN", "MULTI-TISSUE_STRUCTURE", 0, 3], ["MLN", "CELL_TYPE", 0, 3]]], ["(B) The frequency of CD4 + and CD8 + T cells producing IFN-\u2425 and IL-2 or TNF-\u2423 alone was analyzed after stimulation for 6 h.", [["CD4 + and CD8 + T cells", "ANATOMY", 21, 44], ["CD4", "GENE_OR_GENE_PRODUCT", 21, 24], ["CD8", "GENE_OR_GENE_PRODUCT", 31, 34], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 55, 60], ["IL-2", "GENE_OR_GENE_PRODUCT", 65, 69], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 73, 78], ["CD4", "PROTEIN", 21, 24], ["CD8", "PROTEIN", 31, 34], ["T cells", "CELL_TYPE", 37, 44], ["IFN", "PROTEIN", 55, 58], ["TNF", "PROTEIN", 73, 76], ["CD4", "TEST", 21, 24], ["CD8", "TEST", 31, 34], ["T cells", "PROBLEM", 37, 44], ["IFN", "TEST", 55, 58], ["IL", "TEST", 65, 67], ["TNF", "TEST", 73, 76]]], ["(C) Frequency of CD4 + and CD8 + T cells expressing two or three of IFN-\u2425, IL-2 and TNF-\u2423 was analyzed.", [["CD4 +", "ANATOMY", 17, 22], ["CD8 + T cells", "ANATOMY", 27, 40], ["CD4", "GENE_OR_GENE_PRODUCT", 17, 20], ["CD8", "GENE_OR_GENE_PRODUCT", 27, 30], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 68, 73], ["IL-2", "GENE_OR_GENE_PRODUCT", 75, 79], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 84, 89], ["CD4", "PROTEIN", 17, 20], ["CD8", "PROTEIN", 27, 30], ["T cells", "CELL_TYPE", 33, 40], ["IFN", "PROTEIN", 68, 71], ["IL", "PROTEIN", 75, 77], ["TNF", "PROTEIN", 84, 87], ["CD4", "TEST", 17, 20], ["CD8 + T cells", "PROBLEM", 27, 40], ["IFN", "TEST", 68, 71], ["IL", "TEST", 75, 77], ["TNF", "TEST", 84, 87]]], ["(D) Proportion of total triple, double and single positive IFN-\u2425, IL-2 and TNF-\u2423 producing CD4 + and CD8 + T cells was shown in pie charts.", [["CD4 + and CD8 + T cells", "ANATOMY", 91, 114], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 59, 64], ["IL-2", "GENE_OR_GENE_PRODUCT", 66, 70], ["TNF", "GENE_OR_GENE_PRODUCT", 75, 78], ["CD4", "GENE_OR_GENE_PRODUCT", 91, 94], ["CD8", "GENE_OR_GENE_PRODUCT", 101, 104], ["IFN", "PROTEIN", 59, 62], ["TNF", "PROTEIN", 75, 78], ["CD4 + and CD8 + T cells", "CELL_TYPE", 91, 114], ["total triple", "TEST", 18, 30], ["IFN", "TEST", 59, 62], ["IL", "TEST", 66, 68], ["TNF", "TEST", 75, 78], ["CD4", "TEST", 91, 94], ["CD8", "TEST", 101, 104]]], ["The results were expressed as the mean \u00b1 SD (n = 6) from three independent experiments. * P < 0.05, ** P < 0.01.VSV-VP1 immunization promotes dendritic cell (DC) maturation and increases frequency of polyfunctional T cellsAs DC play an important role in the induction of the adaptive immune response, we further examined the maturation of MLN DC in the immunized mice using flow cytometry.", [["dendritic cell", "ANATOMY", 142, 156], ["DC", "ANATOMY", 158, 160], ["T cells", "ANATOMY", 215, 222], ["DC", "ANATOMY", 225, 227], ["MLN DC", "ANATOMY", 339, 345], ["VSV-VP1", "ORGANISM", 112, 119], ["dendritic cell", "CELL", 142, 156], ["DC", "CELL", 158, 160], ["T cells", "CELL", 215, 222], ["DC", "CELL", 225, 227], ["MLN DC", "CELL", 339, 345], ["mice", "ORGANISM", 363, 367], ["VP1", "PROTEIN", 116, 119], ["DC", "CELL_TYPE", 158, 160], ["polyfunctional T cells", "CELL_TYPE", 200, 222], ["DC", "CELL_TYPE", 225, 227], ["MLN DC", "CELL_TYPE", 339, 345], ["mice", "SPECIES", 363, 367], ["VSV", "SPECIES", 112, 115], ["mice", "SPECIES", 363, 367], ["VSV", "TREATMENT", 112, 115], ["VP1 immunization", "TREATMENT", 116, 132], ["dendritic cell (DC) maturation", "TREATMENT", 142, 172], ["polyfunctional T cells", "PROBLEM", 200, 222], ["flow cytometry", "TEST", 374, 388], ["dendritic cell", "OBSERVATION", 142, 156], ["MLN", "ANATOMY", 339, 342]]], ["Two weeks after final immunization, MLN cells were isolated and stained by maturation makers MHCII, CD40, CD80 or CD86 together with CD11c, which is a characteristic marker of myeloid-derived DC.", [["MLN cells", "ANATOMY", 36, 45], ["myeloid", "ANATOMY", 176, 183], ["DC", "ANATOMY", 192, 194], ["MLN cells", "CELL", 36, 45], ["MHCII", "GENE_OR_GENE_PRODUCT", 93, 98], ["CD40", "GENE_OR_GENE_PRODUCT", 100, 104], ["CD80", "GENE_OR_GENE_PRODUCT", 106, 110], ["CD86", "GENE_OR_GENE_PRODUCT", 114, 118], ["CD11c", "GENE_OR_GENE_PRODUCT", 133, 138], ["myeloid-derived DC", "CELL", 176, 194], ["MLN cells", "CELL_TYPE", 36, 45], ["MHCII", "PROTEIN", 93, 98], ["CD40", "PROTEIN", 100, 104], ["CD80", "PROTEIN", 106, 110], ["CD86", "PROTEIN", 114, 118], ["CD11c", "PROTEIN", 133, 138], ["myeloid-derived DC", "CELL_TYPE", 176, 194], ["final immunization", "TREATMENT", 16, 34], ["MLN cells", "TREATMENT", 36, 45], ["CD40", "TEST", 100, 104], ["CD11c", "TEST", 133, 138], ["myeloid", "PROBLEM", 176, 183], ["MLN cells", "OBSERVATION", 36, 45], ["myeloid", "OBSERVATION", 176, 183]]], ["Few DC fully maturated in the VSV-GFP, chito-pCDNA3.1 and PBS immunized groups.", [["DC", "ANATOMY", 4, 6], ["VSV", "ORGANISM", 30, 33], ["GFP", "GENE_OR_GENE_PRODUCT", 34, 37], ["chito-pCDNA3.1", "GENE_OR_GENE_PRODUCT", 39, 53], ["DC", "CELL_TYPE", 4, 6], ["VSV", "SPECIES", 30, 33], ["the VSV", "TEST", 26, 33], ["chito", "TEST", 39, 44], ["PBS immunized groups", "TREATMENT", 58, 78]]], ["Intranasal immunization with chito-pcDNA3.1-VP1 mildly promoted DC maturation compared with the levels of maturation seen for the VSV-VP1 immunized group, in which the cell surface expressions of MHCII, CD40, CD80 or CD86 molecules were efficiently up-regulated ( Fig. 6A ; P < 0.05).VSV-VP1 immunization promotes dendritic cell (DC) maturation and increases frequency of polyfunctional T cellsTo further explore the consequences of DC maturation, we next measured the development of polyfunctional T cells.", [["DC", "ANATOMY", 64, 66], ["cell surface", "ANATOMY", 168, 180], ["dendritic cell", "ANATOMY", 314, 328], ["DC", "ANATOMY", 330, 332], ["T cells", "ANATOMY", 387, 394], ["DC", "ANATOMY", 433, 435], ["T cells", "ANATOMY", 499, 506], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 35, 43], ["VP1", "GENE_OR_GENE_PRODUCT", 44, 47], ["DC", "CELL", 64, 66], ["VSV-VP1 immunized", "ORGANISM", 130, 147], ["cell", "CELL", 168, 172], ["MHCII", "GENE_OR_GENE_PRODUCT", 196, 201], ["CD40", "GENE_OR_GENE_PRODUCT", 203, 207], ["CD80", "GENE_OR_GENE_PRODUCT", 209, 213], ["CD86", "GENE_OR_GENE_PRODUCT", 217, 221], ["VSV-VP1", "ORGANISM", 284, 291], ["dendritic cell", "CELL", 314, 328], ["DC", "CELL", 330, 332], ["T cells", "CELL", 387, 394], ["DC", "CELL", 433, 435], ["polyfunctional T cells", "CELL", 484, 506], ["pcDNA3.1", "DNA", 35, 43], ["VP1", "DNA", 44, 47], ["DC", "CELL_TYPE", 64, 66], ["MHCII", "PROTEIN", 196, 201], ["CD40", "PROTEIN", 203, 207], ["CD80", "PROTEIN", 209, 213], ["CD86 molecules", "PROTEIN", 217, 231], ["VP1", "PROTEIN", 288, 291], ["DC", "CELL_TYPE", 330, 332], ["polyfunctional T cells", "CELL_TYPE", 372, 394], ["DC", "CELL_TYPE", 433, 435], ["polyfunctional T cells", "CELL_TYPE", 484, 506], ["VSV", "SPECIES", 284, 287], ["Intranasal immunization", "TREATMENT", 0, 23], ["chito", "TEST", 29, 34], ["VP1", "PROBLEM", 44, 47], ["DC maturation", "TREATMENT", 64, 77], ["the VSV", "TEST", 126, 133], ["CD40", "TEST", 203, 207], ["CD86 molecules", "TEST", 217, 231], ["VSV", "TEST", 284, 287], ["VP1 immunization", "TREATMENT", 288, 304], ["dendritic cell (DC) maturation", "TREATMENT", 314, 344], ["polyfunctional T cells", "PROBLEM", 372, 394], ["DC maturation", "TREATMENT", 433, 446], ["polyfunctional T cells", "PROBLEM", 484, 506], ["dendritic cell", "OBSERVATION", 314, 328], ["polyfunctional T cells", "OBSERVATION", 372, 394], ["polyfunctional T cells", "OBSERVATION", 484, 506]]], ["Previous reports have shown that T cells with multiple effector functions, such as the concomitant production of IFN-\u2425, TNF-\u2423, and IL-2, are functionally superior to their single cytokine-producing counterparts for the clearance of viral pathogens [45, 46] .", [["T cells", "ANATOMY", 33, 40], ["T cells", "CELL", 33, 40], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 113, 118], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 120, 125], ["IL-2", "GENE_OR_GENE_PRODUCT", 131, 135], ["T cells", "CELL_TYPE", 33, 40], ["IFN", "PROTEIN", 113, 116], ["TNF", "PROTEIN", 120, 123], ["IL", "PROTEIN", 131, 133], ["cytokine", "PROTEIN", 179, 187], ["T cells", "PROBLEM", 33, 40], ["multiple effector functions", "PROBLEM", 46, 73], ["IFN", "TEST", 113, 116], ["TNF", "TEST", 120, 123], ["viral pathogens", "PROBLEM", 232, 247]]], ["Therefore, we evaluated the phenotype and proportion of polyfunctional T cells in immunized mice using intracellular cytokine staining.VSV-VP1 immunization promotes dendritic cell (DC) maturation and increases frequency of polyfunctional T cellsMultiple T cell populations could be delineated based on the expression of IFN-\u2425, IL-2 and TNF-\u2423.", [["T cells", "ANATOMY", 71, 78], ["intracellular", "ANATOMY", 103, 116], ["dendritic cell", "ANATOMY", 165, 179], ["DC", "ANATOMY", 181, 183], ["T cells", "ANATOMY", 238, 245], ["T cell", "ANATOMY", 254, 260], ["polyfunctional T cells", "CELL", 56, 78], ["mice", "ORGANISM", 92, 96], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 103, 116], ["VSV-VP1", "ORGANISM", 135, 142], ["dendritic cell", "CELL", 165, 179], ["DC", "CELL", 181, 183], ["T cells", "CELL", 238, 245], ["T cell populations", "CELL", 254, 272], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 320, 325], ["IL-2", "GENE_OR_GENE_PRODUCT", 327, 331], ["TNF", "GENE_OR_GENE_PRODUCT", 336, 339], ["polyfunctional T cells", "CELL_TYPE", 56, 78], ["cytokine", "PROTEIN", 117, 125], ["VP1", "PROTEIN", 139, 142], ["DC", "CELL_TYPE", 181, 183], ["polyfunctional T cells", "CELL_TYPE", 223, 245], ["T cell populations", "CELL_TYPE", 254, 272], ["IFN", "PROTEIN", 320, 323], ["TNF", "PROTEIN", 336, 339], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["VSV", "SPECIES", 135, 138], ["the phenotype", "PROBLEM", 24, 37], ["polyfunctional T cells", "TREATMENT", 56, 78], ["immunized mice", "TREATMENT", 82, 96], ["intracellular cytokine staining", "TREATMENT", 103, 134], ["VSV", "TEST", 135, 138], ["VP1 immunization", "TREATMENT", 139, 155], ["dendritic cell (DC) maturation", "TREATMENT", 165, 195], ["polyfunctional T cells", "PROBLEM", 223, 245], ["Multiple T cell populations", "PROBLEM", 245, 272], ["IFN", "TEST", 320, 323], ["IL", "TEST", 327, 329], ["TNF", "TEST", 336, 339], ["polyfunctional T cells", "OBSERVATION", 56, 78], ["cytokine staining", "OBSERVATION", 117, 134], ["dendritic cell", "OBSERVATION", 165, 179]]], ["CD4 + or CD8 + T population was first gated, and the expression levels of IFN-\u2425, TNF-\u2423, and IL-2 were further analyzed.", [["CD4 +", "ANATOMY", 0, 5], ["CD8 + T population", "ANATOMY", 9, 27], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 9, 12], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 74, 79], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 81, 86], ["IL-2", "GENE_OR_GENE_PRODUCT", 92, 96], ["CD4", "PROTEIN", 0, 3], ["CD8", "PROTEIN", 9, 12], ["IFN", "PROTEIN", 74, 77], ["TNF", "PROTEIN", 81, 84], ["IL", "PROTEIN", 92, 94], ["CD4", "TEST", 0, 3], ["CD8 + T population", "PROBLEM", 9, 27], ["the expression levels", "TEST", 49, 70], ["IFN", "TEST", 74, 77], ["\u2425", "TEST", 78, 79], ["TNF", "TEST", 81, 84], ["IL", "TEST", 92, 94]]], ["Single-positive CD4 + or CD8 + T cells expressing IFN-\u2425, TNF-\u2423, or IL-2 was significantly increased in the VSV-VP1 immunization group (4.64% for CD4 + IFN-\u2425 + , 16.48% for CD4 + IL-2 + and 23.04% for CD4 + TNF-\u2423 + ) upon VP1 peptide stimulation and was significantly higher than those in the chito-pcDNA3.1-VP1 immunization group.", [["CD4 + or CD8 + T cells", "ANATOMY", 16, 38], ["CD4", "GENE_OR_GENE_PRODUCT", 16, 19], ["CD8", "GENE_OR_GENE_PRODUCT", 25, 28], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 50, 55], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 57, 62], ["IL-2", "GENE_OR_GENE_PRODUCT", 67, 71], ["VSV-VP1", "ORGANISM", 107, 114], ["CD4", "GENE_OR_GENE_PRODUCT", 145, 148], ["IFN", "GENE_OR_GENE_PRODUCT", 151, 154], ["CD4", "GENE_OR_GENE_PRODUCT", 172, 175], ["IL-2", "GENE_OR_GENE_PRODUCT", 178, 182], ["CD4", "GENE_OR_GENE_PRODUCT", 200, 203], ["TNF", "GENE_OR_GENE_PRODUCT", 206, 209], ["VP1", "ORGANISM", 221, 224], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 298, 306], ["VP1", "ORGANISM", 307, 310], ["CD4", "PROTEIN", 16, 19], ["CD8 + T cells", "CELL_TYPE", 25, 38], ["IFN", "PROTEIN", 50, 53], ["TNF", "PROTEIN", 57, 60], ["IL", "PROTEIN", 67, 69], ["CD4", "PROTEIN", 145, 148], ["IFN", "PROTEIN", 151, 154], ["CD4", "PROTEIN", 172, 175], ["IL", "PROTEIN", 178, 180], ["CD4", "PROTEIN", 200, 203], ["TNF", "PROTEIN", 206, 209], ["VSV", "SPECIES", 107, 110], ["CD8", "TEST", 25, 28], ["T cells", "TEST", 31, 38], ["IFN", "TEST", 50, 53], ["\u2425", "TEST", 54, 55], ["TNF", "TEST", 57, 60], ["IL", "TEST", 67, 69], ["the VSV", "TEST", 103, 110], ["VP1 immunization group", "TEST", 111, 133], ["CD4", "TEST", 145, 148], ["IFN", "TEST", 151, 154], ["CD4", "TEST", 172, 175], ["IL", "TEST", 178, 180], ["CD4", "TEST", 200, 203], ["TNF", "TEST", 206, 209], ["VP1 peptide stimulation", "TEST", 221, 244], ["the chito", "TEST", 288, 297], ["VP1 immunization group", "TREATMENT", 307, 329], ["increased", "OBSERVATION_MODIFIER", 90, 99]]], ["T cells expressing these cytokines were barely detectable in the control immunization groups: VSV-GFP, chito-pcDNA3.1 and PBS ( Fig. 6B ; P < 0.05).", [["T cells", "ANATOMY", 0, 7], ["T cells", "CELL", 0, 7], ["VSV", "ORGANISM", 94, 97], ["GFP", "GENE_OR_GENE_PRODUCT", 98, 101], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 109, 117], ["T cells", "CELL_TYPE", 0, 7], ["cytokines", "PROTEIN", 25, 34], ["VSV", "SPECIES", 94, 97], ["these cytokines", "TEST", 19, 34], ["VSV", "TEST", 94, 97], ["GFP", "TEST", 98, 101], ["chito-", "TEST", 103, 109], ["PBS", "TEST", 122, 125], ["P", "TEST", 138, 139]]], ["To assess whether VSV-VP1-induced T cells were producing more than one of these cytokines, we next examined the co-expression patterns of IFN-\u2425, TNF-\u2423, and IL-2.", [["T cells", "ANATOMY", 34, 41], ["VSV", "ORGANISM", 18, 21], ["-VP1", "ORGANISM", 21, 25], ["T cells", "CELL", 34, 41], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 138, 143], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 145, 150], ["IL-2", "GENE_OR_GENE_PRODUCT", 156, 160], ["VP1", "PROTEIN", 22, 25], ["T cells", "CELL_TYPE", 34, 41], ["cytokines", "PROTEIN", 80, 89], ["IFN", "PROTEIN", 138, 141], ["TNF", "PROTEIN", 145, 148], ["IL", "PROTEIN", 156, 158], ["VSV", "SPECIES", 18, 21], ["VSV", "TEST", 18, 21], ["VP1", "TEST", 22, 25], ["T cells", "PROBLEM", 34, 41], ["these cytokines", "TEST", 74, 89], ["IFN", "TEST", 138, 141], ["TNF", "TEST", 145, 148], ["IL", "TEST", 156, 158]]], ["Analysis of IFN-\u2425 + TNF-\u2423 + , IFN-\u2425 + IL-2 + , and TNF-\u2423 + IL-2 + double-positive CD4 + T cells revealed that the proportion of IFN-\u2425 + IL-2 + cells was the lowest (1.69% for the VSV-VP1 immunized group and 0.88% for the chito-pcDNA3.1-VP1immunized group).", [["CD4 + T cells", "ANATOMY", 82, 95], ["IL-2 + cells", "ANATOMY", 136, 148], ["IFN", "GENE_OR_GENE_PRODUCT", 12, 15], ["TNF", "GENE_OR_GENE_PRODUCT", 20, 23], ["IFN", "GENE_OR_GENE_PRODUCT", 30, 33], ["IL-2", "GENE_OR_GENE_PRODUCT", 38, 42], ["TNF", "GENE_OR_GENE_PRODUCT", 51, 54], ["IL-2", "GENE_OR_GENE_PRODUCT", 59, 63], ["CD4", "GENE_OR_GENE_PRODUCT", 82, 85], ["IL-2", "GENE_OR_GENE_PRODUCT", 136, 140], ["VSV", "ORGANISM", 179, 182], ["VP1", "ORGANISM", 183, 186], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 227, 235], ["IFN", "PROTEIN", 12, 15], ["TNF", "PROTEIN", 20, 23], ["IFN", "PROTEIN", 30, 33], ["TNF", "PROTEIN", 51, 54], ["CD4", "PROTEIN", 82, 85], ["T cells", "CELL_TYPE", 88, 95], ["IFN", "PROTEIN", 128, 131], ["pcDNA3.1", "PROTEIN", 227, 235], ["VSV", "SPECIES", 179, 182], ["Analysis", "TEST", 0, 8], ["IFN", "TEST", 12, 15], ["TNF", "TEST", 20, 23], ["IFN", "TEST", 30, 33], ["IL", "TEST", 38, 40], ["TNF", "TEST", 51, 54], ["IL", "TEST", 59, 61], ["double", "TEST", 66, 72], ["T cells", "TEST", 88, 95], ["IFN", "TEST", 128, 131], ["IL", "TEST", 136, 138], ["the VSV", "TEST", 175, 182], ["VP1", "TEST", 183, 186], ["the chito", "TEST", 217, 226]]], ["TNF-\u2423 + IL-2 + double-positive T cells were the most abundant, reaching 18.10% for the VSV-VP1 immunized group and 7.92% for the chito-pcDNA3.1-VP1 immunized group.", [["T cells", "ANATOMY", 31, 38], ["TNF", "GENE_OR_GENE_PRODUCT", 0, 3], ["IL-2", "GENE_OR_GENE_PRODUCT", 8, 12], ["VSV-VP1", "ORGANISM", 87, 94], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 135, 143], ["VP1", "ORGANISM", 144, 147], ["TNF", "PROTEIN", 0, 3], ["IL-2 + double-positive T cells", "CELL_LINE", 8, 38], ["pcDNA3.1", "PROTEIN", 135, 143], ["VSV", "SPECIES", 87, 90], ["TNF", "TEST", 0, 3], ["IL", "TEST", 8, 10], ["double-positive T cells", "PROBLEM", 15, 38], ["the VSV", "TEST", 83, 90], ["VP1", "TEST", 91, 94], ["the chito", "TEST", 125, 134]]], ["The percentage of the IFN-\u2425 + TNF-\u2423 + IL-2 + triple-positive polyfunctional cells was higher than that of the IFN-\u2425 + TNF-\u2423 + double-positive cells (4.28% for the VSV-VP1 immunized group and 1.52% for the chito-pcDNA3.1-VP1 immunized group).", [["cells", "ANATOMY", 76, 81], ["cells", "ANATOMY", 142, 147], ["IFN", "GENE_OR_GENE_PRODUCT", 22, 25], ["TNF", "GENE_OR_GENE_PRODUCT", 30, 33], ["IL-2", "GENE_OR_GENE_PRODUCT", 38, 42], ["cells", "CELL", 76, 81], ["IFN", "GENE_OR_GENE_PRODUCT", 110, 113], ["TNF", "GENE_OR_GENE_PRODUCT", 118, 121], ["VSV-VP1", "ORGANISM", 163, 170], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 211, 219], ["IFN", "PROTEIN", 22, 25], ["TNF", "PROTEIN", 30, 33], ["IL-2 + triple-positive polyfunctional cells", "CELL_LINE", 38, 81], ["IFN", "PROTEIN", 110, 113], ["TNF", "PROTEIN", 118, 121], ["pcDNA3.1", "PROTEIN", 211, 219], ["VP1", "PROTEIN", 220, 223], ["VSV", "SPECIES", 163, 166], ["the IFN", "TEST", 18, 25], ["TNF", "TEST", 30, 33], ["IL", "TEST", 38, 40], ["triple", "TEST", 45, 51], ["positive polyfunctional cells", "PROBLEM", 52, 81], ["the IFN", "TEST", 106, 113], ["TNF", "TEST", 118, 121], ["double-positive cells", "PROBLEM", 126, 147], ["the VSV", "TEST", 159, 166], ["VP1", "TEST", 167, 170], ["the chito", "TEST", 201, 210], ["polyfunctional cells", "OBSERVATION", 61, 81]]], ["Similar levels of IFN-\u2425, TNF-\u2423, and IL-2 expression were seen in CD8 + T cells (Fig. 6C) .", [["CD8 + T cells", "ANATOMY", 65, 78], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 18, 23], ["TNF-\u2423", "GENE_OR_GENE_PRODUCT", 25, 30], ["IL-2", "GENE_OR_GENE_PRODUCT", 36, 40], ["CD8", "GENE_OR_GENE_PRODUCT", 65, 68], ["IFN", "PROTEIN", 18, 21], ["TNF", "PROTEIN", 25, 28], ["CD8", "PROTEIN", 65, 68], ["T cells", "CELL_TYPE", 71, 78], ["IFN", "TEST", 18, 21], ["TNF", "TEST", 25, 28], ["IL", "TEST", 36, 38]]], ["Analysis of the proportions of the single-, double-, or triple-positive T cells in the VSV-VP1 and chito-pcDNA3.1-VP1 immunization groups indicated that VSV-VP1 immunization can enhance the magnitude of polyfunctional CD4 + and CD8 + T cells as detected by increased double-, or triple-positive populations (Fig. 6D ).DiscussionIn the present study, we generated a VSV-based vaccine encoding CVB3 major antigenic protein VP1.", [["T cells", "ANATOMY", 72, 79], ["CD4 + and CD8 + T cells", "ANATOMY", 218, 241], ["T cells", "CELL", 72, 79], ["VSV-VP1", "ORGANISM", 87, 94], ["chito-pcDNA3.1-VP1", "ORGANISM", 99, 117], ["VSV-VP1", "ORGANISM", 153, 160], ["CD4", "GENE_OR_GENE_PRODUCT", 218, 221], ["CD8", "GENE_OR_GENE_PRODUCT", 228, 231], ["VSV", "ORGANISM", 365, 368], ["CVB3", "ORGANISM", 392, 396], ["VP1", "GENE_OR_GENE_PRODUCT", 421, 424], ["single-, double-, or triple-positive T cells", "CELL_LINE", 35, 79], ["polyfunctional CD4 + and CD8 + T cells", "CELL_TYPE", 203, 241], ["CVB3 major antigenic protein VP1", "PROTEIN", 392, 424], ["VSV", "SPECIES", 87, 90], ["VSV", "SPECIES", 153, 156], ["VSV", "SPECIES", 365, 368], ["CVB3", "SPECIES", 392, 396], ["triple-positive T cells", "PROBLEM", 56, 79], ["the VSV", "TEST", 83, 90], ["VP1", "TEST", 91, 94], ["chito", "TEST", 99, 104], ["VP1 immunization groups", "TREATMENT", 114, 137], ["VSV", "TEST", 153, 156], ["VP1 immunization", "TREATMENT", 157, 173], ["polyfunctional CD4", "TEST", 203, 221], ["CD8 + T cells", "PROBLEM", 228, 241], ["increased double-, or triple-positive populations", "PROBLEM", 257, 306], ["the present study", "TEST", 331, 348], ["a VSV-based vaccine", "TREATMENT", 363, 382], ["VSV", "ANATOMY", 87, 90], ["polyfunctional CD4", "OBSERVATION", 203, 221], ["increased", "OBSERVATION_MODIFIER", 257, 266], ["double", "OBSERVATION_MODIFIER", 267, 273]]], ["Although VSV-based vectors have been widely used as vaccine platforms, few studies have characterized the capacity of VSV-based vaccines to induce potent mucosal immunity.", [["mucosal", "ANATOMY", 154, 161], ["VSV", "ORGANISM", 9, 12], ["VSV", "ORGANISM", 118, 121], ["mucosal", "MULTI-TISSUE_STRUCTURE", 154, 161], ["VSV", "SPECIES", 9, 12], ["VSV", "SPECIES", 118, 121], ["VSV-based vectors", "TREATMENT", 9, 26], ["vaccine platforms", "TEST", 52, 69], ["few studies", "TEST", 71, 82], ["VSV-based vaccines", "TREATMENT", 118, 136]]], ["We compared the antigen-specific mucosal immunity elicited by intranasal administration of a VSV-VP1 vaccine with that of a chitosan-based mucosal vaccine, chitosan-pcDNA3.1-VP1 [14] .", [["mucosal", "ANATOMY", 33, 40], ["mucosal", "ANATOMY", 139, 146], ["chitosan", "CHEMICAL", 124, 132], ["chitosan-pcDNA3.1-VP1", "CHEMICAL", 156, 177], ["mucosal", "MULTI-TISSUE_STRUCTURE", 33, 40], ["VSV", "ORGANISM", 93, 96], ["VP1", "ORGANISM", 97, 100], ["chitosan", "SIMPLE_CHEMICAL", 124, 132], ["mucosal", "ORGAN", 139, 146], ["chitosan", "SIMPLE_CHEMICAL", 156, 164], ["pcDNA3.1", "ORGANISM", 165, 173], ["VP1", "ORGANISM", 174, 177], ["VSV", "SPECIES", 93, 96], ["the antigen", "TEST", 12, 23], ["a VSV", "TREATMENT", 91, 96], ["VP1 vaccine", "TREATMENT", 97, 108], ["a chitosan", "TREATMENT", 122, 132], ["mucosal vaccine", "TREATMENT", 139, 154], ["chitosan", "TEST", 156, 164], ["mucosal", "ANATOMY", 139, 146]]], ["With a single-dose intranasal delivery of VSV-VP1, mice exhibited significantly higher levels of both mucosal and systemic immune responses than mice vaccinated with chito-pcDNA3.1-VP1.", [["mucosal", "ANATOMY", 102, 109], ["VSV-VP1", "ORGANISM", 42, 49], ["mice", "ORGANISM", 51, 55], ["mucosal", "PATHOLOGICAL_FORMATION", 102, 109], ["mice", "ORGANISM", 145, 149], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 172, 180], ["VP1", "GENE_OR_GENE_PRODUCT", 181, 184], ["pcDNA3.1", "DNA", 172, 180], ["VP1", "DNA", 181, 184], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 145, 149], ["VSV", "SPECIES", 42, 45], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 145, 149], ["a single-dose intranasal delivery of VSV", "TREATMENT", 5, 45], ["VP1", "TEST", 46, 49], ["chito", "TEST", 166, 171], ["VP1", "PROBLEM", 181, 184], ["mucosal", "ANATOMY", 102, 109]]], ["This improvement in multiple aspects of immunity is one of the most important virtues of mucosal vaccination [43] .", [["mucosal", "ANATOMY", 89, 96], ["mucosal", "ORGANISM_SUBDIVISION", 89, 96], ["improvement", "OBSERVATION_MODIFIER", 5, 16], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["mucosal", "ANATOMY", 89, 96]]], ["While the peak levels of antigen-specific fecal sIgA in the VSV-VP1 and chito-pcDNA3.1-VP1 groups were similar, the induction of antigen-specific sIgA in the VSV-VP1 immunized group was much faster than that in the chito-pcDNA3.1-VP1 immunized group.", [["antigen", "GENE_OR_GENE_PRODUCT", 25, 32], ["sIgA", "GENE_OR_GENE_PRODUCT", 48, 52], ["VSV-VP1", "ORGANISM", 60, 67], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 78, 86], ["antigen", "GENE_OR_GENE_PRODUCT", 129, 136], ["sIgA", "GENE_OR_GENE_PRODUCT", 146, 150], ["VSV-VP1", "ORGANISM", 158, 165], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 221, 229], ["VP1", "ORGANISM", 230, 233], ["fecal sIgA", "PROTEIN", 42, 52], ["VSV-VP1 and chito-pcDNA3.1-VP1 groups", "DNA", 60, 97], ["sIgA", "PROTEIN", 146, 150], ["pcDNA3.1", "PROTEIN", 221, 229], ["VSV", "SPECIES", 60, 63], ["VSV", "SPECIES", 60, 63], ["VSV", "SPECIES", 158, 161], ["the peak levels", "TEST", 6, 21], ["antigen", "TEST", 25, 32], ["fecal sIgA", "TEST", 42, 52], ["the VSV", "TEST", 56, 63], ["VP1", "TEST", 64, 67], ["chito", "TEST", 72, 77], ["antigen", "TEST", 129, 136], ["the VSV", "TEST", 154, 161], ["the chito", "TEST", 211, 220], ["fecal sIgA", "ANATOMY", 42, 52]]], ["Since the same antigen, VP1, was used for both delivery systems in this study, these results demonstrate that the VSV-based vector is more potent at inducing mucosal immunity than the chitosan-based delivery system.", [["mucosal", "ANATOMY", 158, 165], ["chitosan", "CHEMICAL", 184, 192], ["VP1", "GENE_OR_GENE_PRODUCT", 24, 27], ["VSV", "ORGANISM", 114, 117], ["mucosal", "ORGAN", 158, 165], ["chitosan", "SIMPLE_CHEMICAL", 184, 192], ["VP1", "PROTEIN", 24, 27], ["VSV", "SPECIES", 114, 117], ["VP1", "TEST", 24, 27], ["both delivery systems", "TREATMENT", 42, 63], ["this study", "TEST", 67, 77], ["the chitosan-based delivery system", "TREATMENT", 180, 214]]], ["The increased protection against viral myocarditis in VSV-VP1 immunized mice may result from the elevated humoral response as well as the cellular immunity comparing to that of chito-pcDNA3.1-VP1.DiscussionOral delivery is a simple alternate way to induce mucosal immunity.", [["cellular", "ANATOMY", 138, 146], ["mucosal", "ANATOMY", 256, 263], ["myocarditis", "DISEASE", 39, 50], ["VSV-VP1", "ORGANISM", 54, 61], ["mice", "ORGANISM", 72, 76], ["cellular", "CELL", 138, 146], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 183, 191], ["VP1", "GENE_OR_GENE_PRODUCT", 192, 195], ["mucosal", "MULTI-TISSUE_STRUCTURE", 256, 263], ["pcDNA3.1", "DNA", 183, 191], ["VP1", "DNA", 192, 195], ["mice", "SPECIES", 72, 76], ["VSV", "SPECIES", 54, 57], ["mice", "SPECIES", 72, 76], ["The increased protection", "TREATMENT", 0, 24], ["viral myocarditis in VSV", "PROBLEM", 33, 57], ["VP1 immunized mice", "TREATMENT", 58, 76], ["the elevated humoral response", "PROBLEM", 93, 122], ["chito", "TEST", 177, 182], ["VP1", "PROBLEM", 192, 195], ["DiscussionOral delivery", "TREATMENT", 196, 219], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["viral", "OBSERVATION_MODIFIER", 33, 38], ["myocarditis", "OBSERVATION", 39, 50], ["humoral response", "OBSERVATION", 106, 122]]], ["Ma et al. found that a VSV-based vaccine against human norovirus administrated with the combination of intranasal and oral delivery could induce antigen-specific IgA in both the gastrointestinal tract and vagina [47] .", [["oral", "ANATOMY", 118, 122], ["gastrointestinal tract", "ANATOMY", 178, 200], ["vagina", "ANATOMY", 205, 211], ["norovirus", "DISEASE", 55, 64], ["VSV", "ORGANISM", 23, 26], ["human", "ORGANISM", 49, 54], ["norovirus", "ORGANISM", 55, 64], ["oral", "ORGANISM_SUBDIVISION", 118, 122], ["IgA", "GENE_OR_GENE_PRODUCT", 162, 165], ["gastrointestinal tract", "ORGAN", 178, 200], ["vagina", "ORGAN", 205, 211], ["IgA", "PROTEIN", 162, 165], ["human", "SPECIES", 49, 54], ["VSV", "SPECIES", 23, 26], ["human", "SPECIES", 49, 54], ["a VSV-based vaccine", "TREATMENT", 21, 40], ["human norovirus", "PROBLEM", 49, 64], ["intranasal", "TREATMENT", 103, 113], ["oral delivery", "TREATMENT", 118, 131], ["IgA", "OBSERVATION", 162, 165], ["gastrointestinal tract", "ANATOMY", 178, 200], ["vagina", "ANATOMY", 205, 211]]], ["Based on their success with oral delivery, it would likely be worthwhile to investigate the capacity of VSV-VP1 vaccination to induce mucosal and systemic immunity by oral delivery, alone or in combination with intranasal delivery.DiscussionSeveral features make VSV an ideal CVB3 vaccine delivery mechanism.", [["oral", "ANATOMY", 28, 32], ["mucosal", "ANATOMY", 134, 141], ["oral", "ANATOMY", 167, 171], ["oral", "ORGANISM_SUBDIVISION", 28, 32], ["VSV", "ORGANISM", 104, 107], ["VP1", "ORGANISM", 108, 111], ["mucosal", "MULTI-TISSUE_STRUCTURE", 134, 141], ["oral", "ORGANISM_SUBDIVISION", 167, 171], ["VSV", "ORGANISM", 263, 266], ["CVB3", "ORGANISM", 276, 280], ["VSV", "SPECIES", 104, 107], ["VSV", "SPECIES", 263, 266], ["CVB3", "SPECIES", 276, 280], ["oral delivery", "TREATMENT", 28, 41], ["VSV", "TREATMENT", 104, 107], ["VP1 vaccination", "TREATMENT", 108, 123], ["mucosal and systemic immunity", "TREATMENT", 134, 163], ["oral delivery", "TREATMENT", 167, 180], ["intranasal delivery", "TREATMENT", 211, 230], ["VSV an ideal CVB3 vaccine delivery mechanism", "TREATMENT", 263, 307], ["mucosal", "ANATOMY", 134, 141]]], ["First, VSV can induce strong mucosal immunity by intranasal or oral immunization.", [["mucosal", "ANATOMY", 29, 36], ["oral", "ANATOMY", 63, 67], ["VSV", "ORGANISM", 7, 10], ["mucosal", "MULTI-TISSUE_STRUCTURE", 29, 36], ["oral", "ORGANISM_SUBDIVISION", 63, 67], ["VSV", "SPECIES", 7, 10], ["oral immunization", "TREATMENT", 63, 80]]], ["Because the gastrointestinal tract is the main route through which CVB3 invades the host, it is critical to induce mucosal immune responses that can block virus infection at the initial stage and the primary site.", [["gastrointestinal tract", "ANATOMY", 12, 34], ["mucosal", "ANATOMY", 115, 122], ["primary site", "ANATOMY", 200, 212], ["gastrointestinal tract", "DISEASE", 12, 34], ["infection", "DISEASE", 161, 170], ["gastrointestinal tract", "ORGAN", 12, 34], ["CVB3", "ORGANISM", 67, 71], ["mucosal", "ANATOMICAL_SYSTEM", 115, 122], ["CVB3", "SPECIES", 67, 71], ["the gastrointestinal tract", "PROBLEM", 8, 34], ["mucosal immune responses", "PROBLEM", 115, 139], ["block virus infection", "PROBLEM", 149, 170], ["gastrointestinal tract", "ANATOMY", 12, 34], ["CVB3", "OBSERVATION", 67, 71]]], ["Second, being a virus, VSV can induce strong cellular immunity to compensate the impaired cellular immunity after CVB3 infection.", [["cellular", "ANATOMY", 45, 53], ["cellular", "ANATOMY", 90, 98], ["CVB3 infection", "DISEASE", 114, 128], ["VSV", "ORGANISM", 23, 26], ["cellular", "CELL", 45, 53], ["cellular", "CELL", 90, 98], ["CVB3", "ORGANISM", 114, 118], ["VSV", "SPECIES", 23, 26], ["CVB3", "SPECIES", 114, 118], ["a virus", "PROBLEM", 14, 21], ["CVB3 infection", "PROBLEM", 114, 128], ["virus", "OBSERVATION", 16, 21], ["infection", "OBSERVATION", 119, 128]]], ["Kemball et al. found that CVB3 infection rapidly induces phenotypic changes in conventional DC, and markedly impairs specific CD8 + T cell antigen presentation through MHCI pathway in vivo [48, 49] .", [["DC", "ANATOMY", 92, 94], ["CD8 + T cell", "ANATOMY", 126, 138], ["CVB3 infection", "DISEASE", 26, 40], ["CVB3", "ORGANISM", 26, 30], ["DC", "CELL", 92, 94], ["CD8 + T cell antigen", "GENE_OR_GENE_PRODUCT", 126, 146], ["MHCI", "GENE_OR_GENE_PRODUCT", 168, 172], ["DC", "CELL_TYPE", 92, 94], ["CD8", "PROTEIN", 126, 129], ["MHCI", "PROTEIN", 168, 172], ["CVB3", "SPECIES", 26, 30], ["CVB3 infection", "PROBLEM", 26, 40], ["phenotypic changes", "PROBLEM", 57, 75], ["CVB3", "OBSERVATION_MODIFIER", 26, 30], ["infection", "OBSERVATION", 31, 40]]], ["Third, the VSV reverse genetics system is well characterized and easy to manipulate [24, 25] .", [["VSV", "ORGANISM", 11, 14], ["VSV", "SPECIES", 11, 14]]], ["High titers of recombinant VSV can be achieved by propagating virus in mammalian cell lines approved for vaccine production.", [["cell lines", "ANATOMY", 81, 91], ["VSV", "ORGANISM", 27, 30], ["mammalian cell lines", "CELL", 71, 91], ["mammalian cell lines", "CELL_LINE", 71, 91], ["VSV", "SPECIES", 27, 30], ["High titers of recombinant VSV", "PROBLEM", 0, 30], ["propagating virus", "PROBLEM", 50, 67], ["mammalian cell lines", "TREATMENT", 71, 91], ["vaccine production", "TREATMENT", 105, 123], ["recombinant VSV", "OBSERVATION", 15, 30], ["virus", "OBSERVATION", 62, 67], ["mammalian cell lines", "OBSERVATION", 71, 91]]], ["Compared with other potential vaccine platforms such as baculovirus, the VSV system is faster and less expensive.", [["baculovirus", "ORGANISM", 56, 67], ["VSV", "ORGANISM", 73, 76], ["baculovirus", "SPECIES", 56, 67], ["VSV", "SPECIES", 73, 76], ["baculovirus", "TREATMENT", 56, 67]]], ["Finally, VSV vaccines can be administered needle-free.", [["VSV", "ORGANISM", 9, 12], ["VSV", "SPECIES", 9, 12], ["VSV vaccines", "TREATMENT", 9, 21]]], ["This is especially valuable for people who live in rural regions that are short of health care.DiscussionThe polyfunctional T cells induced by immunization with VSV-VP1 are an important component of the robust immune response induced by this vaccine.", [["T cells", "ANATOMY", 124, 131], ["people", "ORGANISM", 32, 38], ["T cells", "CELL", 124, 131], ["VSV-VP1", "ORGANISM", 161, 168], ["polyfunctional T cells", "CELL_TYPE", 109, 131], ["VP1", "PROTEIN", 165, 168], ["people", "SPECIES", 32, 38], ["VSV", "SPECIES", 161, 164], ["The polyfunctional T cells", "TREATMENT", 105, 131], ["VSV", "TREATMENT", 161, 164], ["VP1", "PROBLEM", 165, 168], ["this vaccine", "TREATMENT", 237, 249]]], ["Numerous studies have shown that the quality, rather than the level, of T cell responses is crucial for determining the outcome of various infections [45, 46, 50] .", [["T cell", "ANATOMY", 72, 78], ["infections", "DISEASE", 139, 149], ["T cell", "CELL", 72, 78], ["Numerous studies", "TEST", 0, 16], ["various infections", "PROBLEM", 131, 149]]], ["For HCV, it was reported that the resolution obtained under early interferon therapy correlated with the development of polyfunctional IFN-\u2425/IL-2/CD107\u2423 + specific CD8 + T cells [51] .", [["IL-2/CD107\u2423 + specific CD8 + T cells", "ANATOMY", 141, 177], ["HCV", "ORGANISM", 4, 7], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 135, 140], ["IL-2", "GENE_OR_GENE_PRODUCT", 141, 145], ["CD107", "GENE_OR_GENE_PRODUCT", 146, 151], ["CD8", "GENE_OR_GENE_PRODUCT", 164, 167], ["interferon", "PROTEIN", 66, 76], ["IFN", "PROTEIN", 135, 138], ["CD107", "PROTEIN", 146, 151], ["CD8", "PROTEIN", 164, 167], ["T cells", "CELL_TYPE", 170, 177], ["HCV", "SPECIES", 4, 7], ["HCV", "PROBLEM", 4, 7], ["early interferon therapy", "TREATMENT", 60, 84], ["polyfunctional IFN", "TEST", 120, 138], ["IL", "TEST", 141, 143], ["CD107", "TEST", 146, 151]]], ["While the chito-pcDNA3.1-VP1 vaccine could induce some polyfunctional T cells (1.52% triple-positive IFN-\u2425 + TNF-\u2423 + IL-2 + CD4 + T cells), immunization with VSV-VP1 resulted in the striking increase of this population up to 4.28%.", [["T cells", "ANATOMY", 70, 77], ["IL-2 + CD4 + T cells", "ANATOMY", 117, 137], ["VSV-VP1", "CHEMICAL", 158, 165], ["pcDNA3.1", "GENE_OR_GENE_PRODUCT", 16, 24], ["VP1", "GENE_OR_GENE_PRODUCT", 25, 28], ["T cells", "CELL", 70, 77], ["IFN", "GENE_OR_GENE_PRODUCT", 101, 104], ["TNF", "GENE_OR_GENE_PRODUCT", 109, 112], ["IL-2", "GENE_OR_GENE_PRODUCT", 117, 121], ["VSV", "ORGANISM", 158, 161], ["-VP1", "ORGANISM", 161, 165], ["pcDNA3.1", "DNA", 16, 24], ["polyfunctional T cells", "CELL_TYPE", 55, 77], ["IFN", "PROTEIN", 101, 104], ["TNF", "PROTEIN", 109, 112], ["IL", "PROTEIN", 117, 119], ["CD4", "PROTEIN", 124, 127], ["T cells", "CELL_TYPE", 130, 137], ["VSV", "SPECIES", 158, 161], ["the chito", "TEST", 6, 15], ["VP1 vaccine", "TREATMENT", 25, 36], ["some polyfunctional T cells", "PROBLEM", 50, 77], ["triple", "TEST", 85, 91], ["IFN", "TEST", 101, 104], ["TNF", "TEST", 109, 112], ["IL", "TEST", 117, 119], ["CD4", "TEST", 124, 127], ["immunization", "TREATMENT", 140, 152], ["VSV", "TEST", 158, 161], ["VP1", "PROBLEM", 162, 165], ["increase", "OBSERVATION_MODIFIER", 191, 199]]], ["In addition, the VSV-VP1 vaccine induced up to 18.10% double-positive TNF-\u2423 + IL-2 + CD4 + T cells.", [["IL-2 + CD4 + T cells", "ANATOMY", 78, 98], ["VSV-VP1", "ORGANISM", 17, 24], ["TNF", "GENE_OR_GENE_PRODUCT", 70, 73], ["IL-2", "GENE_OR_GENE_PRODUCT", 78, 82], ["TNF", "PROTEIN", 70, 73], ["CD4", "PROTEIN", 85, 88], ["T cells", "CELL_TYPE", 91, 98], ["VSV", "SPECIES", 17, 20], ["the VSV", "TEST", 13, 20], ["VP1 vaccine", "TEST", 21, 32], ["double", "TEST", 54, 60], ["TNF", "TEST", 70, 73], ["IL", "TEST", 78, 80]]], ["Based on previous studies, we speculate that these polyfunctional T cells could establish long-lasting immunological memory and will likely give rise to a strong and robust secondary response upon challenge with CVB3.DiscussionDC play a central role in priming immune responses and are therefore of interest for vaccine capacity.", [["T cells", "ANATOMY", 66, 73], ["T cells", "CELL", 66, 73], ["CVB3", "ORGANISM", 212, 216], ["polyfunctional T cells", "CELL_TYPE", 51, 73], ["DiscussionDC", "PROTEIN", 217, 229], ["CVB3", "SPECIES", 212, 216], ["previous studies", "TEST", 9, 25], ["these polyfunctional T cells", "PROBLEM", 45, 73], ["CVB3", "TREATMENT", 212, 216], ["vaccine capacity", "TREATMENT", 312, 328]]], ["The immunological paradigm holds that DC capture antigens, while inflammatory signals trigger their maturation and migration to the draining lymph nodes to initiate an antigen-specific immune response.", [["DC", "ANATOMY", 38, 40], ["lymph nodes", "ANATOMY", 141, 152], ["DC", "CELL", 38, 40], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 141, 152], ["DC", "CELL_TYPE", 38, 40], ["The immunological paradigm", "TREATMENT", 0, 26], ["inflammatory signals", "PROBLEM", 65, 85], ["the draining lymph nodes", "PROBLEM", 128, 152], ["an antigen", "TEST", 165, 175], ["lymph nodes", "OBSERVATION", 141, 152]]], ["Viral vectors, such as recombinant adenovirus 35, that can efficiently infect and cause maturation of DC in vivo induce optimal vaccine responses [52] .", [["DC", "ANATOMY", 102, 104], ["Viral", "ORGANISM", 0, 5], ["recombinant adenovirus 35", "ORGANISM", 23, 48], ["DC", "CELL", 102, 104], ["DC", "CELL_TYPE", 102, 104], ["Viral vectors", "TREATMENT", 0, 13], ["recombinant adenovirus", "TREATMENT", 23, 45]]], ["As previously described in vitro for BMDC [53, 54] , we observed that VSV infection significantly improved the maturation of MLN DC through the up-regulation of different molecules 2 weeks post-final immunization.", [["MLN DC", "ANATOMY", 125, 131], ["VSV infection", "DISEASE", 70, 83], ["BMDC", "CELL", 37, 41], ["VSV", "ORGANISM", 70, 73], ["MLN DC", "CELL", 125, 131], ["BMDC", "CELL_TYPE", 37, 41], ["MLN DC", "CELL_TYPE", 125, 131], ["VSV", "SPECIES", 70, 73], ["VSV infection", "PROBLEM", 70, 83], ["MLN DC", "TREATMENT", 125, 131], ["final immunization", "TREATMENT", 194, 212], ["VSV", "OBSERVATION_MODIFIER", 70, 73], ["infection", "OBSERVATION", 74, 83], ["MLN", "ANATOMY", 125, 128]]], ["One reason for this might be that the stimulation caused by VSV infection is stronger and lasts longer than that caused by chitosan-incorporated DNA at the sites of immunization.", [["sites", "ANATOMY", 156, 161], ["infection", "DISEASE", 64, 73], ["chitosan", "CHEMICAL", 123, 131], ["VSV", "ORGANISM", 60, 63], ["chitosan", "SIMPLE_CHEMICAL", 123, 131], ["DNA", "CELLULAR_COMPONENT", 145, 148], ["VSV", "SPECIES", 60, 63], ["the stimulation", "PROBLEM", 34, 49], ["VSV infection", "PROBLEM", 60, 73], ["incorporated DNA", "PROBLEM", 132, 148], ["immunization", "TREATMENT", 165, 177], ["infection", "OBSERVATION", 64, 73]]], ["The increased maturation of MLN DC in VSV-VP1immunized mice likely results from the sustained migration and activation of peripheral DC from the inoculation site.", [["MLN DC", "ANATOMY", 28, 34], ["peripheral DC", "ANATOMY", 122, 135], ["MLN DC", "CELL", 28, 34], ["VSV-VP1immunized mice", "ORGANISM", 38, 59], ["peripheral DC", "CELL", 122, 135], ["MLN DC", "CELL_TYPE", 28, 34], ["peripheral DC", "CELL_TYPE", 122, 135], ["mice", "SPECIES", 55, 59], ["mice", "SPECIES", 55, 59], ["MLN DC in VSV", "TREATMENT", 28, 41], ["the sustained migration", "PROBLEM", 80, 103], ["peripheral DC from the inoculation site", "TREATMENT", 122, 161], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["maturation", "OBSERVATION_MODIFIER", 14, 24], ["MLN", "ANATOMY", 28, 31], ["sustained", "OBSERVATION_MODIFIER", 84, 93], ["migration", "OBSERVATION", 94, 103], ["peripheral DC", "OBSERVATION", 122, 135]]], ["Additional experiments are ongoing to address this hypothesis.DiscussionThis study characterized the potency of a VSV-based vaccine vector for the induction of mucosal immunity.", [["mucosal", "ANATOMY", 160, 167], ["VSV", "ORGANISM", 114, 117], ["mucosal", "MULTI-TISSUE_STRUCTURE", 160, 167], ["VSV", "SPECIES", 114, 117], ["this hypothesis", "PROBLEM", 46, 61], ["This study", "TEST", 72, 82], ["a VSV-based vaccine vector", "TREATMENT", 112, 138], ["mucosal immunity", "TREATMENT", 160, 176]]], ["Vaccination with VSV-VP1 promoted mucosal DC maturation, enhanced antigenspecific mucosal immunity as well as systemic immunity, and could alleviate CVB3-induced viral myocarditis.", [["mucosal DC", "ANATOMY", 34, 44], ["mucosal", "ANATOMY", 82, 89], ["myocarditis", "DISEASE", 168, 179], ["VSV-VP1", "ORGANISM", 17, 24], ["mucosal DC", "CELL", 34, 44], ["mucosal", "MULTI-TISSUE_STRUCTURE", 82, 89], ["CVB3", "ORGANISM", 149, 153], ["VP1", "PROTEIN", 21, 24], ["mucosal DC", "CELL_TYPE", 34, 44], ["VSV", "SPECIES", 17, 20], ["CVB3", "SPECIES", 149, 153], ["Vaccination", "TREATMENT", 0, 11], ["VSV", "TREATMENT", 17, 20], ["VP1", "TREATMENT", 21, 24], ["mucosal DC maturation", "TREATMENT", 34, 55], ["CVB3", "PROBLEM", 149, 153], ["viral myocarditis", "PROBLEM", 162, 179], ["mucosal", "ANATOMY", 34, 41], ["viral myocarditis", "OBSERVATION", 162, 179]]], ["Our study might also provide insight into the importance of mucosal immunity for the further development of VSV-based vaccines.", [["mucosal", "ANATOMY", 60, 67], ["mucosal", "ANATOMICAL_SYSTEM", 60, 67], ["VSV", "ORGANISM", 108, 111], ["VSV", "SPECIES", 108, 111], ["Our study", "TEST", 0, 9], ["mucosal immunity", "TREATMENT", 60, 76], ["VSV-based vaccines", "TREATMENT", 108, 126]]]], "28ba08ad41b38304edac6a64c3e9143c1eccd58c": [["the spread of this virus at this moment is suggested to be \"social distancing\", which is being 139 practiced by many countries at this crisis time and has led to reduction GHG emissions in air roads.", [["this virus", "PROBLEM", 14, 24], ["spread", "OBSERVATION_MODIFIER", 4, 10], ["GHG emissions", "OBSERVATION", 172, 185], ["air roads", "OBSERVATION", 189, 198]]], ["But we have paid a heavy cost for this development in terms of poisoning the air we breathe.", [["poisoning", "DISEASE", 63, 72]]], ["As 144 per press release of World Health Organization (2 nd May, 2018), around 7 million people die every 145 year from exposure to fine particles in polluted air [World Health Organization, 2018] Benzene.277The correlations between the above pollutant concentrations at Ghaziabad during the four 278 weeks i.e. two before and two during lockdown are shown in Table 3365Effect of COVID-19 on air quality was also studied through Air Quality index (AQI) which 366 is one of the important tools to measure the level of pollution due to major air pollutants.", [["Benzene", "CHEMICAL", 197, 204], ["COVID-19", "CHEMICAL", 380, 388], ["Benzene", "CHEMICAL", 197, 204], ["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95], ["COVID", "TEST", 380, 385], ["major air pollutants", "PROBLEM", 534, 554], ["air pollutants", "OBSERVATION", 540, 554]]], ["Remain Shut Due to Lockdown, Retrieved from https://www.news18.com/news/buzz/ganga-523 river-water-has-now-become-fit-for-drinking-as-industries-remain-shut-due-to-lockdown- The Hindu (2020).Cauvery, tributaries look cleaner as pandemic keeps pollution away,552Retrieved from www.thehindu.com/news/national/ karnataka/ cauvery-tributaries-in-old-553 mysuru-region-look-cleaner-as-pandemic-keeps-pollution-away/article31210429.eceThe 554 Tribune (2020).", [["thehindu.com", "CHEMICAL", 280, 292], ["tributaries", "ANATOMY", 200, 211], ["tributaries", "ANATOMY", 327, 338]]], ["Lockdown helps improve Health of Ganga, Retrieved from 555 www.tribuneindia.com/news/nation/lockdown-helps-improve-health-of-ganga-64936World 556 Economic Forum (2020), The deadly link between COVID-19 and air pollution, Retrieved 557 from https://www.weforum.org/agenda/2020/04/the-deadly-link-between-covid-19-and-air-558 pollution", [["COVID", "TEST", 193, 198], ["air pollution", "OBSERVATION", 206, 219]]]], "PMC7429074": [["In the midst of the coronavirus disease (Covid)-19 pandemic, face shields have become an essential component of personal protective equipment (PPE) while carrying out aerosol-generating medical procedures (AGMP) (1).", [["coronavirus disease", "DISEASE", 20, 39], ["coronavirus", "ORGANISM", 20, 31], ["the coronavirus disease", "PROBLEM", 16, 39], ["pandemic", "PROBLEM", 51, 59], ["face shields", "TREATMENT", 61, 73], ["personal protective equipment", "TREATMENT", 112, 141], ["medical procedures", "TREATMENT", 186, 204], ["coronavirus disease", "OBSERVATION", 20, 39], ["essential", "OBSERVATION_MODIFIER", 89, 98], ["component", "OBSERVATION_MODIFIER", 99, 108]]], ["Yet there is a global shortage of PPE that is affecting the care of patients and the safety of health care workers (HCWs), which is forcing the latter to be innovative and identify new sources of PPE across the globe (2).", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["global", "OBSERVATION_MODIFIER", 15, 21], ["shortage", "OBSERVATION_MODIFIER", 22, 30], ["globe", "ANATOMY", 211, 216]]], ["Lee et al. have suggested the use of prefilled plastic bags with oxygen, and Shailesh Kumar advocated wearing a C-Arm plastic cover along with a nasal cannula attached to an oxygen delivery source that delivers oxygen inside the cover to the intubator (3,4).", [["nasal", "ANATOMY", 145, 150], ["oxygen", "CHEMICAL", 65, 71], ["oxygen", "CHEMICAL", 174, 180], ["oxygen", "CHEMICAL", 211, 217], ["oxygen", "CHEMICAL", 65, 71], ["oxygen", "CHEMICAL", 174, 180], ["oxygen", "CHEMICAL", 211, 217], ["oxygen", "SIMPLE_CHEMICAL", 65, 71], ["oxygen", "SIMPLE_CHEMICAL", 174, 180], ["oxygen", "SIMPLE_CHEMICAL", 211, 217], ["prefilled plastic bags", "TREATMENT", 37, 59], ["oxygen", "TREATMENT", 65, 71], ["a C-Arm plastic cover", "TREATMENT", 110, 131], ["a nasal cannula", "TREATMENT", 143, 158], ["an oxygen delivery source", "TREATMENT", 171, 196], ["oxygen", "TREATMENT", 211, 217], ["nasal cannula", "ANATOMY", 145, 158]]]], "PMC7278271": [["Risikoursachen und -wirkungen in der ProduktionIn einem Industrie- und Handelsunternehmen k\u00f6nnen Risiken an jedem Punkt entlang der Wertsch\u00f6pfungskette entstehen.", [["Risikoursachen", "TEST", 0, 14]]], ["Insbesondere durch den zunehmenden Trend zur Konzentration auf Kernkompetenzen (Verringerung von intraorganisationaler Arbeitsteilung bzw.", [["Insbesondere durch den zunehmenden Trend zur Konzentration auf Kernkompetenzen (Verringerung von intraorganisationaler Arbeitsteilung bzw", "SPECIES", 0, 137]]], ["Fertigungstiefe im Unternehmen) entwickeln sich zunehmend differenziertere Supply Chains.Risikoursachen und -wirkungen in der ProduktionAus einer Makroperspektive kann die Wertsch\u00f6pfungskette eines produzierenden Unternehmens als Prozess von vorgelagerten und nachgelagerten Prozessen \u2013 von der Rohstoffbeschaffung bis zum Service beim Endkunden \u2013 betrachtet werden (siehe Abb.", [["Risikoursachen und -wirkungen in der ProduktionAus einer Makroperspektive kann die Wertsch\u00f6pfungskette eines produzierenden Unternehmens als Prozess von vorgelagerten und nachgelagerten Prozessen \u2013 von der Rohstoffbeschaffung bis zum Service beim Endkunden \u2013 betrachtet werden", "SPECIES", 89, 365], ["Risikoursachen", "TREATMENT", 89, 103]]], ["10.1007/978-3-658-29446-5_7 eingegangen.", [["10.1007/978-3-658-29446-5_7 eingegangen", "CHEMICAL", 0, 39]]], ["Alle Aktivit\u00e4ten, die Teil der Wertsch\u00f6pfungskette sind, k\u00f6nnen mit dem Begriff Supply Chain Management (SCM) zusammengefasst werden.1Risikoursachen und -wirkungen in der ProduktionDer Wert eines Produktes oder auch einer Dienstleistung besteht nicht nur aus dem eigentlichen Produkt oder der Dienstleistung, sondern \u2013 betrachtet aus einer Mikroperspektive \u2013 aus sehr vielen unterschiedlichen Komponenten, die in den \u201eWertsch\u00f6pfungsstufen\u201c entstehen.", [["1Risikoursachen und -wirkungen in der ProduktionDer Wert eines Produktes oder auch einer Dienstleistung besteht nicht nur aus dem eigentlichen Produkt oder der Dienstleistung, sondern \u2013 betrachtet aus einer Mikroperspektive \u2013 aus sehr vielen unterschiedlichen Komponenten, die in den \u201eWertsch\u00f6pfungsstufen\u201c entstehen", "SPECIES", 133, 449], ["k\u00f6nnen mit dem Begriff Supply Chain Management (SCM) zusammengefasst werden", "TREATMENT", 57, 132]]], ["In diesem Kontext spricht man auch von einem Wertsch\u00f6pfungsnetzwerk.Risikoursachen und -wirkungen in der ProduktionNachfolgend ist am Beispiel des Rohstoffs Kohle ein typisches Wertsch\u00f6pfungsnetzwerk skizziert:Die Kohle wird in einem Bergwerk oder im Tagebau gef\u00f6rdert und an ein Stahlwerk verkauft.Das Stahlwerk verfeuert die Kohle \u2013 mit Stahlschrott \u2013 in Hoch\u00f6fen.", [["man", "SPECIES", 26, 29], ["Risikoursachen und -wirkungen in der ProduktionNachfolgend ist am Beispiel des Rohstoffs Kohle ein typisches Wertsch\u00f6pfungsnetzwerk skizziert:Die Kohle wird in einem Bergwerk oder im Tagebau gef\u00f6rdert und an ein Stahlwerk verkauft", "SPECIES", 68, 298], ["Risikoursachen", "TEST", 68, 82]]], ["Der Rohstahl wird in eine Stahlgie\u00dfpfanne abgegossen.", [["Der Rohstahl wird", "TREATMENT", 0, 17]]], ["Der Stahl wird dann \u2013 f\u00fcr das Strangguss-Verfahren in die so genannte Kokille abgegossen, bevor der Rohstahl durch Umformen oder Walzen weiterverarbeitet wird.Das Stahlwerk verkauft den Stahl an Automobilzulieferer, der sie in ein Karosserieteil verarbeitet, welches wiederum an einenAutomobilhersteller verkauft und dort zu einem Auto verbaut wird.Das Auto wird an einen H\u00e4ndler verkauft und landet schlie\u00dflich beimVerbraucher, der das Auto kauft.Risikoursachen und -wirkungen in der ProduktionAn dem kleinen Beispiel erkennt man, dass die \u201esupply chain\u201c ein Netzwerk von Organisationseinheiten ist, die durch Interaktion eine Leistung in Form eines Produkts oder einer Dienstleistung erbringen (vgl.", [["Risikoursachen und -wirkungen in der ProduktionAn dem kleinen Beispiel erkennt man, dass die \u201esupply chain\u201c ein Netzwerk von Organisationseinheiten ist, die durch Interaktion eine Leistung in Form eines Produkts oder einer Dienstleistung erbringen", "SPECIES", 448, 695]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["Eine Wertsch\u00f6pfungskette besteht in der Regel aus Zulieferern, Produktionsstandorten, Logistikdienstleitern, Logistik- und Distributionszentren und einer H\u00e4ndlerorganisation sowie aus Rohstoffen, Halbfertigerzeugnissen und Fertigwaren, die zwischen den einzelnen Organisationselementen flie\u00dfen.", [["Logistik- und Distributionszentren und einer H\u00e4ndlerorganisation sowie aus Rohstoffen, Halbfertigerzeugnissen und Fertigwaren, die zwischen den einzelnen Organisationselementen flie\u00dfen", "SPECIES", 109, 293], ["Produktionsstandorten", "TREATMENT", 63, 84], ["Logistikdienstleitern", "TREATMENT", 86, 107], ["Logistik", "TREATMENT", 109, 117]]], ["Erg\u00e4nzt werden kann auch noch der Informations-, der Kapital-, Service und Wissenstransfer.3Risikoursachen und -wirkungen in der ProduktionDaher kann man eine derartige Wertsch\u00f6pfungskette auch als ein unternehmens\u00fcbergreifendes virtuelles Organisationsgebilde (= Netzwerk) betrachten, das als gesamtheitlich zu betrachtendes Leistungssystem spezifische Wirtschaftsg\u00fcter produziert.Risikoursachen und -wirkungen in der ProduktionDas oben skizzierte Beispiel k\u00f6nnte man daher auch noch um das Recycling des Autos erg\u00e4nzen, so dass die \u201esupply chain\u201c sich von der Rohstoffgewinnung bis zum Recycling von Alt-Produkten erstreckt.Risikoursachen und -wirkungen in der ProduktionDas Supply Chain Management zielt in diesem Zusammenhang auf eine langfristige (strategische), mittelfristige (taktische) und kurzfristige (operative) Verbesserung von Effektivit\u00e4t und Effizienz industrieller Wertsch\u00f6pfungsketten ab.", [["man", "SPECIES", 465, 468], ["Risikoursachen und -wirkungen in der ProduktionDas oben skizzierte Beispiel k\u00f6nnte man daher auch noch um das Recycling des Autos erg\u00e4nzen, so dass die \u201esupply chain\u201c sich von der Rohstoffgewinnung bis zum Recycling von Alt-Produkten erstreckt", "SPECIES", 382, 625], ["Risikoursachen", "TEST", 382, 396], ["Risikoursachen", "TREATMENT", 626, 640], ["Chain Management", "TREATMENT", 684, 700], ["zielt in diesem Zusammenhang auf eine langfristige (strategische)", "TREATMENT", 701, 766], ["mittelfristige (taktische)", "TREATMENT", 768, 794]]], ["Auch das Risiko-Management muss daher die komplette Wertsch\u00f6pfungskette analysieren und potenzielle Risiken entsprechend bewerten.Risikoursachen und -wirkungen in der ProduktionErgebnis der Verschlankung der Wertsch\u00f6pfungsketten in den vergangenen Jahrzehnten \u2013 als Folge des zunehmenden globalen Wettbewerbs und der gestiegenen Anforderungen auf der Kundenseite \u2013 sind reduzierte Lagerbest\u00e4nde (Just-in-time-Produktion oder Just-in-time-Logistik), hoch ausgelastete Kapazit\u00e4ten und optimierte Durchlaufzeiten.Risikoursachen und -wirkungen in der ProduktionSo bezeichnet man als Just-in-time-Produktion (JIT) eine fertigungs- bzw. bedarfssynchrone Produktionsstrategie.4 Hierbei wird das Ziel verfolgt, \u00fcber durchg\u00e4ngige Material- und Informationsfl\u00fcsse entlang der Wertsch\u00f6pfungskette eine schnellere Auftragsbearbeitung zu erm\u00f6glichen.", [["man", "SPECIES", 571, 574], ["Risikoursachen und -wirkungen in der ProduktionErgebnis der Verschlankung der Wertsch\u00f6pfungsketten in den vergangenen Jahrzehnten \u2013 als Folge des zunehmenden globalen Wettbewerbs und der gestiegenen Anforderungen auf der Kundenseite \u2013 sind reduzierte Lagerbest\u00e4nde (Just-in-time-Produktion oder Just-in-time-Logistik", "SPECIES", 130, 446], ["bedarfssynchrone Produktionsstrategie.4 Hierbei wird das Ziel verfolgt, \u00fcber durchg\u00e4ngige Material- und Informationsfl\u00fcsse entlang der Wertsch\u00f6pfungskette eine schnellere Auftragsbearbeitung zu erm\u00f6glichen", "SPECIES", 631, 836], ["Risikoursachen", "TREATMENT", 130, 144], ["als Folge des zunehmenden globalen", "TREATMENT", 262, 296], ["Kapazit\u00e4ten", "TREATMENT", 467, 478], ["Durchlaufzeiten", "TREATMENT", 494, 509], ["Risikoursachen", "TEST", 510, 524], ["bedarfssynchrone", "TREATMENT", 631, 647]]], ["Ein Produkt \u2013 beispielsweise ein Auto \u2013 wird exakt zu dem Zeitpunkt produziert bzw. geliefert, zu dem es auch ben\u00f6tigt wird.", [["Ein Produkt \u2013 beispielsweise ein Auto \u2013 wird exakt zu dem Zeitpunkt produziert bzw", "SPECIES", 0, 82], ["zu dem es auch ben\u00f6tigt wird", "SPECIES", 95, 123]]], ["Gleichzeitig muss der Lieferant die Vormaterialien und Endprodukte der jeweiligen Baugruppen vorhalten, so dass in der Folge der Hersteller seine Lagerkapazit\u00e4t und seine Lagerkosten verringern kann.Risikoursachen und -wirkungen in der ProduktionAuf der anderen Seite steigt in der Folge der schlanken Wertsch\u00f6pfungsnetzwerke, globaler Lieferanten- und Distributionsnetzwerke auch deren Verwundbarkeit.", [["Gleichzeitig muss der Lieferant die Vormaterialien und Endprodukte der jeweiligen Baugruppen vorhalten, so dass in der Folge der Hersteller seine Lagerkapazit\u00e4t und seine Lagerkosten verringern kann", "SPECIES", 0, 198], ["Risikoursachen", "TEST", 199, 213]]], ["So werden bei einer JIT-Fertigung in aller Regel hohe Konventionalstrafen vereinbart, sofern der Lieferant in Lieferschwierigkeiten ger\u00e4t und in der Konsequenz auch die Wertsch\u00f6pfungskette des Herstellers massiv beeinflusst wird.Risikoursachen und -wirkungen in der ProduktionDie bisherigen Ausf\u00fchrungen verdeutlichen, dass Produktionsrisiken als Teil eines Wertsch\u00f6pfungssystems oder einer Wertsch\u00f6pfungskette betrachtet werden m\u00fcssen.", [["Risikoursachen", "TREATMENT", 229, 243]]], ["10.1007/978-3-658-29446-5_7 verdeutlichen die Verwundbarkeit der Wertsch\u00f6pfungskette am Beispiel der Automobilindustrie in der Folge des T\u014dhoku-Erdbeben im Jahr 2011.", [["10.1007/978-3-658-29446-5_7 verdeutlichen die Verwundbarkeit der Wertsch\u00f6pfungskette am Beispiel der Automobilindustrie in der Folge des T\u014dhoku-Erdbeben im Jahr 2011", "SPECIES", 0, 165]]], ["Ein weiteres Beispiel lieferten uns im Jahr 2020 die Auswirkungen von SARS-CoV-2 / Covid-19 auf die globalen Lieferketten.", [["Ein weiteres Beispiel lieferten uns im Jahr 2020 die Auswirkungen von SARS-CoV-2 / Covid-19 auf die globalen", "SPECIES", 0, 108], ["von SARS", "TEST", 66, 74], ["CoV", "TEST", 75, 78], ["Covid", "TEST", 83, 88]]], ["Einzelne Lieferanten oder eine \u201eKette an Lieferanten\u201c gerieten in Schwierigkeit (bspw. hinsichtlich ihrer Liquidit\u00e4t) und die gesamte Kette verlangsamte sich bzw. brach zusammen.", [["Einzelne Lieferanten", "TREATMENT", 0, 20]]], ["Diese Kettenreaktionen werden auch als \u201eLoopback-Effekte\u201c bezeichnet und \u00e4hneln den Nachbeben nach einem Erdbeben.Risikoursachen und -wirkungen in der ProduktionEmpirische Studien zeigen auf, dass zunehmende Risiken vor allem durch die engere Zusammenarbeit in Wertsch\u00f6pfungsnetzwerken, die fortschreitende Internationalisierung der \u201esupply chains\u201c sowie eine starke Effizienzfokussierung induziert werden.", [["Diese Kettenreaktionen werden auch als \u201eLoopback-Effekte\u201c bezeichnet und \u00e4hneln den Nachbeben nach einem Erdbeben", "SPECIES", 0, 113], ["Risikoursachen", "TEST", 114, 128], ["Zusammenarbeit", "TREATMENT", 243, 257]]], ["So wurden als wichtige Treiber die Globalisierung der Wertsch\u00f6pfungsnetzwerke sowie der Abbau von Lagerbest\u00e4nden, der Trend zu Lean Management und der anhaltende Trend zum Outsourcing identifiziert.6Risikoursachen und -wirkungen in der ProduktionDer Industrieversicherer Allianz Global Corporate & Specialty7 f\u00fchrt regelm\u00e4\u00dfig unter mehreren Tausend Experten eine Umfrage zu den wichtigsten Risiken in produzierenden Unternehmen durch.", [["Wertsch\u00f6pfungsnetzwerke sowie der Abbau von Lagerbest\u00e4nden, der Trend zu Lean Management und der anhaltende Trend zum Outsourcing identifiziert", "SPECIES", 54, 197], ["6Risikoursachen und -wirkungen in der ProduktionDer Industrieversicherer Allianz Global Corporate & Specialty7 f\u00fchrt regelm\u00e4\u00dfig unter mehreren Tausend Experten eine Umfrage zu den wichtigsten", "SPECIES", 198, 389], ["Specialty7 f\u00fchrt regelm\u00e4\u00dfig", "TREATMENT", 298, 325]]], ["In Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 3, 6], ["Abb", "PROTEIN", 3, 6], ["Abb", "OBSERVATION", 3, 6]]], ["6.3 sind Ergebnisse aus dem Jahr 2019 zusammengefasst.Risikoursachen und -wirkungen in der ProduktionGlobale und lokale IT-Ausf\u00e4lle und die Einf\u00fchrung strengerer Datenschutzbestimmungen r\u00fccken Cyberrisiken zunehmend in den Blickpunkt des Risiko-Managements.", [["Ergebnisse aus dem Jahr 2019 zusammengefasst", "SPECIES", 9, 53], ["Risikoursachen", "TEST", 54, 68], ["aus dem", "OBSERVATION", 20, 27]]], ["Laut dem Allianz Risk Barometer 2019 geh\u00f6ren Cybervorf\u00e4lle gemeinsam mit Betriebsunterbrechungen zu den gr\u00f6\u00dften Gesch\u00e4ftsrisiken weltweit.", [["Laut dem Allianz Risk Barometer", "TREATMENT", 0, 31]]], ["Die Sorge vor rechtlichen Ver\u00e4nderungen im Wirtschaftsumfeld, zum Beispiel hervorgerufen durch Handelskriege, Z\u00f6lle, Wirtschaftssanktionen, nimmt jedoch erstmals Platz drei im deutschen Ranking ein (35 %) und rangiert damit noch vor der Gefahr von Naturkatastrophen (28 %).", [["nimmt jedoch erstmals", "TREATMENT", 140, 161]]], ["Risiken, die von neuen Technologien wie k\u00fcnstlicher Intelligenz oder Autonomen Fahren ausgehen, sind ein weiterer gro\u00dfer Aufsteiger im deutschen Ranking und erreichen erstmals Platz 5 (20 %) gegen\u00fcber Platz 7 im Vorjahr.Risikoursachen und -wirkungen in der ProduktionIn der Wirkung k\u00f6nnen viele der in Abb.", [["Platz", "TEST", 176, 181], ["Platz", "TREATMENT", 201, 206]]], ["6.3 skizzierten Szenarien zu einer Betriebsunterbrechung in der Produktion f\u00fchren.", [["skizzierten Szenarien zu einer", "TREATMENT", 4, 34]]], ["Auff\u00e4llig ist zudem, dass Cyber- und Betriebsunterbrechungsrisiken miteinander verkn\u00fcpft sind, da beispielsweise Ransomware-Angriffe oder IT-Ausf\u00e4lle oft zu Betriebs- und Serviceunterbrechungen f\u00fchren.", [["Auff\u00e4llig ist zudem, dass Cyber- und Betriebsunterbrechungsrisiken miteinander verkn\u00fcpft sind, da beispielsweise Ransomware-Angriffe oder IT-Ausf\u00e4lle oft zu Betriebs- und Serviceunterbrechungen f\u00fchren", "SPECIES", 0, 200]]], ["So sind Cybervorf\u00e4lle laut Allianz Risk Barometer die am meisten gef\u00fcrchteten Ausl\u00f6ser von Betriebsunterbrechungen (50 % der Antworten), gefolgt von Feuer/Explosion (40 %) und Naturkatastrophen (38 %).Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenSo f\u00fchrte beispielsweise das Erdbeben von K\u014dbe (Hanshin-Awaji-Erdbebenkatastrophe, offizielle Bezeichnung S\u00fcd-Hy\u014dgo-Beben), welches am 17.", [["Naturkatastrophen", "CHEMICAL", 176, 193], ["Methoden zur Analyse von ProduktionsrisikenSo f\u00fchrte beispielsweise das Erdbeben von K\u014dbe (Hanshin-Awaji-Erdbebenkatastrophe, offizielle Bezeichnung S\u00fcd-Hy\u014dgo-Beben)", "SPECIES", 282, 447], ["von Betriebsunterbrechungen", "TREATMENT", 87, 114], ["Hanshin", "TEST", 373, 380], ["Erdbebenkatastrophe", "TREATMENT", 387, 406]]], ["Januar 1995 eine St\u00e4rke von M = 7,39 erreichte, nicht nur zu einer Naturkatastrophe mit einer der h\u00f6chsten Schadenssummen aller Zeiten in Japan, sondern vor allem auch zu massiven Sch\u00e4den im Bereich der Wertsch\u00f6pfungskette von diversen Computerherstellen.", [["erreichte", "TREATMENT", 37, 46]]], ["Die Gesamtsumme aller durch das Erdbeben verursachten Sch\u00e4den wird auf etwa 100 Milliarden US-Dollar \u2013 ohne Ber\u00fccksichtigung von Folgesch\u00e4den durch Produktionsunterbrechungen \u2013 gesch\u00e4tzt.", [["Die Gesamtsumme aller durch das Erdbeben verursachten Sch\u00e4den wird auf etwa 100 Milliarden US-Dollar \u2013 ohne Ber\u00fccksichtigung von Folgesch\u00e4den durch Produktionsunterbrechungen \u2013 gesch\u00e4tzt", "SPECIES", 0, 186]]], ["Die Ursache f\u00fcr das schwere Beben liegt in der tektonischen Struktur, da vor der Ostk\u00fcste Japans drei Kontinentalplatten (Eurasische Platte, philippinische Platte und Pazifische Platte) aufeinandertreffen.", [["Kontinentalplatten (Eurasische Platte", "TREATMENT", 102, 139]]], ["Es wurden etwa 210.000 Geb\u00e4ude zerst\u00f6rt oder schwer besch\u00e4digt, davon 7500 durch Feuer.10Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenDas Epizentrum lag etwa zwanzig Kilometer s\u00fcdwestlich vom Stadtzentrum von K\u014dbe in der Stra\u00dfe von Akashi, das Hypozentrum lag in einer Tiefe von sechzehn Kilometern.", [["Methoden", "TREATMENT", 170, 178], ["Epizentrum lag etwa zwanzig", "TREATMENT", 217, 244]]], ["Das Hauptbeben dauerte etwa zwanzig Sekunden und setzte achtmal soviel Energie frei wie die Hiroshima-Bombe.Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenTrotz der gesetzlich vorgeschriebenen erdbebensicheren Bauweise (Urban Building Law aus dem Jahr 1919) wurden sowohl Neubauten als auch \u00e4ltere Geb\u00e4ude besch\u00e4digt oder zerst\u00f6rt.", [["von ProduktionsrisikenTrotz der gesetzlich vorgeschriebenen erdbebensicheren Bauweise (Urban Building Law aus dem Jahr 1919) wurden sowohl Neubauten als auch \u00e4ltere Geb\u00e4ude besch\u00e4digt oder zerst\u00f6rt", "SPECIES", 210, 407], ["Methoden zur Analyse von ProduktionsrisikenTrotz der gesetzlich vorgeschriebenen", "TREATMENT", 189, 269]]], ["Obwohl diese Gesetze im Laufe der Zeit immer wieder nach Schadenbeben in Japan modifiziert und den neuen Erkenntnissen angepasst wurde, hielten auch viele neuere Geb\u00e4ude den Schwingungen und Disalokationen des Untergrunds nicht stand.11Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenIn Kobe wurde zuvor ein Sicherheits-Steuerungssystem zur Verhinderung von \u00dcberschwemmungssch\u00e4den durch gebrochene Wasserleitungen installiert.", [["zuvor ein Sicherheits", "TREATMENT", 374, 395]]], ["Nach einem besonders regenarmen Sommer waren die Zisternen der Stadt nicht mit L\u00f6schwasser aufgef\u00fcllt worden, so dass die Feuerwehr den meisten Br\u00e4nden tatenlos zusehen musste.12Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenIn der Folge des Erdbebens waren alle Transportwege zwischen zwischen Nishainomiya und K\u014dbe schwer besch\u00e4digt.", [["Methoden zur Analyse von ProduktionsrisikenIn der Folge des Erdbebens waren alle Transportwege zwischen zwischen Nishainomiya und K\u014dbe schwer besch\u00e4digt", "SPECIES", 259, 411], ["Nach einem besonders", "TREATMENT", 0, 20]]], ["Ebenso wurden die wesentlichen Versorgungssysteme wie Elektrizit\u00e4t, Wasserversorgung, Gasleitungen und Telekommunikation zum Teil stark zerst\u00f6rt.", [["Ebenso wurden die wesentlichen Versorgungssysteme wie Elektrizit\u00e4t, Wasserversorgung, Gasleitungen und Telekommunikation zum Teil stark zerst\u00f6rt", "SPECIES", 0, 144], ["Gasleitungen", "TREATMENT", 86, 98]]], ["Dadurch wurde das urbane Leben f\u00fcr mehrere Tage erschwert, und auch die Aufr\u00e4umarbeiten konnten nicht in vollen Umfang durchgef\u00fchrt werden.", [["Dadurch wurde das urbane Leben f\u00fcr mehrere", "SPECIES", 0, 42]]], ["Der bedeutende Hafen von K\u014dbe wickelte im Jahr 1998, gemessen am Wert, acht Prozent des gesamten japanischen Au\u00dfenhandels ab und war damit nach den H\u00e4fen Yokohama und T\u014dky\u014d (je elf Prozent) der drittwichtigste Hafen.", [["Der bedeutende Hafen von K\u014dbe wickelte im Jahr 1998, gemessen am Wert, acht Prozent des gesamten japanischen Au\u00dfenhandels ab und war damit nach den H\u00e4fen Yokohama und T\u014dky\u014d (je elf Prozent) der drittwichtigste Hafen", "SPECIES", 0, 215]]], ["Betriebsunterbrechungen f\u00fchrten fast in der kompletten globalen Computerindustrie zu Lieferengp\u00e4ssen und Produktionsunterbrechungen.Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenZur damaligen Zeit wurden die meisten Aktiv-Matrix-Displays (Fl\u00fcssigkristallbildschirme f\u00fcr die Laptop-Fertigung, Thin Film Transistor = TFT) in Japan und \u00fcberwiegend in K\u014dbe produziert.", [["ProduktionsrisikenZur damaligen Zeit wurden die meisten Aktiv-Matrix-Displays (Fl\u00fcssigkristallbildschirme f\u00fcr die Laptop-Fertigung, Thin Film Transistor = TFT)", "SPECIES", 238, 397], ["Methoden zur Analyse von ProduktionsrisikenZur damaligen Zeit", "TREATMENT", 213, 274], ["Displays (Fl\u00fcssigkristallbildschirme f\u00fcr die Laptop", "TREATMENT", 307, 358], ["Fertigung", "TREATMENT", 359, 368], ["Thin Film Transistor = TFT", "TREATMENT", 370, 396]]], ["In der Folge der globalen Vernetzung der Wertsch\u00f6pfungsketten kam es auch im globalen Kontext zu wirtschaftlichen Sch\u00e4den in der Folge von Betriebsunterbrechungen.", [["der Folge der globalen Vernetzung der Wertsch\u00f6pfungsketten kam es auch", "TREATMENT", 3, 73]]], ["Die Produktionsausf\u00e4lle f\u00fchrten beispielsweise zu Lieferengp\u00e4ssen bei den US-amerikanischen Herstellern Apple und IBM Corporation.Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenIn der Folge des Erdbebens fiel auch der japanische Nikkei 225-B\u00f6rsenindex am Tag nach dem Erdbeben um \u00fcber tausend Punkte (5,6 Prozent).", [["Die Produktionsausf\u00e4lle f\u00fchrten beispielsweise zu Lieferengp\u00e4ssen bei den US-amerikanischen Herstellern Apple und IBM Corporation", "SPECIES", 0, 129], ["Methoden zur Analyse von ProduktionsrisikenIn der Folge des Erdbebens fiel auch der japanische Nikkei 225-B\u00f6rsenindex am Tag nach dem Erdbeben um \u00fcber tausend Punkte", "SPECIES", 211, 376]]], ["Auch die B\u00f6rsen in Hongkong und Singapur brachen um 3,6 Prozent bzw. um 3,1 Prozent ein.", [["Singapur brachen um 3,6 Prozent bzw", "SPECIES", 32, 67]]], ["Dies f\u00fchrte indirekt zur Insolvenz der Barings Bank, da deren Mitarbeiter Nick Leeson hohe Summen in Optionen auf den Nikkei investiert hatte.14Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenZielsetzung eines pr\u00e4ventiv ausgerichteten Risiko-Managements ist es, potenzielle Schwachstellen sowie die Ursachen f\u00fcr St\u00f6rungen in der Wertsch\u00f6pfungskette zu identifizieren und ad\u00e4quate Ma\u00dfnahmen zu initiieren, um die Resilienz des gesamten Systems zu erh\u00f6hen.Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenHierbei ist zu ber\u00fccksichtigen, dass ein bestimmtes Risikoszenario h\u00e4ufig erst durch die Kombination mehrerer Ursachen auftritt.", [["Methoden zur Analyse von ProduktionsrisikenZielsetzung eines pr\u00e4ventiv ausgerichteten Risiko-Managements ist es, potenzielle Schwachstellen sowie die Ursachen f\u00fcr St\u00f6rungen in der Wertsch\u00f6pfungskette zu identifizieren und ad\u00e4quate Ma\u00dfnahmen zu initiieren, um die Resilienz des gesamten Systems zu erh\u00f6hen", "SPECIES", 225, 529], ["Methoden", "TREATMENT", 225, 233], ["Zielsetzung eines", "TREATMENT", 268, 285], ["ist es", "TREATMENT", 330, 336]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["In der unternehmerischen Praxis ist nicht selten zu beobachten, dass das, was man als Wirkung bezeichnet, auf die Ursache zur\u00fcckwirkt und damit selbst zur Ursache wird.", [["man", "SPECIES", 78, 81]]], ["Au\u00dferdem k\u00f6nnen in der Praxis so genannte \u201eDominoeffekte\u201c eintreten, sodass einzelne als unwesentlich wahrgenommene Risikoereignisse eine Kette weiterer Risiken mit schwerwiegenden Auswirkungen ausl\u00f6sen k\u00f6nnen.Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenDerartige \u201eDominoeffekte\u201c werden auch als systemische Risiken bezeichnet.", [["genannte", "TREATMENT", 33, 41], ["Dominoeffekte\u201c eintreten", "TREATMENT", 43, 67], ["Dominoeffekte\u201c", "TREATMENT", 345, 359]]], ["Ein systemisches Risiko liegt vor, wenn sich ein auf ein Element eines Systems einwirkendes Ereignis aufgrund der dynamischen Wechselwirkungen zwischen den Elementen des Systems auf das System als ganzes negativ auswirken kann oder wenn sich aufgrund der Wechselwirkungen zwischen den Elementen die Auswirkungen mehrerer auf einzelne Elemente einwirkender Ereignisse so \u00fcberlagern, dass sie sich auf das System als ganzes negativ auswirken k\u00f6nnen.", [["wenn sich ein auf ein Element eines Systems einwirkendes Ereignis aufgrund der dynamischen Wechselwirkungen zwischen den Elementen des Systems auf das System als ganzes negativ auswirken kann oder wenn sich aufgrund der Wechselwirkungen zwischen den Elementen die Auswirkungen mehrerer auf einzelne Elemente einwirkender Ereignisse so \u00fcberlagern, dass sie sich auf das System als ganzes negativ auswirken k\u00f6nnen", "SPECIES", 35, 446], ["wenn sich ein auf ein Element eines Systems", "TREATMENT", 35, 78], ["Ereignis aufgrund der dynamischen Wechselwirkungen zwischen", "TREATMENT", 92, 151]]], ["6.5 sind die Abh\u00e4ngigkeiten und komplexen Wirkungsketten des T\u014dhoku-Erdbeben aus dem Jahr 2011 skizziert.", [["Abh\u00e4ngigkeiten und komplexen Wirkungsketten des T\u014dhoku-Erdbeben aus dem Jahr 2011 skizziert", "SPECIES", 13, 104]]], ["W\u00e4hrend der n\u00f6rdliche Teil des betroffenen Gebiets bereits mehrfach in der Historie von starken Tsunamis verw\u00fcstet wurde (vermutlich etwa 1611, 1896, 1933), gab es in der s\u00fcdlichen Region (Sendai) wohl nur im Jahr 869 einen \u00e4hnlich hohen Tsunami.15 Auf der Basis diverser wissenschaftlicher Analysen historischer seismischer Flutwellen und von GPS-Messungen l\u00e4sst sich eine Spannweite von Wiederkehrperioden von 440 bis 1500 Jahren f\u00fcr ein Gro\u00dfbeben der Magnitude M = 9,0 in dieser Region Japans sch\u00e4tzen.16Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenDie Konsequenz war, dass einige Fabrikationsst\u00e4tten japanischer Automobilhersteller und Zulieferbetriebe ihren Betrieb einstellen mussten.", [["W\u00e4hrend der n\u00f6rdliche Teil des betroffenen Gebiets bereits mehrfach in der Historie von starken Tsunamis verw\u00fcstet wurde (vermutlich etwa 1611, 1896, 1933)", "SPECIES", 0, 155], ["Analysen historischer seismischer Flutwellen und von GPS-Messungen l\u00e4sst sich eine Spannweite von Wiederkehrperioden von 440 bis 1500 Jahren f\u00fcr ein Gro\u00dfbeben der Magnitude M = 9,0", "SPECIES", 291, 471], ["der n\u00f6rdliche Teil des betroffenen", "TREATMENT", 8, 42], ["dass einige Fabrikationsst\u00e4tten japanischer", "TREATMENT", 651, 694]]], ["Mikroprozessoren produziert.", [["Mikroprozessoren", "CHEMICAL", 0, 16], ["Mikroprozessoren produziert", "TREATMENT", 0, 27]]], ["Sie werden u. a. in Geld- und Telefonkarten, Mobiltelefonen, Waschmaschinen sowie in den Steuerger\u00e4ten in Kraftfahrzeugen (beispielsweise ABS, ESP, Airbag, Motorregelung) eingebaut.", [["ESP", "PROBLEM", 143, 146]]], ["Betroffen waren auch Hersteller von Silizium-Wafer.", [["Betroffen", "TREATMENT", 0, 9]]], ["Diese werden aus ein- oder polykristallinen (Halbleiter-)Rohlingen (Ingots) hergestellt und dienen in der Regel als Substrat (Grundplatte) f\u00fcr elektronische Bauelemente, unter anderem f\u00fcr integrierte Schaltkreise, mikromechanische Bauelemente oder fotoelektrische Beschichtungen.", [["Diese werden aus ein- oder polykristallinen (Halbleiter-)Rohlingen", "SPECIES", 0, 66], ["polykristallinen (Halbleiter-)Rohlingen (Ingots)", "TREATMENT", 27, 75]]], ["Au\u00dferdem wurden rund um Fukushima Leiterplatten (Printed Circuit Boards) und Lithium-Ionen-Batterien hergestellt.", [["Lithium", "CHEMICAL", 77, 84], ["Lithium", "TREATMENT", 77, 84]]], ["Rund 60 Prozent des Weltumsatzes an Silizium-Wafern wurden im Jahr 2010 aus Japan importiert.", [["Rund 60 Prozent des Weltumsatzes an Silizium-Wafern wurden im Jahr 2010 aus Japan importiert", "SPECIES", 0, 92]]], ["Ein weiteres wichtiges Exportprodukt sind Bismaleimide-Triazine, eine Verbindungskomponente, die in Kombination mit anderen Harzbausteinen und Glasgewebe als Verst\u00e4rkung dient, in denen die ausgezeichnete thermische Stabilit\u00e4t von Polyimid mit den guten dielektrischen Eigenschaften von Cyanatester vereint sind.", [["Kombination mit anderen Harzbausteinen und Glasgewebe als Verst\u00e4rkung dient, in denen die ausgezeichnete thermische Stabilit\u00e4t von Polyimid mit den guten dielektrischen Eigenschaften von Cyanatester vereint sind", "SPECIES", 100, 311], ["Bismaleimide", "TREATMENT", 42, 54], ["Triazine", "TREATMENT", 55, 63]]], ["Rund 90 Prozent der Bismaleimide-Triazine stammen aus Japan.Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenDie japanische Regierung hat die gesch\u00e4tzten Kosten in der Folge des T\u014dhoku-Erdbebens auf rund 25 Billionen Yen (220 Mrd.", [["Methoden zur Analyse von ProduktionsrisikenDie japanische Regierung hat die gesch\u00e4tzten Kosten in der Folge des T\u014dhoku-Erdbebens auf rund 25 Billionen Yen (220 Mrd.", "SPECIES", 141, 305], ["Prozent der Bismaleimide", "TREATMENT", 8, 32], ["Triazine stammen aus Japan", "TREATMENT", 33, 59], ["Methoden zur Analyse von ProduktionsrisikenDie japanische", "TREATMENT", 141, 198]]], ["Werden jedoch die Havarien der Kernkraftwerke von Fukushima-Daiichi ber\u00fccksichtigt, muss der Schaden als wesentlich h\u00f6her bewertet werden.", [["Werden jedoch die Havarien der Kernkraftwerke von Fukushima-Daiichi ber\u00fccksichtigt, muss der Schaden als wesentlich h\u00f6her bewertet werden", "SPECIES", 0, 137]]], ["Au\u00dferdem kann das T\u014dhoku-Erdbeben als die erste Naturkatastrophe betrachtet werden, die in vielen L\u00e4ndern weitab von der betroffenen Region zu nachhaltigen energiepolitischen Ver\u00e4nderungen (Atomausstieg in Deutschland und der Schweiz, Nichteinstieg in Italien) gef\u00fchrt hat.Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenDie beiden Ereignisse in K\u014dbe (1995) und T\u014dhoku (2011) haben vor allem vor Augen gef\u00fchrt, dass in einer globalisierten Weltwirtschaft sich kein Risiko mehr isoliert betrachten l\u00e4sst.", [["Methoden zur Analyse von ProduktionsrisikenDie beiden Ereignisse in K\u014dbe (1995) und T\u014dhoku (2011)", "SPECIES", 354, 451]]], ["So kann eine Betriebsunterbrechung bei einem Zulieferer in Asien direkte und massive R\u00fcckwirkungen auf einen Dritthersteller auf der anderen Seite der Erde haben.", [["Asien direkte und massive R\u00fcckwirkungen auf einen Dritthersteller auf der anderen Seite der Erde haben", "SPECIES", 59, 161], ["kann eine Betriebsunterbrechung bei einem Zulieferer", "TREATMENT", 3, 55], ["Asien direkte und massive R\u00fcckwirkungen auf einen", "TREATMENT", 59, 108]]], ["Und auch die globalen Auswirkungen von SARS-CoV-2 / Covid-19 und der (fast) weltweite \u201eShut Down\u201c im Jahr 2020 haben vielen Unternehmen die Verwundbarkeit der Supply Chain schmerzhaft verdeutlicht.Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenIm Kap.", [["SARS-CoV-2 / Covid-19 und der (fast) weltweite \u201eShut Down\u201c im Jahr 2020 haben vielen Unternehmen die Verwundbarkeit der Supply Chain schmerzhaft verdeutlicht", "SPECIES", 39, 196], ["von SARS", "TEST", 35, 43], ["CoV", "TEST", 44, 47], ["Covid", "TEST", 52, 57]]], ["Im Zusammenhang mit Risiken im Kontext Produktion werden die folgenden Methoden vertiefend beschrieben:Szenarioanalyse/-technik, FMEA (Failure Mode and Effects Analysis), Fehlerbaumanalyse,Bow-Tie-Analyse, Key Risk Indicator (Fr\u00fchwarnindikatoren),CIRS, HAZOP, stochastische Szenarioanalyse.Praxisbeispiel: Erdbeben von K\u014dbe und Auswirkungen im Bereich der Produktion ::: Methoden zur Analyse von ProduktionsrisikenDie \u201estochastische\u201c Szenarioanalyse wird im anschlie\u00dfenden Kap.", [["Im Zusammenhang mit Risiken im Kontext Produktion werden die folgenden Methoden vertiefend beschrieben:Szenarioanalyse/-technik", "SPECIES", 0, 127], ["Im Zusammenhang mit Risiken im Kontext Produktion", "TREATMENT", 0, 49], ["Analysis", "TEST", 160, 168], ["Fehlerbaumanalyse", "TREATMENT", 171, 188], ["CIRS", "TEST", 247, 251], ["Szenarioanalyse", "TREATMENT", 434, 449]]], ["Weitere Kollektionsmethoden und analytischen Methoden wurden bereits im Kap.", [["Kollektionsmethoden und analytischen Methoden", "TREATMENT", 8, 53]]], ["10.1007/978-3-658-29446-5_3 beschrieben.Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#Die Szenariotechnik ist urspr\u00fcnglich als Methode der Zukunftsforschung18 entwickelt worden.", [["10.1007/978-3-658-29446-5_3 beschrieben", "CHEMICAL", 0, 39], ["Szenariotechnik ist urspr\u00fcnglich als Methode der Zukunftsforschung18 entwickelt worden", "SPECIES", 127, 213]]], ["Sie wurde in den 1950er-und 1960er-Jahren von Herman Kahn19 und Mitarbeitern in den USA entwickelt und vor allem als Prognosetechnik bei nicht linearen Verl\u00e4ufen und unberechenbaren Ereignissen eingesetzt.", [["den 1950er-und 1960er-Jahren von Herman Kahn19 und Mitarbeitern in den USA entwickelt und vor allem als Prognosetechnik bei nicht linearen Verl\u00e4ufen und unberechenbaren Ereignissen eingesetzt", "SPECIES", 13, 204]]], ["Im Hinblick auf die Zukunftsforschung definiert Kahn seine Szenarien als \u201e[\u2026] hypothetische Folge von Ereignissen, die konstruiert werden, um die Aufmerksamkeit auf kausale Prozesse und Entscheidungspunkte zu lenken.\u201c20 Dabei \u201e[\u2026] beschr\u00e4nkt sich die Szenario-Technik im Gegensatz zu den meisten Prognosetechniken nicht nur auf die Verarbeitung quantitativer Informationen\u201c,21 sondern greift vor allem auch auf qualitative Daten zur\u00fcck.", [["Im Hinblick auf die Zukunftsforschung definiert Kahn seine Szenarien als \u201e[\u2026] hypothetische Folge von Ereignissen, die konstruiert werden, um die Aufmerksamkeit auf kausale Prozesse und Entscheidungspunkte zu lenken", "SPECIES", 0, 215], ["Szenario", "TREATMENT", 251, 259]]], ["Darauf aufbauende, komplexe Systemanalysen sollen f\u00fcr ein umfassendes Verst\u00e4ndnis des Systems sorgen und alternative Zukunftsbilder hervorbringen.Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#Inzwischen ist die Prognosefunktion in den Hintergrund getreten und Szenarien dienen mehr als Entscheidungshilfe (\u201eWas w\u00e4re, wenn \u2026\u201c) beispielsweise im Zusammenhang mit der Strategischen Planung.", [["Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#Inzwischen ist die Prognosefunktion in den Hintergrund getreten und Szenarien dienen mehr als Entscheidungshilfe (\u201eWas w\u00e4re, wenn \u2026\u201c) beispielsweise im Zusammenhang mit der Strategischen Planung", "SPECIES", 146, 423], ["Darauf aufbauende", "TREATMENT", 0, 17], ["komplexe Systemanalysen sollen", "TREATMENT", 19, 49], ["Zukunftsbilder hervorbringen", "TREATMENT", 117, 145], ["Szenariotechnik", "TREATMENT", 146, 161], ["Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#Inzwischen ist die Prognosefunktion", "TREATMENT", 162, 264]]], ["Sie basiert im Kern auf der Entwicklung und Analyse m\u00f6glicher Entwicklungen der Zukunft.", [["Sie basiert im Kern auf der Entwicklung und Analyse m\u00f6glicher Entwicklungen der Zukunft", "SPECIES", 0, 87]]], ["Szenarios werden h\u00e4ufig in Form eines Szenariotrichters dargestellt (vgl.", [["Szenarios", "TREATMENT", 0, 9]]], ["Abb.", [["Abb", "GENE_OR_GENE_PRODUCT", 0, 3], ["Abb", "PROTEIN", 0, 3]]], ["Die Zukunftsbilder befinden sich folglich auf der Schnittstelle des Trichters, wohingegen die Gegenwart immer am engsten Punkt des Trichters liegt.", [["Die Zukunftsbilder befinden sich folglich auf der Schnittstelle des Trichters, wohingegen die Gegenwart immer am engsten Punkt des Trichters liegt", "SPECIES", 0, 146]]], ["Dieses Trendszenario stellt die zuk\u00fcnftige Entwicklung unter der Annahme stabiler Umweltentwicklungen dar (ceteris paribus).Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#Jenes Extremszenario, das die bestm\u00f6gliche Entwicklung (\u201ebest case\u201c) aufzeigt, stellt das obere Ende des Trichters dar, wohingegen der sogenannte \u201eworst case\u201c, also die schlechteste Entwicklungsm\u00f6glichkeit, das untere Ende bildet.Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#In der Praxis ist eine enorme Vielfalt an Definitionen und Varianten der Szenariomethode anzutreffen.", [["ceteris paribus", "ORGANISM", 107, 122], ["ceteris paribus", "SPECIES", 107, 122], ["Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#In der Praxis ist eine enorme Vielfalt an Definitionen und Varianten der Szenariomethode anzutreffen", "SPECIES", 437, 620], ["Szenariotechnik", "TREATMENT", 124, 139], ["Szenarioanalyse", "TREATMENT", 140, 155], ["Szenariotechnik/Szenarioanalyse", "TREATMENT", 437, 468], ["an Definitionen und Varianten der Szenariomethode anzutreffen", "TREATMENT", 559, 620]]], ["In Kap.", [["Kap", "PROTEIN", 3, 6]]], ["10.1007/978-3-658-29446-5_4 \u201eStrategische Chancen und Risiken\u201c wird ein achtstufiges Vorgehen der deterministischen Szenarioanalyse im Detail beschrieben.Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#Im Folgenden ist ein einfaches vierstufiges Vorgehen skizziert:22Schritt 1: Aufgaben- und Problemanalyse: Im Rahmen der Aufgaben- und Problemanalyse wird der Untersuchungsgegenstand zun\u00e4chst festgelegt und beschrieben.", [["Folgenden ist ein einfaches vierstufiges Vorgehen skizziert:22Schritt 1: Aufgaben- und Problemanalyse: Im Rahmen der Aufgaben- und Problemanalyse wird der Untersuchungsgegenstand zun\u00e4chst festgelegt und beschrieben", "SPECIES", 240, 454], ["Szenariotechnik", "TREATMENT", 154, 169], ["Szenarioanalyse", "TREATMENT", 170, 185]]], ["Anschlie\u00dfend werden die Faktoren/Deskriptoren ermittelt, die den Untersuchungsgegenstand bzw. die k\u00fcnftigen Szenarios dieses Feldes beschreiben und m\u00f6glicherweise beeinflussen.", [["Anschlie\u00dfend werden die Faktoren/Deskriptoren ermittelt, die den Untersuchungsgegenstand bzw", "SPECIES", 0, 92]]], ["Output dieser Phase sind eine detaillierte Aufgaben- und Problembeschreibung sowie eine Faktorenliste.Schritt 2: Einflussanalyse: Eine gute System- und Einflussanalyse muss die wesentlichen Systemelemente (Schl\u00fcsselfaktoren) und Beziehungen erfassen.", [["Output", "TEST", 0, 6], ["Phase", "TEST", 14, 19], ["Aufgaben", "TEST", 43, 51], ["Eine gute System", "TREATMENT", 130, 146]]], ["Im direkten Vergleich wird ermittelt, welchen Einfluss (keinen, mittlere Wirkung, hohe Wirkung) ein Faktor auf einen anderen Faktor besitzt.", [["Im direkten Vergleich wird ermittelt, welchen Einfluss (keinen, mittlere Wirkung, hohe Wirkung) ein Faktor auf einen anderen Faktor besitzt", "SPECIES", 0, 139]]], ["Anschlie\u00dfend k\u00f6nnen jeweils die Aktiv- und die Passivwirkungen kumuliert und die Faktoren in einer Einflussmatrix miteinander verglichen werden.Output dieser Phase sind die Vernetzungstabelle und eine Einflussfaktorenmatrix sowie eine \u00dcbersicht \u00fcber die Gr\u00f6\u00dfe des Einflusses der einzelnen Faktoren.", [["Output", "TEST", 144, 150], ["Phase sind die Vernetzungstabelle", "TREATMENT", 158, 191]]], ["Mit Hilfe dessen kann man die meist sehr gro\u00dfe Anzahl von Einflussfaktoren auf eine handhabbare Anzahl reduzieren, wenn man nur die einflussreichsten Faktoren ausw\u00e4hlt.Schritt 3: Trendprojektion und Ermittlung von Szenarios: Zun\u00e4chst gilt es, die unterschiedlichen Entwicklungsm\u00f6glichkeiten f\u00fcr die einzelnen ausgew\u00e4hlten Faktoren zu ermitteln.", [["man", "SPECIES", 22, 25], ["Zun\u00e4chst gilt es", "TREATMENT", 225, 241]]], ["Die unterschiedlichen Auspr\u00e4gungen k\u00f6nnen generisch in einem morphologischen Kasten ermittelt werden.Durch die mathematische Kombination der verschiedenen Faktorauspr\u00e4gungen entstehen m\u00f6gliche Szenarios.", [["Die", "PROBLEM", 0, 3]]], ["Beispielsweise kombiniert man die erste Auspr\u00e4gung des ersten Faktors mit der zweiten Auspr\u00e4gung des dritten Faktors: \u201ePolitische Risiken in Drittl\u00e4ndern\u201c mit der Auspr\u00e4gung \u201eSingle-Sourcing-Risiken\u201c wird kombiniert mit der Auspr\u00e4gung des Faktors 3 \u201eTechnologieabh\u00e4ngigkeit\u201c.", [["Beispielsweise kombiniert man die erste Auspr\u00e4gung des ersten Faktors mit der zweiten Auspr\u00e4gung des dritten Faktors: \u201ePolitische Risiken in Drittl\u00e4ndern\u201c mit der Auspr\u00e4gung \u201eSingle-Sourcing-Risiken\u201c wird kombiniert mit der Auspr\u00e4gung des Faktors 3 \u201eTechnologieabh\u00e4ngigkeit\u201c", "SPECIES", 0, 274], ["Risiken\u201c wird", "TREATMENT", 191, 204]]], ["Diese Filterung kann mit einer paarweisen Analyse oder mit Hilfe einer Konsistenzmatrix erfolgen (vgl. hierzu Abb.", [["hierzu", "CHEMICAL", 103, 109], ["Abb", "GENE_OR_GENE_PRODUCT", 110, 113], ["Abb", "PROTEIN", 110, 113]]], ["10.1007/978-3-658-29446-5_4).", [["10.1007/978-3-658-29446-5_4", "CHEMICAL", 0, 27]]], ["Um effektiv mit den Szenarios arbeiten zu k\u00f6nnen, ist es sinnvoll, eine Anzahl von vier bis acht Szenarios auszuw\u00e4hlen.", [["ist es sinnvoll", "TREATMENT", 50, 65]]], ["\u00dcblicherweise wird man wenigstens die beiden Extremszenarios, das Trendszenario und eventuell wenige, ausgew\u00e4hlte Szenarios weiter betrachten.", [["man", "SPECIES", 19, 22]]], ["Man sollte aber darauf achten, nicht ausschlie\u00dflich die beiden Extremszenarios weiter zu betrachten, sich also nicht nur auf eine schwarze oder wei\u00dfe Zukunft einstellen.Output dieser Phase sind die m\u00f6glichen Auspr\u00e4gungen der einzelnen Faktoren/Deskriptoren, sowie ihre Kombination/B\u00fcndelung zu verschiedenen Szenarios.", [["Man", "SPECIES", 0, 3], ["Auspr\u00e4gungen der einzelnen Faktoren/Deskriptoren, sowie ihre Kombination/B\u00fcndelung zu verschiedenen", "SPECIES", 208, 307], ["Output", "TEST", 169, 175], ["m\u00f6glichen", "TEST", 198, 207]]], ["Anschlie\u00dfend bietet sich eine Beschreibung/Ausformulierung der Szenarios an, um sie verst\u00e4ndlicher und leichter kommunizierbar zu machen.Schritt 4: Bewertung und InterpretationDie ausgew\u00e4hlten Szenarios werden in dieser Phase weiter untersucht.", [["Anschlie\u00dfend bietet sich eine Beschreibung/Ausformulierung der Szenarios an, um sie verst\u00e4ndlicher und leichter kommunizierbar zu machen", "SPECIES", 0, 136], ["Anschlie\u00dfend bietet sich", "TREATMENT", 0, 24]]], ["Eintrittswahrscheinlichkeiten und den mit den jeweiligen Szenarios verbundenen Chancen und Risiken gegen\u00fcbergestellt.", [["Eintrittswahrscheinlichkeiten und den mit den jeweiligen Szenarios verbundenen Chancen und Risiken gegen\u00fcbergestellt", "SPECIES", 0, 116]]], ["Nach dieser Betrachtung k\u00f6nnen Unternehmen Ma\u00dfnahmen/Handlungsoptionen f\u00fcr die einzelnen Szenarios definieren, um sich f\u00fcr diese zu r\u00fcsten.", [["Nach dieser Betrachtung k\u00f6nnen Unternehmen Ma\u00dfnahmen/Handlungsoptionen f\u00fcr die einzelnen Szenarios definieren, um sich f\u00fcr diese zu r\u00fcsten", "SPECIES", 0, 138], ["Nach dieser", "TREATMENT", 0, 11]]], ["Mit Hilfe von Szenarios kann ein Unternehmen ebenfalls seine Strategie \u00fcberpr\u00fcfen.", [["Mit Hilfe von Szenarios kann ein Unternehmen ebenfalls seine Strategie \u00fcberpr\u00fcfen", "TREATMENT", 0, 81]]], ["Szenarios helfen in diesem Fall bei der zukunftsrobusten Strategiefindung.Output dieser Phase ist Bewertung und Gegen\u00fcberstellung sowie abgeleitete Handlungsoptionen und Ma\u00dfnahmen der ausgew\u00e4hlten Szenarios.Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#Beim Einsatz der Szenariotechnik im Risiko-Management k\u00f6nnen eine Reihe von Anforderungen definiert werden:24Sachkompetenz: Kenntnisse \u00fcber Untersuchungsgegenstand und -raum,Vorstellungen und Kenntnisse \u00fcber grundlegende \u00f6konomische und gesellschaftliche Zusammenh\u00e4nge und Prozesse,Methodenkompetenz,Fantasie und Kreativit\u00e4t.Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#Da eine einzelne Person alle Anforderungen nur in den seltensten F\u00e4llen erf\u00fcllen kann, sollte die Szenariotechnik immer nur im Rahmen von (interdisziplin\u00e4r zusammengesetzten) Workshops angewendet werden.", [["Einsatz der Szenariotechnik im Risiko-Management k\u00f6nnen eine Reihe von Anforderungen definiert werden:24Sachkompetenz: Kenntnisse \u00fcber Untersuchungsgegenstand und -raum,Vorstellungen und Kenntnisse \u00fcber grundlegende \u00f6konomische und gesellschaftliche Zusammenh\u00e4nge und Prozesse,Methodenkompetenz,Fantasie und Kreativit\u00e4t", "SPECIES", 295, 614], ["Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#Da eine einzelne Person alle Anforderungen nur in den seltensten F\u00e4llen erf\u00fcllen kann, sollte die Szenariotechnik immer nur im Rahmen von (interdisziplin\u00e4r zusammengesetzten) Workshops angewendet werden", "SPECIES", 615, 900], ["Szenarios", "TREATMENT", 0, 9], ["Output", "TEST", 74, 80], ["Szenariotechnik", "TREATMENT", 207, 222], ["Szenarioanalyse", "TREATMENT", 223, 238], ["Einsatz der Szenariotechnik", "TREATMENT", 295, 322], ["Vorstellungen", "TEST", 464, 477], ["Methodenkompetenz", "TREATMENT", 572, 589], ["Szenariotechnik", "TREATMENT", 615, 630], ["Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#Da eine einzelne", "TREATMENT", 631, 714]]], ["So eignet sich die Szenariotechnik ideal f\u00fcr die Risikoevaluierung im Rahmen von Projektteams oder Risikokomitees.Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#In der Unternehmenspraxis sind unterschiedliche Typen von Szenarien bekannt, deren \u00dcberg\u00e4nge jedoch flie\u00dfend sind.Szenariotechnik/Szenarioanalyse (deterministisch)#!start#17#!sep#Fn17#!sep#fn#!end#", [["Szenariotechnik", "TREATMENT", 114, 129], ["Szenarioanalyse", "TREATMENT", 130, 145], ["Szenariotechnik", "TREATMENT", 311, 326], ["Szenarioanalyse", "TREATMENT", 327, 342]]]], "d58d2bd0ad70cd554be34dbe1c63021f9eefe489": [["virtual) to effectively engage in health care team training and simulation-based education while maintaining social distancing during the COVID-19 pandemic.", [["the COVID", "TEST", 134, 143], ["pandemic", "PROBLEM", 147, 155]]]], "PMC7223383": [["IntroductionFive years have passed since the adoption of the Sendai Framework for Disaster Risk Reduction 2015\u20132030 (UNDRR 2015) by 187 United Nations (UN) member states at the Third UN World Conference on Disaster Risk Reduction in Japan in March 2015 (UNDRR 2015).1 With the synchronous adoption of the Sendai Framework as a landmark UN agreement that links closely with the Sustainable Development Goals (SDGs) (UNGA 2015), Paris Climate Agreement (UNFCCC 2015), and the outcomes of the World Humanitarian Summit (UNGA 2016a) and Habitat III (UNGA 2016b) the aim has been to develop dynamic, local, preventive, and adaptive governance systems at the global, national, and local levels.", [["adaptive governance systems", "TREATMENT", 618, 645]]], ["These landmark UN agreements aim to develop and lead a global process that can create a rare but important opportunity to build coherence across different but overlapping policy areas (Murray et al. 2017).", [["a global process", "PROBLEM", 53, 69]]], ["Taken together, these frameworks aim for a more complete agenda for action that spans health, development, humanitarian action, disaster risk management (DRM), and climate change adaptation.IntroductionCommunicating and understanding the value of the Sendai Framework across all sectors, including for and to health professionals, is critical for progress on the health priorities.", [["Sendai", "ORGANISM", 251, 257], ["humanitarian action", "TREATMENT", 107, 126], ["disaster risk management", "TREATMENT", 128, 152], ["climate change adaptation", "TREATMENT", 164, 189]]], ["The Sendai Framework recognizes that by reducing and managing conditions of hazard, exposure, and vulnerability\u2014while building the capacity of communities and countries for prevention, preparedness, response, and recovery\u2014losses and impacts on health from disasters can be more effectively alleviated through a multisectoral approach rather than focusing exclusively on emergency response.IntroductionWhile there were several references to health in the Hyogo Framework for Action 2005\u20132015 (UNDRR 2005), the adoption of the Sendai Framework marks the first time that the fields of health and DRM have been substantially interwoven at the global multisectoral policy level.", [["a multisectoral approach", "TREATMENT", 309, 333], ["substantially", "OBSERVATION_MODIFIER", 607, 620], ["interwoven", "OBSERVATION_MODIFIER", 621, 631]]], ["This article builds on previous efforts to discuss this merger (Aitsi-Selmi and Murray 2015; Aitsi-Selmi et al. 2015b; Maini et al. 2017) and explores its effects 5 years on, not just in terms of global policy and partnership, but also in terms of the effects for scientific research and data in the field of DRM.Leading into the Sendai FrameworkThe health sector has a long-standing history of excellence in developing evidence-based policy and practice, with globally recognized organizations dedicated to this endeavor.Leading into the Sendai FrameworkCochrane is a leading example of such an organization.", [["Sendai", "ORGANISM", 539, 545], ["scientific research", "TEST", 264, 283], ["Sendai FrameworkCochrane", "OBSERVATION", 539, 563]]], ["It advocates the principles of evidence-based medicine as critical to health policy and practice, and in assessing the effectiveness of interventions for disease prevention, treatment, and rehabilitation (Turner et al. 2017).", [["interventions", "TREATMENT", 136, 149], ["disease prevention", "TREATMENT", 154, 172], ["treatment", "TREATMENT", 174, 183]]], ["The organization, which has charitable status in the United Kingdom, uses evidence from systematic reviews to provide up-to-date advice on interventions in the context of planning for or responding to disasters, humanitarian crises, and other major healthcare emergencies (Khalid et al. 2019).", [["interventions", "TREATMENT", 139, 152]]], ["The Yokohama Strategy and Plan of Action for a Safer World (International Decade for Natural Disaster Reduction 1994) did not mention health or health care facilities at all.", [["Natural Disaster Reduction", "TREATMENT", 85, 111]]], ["Its successor, the Hyogo Framework, mentions health as a sector and health care facilities three times, but not as an explicit goal or outcome of DRM.Leading into the Sendai FrameworkThe World Health Organization (WHO) and its partners have a set of programs for managing and preventing health emergencies that predate the adoption of the Sendai Framework.", [["Sendai", "ORGANISM", 339, 345]]], ["The impetus for its launch came from both the 2008\u20132009 World Disaster Reduction Campaign on Hospitals Safe from Disasters (UNGA 2008) and the 2009 Global Platform for Disaster Risk Reduction (UNGA 2009) when participants supported a proposal to establish a thematic platform dedicated to protecting public health from the risks and consequences of emergencies and disasters and in support of the Hyogo Framework.Leading into the Sendai FrameworkThere are several other key programs.", [["participants", "SPECIES", 209, 221]]], ["Also, the Inter-Agency Standing Committee (IASC) Emergency Response Preparedness (ERP) draft for field testing sets standards for risk analysis and monitoring, and minimum and advanced preparedness including contingency planning, with the aim of optimizing the speed and volume of critical assistance provided immediately following the onset of a humanitarian emergency (IASC 2015).Leading into the Sendai FrameworkBuilding on all this work, the Sendai Framework puts health risks and health resilience at the heart of global DRM efforts.", [["heart", "ANATOMY", 510, 515], ["Sendai", "ORGANISM", 399, 405], ["Sendai", "ORGANISM", 446, 452], ["heart", "ORGAN", 510, 515], ["field testing", "TEST", 97, 110], ["risk analysis", "TEST", 130, 143], ["monitoring", "TEST", 148, 158], ["contingency planning", "TREATMENT", 208, 228], ["heart", "ANATOMY", 510, 515], ["global DRM", "OBSERVATION", 519, 529]]], ["It advocates for involving health sectors throughout planning for emergency proactive and reactive measures globally, as well as highlighting the critical role of science and technology.", [["emergency proactive and reactive measures", "TREATMENT", 66, 107], ["reactive", "OBSERVATION_MODIFIER", 90, 98]]], ["There are 38 references to health, including links to epidemics and pandemics, alongside several references to the 2005 IHR (WHO 2016a) and to rehabilitation as part of disaster recovery.", [["pandemics", "PROBLEM", 68, 77]]], ["(Paragraph 30 i)People with life-threatening and chronic disease, due to their particular needs, should be included in the design of policies and plans to manage their risks before, during and after disasters, including having access to life-saving services.", [["chronic disease", "DISEASE", 49, 64], ["People", "SPECIES", 16, 22], ["chronic disease", "PROBLEM", 49, 64], ["chronic", "OBSERVATION_MODIFIER", 49, 56], ["disease", "OBSERVATION", 57, 64]]], ["(Paragraph 30 k)To promote the resilience of new and existing critical infrastructure, including water, transportation and telecommunications infrastructure, educational facilities, hospitals and other health facilities, to ensure that they remain safe, effective and operational during and after disasters [\u2026]. (paragraph 33 c)Leading into the Sendai FrameworkSupporting the convergence of global health and DRM agendas, examples of organizations long involved in DRM that are now supporting the Sendai Framework are:The World Association for Disaster and Emergency Medicine (WADEM) seeks to improve the delivery of prehospital and emergency care worldwide during disasters and other emergencies.", [["Sendai", "ORGANISM", 345, 351], ["new", "OBSERVATION_MODIFIER", 45, 48]]], ["It is the oldest international emergency and disaster medicine organization and has members from 55 countries and multiple disciplines, such as medicine (including veterinary medicine), nursing, psychology, sociology, emergency management and academia from both governmental and nongovernmental organizations (WADEM 2020).", [["emergency management", "TREATMENT", 218, 238], ["academia", "PROBLEM", 243, 251]]], ["At its 2015 Congress, the WADEM adopted the Cape Town Statement, which explicitly supports the Sendai Framework and its implementation in the health emergency and disaster risk management domain.", [["disaster risk management", "TREATMENT", 163, 187]]], ["As a result, the WADEM was one of the organizations that were most rapid in adopting and supporting the implementation of the Sendai Framework and its impacts on health EDRM (Emergency and Disaster Risk Management) evidence, policy, and practice engagement at its various meetings and congresses since 2015.The International Association of National Public Health Institutes (IANPHI), started in 2006, links, supports, and strengthens the institutes responsible for public health in countries worldwide, particularly in low resource settings.", [["Sendai", "ORGANISM", 126, 132], ["the Sendai Framework", "TREATMENT", 122, 142]]], ["Its focus areas include outbreak investigation and control, disease surveillance, health promotion, and emergency response (Pekka and Jeffrey 2017).", [["outbreak investigation", "TEST", 24, 46], ["disease surveillance", "TEST", 60, 80], ["focus", "OBSERVATION_MODIFIER", 4, 9], ["areas", "OBSERVATION_MODIFIER", 10, 15]]], ["In May 2017, the IFEH endorsed the principles and agenda behind the Sendai Framework.The International Council of Nurses (ICN) is a global federation of over 130 national nursing associations that endeavors to ensure quality nursing care universally, sound health policies, the development of nursing knowledge, competencies, and skills, and the worldwide presence of a competent, professional, fulfilled, and respected nursing workforce (ICN 2020).", [["Sendai", "ORGANISM", 68, 74]]], ["The ICN sees the nursing profession as an essential partner in the response and prevention of disasters and considers that it remains an underused resource in the field of DRM.", [["ICN", "PROTEIN", 4, 7]]], ["In 2019, the ICN updated their Nurses and Disaster Risk Reduction, Response and Recovery policy statement in line with the Sendai Framework, highlighting that \u201cnurses must be involved in the development and implementation of disaster risk reduction, response and recovery policies at the international level\u201d (ICN 2019, p.", [["disaster risk reduction", "TREATMENT", 225, 248]]], ["2).Leading into the Sendai FrameworkBeing part of the UN system, the World Health Organization contributed to the lead-into the Sendai Framework and is now an active supporter and implementer of it.General Programme of Work ::: World Health OrganizationThe WHO reports in its 13th General Programme of Work (GPW 13) for 2019\u20132023 that major global health gains have been made in recent years, yet complex, interconnected threats, such as poverty and inequality to conflict, and poor governance remain.", [["Sendai", "ORGANISM", 128, 134], ["active", "OBSERVATION_MODIFIER", 159, 165], ["supporter", "OBSERVATION", 166, 175]]], ["The GPW 13, which sets out WHO\u2019s strategic direction for the next 5 years and was approved by the Seventy-First World Health Assembly in resolution WHA71.1 on 25 May 2018, is informed by the UN\u2019s 2030 Agenda for Sustainable Development, and in particular SDG 3: to ensure healthy lives and promote wellbeing for all at all ages (WHO 2018).General Programme of Work ::: World Health OrganizationThe focus of GPW 13 is to deliver meaningful, large-scale, country-level impact to promote health, improve health security, and serve vulnerable communities.", [["large", "OBSERVATION_MODIFIER", 440, 445]]], ["A key pillar of this vision is to reduce the risks and impacts of all types of health emergencies.", [["pillar", "OBSERVATION_MODIFIER", 6, 12]]], ["The GPW 13 recognizes that \u201cthe world faces threats from high-impact health emergencies (epidemics, pandemics, conflicts, natural and technological disasters) and the emergence of antimicrobial resistance\u201d (WHO 2018, p.", [["pandemics", "DISEASE", 100, 109], ["antimicrobial resistance", "OBSERVATION", 180, 204]]], ["It has at its heart a set of interconnected strategic priorities and goals through the \u201ctriple billion\u201d target, which includes: 1 billion more people benefitting from universal health coverage; 1 billion more people better protected from health emergencies; and 1 billion more people enjoying better health and well-being (WHO 2018).General Programme of Work ::: World Health OrganizationIn the context of health emergencies, the WHO will \u201cwork with Member States and partners to increase all-hazards health emergency detection and risk management capacities across all phases of risk prevention and detection, emergency preparedness, response and recovery through the implementation of the IHR (2005) and the Sendai Framework for Disaster Risk Reduction\u201d (WHO 2018, p.", [["heart", "ANATOMY", 14, 19], ["heart", "ORGAN", 14, 19], ["people", "ORGANISM", 143, 149], ["people", "ORGANISM", 277, 283], ["people", "SPECIES", 143, 149], ["people", "SPECIES", 209, 215], ["people", "SPECIES", 277, 283], ["universal health coverage", "TREATMENT", 167, 192], ["risk management capacities", "PROBLEM", 532, 558], ["heart", "ANATOMY", 14, 19]]], ["It seeks to ensure that:Populations affected by health emergencies have access to essential life-saving health services and public health interventions;All countries are equipped to mitigate risk from high-threat infectious hazards;All countries assess and address critical gaps in preparedness for health emergencies, including in core capacities under the 2005 IHR and in capacities for all-hazard health emergency risk management;National health emergency programmes are supported by a well-resourced and efficient WHO Health Emergencies Programme.\u201d", [["public health interventions", "TREATMENT", 124, 151], ["high-threat infectious hazards", "PROBLEM", 201, 231]]], ["24)Thematic Platform for Health Emergency and Disaster Risk Management ::: World Health OrganizationRecognizing the complexity of delivering on the ambitions for health in the Sendai Framework, the WHO, together with national ministries of health, UN agencies, and partners, has sought to build greater coherence and interlinkages among these actors and initiatives through the WHO Thematic Platform for Health EDRM, which has the intent to promote health resilience in a consistent manner, both within and beyond the health sector.", [["Sendai", "ORGANISM", 176, 182]]], ["The Thematic Platform was also actively engaged during the negotiations of the Sendai Framework, providing advice on health to member states, and playing a crucial advocacy role.Thematic Platform for Health Emergency and Disaster Risk Management ::: World Health OrganizationSince 2015, the Thematic Platform has provided advice and recommendations on health issues to member states on the implementation of the Sendai Framework and advanced efforts to mainstream DRM within the work of the WHO and other health partners, as well as promoted health within DRM.", [["Sendai", "ORGANISM", 412, 418], ["the Sendai Framework", "TREATMENT", 408, 428]]], ["Some of the key outputs of the Thematic Platform have been facilitating inputs from more than 50 experts to develop and revise a series of fact sheets on various aspects of health emergency and disaster risk management, organize key workshops and forums at the Global Platform for Disaster Risk Reduction, and provide health-related inputs to UNDRR reports and thematic conferences (for example, science and technology).Thematic Platform for Health Emergency and Disaster Risk Management ::: World Health OrganizationThe Thematic Platform is guided by, and supports the implementation of, the Sendai Framework, the SDGs, and the Paris Agreement, along with the IHR, WHO resolutions, and other regional and global frameworks.", [["disaster risk management", "TREATMENT", 194, 218], ["Disaster Risk Reduction", "TREATMENT", 281, 304], ["global frameworks", "OBSERVATION", 706, 723]]], ["Some initiatives, such as the collaboration on disaster education for medical studies, have grown extensively and include links with the International Federation of Medical Students Associations and many academic partners including the Centre for Research Disaster and Emergency Medicine at the University of Eastern Piedmont in Italy.Other Programs for Health Emergencies ::: World Health OrganizationThe WHO, along with its partners, has a number of other ongoing programs that it implements for health emergencies that support the implementation of the IHR, Sendai Framework, Pandemic Influenza Preparedness Framework, and other global policies.", [["Influenza", "DISEASE", 588, 597], ["medical studies", "TEST", 70, 85], ["the IHR", "TREATMENT", 552, 559]]], ["These include:The WHO Strategic Framework for Emergency Preparedness, which lays out the principles and constituents of effective country health emergency preparedness (WHO 2017);The WHO\u2019s An R&D Blueprint for Action to Prevent Epidemics, a global strategy and preparedness plan that supports the rapid implementation of research and development activities during epidemics (WHO 2016b); andThe IHR (2005) Monitoring and Evaluation Framework that includes annual reporting by states parties, simulation exercises, after action reviews, and voluntary joint external evaluation, which is a collaborative process to assess a country\u2019s capacity to adhere to the IHR requirements (WHO 2016c).Other Programs for Health Emergencies ::: World Health OrganizationOther global initiatives include the Global Health Security Agenda (GHSA), a non-binding coalition of countries and organizations working to strengthen capacity to respond to infectious disease threats and promote health security as a national and global priority (Bali and Taaffe 2017).Other Programs for Health Emergencies ::: World Health OrganizationIn their own rights, these initiatives have taken (and continue to take) important steps towards improving the prevention, detection and response to health emergencies globally.", [["Epidemics", "PROBLEM", 228, 237], ["Evaluation", "TEST", 420, 430], ["action reviews", "TEST", 519, 533], ["voluntary joint external evaluation", "TEST", 539, 574], ["infectious disease threats", "PROBLEM", 928, 954]]], ["Furthermore, they point to the fact that the sector is implementing many aspects of the Sendai Framework already, given its references to biological hazards and the IHR (2005).", [["Sendai", "ORGANISM", 88, 94]]], ["The 2019 WHO Health Emergency and Disaster Risk Management Framework aims to facilitate this consistency of approach.Health Emergency and Disaster Risk Management Framework ::: World Health OrganizationDrawing on the learning from 5 years of implementing the health aspects of the Sendai Framework by ministries of health and partners, as well as successive global and regional frameworks on emergency preparedness, DRM, and the IHR of 2005, the WHO launched a new framework for Health EDRM at the Global Platform for Disaster Risk Reduction in 2019 (WHO 2019).", [["Sendai", "ORGANISM", 281, 287], ["Disaster Risk Management", "TREATMENT", 34, 58], ["this consistency of approach", "TREATMENT", 88, 116]]], ["This framework addresses the many issues raised by the Sendai Framework and is designed to provide an overarching frame to bring together the many vital initiatives to deliver disaster risk management and increase preparedness for public health emergencies.", [["disaster risk management", "TREATMENT", 176, 200]]], ["The Framework also aims to embed a Health EDRM within existing health systems, thus enabling a greater emphasis on risk prevention and building health resilience at community and national levels, community resilience, along with preparedness, response, and recovery.Health Emergency and Disaster Risk Management Framework ::: World Health OrganizationThe Health EDRM Framework has a clear vision\u2014the \u201chighest possible standard of health and well-being for all people who are at risk of emergencies, and stronger community and country resilience, health security, universal health coverage and sustainable development\u201d (WHO 2019, p. x) It aims to strengthen capacity, within and beyond the health sector, to tackle the health impacts of all types of emergencies and disasters, as well as to work to reduce the health risks of future events.", [["people", "ORGANISM", 460, 466], ["people", "SPECIES", 460, 466], ["risk prevention", "TREATMENT", 115, 130], ["universal health coverage", "TREATMENT", 563, 588]]], ["The framework is derived from the disciplines of risk management, emergency management, epidemic preparedness and response, and health systems strengthening.", [["risk management", "TREATMENT", 49, 64], ["emergency management", "TREATMENT", 66, 86]]], ["It places an emphasis on multisectoral action and, importantly, recognizes the importance of building resilience as part of the wider health system strengthening approach and the journey to achieve universal health coverage in all country contexts (see Box 1).", [["universal health coverage", "TREATMENT", 198, 223]]], ["It is fully consistent with existing DRM and health emergency policies and seeks to provide a framework for aligning these in future.Health Emergency and Disaster Risk Management Framework ::: World Health OrganizationAt the time of writing, the Health EDRM Framework was recently published, and is in the earliest stages of implementation.", [["consistent with", "UNCERTAINTY", 12, 27], ["DRM", "OBSERVATION", 37, 40]]], ["Plans are in place for wide engagement with ministries of health for training and development on strategies and programs through WHO regional and country offices and partners.", [["training", "TREATMENT", 69, 77]]], ["Specific actions to support operationalization of the Health EDRM Framework include accelerating implementation of the National Action Planning for Health Security (NAPHS) process, strengthening an all-hazards approach to strategic emergency risk assessments and emergency response planning, mainstreaming DRM in all health policies and programs, and supporting improved Sendai Framework reporting by ministries of health.", [["Sendai", "ORGANISM", 371, 377], ["risk assessments", "TEST", 242, 258], ["emergency response planning", "TREATMENT", 263, 290]]], ["Going forward, it will be vital to continue to proactively implement the Framework, particularly at the country level, and to evaluate its impact globally.Regional Approaches ::: World Health OrganizationThere are a number of regional approaches established by WHO Regional Offices, which have referenced the Sendai Framework in efforts to bring together health and DRM.", [["the Sendai Framework", "TREATMENT", 305, 325]]], ["For example, in 2015, the Regional Committee for South East Asia approved the Resolution on Response to Emergencies and Disaster, which reflects emergency and disaster risk management as a flagship priority area (WHO 2015).", [["disaster risk management", "TREATMENT", 159, 183]]], ["It makes explicit reference to the Sendai Framework as well as the IHR and SDGs, and reaffirms the need for DRM policies across sectors and at all levels of government, to ensure the effective response to disasters and other emergencies.Regional Approaches ::: World Health OrganizationThis response was taken one step further by the WHO Regional Office for the Americas/Pan-American Health Organization (PAHO).", [["Sendai", "ORGANISM", 35, 41], ["the IHR and SDGs", "TEST", 63, 79], ["DRM policies", "TREATMENT", 108, 120]]], ["Responding to the ambitious agenda set out in the Sendai Framework as well as reforms to the outbreak response capacity of the WHO, PAHO launched the Regional Plan of Action for Disaster Risk Reduction 2016\u20132021 (PAHO 2016).", [["Sendai", "ORGANISM", 50, 56]]], ["Approved by the member states in September 2016, the plan provides an operational framework to guide the implementation of DRM policies and programs in the health sector.", [["DRM policies", "TREATMENT", 123, 135]]], ["It contains four strategic lines of action that are consistent with the Sendai Framework and are aimed at reducing the health impacts of disasters and emergencies: (1) recognizing disaster risks; (2) strengthening governance of disaster risk management; (3) promoting safe and smart hospitals; and (4) strengthening the sector\u2019s capacity for emergency and disaster preparedness, response, and recovery.Regional Approaches ::: World Health OrganizationA progress report, published in 2018, showed that at least 23 member states of PAHO had undertaken, or were in the process of undertaking, a national evaluation of disaster risk in the health sector.", [["disaster risk management", "TREATMENT", 228, 252], ["a national evaluation", "TEST", 590, 611], ["four", "OBSERVATION_MODIFIER", 12, 16], ["strategic lines", "OBSERVATION", 17, 32], ["consistent with", "UNCERTAINTY", 52, 67]]], ["Furthermore, there had been an increase in the number of countries with full-time staff and an allocated budget for health DRM (PAHO 2018).", [["increase", "OBSERVATION_MODIFIER", 31, 39]]], ["This represents an important step forward in health emergency and disaster risk management, translating global ambitions on health and DRM into a concrete and contextualized set of actions for implementation.", [["disaster risk management", "TREATMENT", 66, 90]]], ["However, more action on the multisectoral dimensions of Health EDRM is needed.", [["Health EDRM", "TREATMENT", 56, 67]]], ["Working in partnership with the UNDRR Science and Technical Advisory Group (UNDRR STAG) and linking health to DRM to implement the Sendai Framework will have significant impact particularly when the call for action in Paragraph 25(g) of the Sendai Framework (UNDRR 2015) to \u201cEnhance the scientific and technical work on disaster risk reduction\u201d is followed.", [["Sendai", "ORGANISM", 131, 137], ["Sendai", "ORGANISM", 241, 247], ["disaster risk reduction", "TREATMENT", 320, 343]]], ["The 2015 UNDRR STAG report recommends the delivery of outputs as detailed in Box 2.The Sendai Framework\u2019s Science and Technology Agenda ::: The Science and Technology AgendaThe use of scientifically derived evidence by government is not without its difficulties, however, particularly in the context of today\u2019s geopolitical climate and ongoing debate about the role of scientific experts in policy making (Ross et al. 2016; Pearce et al. 2018).", [["the delivery of outputs", "TREATMENT", 38, 61]]], ["Possible strategies for achieving this include building on existing programs that are known to be effective, strengthening relationships across sectors nationally and globally, and considering reworking policy narratives (Bardosh et al. 2017).WHO\u2019s Science and Technology Agenda ::: The Science and Technology AgendaAs part of the solutions identified, representatives of the health community and WHO worked together to set up a research network for Health EDRM.", [["existing programs", "TREATMENT", 59, 76]]], ["The Research Network comprises the core group, participants, and a wider information-sharing network.", [["participants", "SPECIES", 47, 59]]], ["WHO headquarters and Regional Offices are involved in the operation of both the Thematic Platform and the Research Network, and work together to discuss research needs, facilitate international research collaboration, and improve knowledge management.", [["knowledge management", "TREATMENT", 230, 250]]], ["The WHO Kobe Centre acts as the secretariat for this platform.WHO\u2019s Science and Technology Agenda ::: The Science and Technology AgendaThe unique value of the Research Network lies in its ability to leverage capacity across the six WHO regions, enabling (1) strengthening of the evidence base on Health EDRM on a global scale; and (2) the rapid dissemination of emerging evidence to member states.", [["base", "OBSERVATION_MODIFIER", 288, 292]]], ["The ability for rapid and widespread dissemination facilitates the implementation of Health EDRM policy and practice founded on the most robust and up-to-date evidence available.", [["widespread", "OBSERVATION_MODIFIER", 26, 36], ["dissemination", "OBSERVATION", 37, 50]]], ["In doing so, this should enable countries to strengthen their capacities in Health EDRM and ultimately contribute to one billion more people being safe during emergencies.WHO\u2019s Science and Technology Agenda ::: The Science and Technology AgendaThe Research Network and other key partners have identified, through a meeting convened by the WHO Kobe Centre in 2018, five research priority areas before, during, and after emergencies and disasters:Health data managementThis research priority focuses on developing tools and methodologies to support timely and accurate data collection, analysis, and dissemination in recognition of the critical importance of reliable data in the provision of effective health support in disaster relief and recovery.Mental health and psychosocial supportEmergencies and disasters can place significant and persistent mental health pressures on those affected, including the responders.", [["people", "ORGANISM", 134, 140], ["people", "SPECIES", 134, 140], ["Health data management", "TREATMENT", 445, 467], ["accurate data collection", "TEST", 558, 582], ["analysis", "TEST", 584, 592], ["effective health support", "TREATMENT", 691, 715], ["disaster relief", "TREATMENT", 719, 734], ["persistent mental health pressures", "PROBLEM", 838, 872], ["persistent", "OBSERVATION_MODIFIER", 838, 848]]], ["Understanding the most effective approaches to embedding mental health and psychosocial support into disaster response is an essential part of Health EDRM.Addressing the health risks and needs of subpopulations, including health literacyUnderstanding the health vulnerabilities, capacities, and inequities of communities and specific subpopulations is critical to disaster risk management.Health workforce development for Health Emergency and Disaster Risk ManagementThis is an overarching research theme of Health EDRM that encompasses all thematic research areas in acknowledging that effective disaster response and risk management hinges on highly skilled, trained, and supported workforces (including community actors).Research methods and ethicsWHO Kobe Centre coordinates the development of the WHO Guidance on Research Methods for Health EDRM\u2014comprehensive guidance (in textbook form) for designing, conducting, and reporting research, including research ethics, in emergencies and disasters (Aung et al. 2019).WHO\u2019s Science and Technology Agenda ::: The Science and Technology AgendaA detailed description of the expert meeting and its findings was published in a series of papers (Aung et al. 2019; G\u00e9n\u00e9reux et al. 2019; Kayano et al. 2019; Kubo et al. 2019).", [["psychosocial support", "TREATMENT", 75, 95], ["disaster risk management", "TREATMENT", 364, 388], ["Disaster Risk Management", "TREATMENT", 443, 467]]], ["The book is structured around six sections: introduction; identifying and understanding the problem; assessing the problems and developing a scoping study; study design; special topics to demonstrate research processes and benefits; and how to become a researcher.", [["the problems", "PROBLEM", 111, 123], ["a scoping study", "TEST", 139, 154]]], ["It includes an extensive series of case studies, 26 from individual countries and 33 from more than two countries or of global relevance.", [["case studies", "TEST", 35, 47], ["extensive", "OBSERVATION_MODIFIER", 15, 24]]], ["It will also enable the harmonization of Health EDRM research with universal terms; the use of mechanisms to facilitate and speed up the ethical review process; increased community participation and stakeholder involvement in generating research ideas and in assessing impact evaluation; and the development of reference materials such as consensus statements.Data, Monitoring, and ReportingThe adoption of the Sendai Framework by the UN member states includes agreement on seven global targets to assess progress in DRM:Substantially reduce global disaster mortality by 2030, aiming to lower the average per 100,000 global mortality rate in the decade 2020\u20132030 compared to the period 2005\u20132015;Substantially reduce the number of affected people globally by 2030, aiming to lower the average global figure per 100,000 in the decade 2020\u20132030 compared to the period 2005\u20132015;Reduce direct disaster economic loss in relation to global gross domestic product (GDP) by 2030;Substantially reduce disaster damage to critical infrastructure and disruption of basic services, among them health and educational facilities, including through developing their resilience by 2030;Substantially increase the number of countries with national and local disaster risk reduction strategies by 2020;Substantially enhance international cooperation to developing countries through adequate and sustainable support to complement their national actions for implementation of the present Framework by 2030;Substantially increase the availability of and access to multi-hazard early warning systems and disaster risk information and assessments to people by 2030.", [["people", "ORGANISM", 740, 746], ["people", "ORGANISM", 1627, 1633], ["people", "SPECIES", 740, 746], ["people", "SPECIES", 1627, 1633], ["impact evaluation", "TEST", 269, 286], ["direct disaster economic loss", "PROBLEM", 883, 912], ["disaster damage", "PROBLEM", 993, 1008], ["local disaster risk reduction strategies", "TREATMENT", 1235, 1275]]], ["12)Data, Monitoring, and ReportingUNDRR has developed technical guidance for monitoring and reporting on national progress in achieving these targets and has prepared a web-based tool to support this reporting (UNDRR 2017) as well as a training package for member states.", [["monitoring", "TEST", 77, 87], ["a training package", "TREATMENT", 234, 252]]], ["Most member states have a Sendai Framework Monitoring National Focal Point with responsibility for national reporting on the Sendai Framework targets.", [["Sendai", "ORGANISM", 125, 131]]], ["Many of these targets (and many of the associated 38 indicators) have clear links to the health impacts of disasters.", [["targets", "OBSERVATION_MODIFIER", 14, 21]]], ["For example, there are health specific indicators on mortality (A-2), people injured and ill (B-2), damage and destruction of health facilities (D-2), and disruption to basic health services (D-7).", [["ill", "DISEASE", 89, 92], ["people", "ORGANISM", 70, 76], ["people", "SPECIES", 70, 76], ["damage and destruction of health facilities", "PROBLEM", 100, 143], ["destruction", "OBSERVATION", 111, 122]]], ["Access to these health data is integral to timely, accurate, and complete reporting to the Sendai Framework Monitor.Data, Monitoring, and ReportingBecause ministries of health hold relevant data related to health outcomes, risks, and capacities, it is vital that ministries of health are engaged with the Sendai Framework Monitoring National Focal Point and work collaboratively with relevant partners to ensure comprehensive and accurate reporting.", [["Sendai", "ORGANISM", 91, 97]]], ["The WHO Technical Guidance Notes on Sendai Framework reporting for ministries of health is one tool that aims to facilitate this engagement, and provides guidance for the health sector on its role in data collection and reporting, as well as detailed descriptions of health specific indicators (WHO due for publication in early 2020).Data, Monitoring, and ReportingHealth sector reporting to the Sendai Framework Monitor will enable ministries of health to measure annual trends of the effects of emergencies and disasters on health, review progress in strengthening capacities, and prioritize areas for further action.", [["Sendai", "ORGANISM", 36, 42], ["further action", "TEST", 604, 618]]], ["There are also clear links to reporting on the SDGs.", [["clear", "OBSERVATION", 15, 20]]], ["Figure 1 highlights the web of links between targets of the Sendai Framework and the SDGs, including the SDG target 3d: Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction, and management of national and global health risks.Data, Monitoring, and ReportingThere are several benefits to building coherence between reporting for the Sendai Framework Monitor and the SDGs.", [["Sendai", "ORGANISM", 60, 66], ["Sendai", "ORGANISM", 390, 396], ["risk reduction", "TREATMENT", 217, 231]]], ["These include increasing awareness at national and subnational levels of government on how the two frameworks align; facilitating key partnerships, which help avoid duplication of data collection and reporting; promoting accountability; and enabling the development of overarching strategies for collective action on findings in order to maximize gains for both the health and disaster risk management sectors.Data, Monitoring, and ReportingThere are several developments that could support the engagement of ministries of health in supplying data for inclusion in the member state reporting process.", [["duplication of data collection", "PROBLEM", 165, 195], ["overarching strategies", "TREATMENT", 269, 291], ["increasing", "OBSERVATION_MODIFIER", 14, 24]]], ["Member states should consider organizing health sector training\u2014regionally, nationally, and subnationally\u2014in methods to improve monitoring and reporting on Sendai targets.", [["Sendai", "ORGANISM", 156, 162], ["Sendai targets", "TREATMENT", 156, 170]]], ["They should also consider further review of UNDRR technical guidance and training for the development of disaster data bases.", [["training", "TREATMENT", 73, 81]]], ["In the medium and longer terms, ministries of health could consider strengthening national and subnational capacities for civil registration and vital statistics, and developing national case registries for mortality and morbidity related to hazardous events, including emergencies and disasters (Green et al. 2019).Conclusion and Way ForwardThe growing recognition of health as a core dimension in DRM has catalyzed the development of Health EDRM, a field that encompasses emergency and disaster medicine, DRM, humanitarian action, global health security, adaptation to climate change, and resilience of health systems, communities, and countries.", [["civil registration", "TEST", 122, 140], ["vital statistics", "TEST", 145, 161], ["mortality", "PROBLEM", 207, 216], ["morbidity", "PROBLEM", 221, 230], ["hazardous events", "PROBLEM", 242, 258], ["disaster medicine", "TREATMENT", 488, 505], ["growing", "OBSERVATION_MODIFIER", 346, 353]]], ["The GPW 13 is structured around three strategic priorities, one of which specifically addresses health emergencies and aims to build and sustain the resilient health systems required to reduce the risks of epidemics and other health emergencies.Conclusion and Way ForwardThe WHO Health EDRM Research Network was established in direct response to contributing to the Sendai Framework in general and the Sendai Framework Monitor in particular.", [["Sendai", "ORGANISM", 402, 408], ["epidemics", "PROBLEM", 206, 215], ["the Sendai Framework Monitor", "TEST", 398, 426]]], ["The health sector is implementing many aspects of the Sendai Framework already, but there is a weakness in the way it recognizes, records, and reports this implementation.", [["Sendai", "ORGANISM", 54, 60], ["a weakness", "PROBLEM", 93, 103], ["weakness", "OBSERVATION", 95, 103]]], ["The policies, programs, and actions taken by governments, WHO, and partners that are aimed at reducing the risks and impacts of emergencies and disasters show the range of health sector actions that could be considered as evidence of implementing the Sendai Framework.Conclusion and Way ForwardGoing forward, effective and efficient coordination of work is critical, building on emergency preparedness and response, while simultaneously putting a greater emphasis on prevention and recovery.", [["Sendai", "ORGANISM", 251, 257]]], ["Ministries of health and their partners are encouraged to engage further with the application of the Health EDRM Framework, with the WHO Thematic Platform for Health EDRM and its associated Research Network, and in reporting to their National Focal Points for the Sendai Framework Monitor.", [["Sendai", "ORGANISM", 264, 270]]], ["This will enable ministries of health to measure the effects of emergencies and disasters on health, review progress in strengthening capacities, and prioritize areas for further action.", [["further action", "TEST", 171, 185]]]], "09349ef71877bc51a5bccdb0398de7efddad9954": [["IntroductionCD4 + T-helper (Th) cells are critical components of the adaptive immunity in the lung (Fig. 1) .", [["IntroductionCD4 + T-helper (Th) cells", "ANATOMY", 0, 37], ["lung", "ANATOMY", 94, 98], ["lung", "ORGAN", 94, 98], ["T-helper (Th) cells", "CELL_TYPE", 18, 37], ["IntroductionCD4 + T-helper (Th) cells", "TREATMENT", 0, 37], ["adaptive immunity", "OBSERVATION", 69, 86], ["lung", "ANATOMY", 94, 98], ["Fig", "OBSERVATION_MODIFIER", 100, 103]]], ["The development of these cells arises after priming with antigen presented by class II major histocompatibility complexes (termed signal 1).", [["cells", "ANATOMY", 25, 30], ["cells", "CELL", 25, 30], ["class II major histocompatibility complexes", "GENE_OR_GENE_PRODUCT", 78, 121], ["signal 1", "GENE_OR_GENE_PRODUCT", 130, 138], ["class II major histocompatibility complexes", "PROTEIN", 78, 121], ["termed signal 1", "PROTEIN", 123, 138], ["these cells", "PROBLEM", 19, 30], ["cells", "OBSERVATION", 25, 30]]], ["Further activation occurs after the engagement of costimulatory molecules and their receptors expressed on both antigenpresenting cells (APCs) and T cells (termed signal 2).", [["antigenpresenting cells", "ANATOMY", 112, 135], ["APCs", "ANATOMY", 137, 141], ["T cells", "ANATOMY", 147, 154], ["antigenpresenting cells", "CELL", 112, 135], ["APCs", "CELL", 137, 141], ["T cells", "CELL", 147, 154], ["costimulatory molecules", "PROTEIN", 50, 73], ["antigenpresenting cells", "CELL_TYPE", 112, 135], ["APCs", "CELL_TYPE", 137, 141], ["T cells", "CELL_TYPE", 147, 154], ["costimulatory molecules", "TREATMENT", 50, 73]]], ["This second signal is critical for both generating antigen-specific effector T cells as well as memory cells.", [["effector T cells", "ANATOMY", 68, 84], ["memory cells", "ANATOMY", 96, 108], ["antigen", "GENE_OR_GENE_PRODUCT", 51, 58], ["T cells", "CELL", 77, 84], ["memory cells", "CELL", 96, 108], ["effector T cells", "CELL_TYPE", 68, 84], ["memory cells", "CELL_TYPE", 96, 108], ["memory cells", "OBSERVATION", 96, 108]]], ["Presentation of antigen in the absences of costimulation can result in T-cell anergy.", [["T-cell", "ANATOMY", 71, 77], ["T-cell", "CELL", 71, 77], ["costimulation", "PROBLEM", 43, 56], ["T-cell anergy", "PROBLEM", 71, 84], ["cell anergy", "OBSERVATION", 73, 84]]], ["Final effector function is due to cytokine/growth factor-directed CD4 + T-cell differentiation (signal 3).", [["CD4 + T-cell", "ANATOMY", 66, 78], ["CD4", "GENE_OR_GENE_PRODUCT", 66, 69], ["cytokine", "PROTEIN", 34, 42], ["growth factor", "PROTEIN", 43, 56], ["CD4", "PROTEIN", 66, 69], ["cytokine/growth factor", "TEST", 34, 56]]], ["This latter aspect of differentiation is driven by lineage-specific transcription factors as well as changes in chromatin remodeling.", [["chromatin", "ANATOMY", 112, 121], ["chromatin", "CELLULAR_COMPONENT", 112, 121], ["transcription factors", "PROTEIN", 68, 89], ["chromatin", "DNA", 112, 121], ["chromatin remodeling", "PROBLEM", 112, 132], ["chromatin remodeling", "OBSERVATION", 112, 132]]], ["The critical role of CD4 + T cells in lung immunity and pulmonary host defenses was clearly demonstrated by the high incidence of pulmonary infections as a complication of human immunodeficiency virus (HIV) infections/acquired immunodeficiency syndrome (1) (2) (3) .Th2 cellsTh2 CD4 + T cells differentiate from naive precursors under the direction of the transcription factor GATA3 and signal transducer and activator of transcription 6 (STAT6) (4) .", [["CD4 + T cells", "ANATOMY", 21, 34], ["lung", "ANATOMY", 38, 42], ["pulmonary", "ANATOMY", 56, 65], ["pulmonary", "ANATOMY", 130, 139], ["Th2 cells", "ANATOMY", 266, 275], ["Th2 CD4 + T cells", "ANATOMY", 275, 292], ["pulmonary infections", "DISEASE", 130, 150], ["human immunodeficiency virus (HIV) infections", "DISEASE", 172, 217], ["acquired immunodeficiency syndrome", "DISEASE", 218, 252], ["CD4", "GENE_OR_GENE_PRODUCT", 21, 24], ["lung", "ORGAN", 38, 42], ["pulmonary", "ORGAN", 56, 65], ["pulmonary", "ORGAN", 130, 139], ["human immunodeficiency virus", "ORGANISM", 172, 200], ["Th2 cells", "CELL", 266, 275], ["CD4", "GENE_OR_GENE_PRODUCT", 279, 282], ["GATA3", "GENE_OR_GENE_PRODUCT", 377, 382], ["signal transducer and activator of transcription 6", "GENE_OR_GENE_PRODUCT", 387, 437], ["STAT6", "GENE_OR_GENE_PRODUCT", 439, 444], ["CD4", "PROTEIN", 21, 24], ["T cells", "CELL_TYPE", 27, 34], ["Th2 cells", "CELL_TYPE", 266, 275], ["Th2 CD4 + T cells", "CELL_TYPE", 275, 292], ["naive precursors", "CELL_TYPE", 312, 328], ["transcription factor", "PROTEIN", 356, 376], ["GATA3", "PROTEIN", 377, 382], ["signal transducer and activator of transcription 6", "PROTEIN", 387, 437], ["STAT6", "PROTEIN", 439, 444], ["human immunodeficiency virus (HIV", "SPECIES", 172, 205], ["human immunodeficiency virus", "SPECIES", 172, 200], ["HIV", "SPECIES", 202, 205], ["T cells", "PROBLEM", 27, 34], ["pulmonary infections", "PROBLEM", 130, 150], ["human immunodeficiency virus (HIV) infections", "PROBLEM", 172, 217], ["acquired immunodeficiency syndrome", "PROBLEM", 218, 252], ["Th2 cells", "PROBLEM", 266, 275], ["Th2 CD4", "TEST", 275, 282], ["signal transducer", "TEST", 387, 404], ["activator of transcription", "TREATMENT", 409, 435], ["lung", "ANATOMY", 38, 42], ["pulmonary", "ANATOMY", 56, 65], ["pulmonary", "ANATOMY", 130, 139], ["infections", "OBSERVATION", 140, 150], ["Th2 cells", "OBSERVATION", 266, 275]]], ["Effector cytokines produced by Th2 cells include interleukin-4 (IL-4), IL-5, and IL-13.", [["Th2 cells", "ANATOMY", 31, 40], ["Th2 cells", "CELL", 31, 40], ["interleukin-4", "GENE_OR_GENE_PRODUCT", 49, 62], ["IL-4", "GENE_OR_GENE_PRODUCT", 64, 68], ["IL-5", "GENE_OR_GENE_PRODUCT", 71, 75], ["IL-13", "GENE_OR_GENE_PRODUCT", 81, 86], ["Effector cytokines", "PROTEIN", 0, 18], ["Th2 cells", "CELL_TYPE", 31, 40], ["interleukin-4 (IL-4", "PROTEIN", 49, 68], ["IL", "PROTEIN", 71, 73], ["IL-13", "PROTEIN", 81, 86], ["Effector cytokines", "TEST", 0, 18], ["interleukin", "TEST", 49, 60], ["IL", "TEST", 64, 66], ["IL", "TEST", 71, 73], ["IL", "TEST", 81, 83]]], ["GATA3 binds directly to the Il4 locus, and IL-4 and signaling via STAT6 is critical for further Th2 proliferation and lineage commitment (4) .", [["GATA3", "GENE_OR_GENE_PRODUCT", 0, 5], ["Il4", "GENE_OR_GENE_PRODUCT", 28, 31], ["IL-4", "GENE_OR_GENE_PRODUCT", 43, 47], ["STAT6", "GENE_OR_GENE_PRODUCT", 66, 71], ["GATA3", "PROTEIN", 0, 5], ["Il4 locus", "DNA", 28, 37], ["IL-4", "PROTEIN", 43, 47], ["STAT6", "PROTEIN", 66, 71], ["GATA3 binds", "PROBLEM", 0, 11], ["further Th2 proliferation", "PROBLEM", 88, 113], ["Il4", "ANATOMY", 28, 31], ["Th2 proliferation", "OBSERVATION", 96, 113]]], ["Th2 effector cytokines mediate immunity against infections with helminths ( Fig. 2) .", [["infections", "DISEASE", 48, 58], ["helminths", "DISEASE", 64, 73], ["Th2 effector cytokines", "PROTEIN", 0, 22], ["Th2 effector cytokines", "TREATMENT", 0, 22]]], ["Deletion of Gata3 in mice results is embryonic lethal, but conditional deletion of Gata3 in T cells confirms the essential role of this transcription factor in Th2 differentiation and the expulsion of helminths from the gastrointestinal tract (5) .", [["embryonic", "ANATOMY", 37, 46], ["T cells", "ANATOMY", 92, 99], ["gastrointestinal tract", "ANATOMY", 220, 242], ["helminths from the gastrointestinal tract", "DISEASE", 201, 242], ["Gata3", "GENE_OR_GENE_PRODUCT", 12, 17], ["mice", "ORGANISM", 21, 25], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 37, 46], ["Gata3", "GENE_OR_GENE_PRODUCT", 83, 88], ["T cells", "CELL", 92, 99], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 220, 242], ["Gata3", "PROTEIN", 12, 17], ["Gata3", "PROTEIN", 83, 88], ["T cells", "CELL_TYPE", 92, 99], ["transcription factor", "PROTEIN", 136, 156], ["mice", "SPECIES", 21, 25], ["mice", "SPECIES", 21, 25], ["Deletion of Gata3", "PROBLEM", 0, 17], ["embryonic lethal", "PROBLEM", 37, 53], ["conditional deletion of Gata3 in T cells", "PROBLEM", 59, 99], ["gastrointestinal tract", "ANATOMY", 220, 242]]], ["IL-5 is an essential growth factor for eosinophilopoiesis (6, 7) .", [["IL-5", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-5", "PROTEIN", 0, 4], ["eosinophilopoiesis", "PROBLEM", 39, 57], ["essential", "OBSERVATION_MODIFIER", 11, 20], ["growth", "OBSERVATION_MODIFIER", 21, 27]]], ["Mice with homozygous deletion of Il5 have substantial reduction in both peripheral and bone marrow eosinophils (6, 7) .", [["peripheral", "ANATOMY", 72, 82], ["bone marrow eosinophils", "ANATOMY", 87, 110], ["Mice", "ORGANISM", 0, 4], ["Il5", "GENE_OR_GENE_PRODUCT", 33, 36], ["peripheral", "TISSUE", 72, 82], ["bone marrow eosinophils", "CELL", 87, 110], ["Il5", "DNA", 33, 36], ["peripheral and bone marrow eosinophils", "CELL_TYPE", 72, 110], ["Mice", "SPECIES", 0, 4], ["homozygous deletion of Il5", "PROBLEM", 10, 36], ["substantial reduction in both peripheral and bone marrow eosinophils", "PROBLEM", 42, 110], ["homozygous deletion", "OBSERVATION", 10, 29], ["substantial", "OBSERVATION_MODIFIER", 42, 53], ["reduction", "OBSERVATION_MODIFIER", 54, 63], ["both", "ANATOMY_MODIFIER", 67, 71], ["peripheral", "ANATOMY_MODIFIER", 72, 82], ["bone", "ANATOMY", 87, 91], ["marrow eosinophils", "OBSERVATION", 92, 110]]], ["In contrast, overexpression of IL-5 protein results in substantial eosinophilia in blood and tissues (8) .", [["blood", "ANATOMY", 83, 88], ["tissues", "ANATOMY", 93, 100], ["eosinophilia", "DISEASE", 67, 79], ["IL-5", "GENE_OR_GENE_PRODUCT", 31, 35], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["tissues", "TISSUE", 93, 100], ["IL-5 protein", "PROTEIN", 31, 43], ["overexpression of IL-5 protein", "TEST", 13, 43], ["substantial eosinophilia in blood and tissues", "PROBLEM", 55, 100], ["substantial", "OBSERVATION_MODIFIER", 55, 66], ["eosinophilia", "OBSERVATION", 67, 79], ["blood", "ANATOMY", 83, 88], ["tissues", "ANATOMY", 93, 100]]], ["IL-13 signals through a receptor complex of IL13RA1 and IL4Ra and activates STAT6 signaling.", [["IL-13", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL13RA1", "GENE_OR_GENE_PRODUCT", 44, 51], ["IL4Ra", "GENE_OR_GENE_PRODUCT", 56, 61], ["STAT6", "GENE_OR_GENE_PRODUCT", 76, 81], ["IL-13", "PROTEIN", 0, 5], ["IL13RA1", "PROTEIN", 44, 51], ["IL4Ra", "PROTEIN", 56, 61], ["STAT6", "PROTEIN", 76, 81], ["a receptor complex of IL13RA1", "TREATMENT", 22, 51], ["IL4Ra", "TREATMENT", 56, 61]]], ["These receptors are expressed on airway epithelium as well as airway smooth muscle.", [["airway epithelium", "ANATOMY", 33, 50], ["airway smooth muscle", "ANATOMY", 62, 82], ["airway epithelium", "TISSUE", 33, 50], ["airway smooth muscle", "TISSUE", 62, 82], ["airway", "ANATOMY", 33, 39], ["epithelium", "ANATOMY_MODIFIER", 40, 50], ["airway", "ANATOMY", 62, 68], ["smooth muscle", "OBSERVATION", 69, 82]]], ["In bronchial epithelium, IL-13 is a major factor in mucous production and goblet cell differentiation in the airway (9, 10) .", [["bronchial epithelium", "ANATOMY", 3, 23], ["mucous", "ANATOMY", 52, 58], ["goblet cell", "ANATOMY", 74, 85], ["airway", "ANATOMY", 109, 115], ["bronchial epithelium", "TISSUE", 3, 23], ["IL-13", "GENE_OR_GENE_PRODUCT", 25, 30], ["mucous", "MULTI-TISSUE_STRUCTURE", 52, 58], ["goblet cell", "CELL", 74, 85], ["airway", "MULTI-TISSUE_STRUCTURE", 109, 115], ["IL-13", "PROTEIN", 25, 30], ["a major factor in mucous production", "PROBLEM", 34, 69], ["goblet cell differentiation", "TEST", 74, 101], ["bronchial epithelium", "ANATOMY", 3, 23], ["mucous production", "OBSERVATION", 52, 69], ["goblet cell differentiation", "OBSERVATION", 74, 101], ["airway", "ANATOMY", 109, 115]]], ["Moreover, IL-13 signaling via STAT6 in airway smooth muscle and in airway epithelium leads to airways hyperresponsiveness to methacholine (9, 10) .", [["airway smooth muscle", "ANATOMY", 39, 59], ["airway epithelium", "ANATOMY", 67, 84], ["airways", "ANATOMY", 94, 101], ["methacholine", "CHEMICAL", 125, 137], ["methacholine", "CHEMICAL", 125, 137], ["IL-13", "GENE_OR_GENE_PRODUCT", 10, 15], ["STAT6", "GENE_OR_GENE_PRODUCT", 30, 35], ["airway smooth muscle", "TISSUE", 39, 59], ["airway epithelium", "TISSUE", 67, 84], ["airways", "MULTI-TISSUE_STRUCTURE", 94, 101], ["methacholine", "SIMPLE_CHEMICAL", 125, 137], ["IL-13", "PROTEIN", 10, 15], ["STAT6", "PROTEIN", 30, 35], ["IL", "TEST", 10, 12], ["airways hyperresponsiveness", "PROBLEM", 94, 121], ["methacholine", "TEST", 125, 137], ["airway", "ANATOMY", 39, 45], ["smooth muscle", "ANATOMY", 46, 59], ["airway", "ANATOMY", 67, 73], ["epithelium", "ANATOMY_MODIFIER", 74, 84], ["airways", "ANATOMY", 94, 101], ["hyperresponsiveness", "OBSERVATION", 102, 121]]], ["These cells and effector cytokines have been implicated in diseases such as allergic rhinitis, atopic dermatitis, and asthma (11) .", [["cells", "ANATOMY", 6, 11], ["allergic rhinitis", "DISEASE", 76, 93], ["atopic dermatitis", "DISEASE", 95, 112], ["asthma", "DISEASE", 118, 124], ["cells", "CELL", 6, 11], ["effector cytokines", "PROTEIN", 16, 34], ["effector cytokines", "PROBLEM", 16, 34], ["diseases", "PROBLEM", 59, 67], ["allergic rhinitis", "PROBLEM", 76, 93], ["atopic dermatitis", "PROBLEM", 95, 112], ["asthma", "PROBLEM", 118, 124], ["effector cytokines", "OBSERVATION", 16, 34], ["allergic rhinitis", "OBSERVATION", 76, 93], ["atopic dermatitis", "OBSERVATION", 95, 112], ["asthma", "OBSERVATION", 118, 124]]], ["Anti-IL-5 has been investigated in asthma and although initial studies did not show clear cut efficacy (12) , but subgroups of patients with high sputum eosinophilia respond to IL-5 blockade (12) .", [["sputum", "ANATOMY", 146, 152], ["asthma", "DISEASE", 35, 41], ["sputum eosinophilia", "DISEASE", 146, 165], ["IL-5", "GENE_OR_GENE_PRODUCT", 5, 9], ["patients", "ORGANISM", 127, 135], ["IL-5", "GENE_OR_GENE_PRODUCT", 177, 181], ["IL-5", "PROTEIN", 5, 9], ["IL", "PROTEIN", 177, 179], ["patients", "SPECIES", 127, 135], ["Anti-IL", "TREATMENT", 0, 7], ["asthma", "PROBLEM", 35, 41], ["initial studies", "TEST", 55, 70], ["high sputum eosinophilia", "PROBLEM", 141, 165], ["IL-5 blockade", "TREATMENT", 177, 190], ["asthma", "OBSERVATION", 35, 41], ["high", "OBSERVATION_MODIFIER", 141, 145], ["sputum eosinophilia", "OBSERVATION", 146, 165]]], ["Similarly, initial studies with IL-13 blockade were also negative, but recently, studies suggest that by stratifying patients with IL-13 driven asthma (by assessing the serum level of periostin, an IL-13 regulated gene in lung epithelium) can identify subgroups who respond to anti-IL-13 (13) .", [["serum", "ANATOMY", 169, 174], ["lung epithelium", "ANATOMY", 222, 237], ["asthma", "DISEASE", 144, 150], ["anti-IL-13", "CHEMICAL", 277, 287], ["IL-13", "GENE_OR_GENE_PRODUCT", 32, 37], ["patients", "ORGANISM", 117, 125], ["IL-13", "GENE_OR_GENE_PRODUCT", 131, 136], ["serum", "ORGANISM_SUBSTANCE", 169, 174], ["periostin", "GENE_OR_GENE_PRODUCT", 184, 193], ["IL-13", "GENE_OR_GENE_PRODUCT", 198, 203], ["lung epithelium", "TISSUE", 222, 237], ["anti-IL-13", "GENE_OR_GENE_PRODUCT", 277, 287], ["IL", "PROTEIN", 32, 34], ["IL-13", "PROTEIN", 131, 136], ["periostin", "PROTEIN", 184, 193], ["IL-13 regulated gene", "DNA", 198, 218], ["patients", "SPECIES", 117, 125], ["initial studies", "TEST", 11, 26], ["IL", "TEST", 32, 34], ["IL", "TEST", 131, 133], ["asthma", "PROBLEM", 144, 150], ["the serum level", "TEST", 165, 180], ["an IL", "TEST", 195, 200], ["anti-IL", "TEST", 277, 284], ["lung", "ANATOMY", 222, 226], ["epithelium", "ANATOMY_MODIFIER", 227, 237]]], ["In addition to asthma, IL-13 has been implicated in fibrotic processes in the lung in response to drugs such as bleomycin (14) (15) (16) .Th2 cellsTh2 cells also facilitate B-cell differentiation and antibody responses to T-cell-dependent protein antigens (17) , including the development of an anti-immunoglobulin E (IgE) response.", [["lung", "ANATOMY", 78, 82], ["Th2 cellsTh2 cells", "ANATOMY", 138, 156], ["B-cell", "ANATOMY", 173, 179], ["T-cell", "ANATOMY", 222, 228], ["asthma", "DISEASE", 15, 21], ["bleomycin", "CHEMICAL", 112, 121], ["bleomycin", "CHEMICAL", 112, 121], ["IL-13", "GENE_OR_GENE_PRODUCT", 23, 28], ["lung", "ORGAN", 78, 82], ["bleomycin", "SIMPLE_CHEMICAL", 112, 121], ["14) (15) (16)", "SIMPLE_CHEMICAL", 123, 136], ["Th2 cells", "CELL", 138, 147], ["Th2 cells", "CELL", 147, 156], ["B-cell", "CELL", 173, 179], ["T-cell", "CELL", 222, 228], ["anti-immunoglobulin E", "GENE_OR_GENE_PRODUCT", 295, 316], ["IgE", "GENE_OR_GENE_PRODUCT", 318, 321], ["IL-13", "PROTEIN", 23, 28], ["Th2 cellsTh2 cells", "CELL_LINE", 138, 156], ["T-cell-dependent protein antigens", "PROTEIN", 222, 255], ["anti-immunoglobulin E", "PROTEIN", 295, 316], ["IgE", "PROTEIN", 318, 321], ["asthma", "PROBLEM", 15, 21], ["drugs", "TREATMENT", 98, 103], ["bleomycin", "TREATMENT", 112, 121], ["Th2 cellsTh2 cells", "TEST", 138, 156], ["B-cell differentiation", "TEST", 173, 195], ["antibody responses", "TEST", 200, 218], ["T-cell", "TEST", 222, 228], ["protein antigens", "TEST", 239, 255], ["an anti-immunoglobulin E (IgE)", "TREATMENT", 292, 322], ["asthma", "OBSERVATION", 15, 21], ["fibrotic", "OBSERVATION", 52, 60], ["lung", "ANATOMY", 78, 82], ["Th2 cells", "OBSERVATION", 147, 156], ["B-cell differentiation", "OBSERVATION", 173, 195]]], ["It has been recently recognized that Th2 cell differentiation is not only regulated by IL-4 but also several cytokines produced by the lung epithelium, including thymic stromal lymphopoietin (TSLP), IL-25, and IL-33 (17) .", [["Th2 cell", "ANATOMY", 37, 45], ["lung epithelium", "ANATOMY", 135, 150], ["Th2 cell", "CELL", 37, 45], ["IL-4", "GENE_OR_GENE_PRODUCT", 87, 91], ["lung epithelium", "TISSUE", 135, 150], ["thymic stromal lymphopoietin", "GENE_OR_GENE_PRODUCT", 162, 190], ["TSLP", "GENE_OR_GENE_PRODUCT", 192, 196], ["IL-25", "GENE_OR_GENE_PRODUCT", 199, 204], ["IL-33", "GENE_OR_GENE_PRODUCT", 210, 215], ["IL-4", "PROTEIN", 87, 91], ["cytokines", "PROTEIN", 109, 118], ["TSLP", "PROTEIN", 192, 196], ["IL", "PROTEIN", 199, 201], ["IL", "PROTEIN", 210, 212], ["several cytokines", "PROBLEM", 101, 118], ["thymic stromal lymphopoietin (TSLP)", "TREATMENT", 162, 197], ["IL", "TEST", 210, 212], ["Th2 cell differentiation", "OBSERVATION", 37, 61], ["not only", "UNCERTAINTY", 65, 73], ["several", "OBSERVATION_MODIFIER", 101, 108], ["cytokines", "OBSERVATION", 109, 118], ["lung", "ANATOMY", 135, 139], ["epithelium", "ANATOMY_MODIFIER", 140, 150], ["thymic", "ANATOMY", 162, 168], ["stromal lymphopoietin", "OBSERVATION", 169, 190]]], ["It has been shown recently that polymorphism in both IL-33 and its receptors ST2 is associated with asthma, strongly implicating Th2 cells and specifically the IL-33 ST2 signaling pathway in this disease.", [["Th2 cells", "ANATOMY", 129, 138], ["asthma", "DISEASE", 100, 106], ["IL-33", "GENE_OR_GENE_PRODUCT", 53, 58], ["ST2", "GENE_OR_GENE_PRODUCT", 77, 80], ["Th2 cells", "CELL", 129, 138], ["IL-33", "GENE_OR_GENE_PRODUCT", 160, 165], ["ST2", "GENE_OR_GENE_PRODUCT", 166, 169], ["IL-33", "PROTEIN", 53, 58], ["ST2", "PROTEIN", 77, 80], ["Th2 cells", "CELL_TYPE", 129, 138], ["ST2", "PROTEIN", 166, 169], ["its receptors ST2", "TEST", 63, 80], ["asthma", "PROBLEM", 100, 106], ["Th2 cells", "PROBLEM", 129, 138], ["the IL", "TEST", 156, 162], ["this disease", "PROBLEM", 191, 203], ["polymorphism", "OBSERVATION_MODIFIER", 32, 44], ["associated with", "UNCERTAINTY", 84, 99], ["asthma", "OBSERVATION", 100, 106], ["Th2 cells", "OBSERVATION", 129, 138], ["disease", "OBSERVATION", 196, 203]]], ["(18) , were defined by their ability to express interferon-c (IFN-c).", [["interferon-c", "GENE_OR_GENE_PRODUCT", 48, 60], ["IFN-c", "GENE_OR_GENE_PRODUCT", 62, 67], ["interferon-c", "PROTEIN", 48, 60], ["IFN-c", "PROTEIN", 62, 67], ["interferon-c (IFN-c)", "TREATMENT", 48, 68]]], ["Differentiation of CD4 + Th1 cells is controlled by the transcription factors T-bet (19) and STAT4.", [["CD4 + Th1 cells", "ANATOMY", 19, 34], ["CD4", "GENE_OR_GENE_PRODUCT", 19, 22], ["T-bet (19)", "GENE_OR_GENE_PRODUCT", 78, 88], ["STAT4", "GENE_OR_GENE_PRODUCT", 93, 98], ["CD4", "PROTEIN", 19, 22], ["Th1 cells", "CELL_TYPE", 25, 34], ["transcription factors", "PROTEIN", 56, 77], ["T-bet (19)", "PROTEIN", 78, 88], ["STAT4", "PROTEIN", 93, 98], ["CD4", "TEST", 19, 22], ["Th1 cells", "PROBLEM", 25, 34], ["CD4", "OBSERVATION", 19, 22], ["Th1 cells", "OBSERVATION", 25, 34]]], ["Differentiation is controlled by IL-12p70, which is a heterodimer of IL-12p35 and IL-12p40 subunits (20) .", [["IL-12p70", "GENE_OR_GENE_PRODUCT", 33, 41], ["IL-12p35", "GENE_OR_GENE_PRODUCT", 69, 77], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 82, 90], ["IL-12p70", "PROTEIN", 33, 41], ["IL-12p35 and IL-12p40 subunits", "PROTEIN", 69, 99], ["a heterodimer of IL", "TREATMENT", 52, 71], ["IL", "TREATMENT", 82, 84]]], ["However, both in vitro and in vivo Th1 differentiation can be independent of IL-12.", [["IL-12", "GENE_OR_GENE_PRODUCT", 77, 82], ["IL-12", "PROTEIN", 77, 82]]], ["One critical IL-12-independent pathway is through the induction of type I interferons that can facilitate Th1 differentiation in certain situations (21) .", [["IL-12", "GENE_OR_GENE_PRODUCT", 13, 18], ["type I interferons", "GENE_OR_GENE_PRODUCT", 67, 85], ["IL-12", "PROTEIN", 13, 18], ["type I interferons", "PROTEIN", 67, 85], ["type I interferons", "TREATMENT", 67, 85]]], ["IFN-c which signals via a receptor complex consisting of two IFN-cR1 and two IFN-cR2 chains can signal in an autocrine paracrine fashion to further amplify Th1 differentiation and lineage commitment.", [["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["IFN-cR1", "GENE_OR_GENE_PRODUCT", 61, 68], ["IFN-cR2", "GENE_OR_GENE_PRODUCT", 77, 84], ["Th1", "CELL", 156, 159], ["IFN-c", "PROTEIN", 0, 5], ["receptor complex", "PROTEIN", 26, 42], ["IFN", "PROTEIN", 61, 64], ["cR1", "PROTEIN", 65, 68], ["IFN", "PROTEIN", 77, 80], ["cR2 chains", "PROTEIN", 81, 91], ["a receptor complex", "TEST", 24, 42], ["an autocrine paracrine fashion", "TREATMENT", 106, 136]]], ["IFN-c receptors are expressed on a wide variety of cells including myeloid cells including macrophages and dendritic cells (DCs), as well as structural cells in the lung such as epithelial cells and fibroblasts (22) .", [["cells", "ANATOMY", 51, 56], ["myeloid cells", "ANATOMY", 67, 80], ["macrophages", "ANATOMY", 91, 102], ["dendritic cells", "ANATOMY", 107, 122], ["DCs", "ANATOMY", 124, 127], ["cells", "ANATOMY", 152, 157], ["lung", "ANATOMY", 165, 169], ["epithelial cells", "ANATOMY", 178, 194], ["fibroblasts", "ANATOMY", 199, 210], ["IFN-c receptors", "GENE_OR_GENE_PRODUCT", 0, 15], ["cells", "CELL", 51, 56], ["myeloid cells", "CELL", 67, 80], ["macrophages", "CELL", 91, 102], ["dendritic cells", "CELL", 107, 122], ["DCs", "CELL", 124, 127], ["cells", "CELL", 152, 157], ["lung", "ORGAN", 165, 169], ["epithelial cells", "CELL", 178, 194], ["fibroblasts", "CELL", 199, 210], ["IFN-c receptors", "PROTEIN", 0, 15], ["myeloid cells", "CELL_TYPE", 67, 80], ["macrophages", "CELL_TYPE", 91, 102], ["dendritic cells", "CELL_TYPE", 107, 122], ["DCs", "CELL_TYPE", 124, 127], ["structural cells", "CELL_TYPE", 141, 157], ["epithelial cells", "CELL_TYPE", 178, 194], ["fibroblasts", "CELL_TYPE", 199, 210], ["myeloid cells", "PROBLEM", 67, 80], ["macrophages", "PROBLEM", 91, 102], ["dendritic cells", "PROBLEM", 107, 122], ["structural cells in the lung", "PROBLEM", 141, 169], ["epithelial cells", "PROBLEM", 178, 194], ["fibroblasts", "PROBLEM", 199, 210], ["myeloid cells", "OBSERVATION", 67, 80], ["dendritic cells", "OBSERVATION", 107, 122], ["structural cells", "OBSERVATION", 141, 157], ["lung", "ANATOMY", 165, 169], ["epithelial cells", "OBSERVATION", 178, 194], ["fibroblasts", "OBSERVATION_MODIFIER", 199, 210]]], ["IFN-cR1 and IFN-cR2 activate Janus-associated kinases 1 and 2 (JAK1/2), which phosphorylates STAT1.", [["IFN-cR1", "GENE_OR_GENE_PRODUCT", 0, 7], ["IFN-cR2", "GENE_OR_GENE_PRODUCT", 12, 19], ["Janus-associated kinases 1", "GENE_OR_GENE_PRODUCT", 29, 55], ["2", "GENE_OR_GENE_PRODUCT", 60, 61], ["JAK1", "GENE_OR_GENE_PRODUCT", 63, 67], ["2", "GENE_OR_GENE_PRODUCT", 68, 69], ["STAT1", "GENE_OR_GENE_PRODUCT", 93, 98], ["IFN", "PROTEIN", 0, 3], ["cR1", "PROTEIN", 4, 7], ["IFN", "PROTEIN", 12, 15], ["cR2", "PROTEIN", 16, 19], ["Janus-associated kinases 1 and 2 (JAK1/2", "PROTEIN", 29, 69], ["STAT1", "PROTEIN", 93, 98], ["IFN", "TEST", 0, 3], ["cR1", "TEST", 4, 7], ["IFN", "TEST", 12, 15], ["Janus", "TEST", 29, 34], ["kinases", "TEST", 46, 53], ["JAK1", "TEST", 63, 67]]], ["STAT1 undergoes homodimerization and translocation to the nucleus and binds to DNA-encoded c-activated sequences that ultimately control gene transcription (22) .Th1 cells, initially described by Mossman and CoffmanIFN-c is critical for mediating immunity and host resistance to many intracellular infections including Mycobacterium tuberculosis, Listeria moncytogenes, and Salmonella typhimurium.", [["nucleus", "ANATOMY", 58, 65], ["Th1 cells", "ANATOMY", 162, 171], ["intracellular", "ANATOMY", 284, 297], ["infections", "DISEASE", 298, 308], ["Mycobacterium tuberculosis", "DISEASE", 319, 345], ["Listeria moncytogenes", "DISEASE", 347, 368], ["STAT1", "GENE_OR_GENE_PRODUCT", 0, 5], ["nucleus", "CELLULAR_COMPONENT", 58, 65], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["Th1 cells", "CELL", 162, 171], ["Mossman", "GENE_OR_GENE_PRODUCT", 196, 203], ["CoffmanIFN-c", "GENE_OR_GENE_PRODUCT", 208, 220], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 284, 297], ["Mycobacterium tuberculosis", "ORGANISM", 319, 345], ["Listeria moncytogenes", "ORGANISM", 347, 368], ["Salmonella typhimurium", "ORGANISM", 374, 396], ["STAT1", "PROTEIN", 0, 5], ["c-activated sequences", "DNA", 91, 112], ["Th1 cells", "CELL_TYPE", 162, 171], ["Mossman and CoffmanIFN-c", "PROTEIN", 196, 220], ["Mycobacterium tuberculosis", "SPECIES", 319, 345], ["Listeria moncytogenes", "SPECIES", 347, 368], ["Salmonella typhimurium", "SPECIES", 374, 396], ["Mycobacterium tuberculosis", "SPECIES", 319, 345], ["Listeria moncytogenes", "SPECIES", 347, 368], ["Salmonella typhimurium", "SPECIES", 374, 396], ["homodimerization", "TREATMENT", 16, 32], ["Th1 cells", "PROBLEM", 162, 171], ["host resistance", "PROBLEM", 260, 275], ["many intracellular infections", "PROBLEM", 279, 308], ["Mycobacterium tuberculosis", "PROBLEM", 319, 345], ["Listeria moncytogenes", "PROBLEM", 347, 368], ["Salmonella typhimurium", "PROBLEM", 374, 396], ["homodimerization", "OBSERVATION", 16, 32], ["nucleus", "ANATOMY", 58, 65], ["intracellular", "OBSERVATION_MODIFIER", 284, 297], ["infections", "OBSERVATION", 298, 308], ["Mycobacterium tuberculosis", "OBSERVATION", 319, 345], ["Salmonella typhimurium", "OBSERVATION", 374, 396]]], ["Patients with mutations IL-12p40, IFN-c, or receptors for IL-12 or IFN-c have increased susceptibility to intracellular infections due to these organisms (23, 24) .", [["intracellular", "ANATOMY", 106, 119], ["infections", "DISEASE", 120, 130], ["Patients", "ORGANISM", 0, 8], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 24, 32], ["IFN-c", "GENE_OR_GENE_PRODUCT", 34, 39], ["IL-12", "GENE_OR_GENE_PRODUCT", 58, 63], ["IFN-c", "GENE_OR_GENE_PRODUCT", 67, 72], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 106, 119], ["IFN", "PROTEIN", 34, 37], ["IL-12", "PROTEIN", 58, 63], ["IFN", "PROTEIN", 67, 70], ["Patients", "SPECIES", 0, 8], ["mutations IL", "TEST", 14, 26], ["IFN", "TEST", 34, 37], ["IL", "TEST", 58, 60], ["IFN", "PROBLEM", 67, 70], ["increased susceptibility", "PROBLEM", 78, 102], ["intracellular infections", "PROBLEM", 106, 130], ["these organisms", "PROBLEM", 138, 153], ["infections", "OBSERVATION", 120, 130]]], ["Patients with IFN-c receptor mutations can develop disseminated infection with bacillus Calmette-Guerin (BCG) that is resistant to antibiotics and IFN-c therapy (23, 25) .", [["infection", "DISEASE", 64, 73], ["bacillus Calmette-Guerin", "CHEMICAL", 79, 103], ["IFN", "CHEMICAL", 147, 150], ["Patients", "ORGANISM", 0, 8], ["IFN-c receptor", "GENE_OR_GENE_PRODUCT", 14, 28], ["bacillus Calmette-Guerin", "ORGANISM", 79, 103], ["BCG", "ORGANISM", 105, 108], ["IFN-c", "GENE_OR_GENE_PRODUCT", 147, 152], ["IFN", "PROTEIN", 14, 17], ["IFN", "PROTEIN", 147, 150], ["Patients", "SPECIES", 0, 8], ["bacillus Calmette-Guerin", "SPECIES", 79, 103], ["IFN-c receptor mutations", "TREATMENT", 14, 38], ["disseminated infection", "PROBLEM", 51, 73], ["bacillus Calmette", "TREATMENT", 79, 96], ["Guerin (BCG", "TREATMENT", 97, 108], ["antibiotics", "TREATMENT", 131, 142], ["IFN-c therapy", "TREATMENT", 147, 160], ["disseminated", "OBSERVATION_MODIFIER", 51, 63], ["infection", "OBSERVATION", 64, 73]]], ["Patients with IL-12p40 mutations can also develop BCG or S. typhimurium infection, but theoretically can respond to IFN-c (24) .", [["S. typhimurium infection", "DISEASE", 57, 81], ["Patients", "ORGANISM", 0, 8], ["IL-12p40", "GENE_OR_GENE_PRODUCT", 14, 22], ["S. typhimurium", "ORGANISM", 57, 71], ["IFN-c", "GENE_OR_GENE_PRODUCT", 116, 121], ["IL", "PROTEIN", 14, 16], ["IFN", "PROTEIN", 116, 119], ["Patients", "SPECIES", 0, 8], ["S. typhimurium", "SPECIES", 57, 71], ["S. typhimurium", "SPECIES", 57, 71], ["IL-12p40 mutations", "TREATMENT", 14, 32], ["BCG", "PROBLEM", 50, 53], ["S. typhimurium infection", "PROBLEM", 57, 81], ["IFN", "TEST", 116, 119], ["typhimurium", "OBSERVATION_MODIFIER", 60, 71], ["infection", "OBSERVATION", 72, 81]]], ["Thus, there is strong evidence that this pathway is essential for human control of these intracellular pathogens.Th17 cellsTh17 cells are recently described effector lineage of T-helper cells that produces IL-17A, IL-17F, IL-21, IL-22, and IL-26 (the latter expressed in human cells).", [["intracellular", "ANATOMY", 89, 102], ["Th17 cellsTh17 cells", "ANATOMY", 113, 133], ["T-helper cells", "ANATOMY", 177, 191], ["cells", "ANATOMY", 277, 282], ["human", "ORGANISM", 66, 71], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 102], ["Th17 cellsTh17 cells", "CELL", 113, 133], ["T-helper cells", "CELL", 177, 191], ["IL-17A", "GENE_OR_GENE_PRODUCT", 206, 212], ["IL-17F", "GENE_OR_GENE_PRODUCT", 214, 220], ["IL-21", "GENE_OR_GENE_PRODUCT", 222, 227], ["IL-22", "GENE_OR_GENE_PRODUCT", 229, 234], ["IL-26", "GENE_OR_GENE_PRODUCT", 240, 245], ["human", "ORGANISM", 271, 276], ["cells", "CELL", 277, 282], ["Th17 cellsTh17 cells", "CELL_LINE", 113, 133], ["T-helper cells", "CELL_TYPE", 177, 191], ["IL-26", "PROTEIN", 240, 245], ["human cells", "CELL_TYPE", 271, 282], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 271, 276], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 271, 276], ["these intracellular pathogens", "PROBLEM", 83, 112], ["Th17 cellsTh17 cells", "TREATMENT", 113, 133], ["IL", "TEST", 206, 208], ["IL", "TEST", 214, 216], ["IL", "TEST", 222, 224], ["IL", "TEST", 229, 231], ["IL", "TEST", 240, 242], ["intracellular", "OBSERVATION_MODIFIER", 89, 102], ["pathogens", "OBSERVATION", 103, 112], ["lineage", "OBSERVATION_MODIFIER", 166, 173]]], ["Th17 cells differentiate under control of the transcription factors retinoid orphan receptor-c (RORc), ROR-a, and STAT3 (26, 27) .", [["Th17 cells", "ANATOMY", 0, 10], ["retinoid", "CHEMICAL", 68, 76], ["Th17 cells", "CELL", 0, 10], ["retinoid orphan receptor-c", "GENE_OR_GENE_PRODUCT", 68, 94], ["RORc", "GENE_OR_GENE_PRODUCT", 96, 100], ["ROR-a", "GENE_OR_GENE_PRODUCT", 103, 108], ["STAT3", "GENE_OR_GENE_PRODUCT", 114, 119], ["Th17 cells", "CELL_TYPE", 0, 10], ["transcription factors", "PROTEIN", 46, 67], ["retinoid orphan receptor", "PROTEIN", 68, 92], ["-c", "PROTEIN", 92, 94], ["RORc", "PROTEIN", 96, 100], ["ROR", "PROTEIN", 103, 106], ["STAT3", "PROTEIN", 114, 119], ["Th17 cells", "TREATMENT", 0, 10], ["ROR", "TEST", 103, 106], ["STAT3", "TEST", 114, 119]]], ["It was initially believed that one of the critical instructional cytokines for Th17 differentiation was IL-23 (28) ; however, IL-23 receptors are not expressed on naive CD4 + T cells.", [["Th17", "ANATOMY", 79, 83], ["CD4 + T cells", "ANATOMY", 169, 182], ["Th17", "CELL", 79, 83], ["IL-23", "GENE_OR_GENE_PRODUCT", 104, 109], ["IL-23 receptors", "GENE_OR_GENE_PRODUCT", 126, 141], ["CD4", "GENE_OR_GENE_PRODUCT", 169, 172], ["cytokines", "PROTEIN", 65, 74], ["IL-23 receptors", "PROTEIN", 126, 141], ["naive CD4 + T cells", "CELL_TYPE", 163, 182], ["IL", "TEST", 104, 106], ["IL", "TEST", 126, 128]]], ["Landmark studies published in 2005 showed that these cells develop independently of STAT4 or STAT6 as well as T-bet or GATA3 (29, 30) .", [["cells", "ANATOMY", 53, 58], ["cells", "CELL", 53, 58], ["STAT4", "GENE_OR_GENE_PRODUCT", 84, 89], ["STAT6", "GENE_OR_GENE_PRODUCT", 93, 98], ["T-bet", "GENE_OR_GENE_PRODUCT", 110, 115], ["GATA3", "GENE_OR_GENE_PRODUCT", 119, 124], ["STAT4", "PROTEIN", 84, 89], ["STAT6", "PROTEIN", 93, 98], ["T-bet", "PROTEIN", 110, 115], ["GATA3", "PROTEIN", 119, 124], ["Landmark studies", "TEST", 0, 16], ["these cells", "PROBLEM", 47, 58], ["GATA3", "TEST", 119, 124]]], ["These data implicated that Th17 cells were a distinct CD4 + T-cell lineage (29, 30) .", [["Th17 cells", "ANATOMY", 27, 37], ["CD4 + T-cell lineage", "ANATOMY", 54, 74], ["Th17 cells", "CELL", 27, 37], ["CD4", "GENE_OR_GENE_PRODUCT", 54, 57], ["Th17 cells", "CELL_TYPE", 27, 37], ["CD4 + T-cell lineage", "CELL_TYPE", 54, 74], ["Th17 cells", "PROBLEM", 27, 37], ["Th17 cells", "OBSERVATION", 27, 37]]], ["Th17 differentiation can occur with stimulation with transforming growth factor-b (TGF-b) and IL-6 (31-33).", [["transforming growth factor-b", "GENE_OR_GENE_PRODUCT", 53, 81], ["TGF-b", "GENE_OR_GENE_PRODUCT", 83, 88], ["IL-6", "GENE_OR_GENE_PRODUCT", 94, 98], ["TGF", "PROTEIN", 83, 86], ["IL", "PROTEIN", 94, 96], ["transforming growth factor", "TEST", 53, 79], ["TGF", "TEST", 83, 86], ["IL", "TEST", 94, 96]]], ["Moreover, this cytokine/ growth factor combination induces the expression of IL-23R (31) (32) (33) .", [["IL-23R (31) (32)", "SIMPLE_CHEMICAL", 77, 93], ["cytokine", "PROTEIN", 15, 23], ["this cytokine/ growth factor combination", "TREATMENT", 10, 50], ["IL", "TEST", 77, 79]]], ["Signaling via IL-23 allows terminal differentiation and expansion of Th17 cells (34) .", [["Th17 cells", "ANATOMY", 69, 79], ["IL-23", "GENE_OR_GENE_PRODUCT", 14, 19], ["Th17 cells", "CELL", 69, 79], ["IL-23", "PROTEIN", 14, 19], ["Th17 cells", "CELL_TYPE", 69, 79], ["expansion of Th17 cells", "PROBLEM", 56, 79], ["expansion", "OBSERVATION_MODIFIER", 56, 65], ["Th17 cells", "OBSERVATION", 69, 79]]], ["Another critical effector cytokine produced by Th17 cells is IL-22, which is controlled by IL-23 as well as the transcription factor the arylhydrocarbon receptor (Ahr) (35) .", [["Th17 cells", "ANATOMY", 47, 57], ["arylhydrocarbon", "CHEMICAL", 137, 152], ["Th17 cells", "CELL", 47, 57], ["IL-22", "GENE_OR_GENE_PRODUCT", 61, 66], ["IL-23", "GENE_OR_GENE_PRODUCT", 91, 96], ["arylhydrocarbon receptor", "GENE_OR_GENE_PRODUCT", 137, 161], ["Ahr", "GENE_OR_GENE_PRODUCT", 163, 166], ["effector cytokine", "PROTEIN", 17, 34], ["Th17 cells", "CELL_TYPE", 47, 57], ["IL-22", "PROTEIN", 61, 66], ["IL-23", "PROTEIN", 91, 96], ["transcription factor", "PROTEIN", 112, 132], ["arylhydrocarbon receptor", "PROTEIN", 137, 161], ["Ahr", "PROTEIN", 163, 166], ["IL", "TEST", 61, 63], ["effector cytokine", "OBSERVATION", 17, 34]]], ["IL-21 (36, 37) can function in an autocrine manner to further expand Th17 differentiation (Fig. 1 ).", [["Th17", "ANATOMY", 69, 73], ["IL-21", "GENE_OR_GENE_PRODUCT", 0, 5], ["Th17", "CELL", 69, 73], ["IL", "TEST", 0, 2]]], ["It has been recently shown in vivo that TGFb activation and thus differentiation of Th17 cells requires activation of latent TGFb by av integrins (38, 39) .", [["Th17 cells", "ANATOMY", 84, 94], ["TGFb", "GENE_OR_GENE_PRODUCT", 40, 44], ["Th17 cells", "CELL", 84, 94], ["TGFb", "GENE_OR_GENE_PRODUCT", 125, 129], ["av integrins", "GENE_OR_GENE_PRODUCT", 133, 145], ["TGFb", "PROTEIN", 40, 44], ["Th17 cells", "CELL_TYPE", 84, 94], ["latent TGFb", "PROTEIN", 118, 129], ["integrins", "PROTEIN", 136, 145], ["TGFb activation", "PROBLEM", 40, 55], ["Th17 cells", "PROBLEM", 84, 94], ["latent TGFb", "PROBLEM", 118, 129], ["av integrins", "TREATMENT", 133, 145], ["Th17 cells", "OBSERVATION", 84, 94], ["latent", "OBSERVATION_MODIFIER", 118, 124], ["TGFb", "OBSERVATION", 125, 129]]], ["This pathway is not required for IL-17 production by cd T cells (38, 39) .T-follicular helper cellsT-follicular helper (Tfh) cells are a subgroup of CD4 + T cells that are located in the B-cell follicle region of secondary lymphoid tissues including lymph nodes and bronchial-associated lymphoid tissues in the lung.", [["cd T cells", "ANATOMY", 53, 63], ["T-follicular helper cellsT-follicular helper (Tfh) cells", "ANATOMY", 74, 130], ["CD4 + T cells", "ANATOMY", 149, 162], ["B-cell follicle", "ANATOMY", 187, 202], ["lymphoid tissues", "ANATOMY", 223, 239], ["lymph nodes", "ANATOMY", 250, 261], ["bronchial", "ANATOMY", 266, 275], ["lymphoid tissues", "ANATOMY", 287, 303], ["lung", "ANATOMY", 311, 315], ["IL-17", "GENE_OR_GENE_PRODUCT", 33, 38], ["cd T cells", "CELL", 53, 63], ["T-follicular helper cellsT-follicular helper (Tfh) cells", "CELL", 74, 130], ["CD4", "GENE_OR_GENE_PRODUCT", 149, 152], ["B-cell follicle", "TISSUE", 187, 202], ["secondary lymphoid tissues", "TISSUE", 213, 239], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 250, 261], ["bronchial-associated lymphoid tissues", "TISSUE", 266, 303], ["lung", "ORGAN", 311, 315], ["IL-17", "PROTEIN", 33, 38], ["cd T cells", "CELL_TYPE", 53, 63], ["T-follicular helper cellsT-follicular helper (Tfh) cells", "CELL_TYPE", 74, 130], ["CD4 + T cells", "CELL_TYPE", 149, 162], ["IL", "TEST", 33, 35], ["T", "TEST", 74, 75], ["CD4 + T cells", "PROBLEM", 149, 162], ["secondary lymphoid tissues", "PROBLEM", 213, 239], ["lymph nodes", "PROBLEM", 250, 261], ["bronchial-associated lymphoid tissues in the lung", "PROBLEM", 266, 315], ["T cells", "OBSERVATION", 155, 162], ["B-", "ANATOMY_MODIFIER", 187, 189], ["cell follicle", "OBSERVATION", 189, 202], ["secondary lymphoid tissues", "OBSERVATION", 213, 239], ["lymph nodes", "OBSERVATION", 250, 261], ["bronchial", "ANATOMY", 266, 275], ["lymphoid tissues", "OBSERVATION", 287, 303], ["lung", "ANATOMY", 311, 315]]], ["These cells regulate Tcell-dependent B-cell activation through the expression of CD40L and IL-21 (40) .", [["cells", "ANATOMY", 6, 11], ["B-cell", "ANATOMY", 37, 43], ["cells", "CELL", 6, 11], ["Tcell", "GENE_OR_GENE_PRODUCT", 21, 26], ["B-cell", "CELL", 37, 43], ["CD40L", "GENE_OR_GENE_PRODUCT", 81, 86], ["IL-21", "GENE_OR_GENE_PRODUCT", 91, 96], ["Tcell", "PROTEIN", 21, 26], ["CD40L", "PROTEIN", 81, 86], ["IL", "PROTEIN", 91, 93], ["These cells", "TEST", 0, 11], ["Tcell", "TEST", 21, 26], ["dependent B-cell activation", "TREATMENT", 27, 54], ["CD40L and IL", "TREATMENT", 81, 93], ["Tcell", "OBSERVATION_MODIFIER", 21, 26], ["dependent", "OBSERVATION_MODIFIER", 27, 36], ["B-cell activation", "OBSERVATION", 37, 54]]], ["These cells develop under the control of the transcription factor Bcl-6 (40) and are also regulated by inducible costimulatory (ICOS).T-regulatory cellsTreg differentiation is controlled by the transcription factors Foxp3 and STAT5 (41) .", [["cells", "ANATOMY", 6, 11], ["T-regulatory cells", "ANATOMY", 134, 152], ["Treg", "ANATOMY", 152, 156], ["cells", "CELL", 6, 11], ["Bcl-6", "GENE_OR_GENE_PRODUCT", 66, 71], ["40", "GENE_OR_GENE_PRODUCT", 73, 75], ["ICOS", "GENE_OR_GENE_PRODUCT", 128, 132], ["T-regulatory cells", "CELL", 134, 152], ["Treg", "CELL", 152, 156], ["Foxp3", "GENE_OR_GENE_PRODUCT", 216, 221], ["STAT5", "GENE_OR_GENE_PRODUCT", 226, 231], ["transcription factor", "PROTEIN", 45, 65], ["Bcl-6", "PROTEIN", 66, 71], ["ICOS", "PROTEIN", 128, 132], ["T-regulatory cells", "CELL_TYPE", 134, 152], ["transcription factors", "PROTEIN", 194, 215], ["Foxp3", "PROTEIN", 216, 221], ["STAT5", "PROTEIN", 226, 231], ["These cells", "PROBLEM", 0, 11], ["the transcription factor Bcl", "TEST", 41, 69], ["regulatory cells", "OBSERVATION", 136, 152]]], ["These cells are essential for mediating tolerance to inhaled antigen in the lung (41) .", [["cells", "ANATOMY", 6, 11], ["lung", "ANATOMY", 76, 80], ["cells", "CELL", 6, 11], ["lung", "ORGAN", 76, 80], ["inhaled antigen", "PROTEIN", 53, 68], ["mediating tolerance", "PROBLEM", 30, 49], ["lung", "ANATOMY", 76, 80]]], ["Deletion of these cells or abrogating their effector molecules, which include IL-10 and TGFb, prevent airways sensitization to allergen as well as allergic inflammation (41) .", [["cells", "ANATOMY", 18, 23], ["airways", "ANATOMY", 102, 109], ["airways sensitization", "DISEASE", 102, 123], ["allergic inflammation", "DISEASE", 147, 168], ["cells", "CELL", 18, 23], ["IL-10", "GENE_OR_GENE_PRODUCT", 78, 83], ["TGFb", "GENE_OR_GENE_PRODUCT", 88, 92], ["airways", "MULTI-TISSUE_STRUCTURE", 102, 109], ["effector molecules", "PROTEIN", 44, 62], ["IL-10", "PROTEIN", 78, 83], ["TGFb", "PROTEIN", 88, 92], ["Deletion of these cells", "PROBLEM", 0, 23], ["abrogating their effector molecules", "PROBLEM", 27, 62], ["IL", "TEST", 78, 80], ["TGFb", "TREATMENT", 88, 92], ["airways sensitization", "PROBLEM", 102, 123], ["allergen", "PROBLEM", 127, 135], ["allergic inflammation", "PROBLEM", 147, 168], ["effector molecules", "OBSERVATION", 44, 62], ["prevent", "UNCERTAINTY", 94, 101], ["airways", "ANATOMY", 102, 109]]], ["These cells can suppress the effector activity of many T-helper subsets and can be thymically derived (natural Tregs) or induced in the periphery (iTregs).", [["cells", "ANATOMY", 6, 11], ["Tregs", "ANATOMY", 111, 116], ["periphery", "ANATOMY", 136, 145], ["iTregs", "ANATOMY", 147, 153], ["cells", "CELL", 6, 11], ["T-helper subsets", "CELL", 55, 71], ["Tregs", "CELL", 111, 116], ["periphery", "CELLULAR_COMPONENT", 136, 145], ["iTregs", "CELL", 147, 153], ["T-helper subsets", "CELL_TYPE", 55, 71], ["natural Tregs", "CELL_TYPE", 103, 116], ["activity", "OBSERVATION_MODIFIER", 38, 46], ["periphery", "ANATOMY_MODIFIER", 136, 145]]], ["An exhaustive review of these cells is beyond the scope of this chapter, but the reader is referred to excellent thorough reviews (41, 42) of these cells if they seek a more in-depth description of these cells.T-regulatory cellsNon-CD4 + T-helper cell sources of Th1/Th2/Th17 effector cytokines in the lung Other cells in the lung exist that produce many of the same effector cytokines as Th1, Th2, or Th17 cells including innate lymphoid cells, natural killer (NK) cells, and cd T cells. cd T cells are resident in mucosal sites including the lung and can produce IFN-c, IL-4, IL-17, and IL-22 (43) .", [["cells", "ANATOMY", 30, 35], ["cells", "ANATOMY", 148, 153], ["cells", "ANATOMY", 204, 209], ["T-regulatory cellsNon-CD4 + T-helper cell", "ANATOMY", 210, 251], ["lung", "ANATOMY", 302, 306], ["cells", "ANATOMY", 313, 318], ["lung", "ANATOMY", 326, 330], ["Th17 cells", "ANATOMY", 402, 412], ["lymphoid cells", "ANATOMY", 430, 444], ["natural killer (NK) cells", "ANATOMY", 446, 471], ["cd T cells", "ANATOMY", 477, 487], ["cd T cells", "ANATOMY", 489, 499], ["mucosal sites", "ANATOMY", 516, 529], ["lung", "ANATOMY", 544, 548], ["cells", "CELL", 30, 35], ["cells", "CELL", 148, 153], ["cells", "CELL", 204, 209], ["T", "GENE_OR_GENE_PRODUCT", 210, 211], ["Th1", "GENE_OR_GENE_PRODUCT", 263, 266], ["Th2", "GENE_OR_GENE_PRODUCT", 267, 270], ["lung Other cells", "CELL", 302, 318], ["lung", "ORGAN", 326, 330], ["Th1", "GENE_OR_GENE_PRODUCT", 389, 392], ["Th2", "GENE_OR_GENE_PRODUCT", 394, 397], ["Th17 cells", "CELL", 402, 412], ["innate lymphoid cells", "CELL", 423, 444], ["natural killer (NK) cells", "CELL", 446, 471], ["cd T cells", "CELL", 477, 487], ["cd T cells", "CELL", 489, 499], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 516, 529], ["lung", "ORGAN", 544, 548], ["IFN-c", "GENE_OR_GENE_PRODUCT", 565, 570], ["IL-4", "GENE_OR_GENE_PRODUCT", 572, 576], ["IL-17", "GENE_OR_GENE_PRODUCT", 578, 583], ["IL-22", "GENE_OR_GENE_PRODUCT", 589, 594], ["Th1/Th2/Th17 effector cytokines", "PROTEIN", 263, 294], ["effector cytokines", "PROTEIN", 367, 385], ["Th1, Th2, or Th17 cells", "CELL_TYPE", 389, 412], ["innate lymphoid cells", "CELL_TYPE", 423, 444], ["natural killer (NK) cells", "CELL_TYPE", 446, 471], ["cd T cells", "CELL_TYPE", 477, 487], ["cd T cells", "CELL_TYPE", 489, 499], ["IFN", "PROTEIN", 565, 568], ["IL", "PROTEIN", 578, 580], ["T", "TEST", 210, 211], ["cellsNon-CD4", "TEST", 223, 235], ["Th1/Th2", "TEST", 263, 270], ["Th17 effector cytokines", "PROBLEM", 271, 294], ["Th17 cells", "PROBLEM", 402, 412], ["innate lymphoid cells", "PROBLEM", 423, 444], ["cells", "TEST", 466, 471], ["cd T cells", "PROBLEM", 477, 487], ["IFN", "TEST", 565, 568], ["IL", "TEST", 572, 574], ["IL", "TEST", 578, 580], ["IL", "TEST", 589, 591], ["T-", "ANATOMY", 238, 240], ["helper cell", "OBSERVATION", 240, 251], ["Th1", "ANATOMY", 263, 266], ["Th17 effector cytokines", "OBSERVATION", 271, 294], ["lung", "ANATOMY", 302, 306], ["lung", "ANATOMY", 326, 330], ["effector cytokines", "OBSERVATION", 367, 385], ["Th17 cells", "OBSERVATION", 402, 412], ["innate lymphoid cells", "OBSERVATION", 423, 444], ["natural killer", "OBSERVATION", 446, 460], ["cd T cells", "OBSERVATION", 477, 487], ["lung", "ANATOMY", 544, 548]]], ["These cells are a major source of early IL-17 after pulmonary infection, and IL-17 production by these cells is regulated by IL-23 and IL-1b (44) (45) (46) (47) (48) . cd T-cell production of IL-10 has been shown to play a key counter-inflammatory role in some pulmonary infections such as Pneumocystis infection (49) .T-regulatory cellsNK cells can also produce IL-4, IFNc, and IL-17 (50) in the lung in response to infection, allergen, or ozone.", [["cells", "ANATOMY", 6, 11], ["pulmonary", "ANATOMY", 52, 61], ["cells", "ANATOMY", 103, 108], ["T-cell", "ANATOMY", 171, 177], ["pulmonary", "ANATOMY", 261, 270], ["T-regulatory cellsNK cells", "ANATOMY", 319, 345], ["lung", "ANATOMY", 397, 401], ["pulmonary infection", "DISEASE", 52, 71], ["pulmonary infections", "DISEASE", 261, 281], ["Pneumocystis infection", "DISEASE", 290, 312], ["infection", "DISEASE", 417, 426], ["ozone", "CHEMICAL", 441, 446], ["ozone", "CHEMICAL", 441, 446], ["cells", "CELL", 6, 11], ["IL-17", "GENE_OR_GENE_PRODUCT", 40, 45], ["pulmonary", "ORGAN", 52, 61], ["IL-17", "GENE_OR_GENE_PRODUCT", 77, 82], ["cells", "CELL", 103, 108], ["IL-23", "GENE_OR_GENE_PRODUCT", 125, 130], ["IL-1b (44) (45) (46)", "SIMPLE_CHEMICAL", 135, 155], ["IL-10", "GENE_OR_GENE_PRODUCT", 192, 197], ["pulmonary", "ORGAN", 261, 270], ["T-regulatory cellsNK cells", "CELL", 319, 345], ["IL-4", "GENE_OR_GENE_PRODUCT", 363, 367], ["IFNc", "GENE_OR_GENE_PRODUCT", 369, 373], ["IL-17", "GENE_OR_GENE_PRODUCT", 379, 384], ["lung", "ORGAN", 397, 401], ["ozone", "SIMPLE_CHEMICAL", 441, 446], ["IL-17", "PROTEIN", 40, 45], ["IL", "PROTEIN", 125, 127], ["IL-10", "PROTEIN", 192, 197], ["T-regulatory cellsNK cells", "CELL_TYPE", 319, 345], ["IL", "PROTEIN", 363, 365], ["IFNc", "PROTEIN", 369, 373], ["early IL", "TEST", 34, 42], ["pulmonary infection", "PROBLEM", 52, 71], ["IL", "TEST", 77, 79], ["these cells", "TEST", 97, 108], ["IL", "TEST", 125, 127], ["IL", "TEST", 135, 137], ["some pulmonary infections", "PROBLEM", 256, 281], ["Pneumocystis infection", "PROBLEM", 290, 312], ["IL", "TEST", 363, 365], ["IFNc", "TEST", 369, 373], ["IL", "TEST", 379, 381], ["infection", "PROBLEM", 417, 426], ["allergen", "PROBLEM", 428, 436], ["early", "OBSERVATION_MODIFIER", 34, 39], ["IL", "OBSERVATION", 40, 42], ["pulmonary", "ANATOMY", 52, 61], ["infection", "OBSERVATION", 62, 71], ["inflammatory", "OBSERVATION", 235, 247], ["pulmonary", "ANATOMY", 261, 270], ["infections", "OBSERVATION", 271, 281], ["Pneumocystis", "OBSERVATION", 290, 302], ["cellsNK cells", "OBSERVATION", 332, 345], ["lung", "ANATOMY", 397, 401], ["infection", "OBSERVATION", 417, 426]]], ["One population that has been extensively studied is a population that expresses an invariant T-cell receptor (iNKT cells) that recognizes a galactolipid Sphingomonas, a-galactosylceramide (51, 52) .", [["T-cell", "ANATOMY", 93, 99], ["iNKT cells", "ANATOMY", 110, 120], ["a-galactosylceramide", "CHEMICAL", 167, 187], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 93, 108], ["iNKT cells", "CELL", 110, 120], ["a-galactosylceramide", "SIMPLE_CHEMICAL", 167, 187], ["invariant T-cell receptor", "PROTEIN", 83, 108], ["iNKT cells", "CELL_TYPE", 110, 120], ["population", "OBSERVATION", 4, 14], ["invariant", "OBSERVATION_MODIFIER", 83, 92], ["iNKT cells", "OBSERVATION", 110, 120]]], ["These cells are elevated in the bronchial alveolar lavage fluid of patients with asthma (53, 54) .", [["cells", "ANATOMY", 6, 11], ["bronchial alveolar lavage fluid", "ANATOMY", 32, 63], ["asthma", "DISEASE", 81, 87], ["cells", "CELL", 6, 11], ["bronchial alveolar lavage fluid", "ORGANISM_SUBSTANCE", 32, 63], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["These cells", "TEST", 0, 11], ["elevated", "PROBLEM", 16, 24], ["the bronchial alveolar lavage fluid", "TEST", 28, 63], ["asthma", "PROBLEM", 81, 87], ["elevated", "OBSERVATION_MODIFIER", 16, 24], ["bronchial", "ANATOMY", 32, 41], ["alveolar", "ANATOMY_MODIFIER", 42, 50], ["lavage fluid", "OBSERVATION", 51, 63], ["asthma", "OBSERVATION", 81, 87]]], ["NKT cells produce IFNc in response to S. pneumoniae pulmonary infection (55) and IL-17 in response to Escherichia coli lipopolysaccharide (LPS) (50) .", [["NKT cells", "ANATOMY", 0, 9], ["pulmonary", "ANATOMY", 52, 61], ["pulmonary infection", "DISEASE", 52, 71], ["lipopolysaccharide", "CHEMICAL", 119, 137], ["LPS", "CHEMICAL", 139, 142], ["NKT cells", "CELL", 0, 9], ["IFNc", "GENE_OR_GENE_PRODUCT", 18, 22], ["S. pneumoniae", "ORGANISM", 38, 51], ["pulmonary", "ORGAN", 52, 61], ["IL-17", "GENE_OR_GENE_PRODUCT", 81, 86], ["Escherichia coli", "ORGANISM", 102, 118], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 119, 137], ["LPS", "SIMPLE_CHEMICAL", 139, 142], ["NKT cells", "CELL_TYPE", 0, 9], ["IFNc", "PROTEIN", 18, 22], ["IL-17", "PROTEIN", 81, 86], ["S. pneumoniae", "SPECIES", 38, 51], ["Escherichia coli", "SPECIES", 102, 118], ["S. pneumoniae", "SPECIES", 38, 51], ["Escherichia coli", "SPECIES", 102, 118], ["NKT cells", "PROBLEM", 0, 9], ["IFNc", "PROBLEM", 18, 22], ["S. pneumoniae pulmonary infection", "PROBLEM", 38, 71], ["IL", "TEST", 81, 83], ["Escherichia coli lipopolysaccharide", "TEST", 102, 137], ["LPS", "TEST", 139, 142], ["pneumoniae", "OBSERVATION_MODIFIER", 41, 51], ["pulmonary", "ANATOMY", 52, 61], ["infection", "OBSERVATION", 62, 71], ["Escherichia coli", "OBSERVATION", 102, 118]]], ["These cells also produce IL-17, and this response is critical for airways hyperresponsiveness to ozone (56) .", [["cells", "ANATOMY", 6, 11], ["airways", "ANATOMY", 66, 73], ["ozone", "CHEMICAL", 97, 102], ["ozone", "CHEMICAL", 97, 102], ["cells", "CELL", 6, 11], ["IL-17", "GENE_OR_GENE_PRODUCT", 25, 30], ["airways", "MULTI-TISSUE_STRUCTURE", 66, 73], ["ozone", "SIMPLE_CHEMICAL", 97, 102], ["IL-17", "PROTEIN", 25, 30], ["IL", "TEST", 25, 27], ["airways hyperresponsiveness", "PROBLEM", 66, 93], ["IL", "OBSERVATION_MODIFIER", 25, 27], ["airways", "ANATOMY", 66, 73], ["hyperresponsiveness", "OBSERVATION", 74, 93]]], ["NK cells can develop under the control of IL-15 and express antiviral molecules such as IFN-c as well as cytotoxic molecules (57) .T-regulatory cellsInnate lymphoid cells are also important sources of effector cytokines in the lung.", [["NK cells", "ANATOMY", 0, 8], ["T-regulatory cells", "ANATOMY", 131, 149], ["lymphoid cells", "ANATOMY", 156, 170], ["lung", "ANATOMY", 227, 231], ["NK cells", "CELL", 0, 8], ["IL-15", "GENE_OR_GENE_PRODUCT", 42, 47], ["IFN-c", "GENE_OR_GENE_PRODUCT", 88, 93], ["T-regulatory cells", "CELL", 131, 149], ["Innate lymphoid cells", "CELL", 149, 170], ["lung", "ORGAN", 227, 231], ["NK cells", "CELL_TYPE", 0, 8], ["IL-15", "PROTEIN", 42, 47], ["antiviral molecules", "PROTEIN", 60, 79], ["IFN-c", "PROTEIN", 88, 93], ["cytotoxic molecules", "PROTEIN", 105, 124], ["T-regulatory cells", "CELL_TYPE", 131, 149], ["Innate lymphoid cells", "CELL_TYPE", 149, 170], ["effector cytokines", "PROTEIN", 201, 219], ["NK cells", "PROBLEM", 0, 8], ["IL", "TEST", 42, 44], ["antiviral molecules", "PROBLEM", 60, 79], ["cytotoxic molecules", "TEST", 105, 124], ["Innate lymphoid cells", "PROBLEM", 149, 170], ["effector cytokines in the lung", "PROBLEM", 201, 231], ["regulatory cells", "OBSERVATION", 133, 149], ["lymphoid cells", "OBSERVATION", 156, 170], ["effector cytokines", "OBSERVATION", 201, 219], ["lung", "ANATOMY", 227, 231]]], ["These cells are defined by the lack of lineage markers and T-cell receptors, but they require IL-7 signaling for their development.", [["cells", "ANATOMY", 6, 11], ["T-cell", "ANATOMY", 59, 65], ["cells", "CELL", 6, 11], ["lineage", "CELL", 39, 46], ["T-cell receptors", "GENE_OR_GENE_PRODUCT", 59, 75], ["IL-7", "GENE_OR_GENE_PRODUCT", 94, 98], ["lineage markers", "PROTEIN", 39, 54], ["T-cell receptors", "PROTEIN", 59, 75], ["IL-7", "PROTEIN", 94, 98], ["IL", "TREATMENT", 94, 96]]], ["Thus, these cells are present in recombination-activating gene 1 (RAG1) or RAG2 \u00c0/\u00c0 mice, but are lacking in RAG2, common c chain (cc) double deleted mice (58, 59) .", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17], ["recombination-activating gene 1", "GENE_OR_GENE_PRODUCT", 33, 64], ["RAG1", "GENE_OR_GENE_PRODUCT", 66, 70], ["RAG2", "GENE_OR_GENE_PRODUCT", 75, 79], ["RAG2", "GENE_OR_GENE_PRODUCT", 109, 113], ["c chain (cc)", "GENE_OR_GENE_PRODUCT", 122, 134], ["mice", "ORGANISM", 150, 154], ["activating gene 1", "DNA", 47, 64], ["RAG1", "DNA", 66, 70], ["RAG2", "PROTEIN", 75, 79], ["RAG2", "PROTEIN", 109, 113], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 150, 154], ["these cells", "PROBLEM", 6, 17]]], ["Retinoid orphan receptor ct (RORct)-expressing cells are critical for the formation of secondary lymphoid tissues (via regulation of lymphotoxin expression) and play critical roles in mucosal immunology in the gastrointestinal tract through the production of IL-17 and IL-22 (60) .", [["cells", "ANATOMY", 47, 52], ["lymphoid tissues", "ANATOMY", 97, 113], ["mucosal", "ANATOMY", 184, 191], ["gastrointestinal tract", "ANATOMY", 210, 232], ["Retinoid orphan receptor ct", "GENE_OR_GENE_PRODUCT", 0, 27], ["RORct", "GENE_OR_GENE_PRODUCT", 29, 34], ["cells", "CELL", 47, 52], ["lymphoid tissues", "TISSUE", 97, 113], ["lymphotoxin", "GENE_OR_GENE_PRODUCT", 133, 144], ["mucosal", "MULTI-TISSUE_STRUCTURE", 184, 191], ["gastrointestinal tract", "ORGAN", 210, 232], ["IL-17", "GENE_OR_GENE_PRODUCT", 259, 264], ["IL-22", "GENE_OR_GENE_PRODUCT", 269, 274], ["Retinoid orphan receptor ct (RORct)-expressing cells", "CELL_LINE", 0, 52], ["lymphotoxin", "PROTEIN", 133, 144], ["IL", "PROTEIN", 259, 261], ["IL", "PROTEIN", 269, 271], ["Retinoid orphan receptor ct (RORct)", "TEST", 0, 35], ["expressing cells", "PROBLEM", 36, 52], ["secondary lymphoid tissues", "PROBLEM", 87, 113], ["lymphotoxin expression", "TREATMENT", 133, 155], ["IL", "TEST", 259, 261], ["IL", "TEST", 269, 271], ["secondary lymphoid tissues", "OBSERVATION", 87, 113], ["mucosal", "ANATOMY", 184, 191], ["gastrointestinal tract", "ANATOMY", 210, 232]]], ["Type 2 ILCs produce IL-5 and IL-13 and participate in the clearance of helminths from the gastrointestinal tract (61) .", [["ILCs", "ANATOMY", 7, 11], ["gastrointestinal tract", "ANATOMY", 90, 112], ["helminths from the gastrointestinal tract", "DISEASE", 71, 112], ["IL-5", "GENE_OR_GENE_PRODUCT", 20, 24], ["IL-13", "GENE_OR_GENE_PRODUCT", 29, 34], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 90, 112], ["ILCs", "CELL_TYPE", 7, 11], ["IL-5 and IL-13", "PROTEIN", 20, 34], ["IL", "TEST", 20, 22], ["IL", "TEST", 29, 31], ["ILCs", "OBSERVATION", 7, 11], ["gastrointestinal tract", "ANATOMY", 90, 112]]], ["These cells appear to be regulated by IL-25 (IL-17E) as well as IL-33, a member of the IL-1 family.T-regulatory cellsRecently, it has been demonstrated that a population of ILCs produce IL-13 in response to IL-33 induced by viral infection, and these cells mediate in part viral induced exacerbation of allergic disease in the lung (62) .", [["cells", "ANATOMY", 6, 11], ["ILCs", "ANATOMY", 173, 177], ["cells", "ANATOMY", 251, 256], ["lung", "ANATOMY", 327, 331], ["viral infection", "DISEASE", 224, 239], ["allergic disease", "DISEASE", 303, 319], ["cells", "CELL", 6, 11], ["IL-25", "GENE_OR_GENE_PRODUCT", 38, 43], ["IL-17E", "GENE_OR_GENE_PRODUCT", 45, 51], ["IL-33", "GENE_OR_GENE_PRODUCT", 64, 69], ["IL-1", "GENE_OR_GENE_PRODUCT", 87, 91], ["ILCs", "CELL", 173, 177], ["IL-13", "GENE_OR_GENE_PRODUCT", 186, 191], ["IL-33", "GENE_OR_GENE_PRODUCT", 207, 212], ["cells", "CELL", 251, 256], ["lung", "ORGAN", 327, 331], ["IL-25 (IL-17E", "PROTEIN", 38, 51], ["IL-33", "PROTEIN", 64, 69], ["IL-1 family", "PROTEIN", 87, 98], ["ILCs", "CELL_TYPE", 173, 177], ["IL-13", "PROTEIN", 186, 191], ["IL-33", "PROTEIN", 207, 212], ["ILCs produce IL", "TREATMENT", 173, 188], ["IL", "TEST", 207, 209], ["viral infection", "PROBLEM", 224, 239], ["these cells", "PROBLEM", 245, 256], ["allergic disease in the lung", "PROBLEM", 303, 331], ["viral", "OBSERVATION_MODIFIER", 224, 229], ["infection", "OBSERVATION", 230, 239], ["viral", "OBSERVATION_MODIFIER", 273, 278], ["allergic disease", "OBSERVATION", 303, 319], ["lung", "ANATOMY", 327, 331]]], ["These cells can also be activated by protease allergens to drive eosinphilic airways inflammation as well as airways hyperresponsiveness (58) under control of IL-33 and TSLP.", [["cells", "ANATOMY", 6, 11], ["eosinphilic airways", "ANATOMY", 65, 84], ["airways", "ANATOMY", 109, 116], ["inflammation", "DISEASE", 85, 97], ["cells", "CELL", 6, 11], ["airways", "MULTI-TISSUE_STRUCTURE", 77, 84], ["airways", "MULTI-TISSUE_STRUCTURE", 109, 116], ["IL-33", "GENE_OR_GENE_PRODUCT", 159, 164], ["TSLP", "GENE_OR_GENE_PRODUCT", 169, 173], ["protease allergens", "PROTEIN", 37, 55], ["IL-33", "PROTEIN", 159, 164], ["TSLP", "PROTEIN", 169, 173], ["protease allergens", "TREATMENT", 37, 55], ["eosinphilic airways inflammation", "PROBLEM", 65, 97], ["airways hyperresponsiveness", "PROBLEM", 109, 136], ["IL", "TEST", 159, 161], ["airways", "ANATOMY", 77, 84], ["inflammation", "OBSERVATION", 85, 97], ["airways", "ANATOMY", 109, 116], ["hyperresponsiveness", "OBSERVATION", 117, 136]]], ["Thus, these cells recapitulate many aspects of CD4 + T-cell immunity in that there are subsets that express similar effector molecules, yet these cells are activated early and their activation is independent of TCR stimulation.Type 2 effectorsBoth IL-4 and IL-13 activates STAT6 signaling in a variety of lung cells including alveolar macrophages, fibroblasts, airway smooth muscle, and airway epithelium.", [["cells", "ANATOMY", 12, 17], ["CD4 + T-cell", "ANATOMY", 47, 59], ["cells", "ANATOMY", 146, 151], ["lung cells", "ANATOMY", 305, 315], ["alveolar macrophages", "ANATOMY", 326, 346], ["fibroblasts", "ANATOMY", 348, 359], ["airway smooth muscle", "ANATOMY", 361, 381], ["airway epithelium", "ANATOMY", 387, 404], ["TCR", "CHEMICAL", 211, 214], ["cells", "CELL", 12, 17], ["CD4", "GENE_OR_GENE_PRODUCT", 47, 50], ["cells", "CELL", 146, 151], ["TCR", "GENE_OR_GENE_PRODUCT", 211, 214], ["IL-4", "GENE_OR_GENE_PRODUCT", 248, 252], ["IL-13", "GENE_OR_GENE_PRODUCT", 257, 262], ["STAT6", "GENE_OR_GENE_PRODUCT", 273, 278], ["lung cells", "CELL", 305, 315], ["alveolar macrophages", "CELL", 326, 346], ["fibroblasts", "CELL", 348, 359], ["airway smooth muscle", "TISSUE", 361, 381], ["airway epithelium", "TISSUE", 387, 404], ["CD4", "PROTEIN", 47, 50], ["effector molecules", "PROTEIN", 116, 134], ["TCR", "PROTEIN", 211, 214], ["Type 2 effectors", "PROTEIN", 227, 243], ["IL", "PROTEIN", 248, 250], ["IL-13", "PROTEIN", 257, 262], ["STAT6", "PROTEIN", 273, 278], ["lung cells", "CELL_TYPE", 305, 315], ["alveolar macrophages", "CELL_TYPE", 326, 346], ["fibroblasts", "CELL_TYPE", 348, 359], ["CD4", "TEST", 47, 50], ["TCR stimulation", "TREATMENT", 211, 226], ["Type 2 effectors", "PROBLEM", 227, 243], ["IL", "TREATMENT", 257, 259], ["alveolar macrophages", "PROBLEM", 326, 346], ["airway epithelium", "PROBLEM", 387, 404], ["effector molecules", "OBSERVATION", 116, 134], ["lung", "ANATOMY", 305, 309], ["alveolar macrophages", "OBSERVATION", 326, 346], ["fibroblasts", "OBSERVATION", 348, 359], ["airway", "ANATOMY", 361, 367], ["smooth muscle", "OBSERVATION", 368, 381], ["airway", "ANATOMY", 387, 393], ["epithelium", "ANATOMY_MODIFIER", 394, 404]]], ["In macrophages, activation of STAT6 leads to what is termed 'alternative macrophage activation' which is characterized by the expression of arginase 1, YM1, YM2, and the macrophage mannose receptor (63) .", [["macrophages", "ANATOMY", 3, 14], ["macrophage", "ANATOMY", 73, 83], ["mannose", "CHEMICAL", 181, 188], ["macrophages", "CELL", 3, 14], ["STAT6", "GENE_OR_GENE_PRODUCT", 30, 35], ["macrophage", "CELL", 73, 83], ["arginase 1", "GENE_OR_GENE_PRODUCT", 140, 150], ["YM1", "GENE_OR_GENE_PRODUCT", 152, 155], ["YM2", "GENE_OR_GENE_PRODUCT", 157, 160], ["macrophage mannose receptor", "GENE_OR_GENE_PRODUCT", 170, 197], ["macrophages", "CELL_TYPE", 3, 14], ["STAT6", "PROTEIN", 30, 35], ["arginase 1", "PROTEIN", 140, 150], ["YM1", "PROTEIN", 152, 155], ["YM2", "PROTEIN", 157, 160], ["macrophage mannose receptor", "PROTEIN", 170, 197], ["arginase", "TEST", 140, 148], ["macrophages", "OBSERVATION", 3, 14], ["STAT6 leads", "OBSERVATION", 30, 41], ["arginase", "OBSERVATION", 140, 148], ["macrophage", "OBSERVATION_MODIFIER", 170, 180]]], ["It has been shown that IL-4 treatment of macrophages can reduce their phagocytic ability, but IL-4 stimulation of macrophages can augment the clearance of apoptotic neutrophils (63) .", [["macrophages", "ANATOMY", 41, 52], ["macrophages", "ANATOMY", 114, 125], ["neutrophils", "ANATOMY", 165, 176], ["IL-4", "GENE_OR_GENE_PRODUCT", 23, 27], ["macrophages", "CELL", 41, 52], ["IL-4", "GENE_OR_GENE_PRODUCT", 94, 98], ["macrophages", "CELL", 114, 125], ["neutrophils", "CELL", 165, 176], ["macrophages", "CELL_TYPE", 41, 52], ["macrophages", "CELL_TYPE", 114, 125], ["apoptotic neutrophils", "CELL_TYPE", 155, 176], ["IL-4 treatment of macrophages", "TREATMENT", 23, 52], ["IL-4 stimulation of macrophages", "TREATMENT", 94, 125], ["apoptotic neutrophils", "TEST", 155, 176]]], ["Alternatively, activated macrophages (AAMs) play regulatory roles in helminth infection and can reduce immunopathology (63) .", [["macrophages", "ANATOMY", 25, 36], ["AAMs", "ANATOMY", 38, 42], ["helminth infection", "DISEASE", 69, 87], ["immunopathology", "DISEASE", 103, 118], ["macrophages", "CELL", 25, 36], ["AAMs", "CELL", 38, 42], ["activated macrophages", "CELL_TYPE", 15, 36], ["AAMs", "CELL_TYPE", 38, 42], ["activated macrophages (AAMs)", "PROBLEM", 15, 43], ["helminth infection", "PROBLEM", 69, 87], ["immunopathology", "PROBLEM", 103, 118], ["macrophages", "OBSERVATION", 25, 36], ["helminth infection", "OBSERVATION", 69, 87]]], ["It has also been shown that AAMs have augmented dectin-1 expression as well as the macrophage mannose receptor.", [["macrophage", "ANATOMY", 83, 93], ["mannose", "CHEMICAL", 94, 101], ["AAMs", "SIMPLE_CHEMICAL", 28, 32], ["dectin-1", "GENE_OR_GENE_PRODUCT", 48, 56], ["macrophage mannose receptor", "GENE_OR_GENE_PRODUCT", 83, 110], ["dectin", "PROTEIN", 48, 54], ["macrophage mannose receptor", "PROTEIN", 83, 110], ["the macrophage mannose receptor", "TREATMENT", 79, 110]]], ["Given that both of these receptors are critical in recognizing the fungal carbohydrates b1,3 glucan and mannan, respectively, AAMs may have greater fungicidal activity.", [["b1,3 glucan", "CHEMICAL", 88, 99], ["AAMs", "CHEMICAL", 126, 130], ["carbohydrates", "CHEMICAL", 74, 87], ["b1,3 glucan", "GENE_OR_GENE_PRODUCT", 88, 99], ["mannan", "SIMPLE_CHEMICAL", 104, 110], ["AAMs", "SIMPLE_CHEMICAL", 126, 130], ["the fungal carbohydrates", "TEST", 63, 87], ["mannan", "TEST", 104, 110], ["greater", "OBSERVATION_MODIFIER", 140, 147], ["fungicidal activity", "OBSERVATION", 148, 167]]], ["Induction of AAMs may also be exploited by pathogens to allow their survival.", [["AAMs", "GENE_OR_GENE_PRODUCT", 13, 17], ["AAMs", "TREATMENT", 13, 17], ["pathogens", "PROBLEM", 43, 52]]], ["For example, Francisella tularensis, a virulent pathogen in the lung, can prolong its intracellular survival via induction of AAMs (64) .Type 2 effectorsAs mentioned earlier, IL-13 induction of STAT6 signaling induces several mucin genes in airway epithelium including Muc5ac and Muc5b as well as inducing goblet cell hyperplasia (65) .", [["lung", "ANATOMY", 64, 68], ["intracellular", "ANATOMY", 86, 99], ["airway epithelium", "ANATOMY", 241, 258], ["goblet cell", "ANATOMY", 306, 317], ["Francisella tularensis", "ORGANISM", 13, 35], ["lung", "ORGAN", 64, 68], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 86, 99], ["AAMs", "GENE_OR_GENE_PRODUCT", 126, 130], ["IL-13", "GENE_OR_GENE_PRODUCT", 175, 180], ["STAT6", "GENE_OR_GENE_PRODUCT", 194, 199], ["mucin", "GENE_OR_GENE_PRODUCT", 226, 231], ["airway epithelium", "TISSUE", 241, 258], ["Muc5ac", "GENE_OR_GENE_PRODUCT", 269, 275], ["Muc5b", "GENE_OR_GENE_PRODUCT", 280, 285], ["goblet cell", "CELL", 306, 317], ["Type 2 effectors", "PROTEIN", 137, 153], ["IL-13", "PROTEIN", 175, 180], ["STAT6", "PROTEIN", 194, 199], ["mucin genes", "DNA", 226, 237], ["Muc5ac", "PROTEIN", 269, 275], ["Muc5b", "PROTEIN", 280, 285], ["Francisella tularensis", "SPECIES", 13, 35], ["Francisella tularensis", "SPECIES", 13, 35], ["Francisella tularensis", "PROBLEM", 13, 35], ["a virulent pathogen in the lung", "PROBLEM", 37, 68], ["Type 2 effectors", "PROBLEM", 137, 153], ["IL", "TREATMENT", 175, 177], ["STAT6 signaling", "PROBLEM", 194, 209], ["several mucin genes in airway epithelium", "PROBLEM", 218, 258], ["Muc5ac and Muc5b", "TEST", 269, 285], ["goblet cell hyperplasia", "PROBLEM", 306, 329], ["Francisella tularensis", "OBSERVATION", 13, 35], ["virulent", "OBSERVATION_MODIFIER", 39, 47], ["pathogen", "OBSERVATION", 48, 56], ["lung", "ANATOMY", 64, 68], ["mucin genes", "OBSERVATION", 226, 237], ["airway", "ANATOMY", 241, 247], ["epithelium", "ANATOMY_MODIFIER", 248, 258], ["goblet cell hyperplasia", "OBSERVATION", 306, 329]]], ["These signaling effects are critical for host defenses against helminths such as Nippostrongylus brasiliensis (66) .", [["helminths such as Nippostrongylus brasiliensis", "DISEASE", 63, 109], ["Nippostrongylus brasiliensis", "ORGANISM", 81, 109], ["Nippostrongylus brasiliensis", "SPECIES", 81, 109], ["Nippostrongylus brasiliensis", "SPECIES", 81, 109], ["Nippostrongylus brasiliensis", "PROBLEM", 81, 109], ["Nippostrongylus brasiliensis", "OBSERVATION", 81, 109]]], ["During viral infection, airways mucins can prevent viral spread; however, in infants this can also contribute to airway obstruction.", [["airways mucins", "ANATOMY", 24, 38], ["airway", "ANATOMY", 113, 119], ["viral infection", "DISEASE", 7, 22], ["airway obstruction", "DISEASE", 113, 131], ["airways mucins", "GENE_OR_GENE_PRODUCT", 24, 38], ["infants", "ORGANISM", 77, 84], ["airway obstruction", "PATHOLOGICAL_FORMATION", 113, 131], ["infants", "SPECIES", 77, 84], ["viral infection", "PROBLEM", 7, 22], ["airways mucins", "TREATMENT", 24, 38], ["viral spread", "PROBLEM", 51, 63], ["airway obstruction", "PROBLEM", 113, 131], ["viral", "OBSERVATION_MODIFIER", 7, 12], ["infection", "OBSERVATION", 13, 22], ["airways", "ANATOMY", 24, 31], ["viral", "OBSERVATION_MODIFIER", 51, 56], ["spread", "OBSERVATION_MODIFIER", 57, 63], ["airway", "ANATOMY", 113, 119], ["obstruction", "OBSERVATION", 120, 131]]], ["The role of IL-13 in viral infection is complex, and IL-13 is not necessarily beneficial to the host.", [["viral infection", "DISEASE", 21, 36], ["IL-13", "GENE_OR_GENE_PRODUCT", 12, 17], ["viral", "ORGANISM", 21, 26], ["IL-13", "GENE_OR_GENE_PRODUCT", 53, 58], ["IL-13", "PROTEIN", 12, 17], ["IL-13", "PROTEIN", 53, 58], ["IL", "TEST", 12, 14], ["viral infection", "PROBLEM", 21, 36], ["viral", "OBSERVATION_MODIFIER", 21, 26], ["infection", "OBSERVATION", 27, 36]]], ["For example, IL-13 has recently been shown to increase the susceptibility of epithelial cells to infection with rhinovirus (67).Type 1 effectorsThere are several mechanisms by which IFN-c controls lung immunity to intracellular pathogens.", [["epithelial cells", "ANATOMY", 77, 93], ["lung", "ANATOMY", 197, 201], ["intracellular", "ANATOMY", 214, 227], ["infection", "DISEASE", 97, 106], ["IL-13", "GENE_OR_GENE_PRODUCT", 13, 18], ["epithelial cells", "CELL", 77, 93], ["rhinovirus", "ORGANISM", 112, 122], ["Type 1", "GENE_OR_GENE_PRODUCT", 128, 134], ["IFN-c", "GENE_OR_GENE_PRODUCT", 182, 187], ["lung", "ORGAN", 197, 201], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 214, 227], ["IL-13", "PROTEIN", 13, 18], ["epithelial cells", "CELL_TYPE", 77, 93], ["Type 1 effectors", "PROTEIN", 128, 144], ["IFN", "PROTEIN", 182, 185], ["IL", "TEST", 13, 15], ["epithelial cells", "PROBLEM", 77, 93], ["infection", "PROBLEM", 97, 106], ["rhinovirus", "PROBLEM", 112, 122], ["Type 1 effectors", "PROBLEM", 128, 144], ["IFN", "TEST", 182, 185], ["intracellular pathogens", "PROBLEM", 214, 237], ["epithelial cells", "OBSERVATION", 77, 93], ["infection", "OBSERVATION", 97, 106], ["rhinovirus", "OBSERVATION", 112, 122], ["lung", "ANATOMY", 197, 201], ["pathogens", "OBSERVATION", 228, 237]]], ["IFN-c can prime macrophages to enhance their intracellular microbiocidal activity (68) in a process termed classical activation of macrophages (69) .", [["macrophages", "ANATOMY", 16, 27], ["intracellular", "ANATOMY", 45, 58], ["macrophages", "ANATOMY", 131, 142], ["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["macrophages", "CELL", 16, 27], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 45, 58], ["macrophages", "CELL", 131, 142], ["IFN-c", "PROTEIN", 0, 5], ["macrophages", "CELL_TYPE", 16, 27], ["macrophages", "CELL_TYPE", 131, 142], ["macrophages", "OBSERVATION", 131, 142]]], ["IFN-c priming augments Toll-like receptor (TLR) signaling (70) .", [["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 23, 41], ["TLR", "GENE_OR_GENE_PRODUCT", 43, 46], ["IFN", "PROTEIN", 0, 3], ["Toll-like receptor", "PROTEIN", 23, 41], ["TLR", "PROTEIN", 43, 46]]], ["IFN-c also increases microbiocidal activity via the induction of inducible nitric oxide synthase, which regulates the production of reactive nitrogen intermediates (71, 72) .", [["IFN", "CHEMICAL", 0, 3], ["nitric oxide", "CHEMICAL", 75, 87], ["nitrogen", "CHEMICAL", 141, 149], ["nitric oxide", "CHEMICAL", 75, 87], ["nitrogen", "CHEMICAL", 141, 149], ["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 75, 96], ["reactive nitrogen intermediates", "SIMPLE_CHEMICAL", 132, 163], ["IFN", "PROTEIN", 0, 3], ["nitric oxide synthase", "PROTEIN", 75, 96], ["microbiocidal activity", "TREATMENT", 21, 43], ["inducible nitric oxide synthase", "TREATMENT", 65, 96], ["reactive nitrogen intermediates", "PROBLEM", 132, 163], ["reactive nitrogen", "OBSERVATION", 132, 149]]], ["IFN-c can also increase the production of reactive oxygen species.", [["IFN", "CHEMICAL", 0, 3], ["oxygen", "CHEMICAL", 51, 57], ["oxygen", "CHEMICAL", 51, 57], ["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["reactive oxygen species", "SIMPLE_CHEMICAL", 42, 65], ["IFN-c", "PROTEIN", 0, 5], ["reactive oxygen species", "PROBLEM", 42, 65], ["reactive", "OBSERVATION_MODIFIER", 42, 50], ["oxygen species", "OBSERVATION", 51, 65]]], ["These activities may explain the therapeutic benefit of IFN-c in patients with chronic granulomatous disease due to mutations in NADPH oxidase (73) (74) (75) .Type 1 effectorsIFN-c signaling also upregulates class II major histocompatibility complex molecules and costimulatory molecules such as CD80 and CD86, which can augment antigen presentation to naive T cells.", [["granulomatous", "ANATOMY", 87, 100], ["T cells", "ANATOMY", 359, 366], ["IFN", "CHEMICAL", 56, 59], ["chronic granulomatous disease", "DISEASE", 79, 108], ["NADPH", "CHEMICAL", 129, 134], ["NADPH", "CHEMICAL", 129, 134], ["IFN-c", "GENE_OR_GENE_PRODUCT", 56, 61], ["patients", "ORGANISM", 65, 73], ["NADPH oxidase", "GENE_OR_GENE_PRODUCT", 129, 142], ["Type 1", "GENE_OR_GENE_PRODUCT", 159, 165], ["IFN-c", "GENE_OR_GENE_PRODUCT", 175, 180], ["class II major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 208, 249], ["CD80", "GENE_OR_GENE_PRODUCT", 296, 300], ["CD86", "GENE_OR_GENE_PRODUCT", 305, 309], ["T cells", "CELL", 359, 366], ["IFN", "PROTEIN", 56, 59], ["Type 1 effectors", "PROTEIN", 159, 175], ["IFN", "PROTEIN", 175, 178], ["class II major histocompatibility complex molecules", "PROTEIN", 208, 259], ["costimulatory molecules", "PROTEIN", 264, 287], ["CD80", "PROTEIN", 296, 300], ["CD86", "PROTEIN", 305, 309], ["naive T cells", "CELL_TYPE", 353, 366], ["patients", "SPECIES", 65, 73], ["IFN", "TREATMENT", 56, 59], ["chronic granulomatous disease", "PROBLEM", 79, 108], ["mutations in NADPH oxidase", "TEST", 116, 142], ["Type 1 effectorsIFN", "PROBLEM", 159, 178], ["costimulatory molecules", "PROBLEM", 264, 287], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["granulomatous", "OBSERVATION", 87, 100]]], ["IFN-c's first observed activity was its ability to suppress viral replication in many target cells including macrophages, fibroblasts, and lung epithelial cells (76) .", [["cells", "ANATOMY", 93, 98], ["macrophages", "ANATOMY", 109, 120], ["fibroblasts", "ANATOMY", 122, 133], ["lung epithelial cells", "ANATOMY", 139, 160], ["IFN-c", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 93, 98], ["macrophages", "CELL", 109, 120], ["fibroblasts", "CELL", 122, 133], ["lung epithelial cells", "CELL", 139, 160], ["IFN", "PROTEIN", 0, 3], ["target cells", "CELL_TYPE", 86, 98], ["macrophages", "CELL_TYPE", 109, 120], ["fibroblasts", "CELL_TYPE", 122, 133], ["lung epithelial cells", "CELL_TYPE", 139, 160], ["IFN", "TEST", 0, 3], ["viral replication", "PROBLEM", 60, 77], ["macrophages", "PROBLEM", 109, 120], ["fibroblasts", "PROBLEM", 122, 133], ["lung epithelial cells", "TEST", 139, 160], ["target cells", "OBSERVATION", 86, 98], ["macrophages", "OBSERVATION", 109, 120], ["fibroblasts", "ANATOMY", 122, 133], ["lung", "ANATOMY", 139, 143], ["epithelial cells", "OBSERVATION", 144, 160]]], ["This occurs in part through the induction of many antiviral genes such as MxA (77) .", [["MxA", "GENE_OR_GENE_PRODUCT", 74, 77], ["antiviral genes", "DNA", 50, 65], ["MxA", "DNA", 74, 77], ["antiviral genes", "OBSERVATION", 50, 65]]], ["However, other respiratory viruses including severe acute respiratory syndrome coronavirus are controlled by IFNc through mechanisms that are independent of MxA (78) .Type 1 effectorsIFN-c signaling in lung structural cells including fibroblasts and epithelium cells induces several chemokine ligands for CXCR3, including CXCL9, CXCL10, and CXCL11.", [["lung structural cells", "ANATOMY", 202, 223], ["fibroblasts", "ANATOMY", 234, 245], ["epithelium cells", "ANATOMY", 250, 266], ["respiratory viruses", "DISEASE", 15, 34], ["acute respiratory syndrome coronavirus", "DISEASE", 52, 90], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 45, 90], ["IFNc", "GENE_OR_GENE_PRODUCT", 109, 113], ["MxA", "GENE_OR_GENE_PRODUCT", 157, 160], ["Type 1", "GENE_OR_GENE_PRODUCT", 167, 173], ["IFN-c", "GENE_OR_GENE_PRODUCT", 183, 188], ["lung structural cells", "CELL", 202, 223], ["fibroblasts", "CELL", 234, 245], ["epithelium cells", "CELL", 250, 266], ["CXCR3", "GENE_OR_GENE_PRODUCT", 305, 310], ["CXCL9", "GENE_OR_GENE_PRODUCT", 322, 327], ["CXCL10", "GENE_OR_GENE_PRODUCT", 329, 335], ["CXCL11", "GENE_OR_GENE_PRODUCT", 341, 347], ["IFNc", "PROTEIN", 109, 113], ["MxA", "PROTEIN", 157, 160], ["Type 1 effectors", "PROTEIN", 167, 183], ["IFN", "PROTEIN", 183, 186], ["lung structural cells", "CELL_TYPE", 202, 223], ["fibroblasts", "CELL_TYPE", 234, 245], ["epithelium cells", "CELL_TYPE", 250, 266], ["chemokine ligands", "PROTEIN", 283, 300], ["CXCR3", "PROTEIN", 305, 310], ["CXCL9", "PROTEIN", 322, 327], ["CXCL10", "PROTEIN", 329, 335], ["CXCL11", "PROTEIN", 341, 347], ["severe acute respiratory syndrome coronavirus", "SPECIES", 45, 90], ["other respiratory viruses", "PROBLEM", 9, 34], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 45, 90], ["Type 1 effectorsIFN", "PROBLEM", 167, 186], ["signaling in lung structural cells", "PROBLEM", 189, 223], ["fibroblasts", "PROBLEM", 234, 245], ["epithelium cells", "PROBLEM", 250, 266], ["several chemokine ligands", "TEST", 275, 300], ["CXCR3", "TEST", 305, 310], ["CXCL9", "TEST", 322, 327], ["CXCL10", "TEST", 329, 335], ["CXCL11", "TEST", 341, 347], ["respiratory viruses", "OBSERVATION", 15, 34], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["acute", "OBSERVATION_MODIFIER", 52, 57], ["respiratory syndrome coronavirus", "OBSERVATION", 58, 90], ["lung", "ANATOMY", 202, 206], ["structural cells", "OBSERVATION", 207, 223], ["epithelium cells", "OBSERVATION", 250, 266]]], ["CXCR3 is expressed on Th1 cells, and thus, the induction of these chemokines by IFN-c may be a critical mechanism to increase the recruitment of Th1 cells.", [["Th1 cells", "ANATOMY", 22, 31], ["Th1 cells", "ANATOMY", 145, 154], ["CXCR3", "GENE_OR_GENE_PRODUCT", 0, 5], ["Th1 cells", "CELL", 22, 31], ["IFN-c", "GENE_OR_GENE_PRODUCT", 80, 85], ["Th1 cells", "CELL", 145, 154], ["CXCR3", "PROTEIN", 0, 5], ["Th1 cells", "CELL_TYPE", 22, 31], ["chemokines", "PROTEIN", 66, 76], ["IFN-c", "PROTEIN", 80, 85], ["Th1 cells", "CELL_TYPE", 145, 154], ["CXCR3", "TEST", 0, 5], ["these chemokines", "TREATMENT", 60, 76], ["IFN", "TEST", 80, 83], ["a critical mechanism", "PROBLEM", 93, 113], ["the recruitment of Th1 cells", "PROBLEM", 126, 154], ["Th1 cells", "OBSERVATION", 22, 31], ["recruitment", "OBSERVATION_MODIFIER", 130, 141], ["Th1 cells", "OBSERVATION", 145, 154]]], ["Moreover, these chemokines are critical for granuloma formation, which is essential for control of many intracellular pathogens such as M. tuberculosis (79, 80) .", [["granuloma", "ANATOMY", 44, 53], ["intracellular", "ANATOMY", 104, 117], ["granuloma", "DISEASE", 44, 53], ["M. tuberculosis", "DISEASE", 136, 151], ["granuloma", "PATHOLOGICAL_FORMATION", 44, 53], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 104, 117], ["M. tuberculosis", "ORGANISM", 136, 151], ["chemokines", "PROTEIN", 16, 26], ["M. tuberculosis", "SPECIES", 136, 151], ["M. tuberculosis", "SPECIES", 136, 151], ["granuloma formation", "PROBLEM", 44, 63], ["many intracellular pathogens", "PROBLEM", 99, 127], ["M. tuberculosis", "PROBLEM", 136, 151], ["granuloma", "OBSERVATION", 44, 53], ["many", "OBSERVATION_MODIFIER", 99, 103], ["intracellular", "OBSERVATION_MODIFIER", 104, 117], ["pathogens", "OBSERVATION", 118, 127], ["tuberculosis", "OBSERVATION", 139, 151]]], ["Systemic and aerosolized IFN-c has been investigated for the potential adjunctive treatment of tuberculosis.", [["IFN", "CHEMICAL", 25, 28], ["tuberculosis", "DISEASE", 95, 107], ["IFN-c", "GENE_OR_GENE_PRODUCT", 25, 30], ["IFN", "PROTEIN", 25, 28], ["Systemic and aerosolized IFN", "TREATMENT", 0, 28], ["the potential adjunctive treatment", "TREATMENT", 57, 91], ["tuberculosis", "PROBLEM", 95, 107], ["aerosolized", "OBSERVATION_MODIFIER", 13, 24], ["IFN", "OBSERVATION", 25, 28], ["tuberculosis", "OBSERVATION", 95, 107]]], ["A recent meta-analysis showed that IFN-c was well tolerated and associated with higher sputum sterilization rates (81); however, definitive randomized control trials are lacking to make firm conclusions on the efficacy of this cytokine.Type 17 effectorsIL-17 can signal in human bronchial epithelium (HBE) to induced chemokine ligands for CXCR2, such as CXCL8, CXCL1, and the granulopoietic growth factor G-CSF (82, 83) .", [["sputum", "ANATOMY", 87, 93], ["bronchial epithelium", "ANATOMY", 279, 299], ["HBE", "ANATOMY", 301, 304], ["IFN-c", "GENE_OR_GENE_PRODUCT", 35, 40], ["effectorsIL-17", "GENE_OR_GENE_PRODUCT", 244, 258], ["human", "ORGANISM", 273, 278], ["bronchial epithelium", "TISSUE", 279, 299], ["HBE", "CELL", 301, 304], ["CXCR2", "GENE_OR_GENE_PRODUCT", 339, 344], ["CXCL8", "GENE_OR_GENE_PRODUCT", 354, 359], ["CXCL1", "GENE_OR_GENE_PRODUCT", 361, 366], ["G-CSF", "GENE_OR_GENE_PRODUCT", 405, 410], ["IFN", "PROTEIN", 35, 38], ["cytokine", "PROTEIN", 227, 235], ["Type 17 effectorsIL-17", "PROTEIN", 236, 258], ["chemokine ligands", "PROTEIN", 317, 334], ["CXCR2", "PROTEIN", 339, 344], ["CXCL8", "PROTEIN", 354, 359], ["CXCL1", "PROTEIN", 361, 366], ["granulopoietic growth factor", "PROTEIN", 376, 404], ["CSF", "PROTEIN", 407, 410], ["human", "SPECIES", 273, 278], ["human", "SPECIES", 273, 278], ["A recent meta-analysis", "TEST", 0, 22], ["IFN", "TEST", 35, 38], ["higher sputum sterilization rates", "PROBLEM", 80, 113], ["definitive randomized control trials", "TREATMENT", 129, 165], ["this cytokine", "TREATMENT", 222, 235], ["Type 17 effectorsIL", "PROBLEM", 236, 255], ["human bronchial epithelium", "PROBLEM", 273, 299], ["chemokine ligands", "TEST", 317, 334], ["CXCR2", "TEST", 339, 344], ["CXCL8", "TEST", 354, 359], ["CXCL1", "TEST", 361, 366], ["the granulopoietic growth factor", "TEST", 372, 404], ["G-CSF", "TEST", 405, 410], ["bronchial epithelium", "ANATOMY", 279, 299], ["granulopoietic", "ANATOMY", 376, 390]]], ["Like other cell systems, HBE responses to IL-17 or IL-17F are augmented by TNF-a (82, 84) .", [["cell systems", "ANATOMY", 11, 23], ["HBE", "ANATOMY", 25, 28], ["cell", "CELL", 11, 15], ["HBE", "CELL", 25, 28], ["IL-17", "GENE_OR_GENE_PRODUCT", 42, 47], ["IL-17F", "GENE_OR_GENE_PRODUCT", 51, 57], ["TNF", "GENE_OR_GENE_PRODUCT", 75, 78], ["IL-17F", "PROTEIN", 51, 57], ["TNF", "PROTEIN", 75, 78], ["IL", "TEST", 42, 44], ["IL", "TEST", 51, 53], ["TNF", "TEST", 75, 78]]], ["HBE cells express IL-17RA, IL-17RC, as well as IL-22R and IL-10R2, the receptors for IL-22 (82, 83) (Fig. 3) .", [["HBE cells", "ANATOMY", 0, 9], ["HBE cells", "CELL", 0, 9], ["IL-17RA", "GENE_OR_GENE_PRODUCT", 18, 25], ["IL-17RC", "GENE_OR_GENE_PRODUCT", 27, 34], ["IL-22R", "GENE_OR_GENE_PRODUCT", 47, 53], ["IL-10R2", "GENE_OR_GENE_PRODUCT", 58, 65], ["IL-22", "GENE_OR_GENE_PRODUCT", 85, 90], ["HBE cells", "CELL_LINE", 0, 9], ["IL", "PROTEIN", 18, 20], ["17RA", "PROTEIN", 21, 25], ["IL", "PROTEIN", 27, 29], ["17RC", "PROTEIN", 30, 34], ["IL", "PROTEIN", 47, 49], ["22R", "PROTEIN", 50, 53], ["IL", "PROTEIN", 58, 60], ["10R2", "PROTEIN", 61, 65], ["IL", "PROTEIN", 85, 87], ["HBE cells", "TEST", 0, 9], ["IL", "TEST", 18, 20], ["IL", "TREATMENT", 27, 29], ["IL", "TREATMENT", 47, 49], ["IL", "TREATMENT", 58, 60], ["IL", "TEST", 85, 87]]], ["As IL-17A and IL-17F can be coexpressed in the same cell, it has been reported that these two IL-17 family members can form three cytokines including IL-17A homodimers, IL-17A/F heterodimers, which have intermediate activity compared with IL-17A homodimers, and IL-17F homodimers, which have the least potent activity (85) .", [["cell", "ANATOMY", 52, 56], ["IL-17A", "GENE_OR_GENE_PRODUCT", 3, 9], ["IL-17F", "GENE_OR_GENE_PRODUCT", 14, 20], ["cell", "CELL", 52, 56], ["IL-17", "GENE_OR_GENE_PRODUCT", 94, 99], ["IL-17A", "GENE_OR_GENE_PRODUCT", 150, 156], ["IL-17A", "GENE_OR_GENE_PRODUCT", 169, 175], ["F", "GENE_OR_GENE_PRODUCT", 176, 177], ["IL-17A", "GENE_OR_GENE_PRODUCT", 239, 245], ["IL-17F", "GENE_OR_GENE_PRODUCT", 262, 268], ["IL-17A and IL-17F", "PROTEIN", 3, 20], ["IL-17 family members", "PROTEIN", 94, 114], ["cytokines", "PROTEIN", 130, 139], ["IL-17A homodimers", "PROTEIN", 150, 167], ["IL-17A/F heterodimers", "PROTEIN", 169, 190], ["IL-17A homodimers", "PROTEIN", 239, 256], ["IL-17F homodimers", "PROTEIN", 262, 279], ["IL", "TREATMENT", 14, 16], ["IL", "TREATMENT", 169, 171], ["heterodimers", "TREATMENT", 178, 190], ["IL", "TREATMENT", 262, 264]]], ["One mechanism by which IL-17 increases the production of chemokines is through increasing mRNA stability of this transcript (86, 87) resulting in augmented protein production.", [["IL-17", "GENE_OR_GENE_PRODUCT", 23, 28], ["IL-17", "PROTEIN", 23, 28], ["chemokines", "PROTEIN", 57, 67], ["augmented protein production", "PROBLEM", 146, 174], ["protein production", "OBSERVATION", 156, 174]]], ["A similar mechanism has also been reported for IL-17-mediated increases in G-CSF production (88) .Type 17 effectorsIL-17RA is ubiquitously expressed on many cells including myeloid cells; however, these cells express very little IL-17RC.", [["cells", "ANATOMY", 157, 162], ["myeloid cells", "ANATOMY", 173, 186], ["cells", "ANATOMY", 203, 208], ["IL-17", "GENE_OR_GENE_PRODUCT", 47, 52], ["G-CSF", "GENE_OR_GENE_PRODUCT", 75, 80], ["Type 17 effectorsIL-17RA", "GENE_OR_GENE_PRODUCT", 98, 122], ["cells", "CELL", 157, 162], ["myeloid cells", "CELL", 173, 186], ["cells", "CELL", 203, 208], ["IL-17RC", "GENE_OR_GENE_PRODUCT", 229, 236], ["IL-17", "PROTEIN", 47, 52], ["CSF", "PROTEIN", 77, 80], ["17RA", "PROTEIN", 118, 122], ["myeloid cells", "CELL_TYPE", 173, 186], ["IL", "PROTEIN", 229, 231], ["17RC", "PROTEIN", 232, 236], ["IL", "TEST", 47, 49], ["G-CSF production", "TEST", 75, 91], ["Type 17 effectorsIL", "PROBLEM", 98, 117], ["myeloid cells", "PROBLEM", 173, 186], ["increases", "OBSERVATION_MODIFIER", 62, 71], ["myeloid cells", "OBSERVATION", 173, 186]]], ["Thus, IL-17A and IL-17F have limited activity on myeloid cells.", [["myeloid cells", "ANATOMY", 49, 62], ["IL-17A", "GENE_OR_GENE_PRODUCT", 6, 12], ["IL-17F", "GENE_OR_GENE_PRODUCT", 17, 23], ["myeloid cells", "CELL", 49, 62], ["IL-17A and IL-17F", "PROTEIN", 6, 23], ["myeloid cells", "CELL_TYPE", 49, 62], ["IL", "TREATMENT", 17, 19], ["limited activity on myeloid cells", "PROBLEM", 29, 62], ["myeloid cells", "OBSERVATION", 49, 62]]], ["It has been reported that IL-17 can enhance IL-12p70 in alveolar macrophages (89) as well CCL2, CCL3, GM-CSF, IL-1b, and IL-9 in CD4 + T cells (90) .", [["alveolar macrophages", "ANATOMY", 56, 76], ["CD4 + T cells", "ANATOMY", 129, 142], ["IL-17", "GENE_OR_GENE_PRODUCT", 26, 31], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 44, 52], ["alveolar macrophages", "CELL", 56, 76], ["CCL2", "GENE_OR_GENE_PRODUCT", 90, 94], ["CCL3", "GENE_OR_GENE_PRODUCT", 96, 100], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 102, 108], ["IL-1b", "GENE_OR_GENE_PRODUCT", 110, 115], ["IL-9", "GENE_OR_GENE_PRODUCT", 121, 125], ["CD4", "GENE_OR_GENE_PRODUCT", 129, 132], ["IL-17", "PROTEIN", 26, 31], ["IL-12p70", "PROTEIN", 44, 52], ["alveolar macrophages", "CELL_TYPE", 56, 76], ["CCL2", "PROTEIN", 90, 94], ["CCL3", "PROTEIN", 96, 100], ["GM", "PROTEIN", 102, 104], ["CSF", "PROTEIN", 105, 108], ["IL", "PROTEIN", 110, 112], ["IL-9", "PROTEIN", 121, 125], ["CD4", "PROTEIN", 129, 132], ["T cells", "CELL_TYPE", 135, 142], ["IL", "TEST", 26, 28], ["IL", "TEST", 44, 46], ["alveolar macrophages", "TEST", 56, 76], ["CCL2", "TEST", 90, 94], ["CCL3", "TEST", 96, 100], ["GM", "TEST", 102, 104], ["CSF", "TEST", 105, 108], ["IL", "TEST", 110, 112], ["IL", "TEST", 121, 123], ["alveolar macrophages", "ANATOMY", 56, 76]]], ["Th17 cells express IL-17RA and IL-17RE, which form a receptor complex for IL-17C (91) (92) (93) .", [["Th17 cells", "ANATOMY", 0, 10], ["Th17 cells", "CELL", 0, 10], ["IL-17RA", "GENE_OR_GENE_PRODUCT", 19, 26], ["IL-17RE", "GENE_OR_GENE_PRODUCT", 31, 38], ["IL-17C", "GENE_OR_GENE_PRODUCT", 74, 80], ["Th17 cells", "CELL_TYPE", 0, 10], ["IL", "PROTEIN", 19, 21], ["17RA", "PROTEIN", 22, 26], ["IL", "PROTEIN", 31, 33], ["17RE", "PROTEIN", 34, 38], ["Th17 cells", "TEST", 0, 10], ["IL", "TEST", 19, 21], ["IL", "TEST", 31, 33], ["IL", "TEST", 74, 76]]], ["IL-17C can increase the production of IL-17 by these cells (91) (92) (93) .", [["cells", "ANATOMY", 53, 58], ["IL-17C", "GENE_OR_GENE_PRODUCT", 0, 6], ["IL-17", "GENE_OR_GENE_PRODUCT", 38, 43], ["cells", "CELL", 53, 58], ["IL-17C", "PROTEIN", 0, 6], ["IL-17", "PROTEIN", 38, 43], ["IL", "TREATMENT", 0, 2], ["the production of IL", "TREATMENT", 20, 40]]], ["IL-17C can be expressed in lung epithelium (unpublished observations) and thus can serve as a feed forward mechanism by which the epithelium could influence interstitial T-cell responses.", [["lung epithelium", "ANATOMY", 27, 42], ["epithelium", "ANATOMY", 130, 140], ["interstitial T-cell", "ANATOMY", 157, 176], ["IL-17C", "GENE_OR_GENE_PRODUCT", 0, 6], ["lung epithelium", "TISSUE", 27, 42], ["epithelium", "TISSUE", 130, 140], ["interstitial T-cell", "CELL", 157, 176], ["IL-17C", "PROTEIN", 0, 6], ["IL", "TREATMENT", 0, 2], ["lung", "ANATOMY", 27, 31], ["epithelium", "ANATOMY_MODIFIER", 32, 42]]], ["In addition to regulating neutrophil recruitment in the lung (94) , IL-17 augments apical bicarbonate transport in HBE cells (95) .", [["neutrophil", "ANATOMY", 26, 36], ["lung", "ANATOMY", 56, 60], ["apical", "ANATOMY", 83, 89], ["HBE cells", "ANATOMY", 115, 124], ["bicarbonate", "CHEMICAL", 90, 101], ["bicarbonate", "CHEMICAL", 90, 101], ["neutrophil", "CELL", 26, 36], ["lung", "ORGAN", 56, 60], ["IL-17", "GENE_OR_GENE_PRODUCT", 68, 73], ["apical", "IMMATERIAL_ANATOMICAL_ENTITY", 83, 89], ["bicarbonate", "SIMPLE_CHEMICAL", 90, 101], ["HBE cells", "CELL", 115, 124], ["IL-17", "PROTEIN", 68, 73], ["HBE cells", "CELL_LINE", 115, 124], ["regulating neutrophil recruitment", "TREATMENT", 15, 48], ["IL", "TREATMENT", 68, 70], ["augments apical bicarbonate transport", "TREATMENT", 74, 111], ["neutrophil recruitment", "OBSERVATION", 26, 48], ["lung", "ANATOMY", 56, 60]]], ["Carbonate anion regulates the activity of b defensins (96) , and this may be an important mechanism of IL-17's net anti-microbial effect in the lung mucosa.Type 17 effectorsIL-17RA is required for host resistance to the extracellular pathogens K. pneumoniae (94) , and in this model IL-17RA regulates the local production of CXCR2 ligands as well Fig. 3 .", [["lung mucosa", "ANATOMY", 144, 155], ["extracellular", "ANATOMY", 220, 233], ["Carbonate", "CHEMICAL", 0, 9], ["Carbonate", "CHEMICAL", 0, 9], ["Carbonate", "SIMPLE_CHEMICAL", 0, 9], ["b defensins", "GENE_OR_GENE_PRODUCT", 42, 53], ["IL-17's", "SIMPLE_CHEMICAL", 103, 110], ["lung mucosa", "MULTI-TISSUE_STRUCTURE", 144, 155], ["effectorsIL-17RA", "GENE_OR_GENE_PRODUCT", 164, 180], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 220, 233], ["pathogens", "ORGANISM", 234, 243], ["K. pneumoniae", "ORGANISM", 244, 257], ["IL-17RA", "GENE_OR_GENE_PRODUCT", 283, 290], ["CXCR2", "GENE_OR_GENE_PRODUCT", 325, 330], ["Type 17 effectorsIL-17RA", "PROTEIN", 156, 180], ["IL-17RA", "PROTEIN", 283, 290], ["CXCR2", "PROTEIN", 325, 330], ["K. pneumoniae", "SPECIES", 244, 257], ["K. pneumoniae", "SPECIES", 244, 257], ["Carbonate anion", "TREATMENT", 0, 15], ["IL", "TREATMENT", 103, 105], ["net anti-microbial effect in the lung mucosa", "PROBLEM", 111, 155], ["Type 17 effectorsIL", "PROBLEM", 156, 175], ["pneumoniae", "PROBLEM", 247, 257], ["this model IL", "TEST", 272, 285], ["CXCR2 ligands", "PROBLEM", 325, 338], ["anti-microbial effect", "OBSERVATION", 115, 136], ["lung mucosa", "ANATOMY", 144, 155], ["pneumoniae", "OBSERVATION", 247, 257]]], ["Th17 cytokines in mucosal immunity.", [["mucosal", "ANATOMY", 18, 25], ["mucosal", "MULTI-TISSUE_STRUCTURE", 18, 25], ["Th17 cytokines", "PROTEIN", 0, 14], ["Th17 cytokines", "TREATMENT", 0, 14], ["mucosal immunity", "OBSERVATION", 18, 34]]], ["Many infections, including those caused by fungi and bacteria, can activate dendritic cells and macrophages to produce interleukin-6 (IL-6), IL-23, and IL-1b.", [["dendritic cells", "ANATOMY", 76, 91], ["macrophages", "ANATOMY", 96, 107], ["infections", "DISEASE", 5, 15], ["dendritic cells", "CELL", 76, 91], ["macrophages", "CELL", 96, 107], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 119, 132], ["IL-6", "GENE_OR_GENE_PRODUCT", 134, 138], ["IL-23", "GENE_OR_GENE_PRODUCT", 141, 146], ["IL-1b", "GENE_OR_GENE_PRODUCT", 152, 157], ["dendritic cells", "CELL_TYPE", 76, 91], ["macrophages", "CELL_TYPE", 96, 107], ["interleukin-6 (IL-6", "PROTEIN", 119, 138], ["IL-23", "PROTEIN", 141, 146], ["IL", "PROTEIN", 152, 154], ["Many infections", "PROBLEM", 0, 15], ["fungi", "PROBLEM", 43, 48], ["bacteria", "PROBLEM", 53, 61], ["dendritic cells", "PROBLEM", 76, 91], ["macrophages", "TEST", 96, 107], ["interleukin", "TEST", 119, 130], ["IL", "TEST", 134, 136], ["IL", "TEST", 141, 143], ["infections", "OBSERVATION", 5, 15], ["dendritic cells", "OBSERVATION", 76, 91]]], ["IL-23 and IL-1b can drive IL-17 production by both innate lymphoid cells and cd T cells.", [["lymphoid cells", "ANATOMY", 58, 72], ["cd T cells", "ANATOMY", 77, 87], ["IL-23", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-1b", "GENE_OR_GENE_PRODUCT", 10, 15], ["IL-17", "GENE_OR_GENE_PRODUCT", 26, 31], ["innate lymphoid cells", "CELL", 51, 72], ["cd T cells", "CELL", 77, 87], ["IL-23", "PROTEIN", 0, 5], ["IL-17", "PROTEIN", 26, 31], ["innate lymphoid cells", "CELL_TYPE", 51, 72], ["cd T cells", "CELL_TYPE", 77, 87], ["IL", "TEST", 0, 2], ["innate lymphoid cells", "OBSERVATION", 51, 72]]], ["Differentiation of Th17 cells requires TGFb, and a critical mechanism of activation of TGFb in the lung is through the activation of this growth factor by av integrins.", [["Th17 cells", "ANATOMY", 19, 29], ["lung", "ANATOMY", 99, 103], ["Th17 cells", "CELL", 19, 29], ["TGFb", "GENE_OR_GENE_PRODUCT", 39, 43], ["TGFb", "GENE_OR_GENE_PRODUCT", 87, 91], ["lung", "ORGAN", 99, 103], ["av integrins", "GENE_OR_GENE_PRODUCT", 155, 167], ["Th17 cells", "CELL_TYPE", 19, 29], ["TGFb", "PROTEIN", 39, 43], ["TGFb", "PROTEIN", 87, 91], ["growth factor", "PROTEIN", 138, 151], ["av integrins", "PROTEIN", 155, 167], ["Th17 cells", "PROBLEM", 19, 29], ["TGFb", "TEST", 39, 43], ["TGFb in the lung", "PROBLEM", 87, 103], ["this growth factor", "PROBLEM", 133, 151], ["av integrins", "TREATMENT", 155, 167], ["Th17 cells", "OBSERVATION", 19, 29], ["TGFb", "OBSERVATION_MODIFIER", 39, 43], ["TGFb", "OBSERVATION", 87, 91], ["lung", "ANATOMY", 99, 103]]], ["IL-17 and IL-22 can signal to the epithelium to augment G-CSF as well as ligands for CXCR2 that mediate the recruitment of neutrophils.", [["epithelium", "ANATOMY", 34, 44], ["neutrophils", "ANATOMY", 123, 134], ["IL-17", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-22", "GENE_OR_GENE_PRODUCT", 10, 15], ["epithelium", "TISSUE", 34, 44], ["G-CSF", "GENE_OR_GENE_PRODUCT", 56, 61], ["CXCR2", "GENE_OR_GENE_PRODUCT", 85, 90], ["neutrophils", "CELL", 123, 134], ["IL-17", "PROTEIN", 0, 5], ["IL-22", "PROTEIN", 10, 15], ["CSF", "PROTEIN", 58, 61], ["CXCR2", "PROTEIN", 85, 90], ["neutrophils", "CELL_TYPE", 123, 134], ["IL", "TEST", 0, 2], ["IL", "TREATMENT", 10, 12], ["CXCR2", "TEST", 85, 90], ["recruitment", "OBSERVATION_MODIFIER", 108, 119]]], ["These two cytokines also induce the expression of anti-microbial proteins such as lipocalin-2 and b-defensins.", [["lipocalin-2", "GENE_OR_GENE_PRODUCT", 82, 93], ["b-defensins", "GENE_OR_GENE_PRODUCT", 98, 109], ["cytokines", "PROTEIN", 10, 19], ["anti-microbial proteins", "PROTEIN", 50, 73], ["lipocalin-2", "PROTEIN", 82, 93], ["b-defensins", "PROTEIN", 98, 109], ["anti-microbial proteins", "TREATMENT", 50, 73], ["lipocalin", "TEST", 82, 91]]], ["IL-22 can also augment epithelial repair.", [["epithelial", "ANATOMY", 23, 33], ["IL-22", "GENE_OR_GENE_PRODUCT", 0, 5], ["epithelial", "TISSUE", 23, 33], ["IL-22", "PROTEIN", 0, 5], ["IL", "TREATMENT", 0, 2], ["epithelial repair", "TREATMENT", 23, 40], ["epithelial repair", "OBSERVATION", 23, 40]]], ["After vaccination, Th17 cells through the production of IL-17 can also induce ligands for CXCR3 that increase the recruitment of IFNcproducing Th1 cells, which can also help control intracellular pathogen growth. granulopoiesis through the regulation of G-CSF.", [["Th17 cells", "ANATOMY", 19, 29], ["IFNcproducing Th1 cells", "ANATOMY", 129, 152], ["intracellular", "ANATOMY", 182, 195], ["Th17 cells", "CELL", 19, 29], ["IL-17", "GENE_OR_GENE_PRODUCT", 56, 61], ["CXCR3", "GENE_OR_GENE_PRODUCT", 90, 95], ["IFNcproducing Th1 cells", "CELL", 129, 152], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 182, 195], ["G-CSF", "GENE_OR_GENE_PRODUCT", 254, 259], ["Th17 cells", "CELL_TYPE", 19, 29], ["IL-17", "PROTEIN", 56, 61], ["CXCR3", "PROTEIN", 90, 95], ["IFNcproducing Th1 cells", "CELL_TYPE", 129, 152], ["G-CSF", "PROTEIN", 254, 259], ["vaccination", "TREATMENT", 6, 17], ["Th17 cells", "TREATMENT", 19, 29], ["the production of IL", "TREATMENT", 38, 58], ["CXCR3", "TEST", 90, 95], ["the recruitment of IFNcproducing Th1 cells", "TREATMENT", 110, 152], ["intracellular pathogen growth", "PROBLEM", 182, 211], ["granulopoiesis", "PROBLEM", 213, 227], ["Th17 cells", "OBSERVATION", 19, 29], ["recruitment", "OBSERVATION_MODIFIER", 114, 125], ["Th1 cells", "OBSERVATION", 143, 152], ["CSF", "ANATOMY", 256, 259]]], ["IL-17RA is dispensable for the control of intracellular pathogen M. tuberculosis (83), but is required for the control of the intracellular pathogen F. tularensis (89) .", [["intracellular", "ANATOMY", 42, 55], ["intracellular", "ANATOMY", 126, 139], ["tuberculosis", "DISEASE", 68, 80], ["IL-17RA", "GENE_OR_GENE_PRODUCT", 0, 7], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 55], ["pathogen M. tuberculosis", "ORGANISM", 56, 80], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 126, 139], ["F. tularensis", "ORGANISM", 149, 162], ["IL-17RA", "PROTEIN", 0, 7], ["M. tuberculosis", "SPECIES", 65, 80], ["F. tularensis", "SPECIES", 149, 162], ["M. tuberculosis", "SPECIES", 65, 80], ["F. tularensis", "SPECIES", 149, 162], ["IL", "TREATMENT", 0, 2], ["intracellular pathogen M. tuberculosis", "PROBLEM", 42, 80], ["tuberculosis", "OBSERVATION", 68, 80]]], ["In this latter model, IL-17 regulates IL-12p70 production by macrophages, which subsequently generates the Th1 CD4 + T-cell response ultimately controls the pathogen (89) .Type 17 effectorsIL-22 signals through STAT3 in HBE cells.", [["macrophages", "ANATOMY", 61, 72], ["Th1 CD4 + T-cell", "ANATOMY", 107, 123], ["HBE cells", "ANATOMY", 220, 229], ["IL-17", "GENE_OR_GENE_PRODUCT", 22, 27], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 38, 46], ["macrophages", "CELL", 61, 72], ["CD4", "GENE_OR_GENE_PRODUCT", 111, 114], ["effectorsIL-22", "GENE_OR_GENE_PRODUCT", 180, 194], ["STAT3", "GENE_OR_GENE_PRODUCT", 211, 216], ["HBE cells", "CELL", 220, 229], ["IL-17", "PROTEIN", 22, 27], ["macrophages", "CELL_TYPE", 61, 72], ["CD4", "PROTEIN", 111, 114], ["STAT3", "PROTEIN", 211, 216], ["HBE cells", "CELL_LINE", 220, 229], ["IL", "TEST", 22, 24], ["the Th1 CD4", "TEST", 103, 114], ["the pathogen", "TEST", 153, 165], ["Type 17 effectorsIL", "PROBLEM", 172, 191], ["STAT3 in HBE cells", "PROBLEM", 211, 229], ["HBE cells", "OBSERVATION", 220, 229]]], ["IL-22 increases the clonogenic potential of HBE cells in colony assays (83) and also augments repair to puncture injury in confluent HBE cells (97) (Fig. 3) .", [["HBE cells", "ANATOMY", 44, 53], ["colony", "ANATOMY", 57, 63], ["HBE cells", "ANATOMY", 133, 142], ["IL-22", "GENE_OR_GENE_PRODUCT", 0, 5], ["HBE cells", "CELL", 44, 53], ["HBE cells", "CELL", 133, 142], ["IL-22", "PROTEIN", 0, 5], ["HBE cells", "CELL_LINE", 44, 53], ["confluent HBE cells", "CELL_LINE", 123, 142], ["IL", "TEST", 0, 2], ["HBE cells", "PROBLEM", 44, 53], ["colony assays", "TEST", 57, 70], ["augments repair", "TREATMENT", 85, 100], ["puncture injury", "PROBLEM", 104, 119], ["confluent HBE cells", "TEST", 123, 142], ["clonogenic potential", "OBSERVATION_MODIFIER", 20, 40], ["HBE cells", "OBSERVATION", 44, 53], ["repair", "OBSERVATION", 94, 100], ["puncture injury", "OBSERVATION", 104, 119], ["confluent", "OBSERVATION_MODIFIER", 123, 132], ["HBE cells", "OBSERVATION", 133, 142]]], ["IL-17 and IL-22 stimulation of HBE and mouse tracheal epithelial cells induces several antimicrobial genes in lung epithelium including lipocalin 2 (83) and regenerating islet-derived protein 3-c (98).", [["HBE", "ANATOMY", 31, 34], ["tracheal epithelial cells", "ANATOMY", 45, 70], ["lung epithelium", "ANATOMY", 110, 125], ["islet", "ANATOMY", 170, 175], ["IL-17", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-22", "GENE_OR_GENE_PRODUCT", 10, 15], ["HBE", "CELL", 31, 34], ["mouse", "ORGANISM", 39, 44], ["tracheal epithelial cells", "CELL", 45, 70], ["lung epithelium", "TISSUE", 110, 125], ["lipocalin 2", "GENE_OR_GENE_PRODUCT", 136, 147], ["islet-derived protein 3-c", "GENE_OR_GENE_PRODUCT", 170, 195], ["HBE", "CELL_LINE", 31, 34], ["mouse tracheal epithelial cells", "CELL_TYPE", 39, 70], ["antimicrobial genes", "DNA", 87, 106], ["lipocalin 2", "PROTEIN", 136, 147], ["regenerating islet-derived protein 3", "PROTEIN", 157, 193], ["mouse", "SPECIES", 39, 44], ["mouse", "SPECIES", 39, 44], ["IL", "TEST", 0, 2], ["IL", "TREATMENT", 10, 12], ["HBE", "PROBLEM", 31, 34], ["mouse tracheal epithelial cells", "PROBLEM", 39, 70], ["several antimicrobial genes in lung epithelium", "PROBLEM", 79, 125], ["lipocalin", "TEST", 136, 145], ["regenerating islet", "TEST", 157, 175], ["protein", "TEST", 184, 191], ["tracheal", "ANATOMY", 45, 53], ["epithelial cells", "OBSERVATION", 54, 70], ["antimicrobial genes", "OBSERVATION", 87, 106], ["lung", "ANATOMY", 110, 114], ["epithelium", "ANATOMY_MODIFIER", 115, 125]]], ["Neutralization of IL-22 during experimental K. pneumoniae lung infection results in rapid bacteremia, which substantially increases mortality in this model.", [["lung", "ANATOMY", 58, 62], ["lung infection", "DISEASE", 58, 72], ["bacteremia", "DISEASE", 90, 100], ["IL-22", "GENE_OR_GENE_PRODUCT", 18, 23], ["K. pneumoniae", "ORGANISM", 44, 57], ["lung", "ORGAN", 58, 62], ["IL-22", "PROTEIN", 18, 23], ["K. pneumoniae", "SPECIES", 44, 57], ["K. pneumoniae", "SPECIES", 44, 57], ["Neutralization of IL", "TREATMENT", 0, 20], ["experimental K. pneumoniae lung infection", "PROBLEM", 31, 72], ["rapid bacteremia", "PROBLEM", 84, 100], ["lung", "ANATOMY", 58, 62], ["infection", "OBSERVATION", 63, 72], ["rapid", "OBSERVATION_MODIFIER", 84, 89], ["bacteremia", "OBSERVATION", 90, 100], ["increases", "OBSERVATION_MODIFIER", 122, 131], ["mortality", "OBSERVATION_MODIFIER", 132, 141]]], ["IL-22 is regulated by IL-23 and recombinant IL-22 can rescue IL-23-deficient mice (83) .", [["IL-22", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-23", "GENE_OR_GENE_PRODUCT", 22, 27], ["IL-22", "GENE_OR_GENE_PRODUCT", 44, 49], ["IL-23", "GENE_OR_GENE_PRODUCT", 61, 66], ["mice", "ORGANISM", 77, 81], ["IL-22", "PROTEIN", 0, 5], ["IL-23", "PROTEIN", 22, 27], ["recombinant IL-22", "PROTEIN", 32, 49], ["IL-23", "PROTEIN", 61, 66], ["mice", "SPECIES", 77, 81], ["IL", "TREATMENT", 0, 2], ["recombinant IL", "TEST", 32, 46], ["IL", "TEST", 61, 63]]], ["A complication pneumonia is acute lung injury which can be exacerbated by mechanical ventilation also called ventilation-induced lung injury (VILI).", [["lung", "ANATOMY", 34, 38], ["lung", "ANATOMY", 129, 133], ["pneumonia", "DISEASE", 15, 24], ["acute lung injury", "DISEASE", 28, 45], ["lung injury", "DISEASE", 129, 140], ["VILI", "DISEASE", 142, 146], ["lung", "ORGAN", 34, 38], ["lung", "ORGAN", 129, 133], ["A complication pneumonia", "PROBLEM", 0, 24], ["acute lung injury", "PROBLEM", 28, 45], ["mechanical ventilation", "TREATMENT", 74, 96], ["ventilation", "TREATMENT", 109, 120], ["induced lung injury", "PROBLEM", 121, 140], ["complication", "OBSERVATION_MODIFIER", 2, 14], ["pneumonia", "OBSERVATION", 15, 24], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["lung", "ANATOMY", 34, 38], ["injury", "OBSERVATION", 39, 45], ["mechanical ventilation", "OBSERVATION", 74, 96], ["lung", "ANATOMY", 129, 133], ["injury", "OBSERVATION", 134, 140]]], ["In a model of VILI, recombinant IL-22 has also been shown to decrease lung leak and improve lung fluid dynamics (99) .", [["lung", "ANATOMY", 70, 74], ["lung fluid", "ANATOMY", 92, 102], ["VILI", "DISEASE", 14, 18], ["IL-22", "GENE_OR_GENE_PRODUCT", 32, 37], ["lung", "ORGAN", 70, 74], ["lung fluid", "MULTI-TISSUE_STRUCTURE", 92, 102], ["recombinant IL-22", "PROTEIN", 20, 37], ["recombinant IL", "TREATMENT", 20, 34], ["lung leak", "PROBLEM", 70, 79], ["lung fluid dynamics", "TEST", 92, 111], ["VILI", "OBSERVATION", 14, 18], ["lung", "ANATOMY", 70, 74], ["leak", "OBSERVATION", 75, 79], ["lung", "ANATOMY", 92, 96], ["fluid", "OBSERVATION", 97, 102]]], ["These data support a potential therapeutic role of IL-22 in diseases such as severe pneumonia or acute respiratory distress syndrome.Type 17 effectorsIn primary infection, early sources of IL-17 and IL-22 can be from innate lymphoid cells (100), NK or NKT cells (100, 101) , or cd T cells (44, 45, 102) .", [["respiratory", "ANATOMY", 103, 114], ["lymphoid cells", "ANATOMY", 224, 238], ["NK", "ANATOMY", 246, 248], ["NKT cells", "ANATOMY", 252, 261], ["cd T cells", "ANATOMY", 278, 288], ["pneumonia", "DISEASE", 84, 93], ["acute respiratory distress syndrome", "DISEASE", 97, 132], ["primary infection", "DISEASE", 153, 170], ["IL-22", "GENE_OR_GENE_PRODUCT", 51, 56], ["IL-17", "GENE_OR_GENE_PRODUCT", 189, 194], ["IL-22", "GENE_OR_GENE_PRODUCT", 199, 204], ["innate lymphoid cells", "CELL", 217, 238], ["100", "CELL", 240, 243], ["NK", "CELL", 246, 248], ["NKT cells", "CELL", 252, 261], ["cd T cells", "CELL", 278, 288], ["IL-22", "PROTEIN", 51, 56], ["Type 17 effectors", "PROTEIN", 133, 150], ["IL", "PROTEIN", 189, 191], ["IL-22", "PROTEIN", 199, 204], ["innate lymphoid cells", "CELL_TYPE", 217, 238], ["NK or NKT cells", "CELL_TYPE", 246, 261], ["cd T cells", "CELL_TYPE", 278, 288], ["IL", "TREATMENT", 51, 53], ["diseases", "PROBLEM", 60, 68], ["severe pneumonia", "PROBLEM", 77, 93], ["acute respiratory distress syndrome", "PROBLEM", 97, 132], ["Type 17 effectors", "PROBLEM", 133, 150], ["primary infection", "PROBLEM", 153, 170], ["IL", "TEST", 189, 191], ["IL", "TEST", 199, 201], ["innate lymphoid cells", "TEST", 217, 238], ["NKT cells", "TEST", 252, 261], ["cd T cells", "TEST", 278, 288], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["pneumonia", "OBSERVATION", 84, 93], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory distress syndrome", "OBSERVATION", 103, 132], ["primary", "OBSERVATION_MODIFIER", 153, 160], ["infection", "OBSERVATION", 161, 170], ["lymphoid cells", "OBSERVATION", 224, 238], ["NK", "ANATOMY", 246, 248], ["NKT cells", "OBSERVATION", 252, 261]]], ["However, CD4 + Th17 cells can be elicited in the lung by vaccination.", [["CD4 + Th17 cells", "ANATOMY", 9, 25], ["lung", "ANATOMY", 49, 53], ["CD4", "GENE_OR_GENE_PRODUCT", 9, 12], ["lung", "ORGAN", 49, 53], ["CD4", "PROTEIN", 9, 12], ["Th17 cells", "CELL_TYPE", 15, 25], ["CD4", "TEST", 9, 12], ["Th17 cells", "PROBLEM", 15, 25], ["Th17 cells", "OBSERVATION", 15, 25], ["lung", "ANATOMY", 49, 53]]], ["Vaccine-induced Th17 responses have been shown to play protective roles in a diverse set of organisms including both intracellular and extracellular bacteria as well as fungi.", [["intracellular", "ANATOMY", 117, 130], ["extracellular bacteria", "ANATOMY", 135, 157], ["Th17", "CELL", 16, 20], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 130], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 135, 148], ["Vaccine", "TREATMENT", 0, 7], ["both intracellular and extracellular bacteria", "PROBLEM", 112, 157], ["fungi", "PROBLEM", 169, 174], ["extracellular bacteria", "OBSERVATION", 135, 157]]], ["For example, Th17 cells induced by vaccination with the antigen from M. tuberculosis ESAT-6 induce a population of Th17 cells that augment the local production of ligands for CXCR3 in the lung and result in substantial enhanced recruitment of protective Th1 cells (103) .", [["Th17 cells", "ANATOMY", 13, 23], ["Th17 cells", "ANATOMY", 115, 125], ["lung", "ANATOMY", 188, 192], ["Th1 cells", "ANATOMY", 254, 263], ["Th17 cells", "CELL", 13, 23], ["M. tuberculosis", "ORGANISM", 69, 84], ["ESAT-6", "GENE_OR_GENE_PRODUCT", 85, 91], ["Th17 cells", "CELL", 115, 125], ["CXCR3", "GENE_OR_GENE_PRODUCT", 175, 180], ["lung", "ORGAN", 188, 192], ["Th1 cells", "CELL", 254, 263], ["Th17 cells", "CELL_TYPE", 13, 23], ["Th17 cells", "CELL_TYPE", 115, 125], ["CXCR3", "PROTEIN", 175, 180], ["Th1 cells", "CELL_TYPE", 254, 263], ["M. tuberculosis", "SPECIES", 69, 84], ["M. tuberculosis", "SPECIES", 69, 84], ["Th17 cells", "PROBLEM", 13, 23], ["the antigen", "TEST", 52, 63], ["M. tuberculosis ESAT", "TEST", 69, 89], ["Th17 cells", "PROBLEM", 115, 125], ["CXCR3 in the lung", "TEST", 175, 192], ["Th17 cells", "OBSERVATION", 13, 23], ["Th17 cells", "OBSERVATION", 115, 125], ["lung", "ANATOMY", 188, 192], ["substantial", "OBSERVATION_MODIFIER", 207, 218], ["enhanced", "OBSERVATION_MODIFIER", 219, 227], ["recruitment", "OBSERVATION_MODIFIER", 228, 239], ["protective Th1 cells", "OBSERVATION", 243, 263]]], ["Fungal-specific Th17 cells have also been shown to be critical for vaccine-induced protection against Coccidioides posadasii, Histoplasma capsulatum, and Blastomyces dermatitidis infection (104) .", [["Th17 cells", "ANATOMY", 16, 26], ["Coccidioides posadasii", "DISEASE", 102, 124], ["Histoplasma capsulatum", "DISEASE", 126, 148], ["Blastomyces dermatitidis infection", "DISEASE", 154, 188], ["Th17 cells", "CELL", 16, 26], ["Coccidioides posadasii", "ORGANISM", 102, 124], ["Histoplasma capsulatum", "ORGANISM", 126, 148], ["Blastomyces dermatitidis", "ORGANISM", 154, 178], ["Th17 cells", "CELL_TYPE", 16, 26], ["Coccidioides posadasii", "SPECIES", 102, 124], ["Histoplasma capsulatum", "SPECIES", 126, 148], ["Blastomyces dermatitidis", "SPECIES", 154, 178], ["Coccidioides posadasii", "SPECIES", 102, 124], ["Histoplasma capsulatum", "SPECIES", 126, 148], ["Blastomyces dermatitidis", "SPECIES", 154, 178], ["vaccine", "TREATMENT", 67, 74], ["Coccidioides posadasii", "PROBLEM", 102, 124], ["Histoplasma capsulatum", "PROBLEM", 126, 148], ["Blastomyces dermatitidis infection", "PROBLEM", 154, 188], ["Th17 cells", "OBSERVATION", 16, 26], ["Histoplasma capsulatum", "OBSERVATION", 126, 148], ["Blastomyces dermatitidis", "OBSERVATION", 154, 178]]], ["In this setting, the protection against fungal challenge was dependent on IL-17 regulation of neutrophil recruitment.Type 17 effectorsVaccination of whole-cell polysaccharides of S. pneumoniae has been shown to induce IL-17 in the lung, and this IL-17 response has been shown to mediate serotype-independent immunity (105).", [["neutrophil", "ANATOMY", 94, 104], ["whole-cell", "ANATOMY", 149, 159], ["lung", "ANATOMY", 231, 235], ["IL-17", "GENE_OR_GENE_PRODUCT", 74, 79], ["neutrophil", "CELL", 94, 104], ["S. pneumoniae", "ORGANISM", 179, 192], ["IL-17", "GENE_OR_GENE_PRODUCT", 218, 223], ["lung", "ORGAN", 231, 235], ["IL-17", "GENE_OR_GENE_PRODUCT", 246, 251], ["IL-17", "PROTEIN", 74, 79], ["Type 17 effectors", "PROTEIN", 117, 134], ["IL-17", "PROTEIN", 218, 223], ["S. pneumoniae", "SPECIES", 179, 192], ["S. pneumoniae", "SPECIES", 179, 192], ["the protection", "TREATMENT", 17, 31], ["fungal challenge", "PROBLEM", 40, 56], ["IL", "TREATMENT", 74, 76], ["neutrophil recruitment", "TREATMENT", 94, 116], ["Type 17 effectors", "PROBLEM", 117, 134], ["Vaccination", "TREATMENT", 134, 145], ["whole-cell polysaccharides", "TREATMENT", 149, 175], ["S. pneumoniae", "PROBLEM", 179, 192], ["IL", "TEST", 218, 220], ["this IL", "TEST", 241, 248], ["neutrophil recruitment", "OBSERVATION", 94, 116], ["whole-cell", "OBSERVATION_MODIFIER", 149, 159], ["pneumoniae", "OBSERVATION", 182, 192], ["lung", "ANATOMY", 231, 235]]], ["Chen et al. (48) have also shown that Th17 cells elicited by K. pneumoniae vaccination recognize conserved outer membrane proteins in the cell wall of the bacteria and these antigens could also provide serotype-independent immunity.", [["Th17 cells", "ANATOMY", 38, 48], ["outer membrane", "ANATOMY", 107, 121], ["cell wall", "ANATOMY", 138, 147], ["Th17 cells", "CELL", 38, 48], ["K. pneumoniae", "ORGANISM", 61, 74], ["outer membrane", "CELLULAR_COMPONENT", 107, 121], ["cell wall", "CELLULAR_COMPONENT", 138, 147], ["Th17 cells", "CELL_TYPE", 38, 48], ["outer membrane proteins", "PROTEIN", 107, 130], ["K. pneumoniae", "SPECIES", 61, 74], ["K. pneumoniae", "SPECIES", 61, 74], ["Th17 cells", "PROBLEM", 38, 48], ["K. pneumoniae vaccination", "TREATMENT", 61, 86], ["the bacteria", "PROBLEM", 151, 163], ["serotype-independent immunity", "TREATMENT", 202, 231], ["Th17 cells", "OBSERVATION", 38, 48], ["cell", "OBSERVATION", 138, 142], ["wall", "ANATOMY_MODIFIER", 143, 147], ["bacteria", "OBSERVATION", 155, 163]]], ["Th17 cells conferred heterologous protection against multiple serotypes of the organism (48) .", [["Th17 cells", "ANATOMY", 0, 10], ["Th17 cells", "CELL", 0, 10], ["Th17 cells", "CELL_LINE", 0, 10], ["Th17 cells", "TREATMENT", 0, 10], ["heterologous protection", "TREATMENT", 21, 44]]], ["Thus, in two models of important human extracelluar pathogens, Th17 cells are capable of mediating serotypeindependent immunity which may advance vaccine approaches against these pathogens.", [["Th17 cells", "ANATOMY", 63, 73], ["human", "ORGANISM", 33, 38], ["Th17 cells", "CELL", 63, 73], ["Th17 cells", "CELL_TYPE", 63, 73], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["important human extracelluar pathogens", "PROBLEM", 23, 61], ["Th17 cells", "TREATMENT", 63, 73], ["mediating serotypeindependent immunity", "TREATMENT", 89, 127], ["vaccine approaches", "TREATMENT", 146, 164], ["these pathogens", "PROBLEM", 173, 188]]], ["It still remains to be defined which specific aspects of Th17 function that are required for protection.", [["Th17", "GENE_OR_GENE_PRODUCT", 57, 61], ["Th17", "OBSERVATION", 57, 61]]], ["There needs to be better understanding of factors important in generating mucosal Th17 cells in the lung such as adjuvants, factor regulating proliferation, homing, and survival.", [["mucosal Th17 cells", "ANATOMY", 74, 92], ["lung", "ANATOMY", 100, 104], ["mucosal Th17 cells", "CELL", 74, 92], ["lung", "ORGAN", 100, 104], ["mucosal Th17 cells", "CELL_TYPE", 74, 92], ["mucosal Th17 cells", "TREATMENT", 74, 92], ["adjuvants", "TREATMENT", 113, 122], ["mucosal Th17 cells", "OBSERVATION", 74, 92], ["lung", "ANATOMY", 100, 104]]], ["More research is needed to also define the contributions of IL-22, IL-17F, and IL-17A/F heterodimers.ConclusionsCD4 + T cells play critical roles in lung immunity, and these cells are impacted by many drugs as well as by HIV infection.", [["ConclusionsCD4 + T cells", "ANATOMY", 101, 125], ["lung", "ANATOMY", 149, 153], ["cells", "ANATOMY", 174, 179], ["HIV infection", "DISEASE", 221, 234], ["IL-22", "GENE_OR_GENE_PRODUCT", 60, 65], ["IL-17F", "GENE_OR_GENE_PRODUCT", 67, 73], ["IL-17A", "GENE_OR_GENE_PRODUCT", 79, 85], ["F heterodimers", "GENE_OR_GENE_PRODUCT", 86, 100], ["lung", "ORGAN", 149, 153], ["cells", "CELL", 174, 179], ["HIV", "ORGANISM", 221, 224], ["IL-22, IL-17F, and IL-17A/F heterodimers", "PROTEIN", 60, 100], ["ConclusionsCD4", "PROTEIN", 101, 115], ["T cells", "CELL_TYPE", 118, 125], ["HIV", "SPECIES", 221, 224], ["IL", "TEST", 60, 62], ["IL", "TREATMENT", 79, 81], ["heterodimers", "TREATMENT", 88, 100], ["ConclusionsCD4", "TEST", 101, 115], ["T cells", "PROBLEM", 118, 125], ["many drugs", "TREATMENT", 196, 206], ["HIV infection", "PROBLEM", 221, 234], ["lung", "ANATOMY", 149, 153], ["immunity", "OBSERVATION", 154, 162], ["infection", "OBSERVATION", 225, 234]]], ["CD4 + T cells are critical targets to achieve therapeutic vaccines against both bacterial and fungal pathogens.", [["CD4 + T cells", "ANATOMY", 0, 13], ["bacterial and fungal pathogens", "DISEASE", 80, 110], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD4", "PROTEIN", 0, 3], ["T cells", "CELL_TYPE", 6, 13], ["CD4", "TEST", 0, 3], ["T cells", "PROBLEM", 6, 13], ["critical targets", "PROBLEM", 18, 34], ["therapeutic vaccines", "TREATMENT", 46, 66], ["both bacterial and fungal pathogens", "PROBLEM", 75, 110], ["fungal pathogens", "OBSERVATION", 94, 110]]], ["Future work will be required to understand the induction and survival of these cells in the lung and how they can be manipulated therapeutically.", [["cells", "ANATOMY", 79, 84], ["lung", "ANATOMY", 92, 96], ["cells", "CELL", 79, 84], ["lung", "ORGAN", 92, 96], ["the induction", "TREATMENT", 43, 56], ["lung", "ANATOMY", 92, 96]]]], "PMC7413017": [["COVID-19 has created a mental health crisisMillions of Canadians are experiencing fear, social isolation, grief, and financial insecurity from COVID-19 that are negatively impacting their mental health, whether or not they become infected.", [["COVID-19", "CHEMICAL", 0, 8], ["grief", "DISEASE", 106, 111], ["grief", "PROBLEM", 106, 111], ["infected", "OBSERVATION", 230, 238]]], ["Particularly vulnerable groups include front-line workers witnessing death and human suffering while worrying about contracting the virus and bringing it home to their families.", [["death", "DISEASE", 69, 74], ["human", "ORGANISM", 79, 84], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84], ["the virus", "PROBLEM", 128, 137]]], ["People with pre-existing mental health issues who were struggling with the status quo must now also manage pandemic-related stressors, including caring for children at home; these individuals will likely need intensified mental health supports.", [["pandemic", "DISEASE", 107, 115], ["People", "ORGANISM", 0, 6], ["children", "ORGANISM", 156, 164], ["People", "SPECIES", 0, 6], ["children", "SPECIES", 156, 164], ["pre-existing mental health issues", "PROBLEM", 12, 45]]], ["In addition, family members of long-term care residents may require support to cope with stress or bereavement issues.", [["support", "TREATMENT", 68, 75]]], ["COVID-19-related mental illness is a looming crisis that needs a coordinated public health response.Ontario\u2019s response to the COVID-19 mental health crisis is physician-centric and therefore problematicOntario\u2019s response to the COVID-19 mental health crisis has focused on Ontario Health Insurance Plan (OHIP)-covered primary medical providers to increase the intensity and scope of available mental healthcare.", [["COVID-19", "CHEMICAL", 0, 8], ["mental illness", "DISEASE", 17, 31], ["COVID", "TEST", 0, 5], ["mental illness", "PROBLEM", 17, 31], ["a looming crisis", "PROBLEM", 35, 51]]], ["On March 13, 2020, Ontario released new OHIP billing codes that enable physicians to provide crisis counselling to patients over the phone (Ministry of Health 2020a).", [["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 115, 123]]], ["The Ontario Ministry of Health\u2019s COVID-19 resource page (Ministry of Health 2020b) lists this resource first for people experiencing mental health issues during COVID-19, followed by a variety of public services that are well known to be underfunded, with 6-month wait-lists (Health Quality Ontario 2015), and without any publicized new capacity to meet the emergent need.Ontario\u2019s response to the COVID-19 mental health crisis is physician-centric and therefore problematicSeveral problems exist with directing people experiencing mental health crises to primary care physicians:Ontario physicians typically do not provide psychotherapy (Kurdyak et al. 2020).", [["people", "ORGANISM", 113, 119], ["people", "ORGANISM", 512, 518], ["people", "SPECIES", 113, 119], ["people", "SPECIES", 512, 518], ["mental health issues", "PROBLEM", 133, 153], ["any publicized new capacity", "PROBLEM", 318, 345], ["problematicSeveral problems", "PROBLEM", 463, 490]]], ["This is because physicians are typically not trained to provide evidence-based psychotherapies, and psychotherapy if not done properly can be harmful (Rose et al. 2002).", [["psychotherapy", "TREATMENT", 100, 113]]], ["Policy actions that direct people with mental health needs to primary care providers therefore pressures and incentivizes over-worked physicians to potentially provide suboptimal care.Payment incentives in medicine have not typically increased public access to evidence-based mental health care (Rudoler et al. 2017), nor have they increased the number of physicians providing the targeted healthcare (Kiran et al. 2012).Shortages of psychiatrist and other public mental health services mean that physicians have nowhere within the public system to refer their patients with severe or emergency mental health issues (Health Quality Ontario 2015).A physician-first approach to emergency mental healthcare pressures an already overburdened primary healthcare system, particularly in rural and northern areas where many people cannot access primary care (Health Quality Ontario 2015).This approach fails to increase public access to psychologists and other non-physician registered mental health providers (RMHPs) who are not covered by OHIP but who may have capacity to provide emergency care that is effective and cost-effective compared with pharmacotherapy alone (Hunsley 2003).Ontario\u2019s response to the COVID-19 mental health crisis is physician-centric and therefore problematicIn short, a physician-centric approach to providing emergency mental health services puts patients at risk from inadequate or inappropriate care while increasing stress on primary care providers whose services are desperately needed elsewhere during COVID-19.An Ontario emergency mental health response requires mental health infrastructure: next steps forward ::: No earnest provincial effort has been made to mobilize psychologists and other RMHPs in response to COVID-19COVID-19 shines a light on Ontario\u2019s patchwork mental health system that puts vulnerable and socio-demographically disadvantaged people at risk.", [["people", "ORGANISM", 27, 33], ["patients", "ORGANISM", 561, 569], ["people", "ORGANISM", 817, 823], ["patients", "ORGANISM", 1371, 1379], ["people", "ORGANISM", 1883, 1889], ["people", "SPECIES", 27, 33], ["patients", "SPECIES", 561, 569], ["people", "SPECIES", 817, 823], ["patients", "SPECIES", 1371, 1379], ["people", "SPECIES", 1883, 1889], ["pressures", "TEST", 95, 104], ["emergency care", "TREATMENT", 1076, 1090], ["pharmacotherapy", "TREATMENT", 1142, 1157], ["emergency mental health services", "TREATMENT", 1333, 1365], ["COVID", "TEST", 1746, 1751]]], ["Using this knowledge base, Ontario and the rest of Canada could quickly mobilize a network of trained professionals to address the COVID-19 mental health crisis as follows.Create trial billing mechanisms through provincial public health insurance for registered mental health providers with relevant expertise.", [["the COVID", "TEST", 127, 136]]], ["Prospective payment models (PPMs) such as those used to fund the new U.S. Certified Community Behavioral Health Clinics offer replicable templates for estimating and controlling the costs of new and widely expanded mental healthcare (Assistant Secretary for Planning and Evaluation 2019).", [["Prospective payment models (PPMs)", "TREATMENT", 0, 33], ["replicable templates", "TREATMENT", 126, 146], ["Evaluation", "TEST", 271, 281]]], ["This will help define the provincial and national mental health service system and its capacity in routine and crisis circumstances, and it will identify critical service gaps and inform meaningful mental health system budgeting and future workforce planning.", [["future workforce planning", "TREATMENT", 233, 258]]], ["Such a change is critical to correcting the current inequities in public access to competent mental healthcare in general, in times of crisis, and into the future.ConclusionThe federal government has just announced $240 million in funding to support online mental healthcare and medical services (May 3, 2020).", [["crisis", "PROBLEM", 135, 141]]], ["In Ontario, structural investments that sustainably integrate non-physician RMHPs into the public insurance system are needed to ensure that the province can quickly, effectively, equitably, and sustainably routinely serve its residents, and respond to the current COVID-19 mental health crisis and future crises.", [["future crises", "PROBLEM", 299, 312]]]], "c42bd40a98ed98881ddbd6d60723bd187958efe6": [["Dear Editor,In a recent article in the Journal, Bruno and colleagues present short-term outcomes in elderly patients with severe COVID-19 disease admitted to a single Italian Infectious Disease unit.", [["COVID-19 disease", "DISEASE", 129, 145], ["Infectious Disease", "DISEASE", 175, 193], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["severe COVID-19 disease", "PROBLEM", 122, 145]]], ["(1) The study found that elderly patients are at increased risk of adverse outcomes due to high number of comorbidities and emphasises the need to improve clinical management in these patients.", [["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 184, 192], ["The study", "TEST", 4, 13], ["adverse outcomes", "PROBLEM", 67, 83], ["high number of comorbidities", "PROBLEM", 91, 119], ["clinical management", "TREATMENT", 155, 174]]], ["In particular, elderly patients who are likely to deteriorate will need to be rapidly identified.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31]]], ["(2) Existing prognostic models for COVID-19 based on clinical, laboratory and radiological variables are at high risk of bias.", [["Existing prognostic models", "TEST", 4, 30], ["COVID", "TEST", 35, 40], ["radiological variables", "TEST", 78, 100]]], ["(3) In the UK, the National Early Warning Score (NEWS) and its updated version NEWS2an a priori weighted composition of the patient's observations -is used routinely to monitor patients in hospital and identify early those who may deteriorate.", [["patient", "ORGANISM", 124, 131], ["patients", "ORGANISM", 177, 185], ["patient", "SPECIES", 124, 131], ["patients", "SPECIES", 177, 185]]], ["(4) Compared to other early warning scores, the NEWS Score has a greater ability to discriminate patients at risk of cardiac arrest, unanticipated intensive care unit admission or death.", [["cardiac", "ANATOMY", 117, 124], ["cardiac arrest", "DISEASE", 117, 131], ["death", "DISEASE", 180, 185], ["patients", "ORGANISM", 97, 105], ["cardiac", "ORGAN", 117, 124], ["patients", "SPECIES", 97, 105], ["the NEWS Score", "TEST", 44, 58], ["cardiac arrest", "PROBLEM", 117, 131], ["death", "PROBLEM", 180, 185], ["cardiac", "ANATOMY", 117, 124], ["arrest", "OBSERVATION", 125, 131]]], ["(5) Currently, guidance from the National Institute of Clinical Excellence (NICE) supports the use of the NEWS2 score to risk assess patients with COVID-19 in the community, who may require hospitalisation.", [["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141]]], ["(6) In a recent rapid review, Greenhalgh and colleagues do not recommend using the NEWS2 Score alone for risk assessment of patients with COVID-19 in the community.", [["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["the NEWS2 Score", "TEST", 79, 94], ["risk assessment", "TEST", 105, 120], ["COVID", "TEST", 138, 143]]], ["(7) Blood pressure and oxygen saturation measurements are difficult to take remotely.", [["Blood", "ANATOMY", 4, 9], ["oxygen", "CHEMICAL", 23, 29], ["oxygen", "CHEMICAL", 23, 29], ["Blood", "ORGANISM_SUBSTANCE", 4, 9], ["oxygen", "SIMPLE_CHEMICAL", 23, 29], ["Blood pressure", "TEST", 4, 18], ["oxygen saturation measurements", "TEST", 23, 53], ["oxygen saturation", "OBSERVATION", 23, 40]]], ["The score also does not include age or comorbidities, strong independent predictors of survival in patients with COVID-19.", [["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["comorbidities", "PROBLEM", 39, 52], ["COVID", "TEST", 113, 118]]], ["The value of the NEWS2 Score in predicting outcome in patients admitted to hospital with COVDI-19 remains uncertain.Dear Editor,We therefore undertook, as part of service evaluation, a prospective pilot assessment of patients with confirmed COVID-19 admitted to a tertiary infectious diseases unit, in the first month of the pandemic reaching the UK.Dear Editor,We studied all patients who had a clinical outcome (either discharged from hospital or died) between 12 th March and 2 nd April 2020.", [["COVDI-19", "CHEMICAL", 89, 97], ["infectious diseases", "DISEASE", 273, 292], ["COVDI-19", "CHEMICAL", 89, 97], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 217, 225], ["patients", "ORGANISM", 377, 385], ["NEWS2", "DNA", 17, 22], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 217, 225], ["patients", "SPECIES", 377, 385], ["COVDI", "TEST", 89, 94], ["service evaluation", "TEST", 163, 181], ["a prospective pilot assessment", "TEST", 183, 213], ["infectious", "OBSERVATION", 273, 283]]], ["Clinical (presenting symptoms, comorbidity and the NEWS2 Score throughout hospital stay), laboratory (routine blood tests) and radiological (chest x-ray reports) findings on admission were collated.", [["blood", "ANATOMY", 110, 115], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["Clinical (presenting symptoms", "PROBLEM", 0, 29], ["comorbidity", "PROBLEM", 31, 42], ["routine blood tests", "TEST", 102, 121], ["radiological (chest x-ray", "TEST", 127, 152], ["chest", "ANATOMY", 141, 146]]], ["Our main aim was to examine the utility of the NEWS2 Score in predicting the clinical deterioration of hospitalised COVID-19 patients.", [["COVID", "DISEASE", 116, 121], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["the NEWS2 Score", "TEST", 43, 58]]], ["Continuous data are expressed as a median (25 th -75 th percentiles) and categorical data are expressed as n (%).", [["categorical data", "TEST", 73, 89]]], ["Independent t-tests and Mann-Whitney U tests were used to compare two continuous variables for normally and non-normally distributed data.", [["Whitney U tests", "TEST", 29, 44]]], ["The chi-squared test was used to compare proportions between groups.Dear Editor,Overall, 17 patients with COVID-19 had an outcome by 2 nd April 2020.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["The chi-squared test", "TEST", 0, 20], ["COVID", "TEST", 106, 111]]], ["All patients who were unsuitable for escalation to intensive care and received ward-based care as per NICE rapid guidance for COVID-19.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["intensive care", "TREATMENT", 51, 65], ["COVID", "TEST", 126, 131]]], ["(5) The majority of patients died (N=10, 59%).", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["Compared to patients who survived, those who died were more likely to be male, with bilateral consolidation on chest radiographs on admission.", [["chest", "ANATOMY", 111, 116], ["patients", "ORGANISM", 12, 20], ["chest", "ORGANISM_SUBDIVISION", 111, 116], ["patients", "SPECIES", 12, 20], ["bilateral consolidation", "PROBLEM", 84, 107], ["chest radiographs", "TEST", 111, 128], ["bilateral", "ANATOMY_MODIFIER", 84, 93], ["consolidation", "OBSERVATION", 94, 107], ["chest", "ANATOMY", 111, 116]]], ["Admission SARS-CoV-2 quantitative PCR Ct values on nasopharyngeal swab did not seem to relate to survival.", [["nasopharyngeal swab", "ANATOMY", 51, 70], ["Admission SARS", "TEST", 0, 14], ["CoV", "TEST", 15, 18], ["quantitative PCR", "TEST", 21, 37], ["Ct values", "TEST", 38, 47], ["nasopharyngeal swab", "TEST", 51, 70], ["nasopharyngeal", "ANATOMY", 51, 65]]], ["All patients who died required some form of oxygen therapy, ranging from nasal canulae to non-invasive ventilation through continuous positive airway pressure.", [["nasal", "ANATOMY", 73, 78], ["airway", "ANATOMY", 143, 149], ["oxygen", "CHEMICAL", 44, 50], ["oxygen", "CHEMICAL", 44, 50], ["patients", "ORGANISM", 4, 12], ["oxygen", "SIMPLE_CHEMICAL", 44, 50], ["airway", "MULTI-TISSUE_STRUCTURE", 143, 149], ["patients", "SPECIES", 4, 12], ["oxygen therapy", "TREATMENT", 44, 58], ["nasal canulae", "TREATMENT", 73, 86], ["non-invasive ventilation", "TREATMENT", 90, 114], ["continuous positive airway pressure", "TREATMENT", 123, 158], ["oxygen therapy", "OBSERVATION", 44, 58], ["positive airway pressure", "OBSERVATION", 134, 158]]], ["Less than half of those who survived required oxygen therapy, all of which were delivered via nasal canulae.", [["nasal", "ANATOMY", 94, 99], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["oxygen therapy", "TREATMENT", 46, 60], ["oxygen therapy", "OBSERVATION", 46, 60], ["nasal", "ANATOMY", 94, 99]]], ["First, we found that the initial NEWS2 score did not predict mortality.", [["NEWS2", "PROTEIN", 33, 38], ["the initial NEWS2 score", "TEST", 21, 44]]], ["For example, four out of the ten patients (40%) who died presented with a NEWS2 score of 0-3 while three out of seven patients (43%) who survived presented with a NEW2 Score of 5 or above.", [["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 118, 126], ["a NEWS2 score", "TEST", 72, 85], ["a NEW2 Score", "TEST", 161, 173]]], ["Secondly, there was no significant difference in the admission NEWS2 score and its components, between patients who died and those who survived, apart from systolic blood pressure.", [["blood", "ANATOMY", 165, 170], ["patients", "ORGANISM", 103, 111], ["blood", "ORGANISM_SUBSTANCE", 165, 170], ["NEWS2", "PROTEIN", 63, 68], ["patients", "SPECIES", 103, 111], ["the admission NEWS2 score", "TEST", 49, 74], ["systolic blood pressure", "TEST", 156, 179], ["no", "UNCERTAINTY", 20, 22], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["difference", "OBSERVATION_MODIFIER", 35, 45]]], ["Thirdly, examining the NEWS2 scores over time, patients who died had a higher variability in their scores compared to those who survived.", [["patients", "ORGANISM", 47, 55], ["NEWS2", "DNA", 23, 28], ["patients", "SPECIES", 47, 55], ["a higher variability", "PROBLEM", 69, 89]]], ["Seven out of ten patients (70%) who died had a maximum daily change in NEWS2 score of over 5, while none of those who survived had such dramatic fluctuations.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["NEWS2 score", "TEST", 71, 82]]], ["(Figure 1 )Dear Editor,In our small pilot of elderly patients admitted to hospital with COVID-19, admission NEWS2 scores did not seem to be useful in predicting clinical outcomes.", [["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["COVID", "TEST", 88, 93], ["admission NEWS2 scores", "TEST", 98, 120], ["small", "OBSERVATION_MODIFIER", 30, 35]]], ["For some patients, death occurred regardless of admission NEWS scores and without a prior deteriorating trend.", [["death", "DISEASE", 19, 24], ["patients", "ORGANISM", 9, 17], ["patients", "SPECIES", 9, 17], ["death", "PROBLEM", 19, 24], ["a prior deteriorating trend", "PROBLEM", 82, 109]]], ["Originally, the NEWS score was developed using data from 35585 acute hospital admissions, most of whom would have had an underlying diagnosis of sepsis.", [["sepsis", "DISEASE", 145, 151], ["sepsis", "PROBLEM", 145, 151], ["sepsis", "OBSERVATION", 145, 151]]], ["However, COVID-19 is caused by SARS-CoV-2, a coronavirus which predominately appears to affect the respiratory system as an initial viral pneumonitis.", [["respiratory system", "ANATOMY", 99, 117], ["coronavirus", "DISEASE", 45, 56], ["pneumonitis", "DISEASE", 138, 149], ["SARS-CoV-2", "ORGANISM", 31, 41], ["coronavirus", "ORGANISM", 45, 56], ["COVID-19", "SPECIES", 9, 17], ["SARS-CoV-2", "SPECIES", 31, 41], ["COVID", "TEST", 9, 14], ["SARS", "PROBLEM", 31, 35], ["CoV", "TEST", 36, 39], ["a coronavirus", "PROBLEM", 43, 56], ["an initial viral pneumonitis", "PROBLEM", 121, 149], ["coronavirus", "OBSERVATION", 45, 56], ["respiratory system", "ANATOMY", 99, 117], ["viral pneumonitis", "OBSERVATION", 132, 149]]], ["In China, a fifth of all COVID-19 inpatients rapidly became critically ill with hypoxia and respiratory failure.", [["respiratory", "ANATOMY", 92, 103], ["critically ill", "DISEASE", 60, 74], ["hypoxia", "DISEASE", 80, 87], ["respiratory failure", "DISEASE", 92, 111], ["inpatients", "ORGANISM", 34, 44], ["all COVID", "TREATMENT", 21, 30], ["critically ill", "PROBLEM", 60, 74], ["hypoxia", "PROBLEM", 80, 87], ["respiratory failure", "PROBLEM", 92, 111], ["hypoxia", "OBSERVATION", 80, 87], ["respiratory failure", "OBSERVATION", 92, 111]]], ["(9) The weighting of the NEWS2 score does not account for the degree of supplemental oxygen (FiO2) a patient may require, thus limiting its utility to identify early deterioration in patients with COVID-19.", [["oxygen", "CHEMICAL", 85, 91], ["FiO2", "CHEMICAL", 93, 97], ["oxygen", "CHEMICAL", 85, 91], ["FiO2", "CHEMICAL", 93, 97], ["COVID-19", "CHEMICAL", 197, 205], ["oxygen", "SIMPLE_CHEMICAL", 85, 91], ["FiO2", "SIMPLE_CHEMICAL", 93, 97], ["patient", "ORGANISM", 101, 108], ["patients", "ORGANISM", 183, 191], ["NEWS2", "PROTEIN", 25, 30], ["patient", "SPECIES", 101, 108], ["patients", "SPECIES", 183, 191], ["the NEWS2 score", "TEST", 21, 36], ["supplemental oxygen (FiO2", "TREATMENT", 72, 97], ["early deterioration", "PROBLEM", 160, 179], ["COVID", "TEST", 197, 202], ["not account for", "UNCERTAINTY", 42, 57]]], ["In our cohort, patient 8 had a NEWS2 score of 2 on day 2 and 3 despite requiring a large increase in FiO2 (from room air to 60%).", [["FiO2", "CHEMICAL", 101, 105], ["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22], ["a NEWS2 score", "TEST", 29, 42], ["a large increase in FiO2", "TREATMENT", 81, 105], ["large", "OBSERVATION_MODIFIER", 83, 88], ["increase", "OBSERVATION_MODIFIER", 89, 97]]], ["A more sensitive early warning score for COVID-19 needs to be urgently developed and validated.DP and SS are supported by National Institute for Health Research (NIHR) Academic Clinical Fellowships.MP is supported by the NIHR and has received grants and personal fees from Gilead Sciences outside of this work.", [["MP", "DISEASE", 198, 200], ["MP", "GENE_OR_GENE_PRODUCT", 198, 200], ["COVID", "TEST", 41, 46], ["DP", "TEST", 95, 97]]]], "PMC7286222": [["BackgroundAvian colibacillosis is a complex of several localized or systemic syndromes, affecting poultry of all age and production categories.", [["colibacillosis", "DISEASE", 16, 30], ["BackgroundAvian colibacillosis", "PROBLEM", 0, 30], ["systemic syndromes", "PROBLEM", 68, 86], ["colibacillosis", "OBSERVATION", 16, 30], ["complex", "OBSERVATION_MODIFIER", 36, 43], ["several", "OBSERVATION_MODIFIER", 47, 54], ["localized", "OBSERVATION_MODIFIER", 55, 64], ["systemic syndromes", "OBSERVATION", 68, 86], ["production categories", "OBSERVATION", 121, 142]]], ["It comprises yolk sac infection and omphalitis, leading to increased mortality rates in newly hatched chicks, cellulitis in broilers or reproductive tract infections in laying hens.", [["yolk sac", "ANATOMY", 13, 21], ["reproductive tract", "ANATOMY", 136, 154], ["yolk sac infection", "DISEASE", 13, 31], ["omphalitis", "DISEASE", 36, 46], ["cellulitis", "DISEASE", 110, 120], ["reproductive tract infections", "DISEASE", 136, 165], ["yolk sac", "MULTI-TISSUE_STRUCTURE", 13, 21], ["chicks", "ORGANISM_SUBDIVISION", 102, 108], ["broilers", "ORGANISM_SUBDIVISION", 124, 132], ["reproductive tract", "ORGANISM_SUBDIVISION", 136, 154], ["chicks", "SPECIES", 102, 108], ["broilers", "SPECIES", 124, 132], ["broilers", "SPECIES", 124, 132], ["yolk sac infection", "PROBLEM", 13, 31], ["omphalitis", "PROBLEM", 36, 46], ["increased mortality rates", "PROBLEM", 59, 84], ["newly hatched chicks", "PROBLEM", 88, 108], ["cellulitis", "PROBLEM", 110, 120], ["reproductive tract infections", "PROBLEM", 136, 165], ["yolk", "OBSERVATION_MODIFIER", 13, 17], ["sac", "OBSERVATION_MODIFIER", 18, 21], ["infection", "OBSERVATION", 22, 31], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["mortality", "OBSERVATION_MODIFIER", 69, 78], ["rates", "OBSERVATION_MODIFIER", 79, 84], ["newly", "OBSERVATION_MODIFIER", 88, 93], ["hatched chicks", "OBSERVATION", 94, 108], ["cellulitis", "OBSERVATION", 110, 120], ["reproductive", "OBSERVATION_MODIFIER", 136, 148], ["tract", "OBSERVATION_MODIFIER", 149, 154], ["infections", "OBSERVATION", 155, 165]]], ["Other forms of manifestation include swollen head syndrome (SHS), respiratory infections and septicemia which frequently result in death or chronic forms of infection.", [["head", "ANATOMY", 45, 49], ["respiratory", "ANATOMY", 66, 77], ["swollen head syndrome", "DISEASE", 37, 58], ["SHS", "DISEASE", 60, 63], ["respiratory infections", "DISEASE", 66, 88], ["septicemia", "DISEASE", 93, 103], ["death", "DISEASE", 131, 136], ["infection", "DISEASE", 157, 166], ["head", "ORGANISM_SUBDIVISION", 45, 49], ["swollen head syndrome", "PROBLEM", 37, 58], ["respiratory infections", "PROBLEM", 66, 88], ["septicemia", "PROBLEM", 93, 103], ["death", "PROBLEM", 131, 136], ["infection", "PROBLEM", 157, 166], ["swollen", "OBSERVATION_MODIFIER", 37, 44], ["head", "ANATOMY", 45, 49], ["syndrome", "OBSERVATION", 50, 58], ["respiratory", "ANATOMY", 66, 77], ["infections", "OBSERVATION", 78, 88], ["septicemia", "OBSERVATION", 93, 103], ["chronic", "OBSERVATION_MODIFIER", 140, 147], ["infection", "OBSERVATION", 157, 166]]], ["Avian colibacillosis thus represents a great economic burden for the poultry industry [1].", [["Avian colibacillosis", "DISEASE", 0, 20], ["Avian", "ORGANISM", 0, 5], ["Avian", "SPECIES", 0, 5], ["Avian colibacillosis", "PROBLEM", 0, 20], ["colibacillosis", "OBSERVATION", 6, 20], ["great", "OBSERVATION_MODIFIER", 39, 44], ["economic", "OBSERVATION_MODIFIER", 45, 53], ["burden", "OBSERVATION", 54, 60]]], ["Despite its importance as a significant cause of disease, the pathogenesis of these infections is not utterly understood.", [["infections", "DISEASE", 84, 94], ["disease", "PROBLEM", 49, 56], ["these infections", "PROBLEM", 78, 94], ["disease", "OBSERVATION", 49, 56], ["infections", "OBSERVATION", 84, 94]]], ["For a long time APEC strains were considered merely opportunistic pathogens, predominantly, but not exclusively associated with O1, O2, O8, O78 and several other serogroups [2].", [["O78", "CHEMICAL", 140, 143], ["O1", "CHEMICAL", 128, 130], ["O2", "CHEMICAL", 132, 134], ["O78", "CHEMICAL", 140, 143], ["O2", "SIMPLE_CHEMICAL", 132, 134], ["O8", "SIMPLE_CHEMICAL", 136, 138], ["a long time APEC strains", "PROBLEM", 4, 28], ["opportunistic pathogens", "PROBLEM", 52, 75], ["O2", "TREATMENT", 132, 134], ["O8", "TREATMENT", 136, 138]]], ["It has been demonstrated that disease-associated E. coli strains encode multiple putative virulence genes and significantly differ from commensals, particularly in the carriage of the ColV plasmid-associated genes, which are considered markers of poultry-adapted pathogenic strains [3\u20135].BackgroundThe ability to cause colibacillosis in chicken defines the APEC (avian-pathogenic E. coli) pathotype.", [["colibacillosis", "DISEASE", 319, 333], ["E. coli", "ORGANISM", 49, 56], ["strains", "ORGANISM", 57, 64], ["ColV", "GENE_OR_GENE_PRODUCT", 184, 188], ["chicken", "ORGANISM", 337, 344], ["APEC (", "ORGANISM", 357, 363], ["avian-pathogenic E. coli", "ORGANISM", 363, 387], ["virulence genes", "DNA", 90, 105], ["ColV plasmid", "DNA", 184, 196], ["E. coli", "SPECIES", 49, 56], ["chicken", "SPECIES", 337, 344], ["E. coli", "SPECIES", 380, 387], ["E. coli", "SPECIES", 49, 56], ["chicken", "SPECIES", 337, 344], ["E. coli", "SPECIES", 380, 387], ["disease", "PROBLEM", 30, 37], ["E. coli strains", "PROBLEM", 49, 64], ["multiple putative virulence genes", "PROBLEM", 72, 105], ["pathogenic strains", "PROBLEM", 263, 281], ["colibacillosis", "PROBLEM", 319, 333], ["the APEC", "TEST", 353, 361], ["pathogenic E. coli) pathotype", "PROBLEM", 369, 398], ["disease", "OBSERVATION", 30, 37], ["coli strains", "OBSERVATION", 52, 64], ["virulence genes", "OBSERVATION", 90, 105], ["colibacillosis", "OBSERVATION", 319, 333], ["E. coli", "OBSERVATION_MODIFIER", 380, 387]]], ["However, not every strain isolated from diseased chicken carries typical virulence-associated genes, underlining an opportunistic character of some types of E. coli infections [6].", [["E. coli infections", "DISEASE", 157, 175], ["chicken", "ORGANISM", 49, 56], ["E. coli", "ORGANISM", 157, 164], ["virulence-associated genes", "DNA", 73, 99], ["chicken", "SPECIES", 49, 56], ["E. coli", "SPECIES", 157, 164], ["chicken", "SPECIES", 49, 56], ["E. coli", "SPECIES", 157, 164], ["every strain", "PROBLEM", 13, 25], ["E. coli infections", "PROBLEM", 157, 175], ["E. coli infections", "OBSERVATION", 157, 175]]], ["On the other hand, APEC-like strains (carrying APEC-associated virulence traits) can be found also in the gut of healthy chicken [7, 8].", [["gut", "ANATOMY", 106, 109], ["APEC-like strains", "ORGANISM", 19, 36], ["gut", "ORGANISM_SUBDIVISION", 106, 109], ["chicken", "ORGANISM", 121, 128], ["chicken", "SPECIES", 121, 128], ["chicken", "SPECIES", 121, 128], ["APEC-like strains", "PROBLEM", 19, 36]]], ["It has been suggested by Maturana et al. [9] that the APEC population composes of distinct subpathotypes associated with different syndromes, similar to the human extraintestinal pathogenic E. coli (ExPEC).", [["extraintestinal pathogenic E. coli", "DISEASE", 163, 197], ["APEC", "ORGANISM", 54, 58], ["human", "ORGANISM", 157, 162], ["extraintestinal pathogenic E. coli", "ORGANISM", 163, 197], ["human", "SPECIES", 157, 162], ["E. coli", "SPECIES", 190, 197], ["human", "SPECIES", 157, 162], ["E. coli", "SPECIES", 190, 197], ["the APEC population", "PROBLEM", 50, 69], ["distinct subpathotypes", "PROBLEM", 82, 104], ["different syndromes", "PROBLEM", 121, 140], ["the human extraintestinal pathogenic E. coli", "PROBLEM", 153, 197], ["distinct subpathotypes", "OBSERVATION", 82, 104], ["E. coli", "OBSERVATION", 190, 197]]], ["Interestingly, the authors showed that SHS and omphalitis isolates formed two distinct groups differing in virulence, suggesting primary and opportunistic character of those infections, respectively.", [["SHS", "CHEMICAL", 39, 42], ["infections", "DISEASE", 174, 184], ["SHS and omphalitis isolates", "PROBLEM", 39, 66], ["those infections", "PROBLEM", 168, 184], ["distinct", "OBSERVATION_MODIFIER", 78, 86], ["groups", "OBSERVATION_MODIFIER", 87, 93], ["opportunistic", "OBSERVATION_MODIFIER", 141, 154], ["infections", "OBSERVATION", 174, 184]]], ["Similarly, chronic salpingitis-peritonitis syndrome resulting from an ascending infection and an acute peritonitis without salpingitis, probably originating from respiratory infection or gut translocation after a stress insult, can be distinguished in layers [10\u201312].BackgroundThere is a close genetic relationship between APEC and human ExPEC.", [["respiratory", "ANATOMY", 162, 173], ["gut", "ANATOMY", 187, 190], ["salpingitis-peritonitis syndrome", "DISEASE", 19, 51], ["infection", "DISEASE", 80, 89], ["peritonitis", "DISEASE", 103, 114], ["salpingitis", "DISEASE", 123, 134], ["respiratory infection", "DISEASE", 162, 183], ["stress insult", "DISEASE", 213, 226], ["gut", "ORGANISM_SUBDIVISION", 187, 190], ["APEC", "ORGANISM", 323, 327], ["human", "ORGANISM", 332, 337], ["ExPEC", "CELL", 338, 343], ["human", "SPECIES", 332, 337], ["human", "SPECIES", 332, 337], ["chronic salpingitis", "PROBLEM", 11, 30], ["peritonitis syndrome", "PROBLEM", 31, 51], ["an ascending infection", "PROBLEM", 67, 89], ["an acute peritonitis", "PROBLEM", 94, 114], ["salpingitis", "PROBLEM", 123, 134], ["respiratory infection", "PROBLEM", 162, 183], ["gut translocation", "PROBLEM", 187, 204], ["a stress insult", "PROBLEM", 211, 226], ["chronic", "OBSERVATION_MODIFIER", 11, 18], ["salpingitis", "OBSERVATION", 19, 30], ["peritonitis", "OBSERVATION", 31, 42], ["ascending", "OBSERVATION_MODIFIER", 70, 79], ["infection", "OBSERVATION", 80, 89], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["peritonitis", "OBSERVATION", 103, 114], ["without", "UNCERTAINTY", 115, 122], ["salpingitis", "OBSERVATION", 123, 134], ["respiratory", "ANATOMY", 162, 173], ["infection", "OBSERVATION", 174, 183]]], ["Zoonotic potential of poultry strains has been implicated.", [["poultry", "ORGANISM", 22, 29], ["poultry strains", "PROBLEM", 22, 37], ["poultry strains", "OBSERVATION", 22, 37]]], ["ExPEC are the main cause of urinary-tract infections (as so called uropathogenic E. coli, UPEC) in humans and meningitis in neonates (neonatal-meningitis E. coli, NMEC), and are also associated with bacteremia, sepsis, cellulitis and other potentially fatal infections [13].", [["urinary-tract", "ANATOMY", 28, 41], ["NMEC", "ANATOMY", 163, 167], ["urinary-tract infections", "DISEASE", 28, 52], ["meningitis", "DISEASE", 110, 120], ["neonatal-meningitis", "DISEASE", 134, 153], ["bacteremia", "DISEASE", 199, 209], ["sepsis", "DISEASE", 211, 217], ["cellulitis", "DISEASE", 219, 229], ["infections", "DISEASE", 258, 268], ["urinary-tract", "ORGANISM_SUBDIVISION", 28, 41], ["E. coli", "ORGANISM", 81, 88], ["humans", "ORGANISM", 99, 105], ["neonates", "ORGANISM", 124, 132], ["neonatal-meningitis E. coli", "ORGANISM", 134, 161], ["NMEC", "CANCER", 163, 167], ["E. coli", "SPECIES", 81, 88], ["humans", "SPECIES", 99, 105], ["E. coli", "SPECIES", 154, 161], ["E. coli", "SPECIES", 81, 88], ["humans", "SPECIES", 99, 105], ["E. coli", "SPECIES", 154, 161], ["ExPEC", "PROBLEM", 0, 5], ["urinary-tract infections", "PROBLEM", 28, 52], ["uropathogenic E. coli", "PROBLEM", 67, 88], ["UPEC", "PROBLEM", 90, 94], ["meningitis in neonates", "PROBLEM", 110, 132], ["meningitis E. coli", "PROBLEM", 143, 161], ["bacteremia", "PROBLEM", 199, 209], ["sepsis", "PROBLEM", 211, 217], ["cellulitis", "PROBLEM", 219, 229], ["other potentially fatal infections", "PROBLEM", 234, 268], ["urinary", "ANATOMY", 28, 35], ["tract infections", "OBSERVATION", 36, 52], ["meningitis", "OBSERVATION", 110, 120], ["associated with", "UNCERTAINTY", 183, 198], ["bacteremia", "OBSERVATION", 199, 209], ["sepsis", "OBSERVATION", 211, 217], ["cellulitis", "OBSERVATION", 219, 229], ["fatal", "OBSERVATION_MODIFIER", 252, 257], ["infections", "OBSERVATION", 258, 268]]], ["Similar to APEC, these strains are characterized by the presence of various virulence-associated genes, participating in adhesion and colonization of different tissues, invasion of internal organs, iron acquisition and avoiding host\u2019s immune responses.", [["tissues", "ANATOMY", 160, 167], ["organs", "ANATOMY", 190, 196], ["iron", "CHEMICAL", 198, 202], ["iron", "CHEMICAL", 198, 202], ["tissues", "TISSUE", 160, 167], ["organs", "ORGAN", 190, 196], ["iron", "SIMPLE_CHEMICAL", 198, 202], ["virulence-associated genes", "DNA", 76, 102], ["APEC", "PROBLEM", 11, 15], ["these strains", "PROBLEM", 17, 30], ["various virulence-associated genes", "PROBLEM", 68, 102], ["colonization of different tissues", "PROBLEM", 134, 167], ["invasion of internal organs", "PROBLEM", 169, 196], ["iron acquisition", "TEST", 198, 214], ["APEC", "OBSERVATION_MODIFIER", 11, 15], ["various", "OBSERVATION_MODIFIER", 68, 75], ["virulence", "OBSERVATION_MODIFIER", 76, 85], ["genes", "OBSERVATION_MODIFIER", 97, 102], ["different tissues", "OBSERVATION_MODIFIER", 150, 167], ["internal organs", "ANATOMY", 181, 196]]], ["ExPEC are typically associated with the phylogenetic groups B2 and D, in contrast to commensal and intestinal pathogenic strains derived from groups A and B1 [14] and to APEC, which are highly variable in distribution to various phylogenetic groups [7].", [["D", "GENE_OR_GENE_PRODUCT", 67, 68], ["intestinal", "ORGAN", 99, 109], ["APEC", "ORGANISM", 170, 174], ["B2", "DNA", 60, 62], ["ExPEC", "PROBLEM", 0, 5], ["intestinal pathogenic strains", "PROBLEM", 99, 128], ["APEC", "PROBLEM", 170, 174], ["intestinal", "ANATOMY", 99, 109], ["highly", "OBSERVATION_MODIFIER", 186, 192], ["variable", "OBSERVATION_MODIFIER", 193, 201]]], ["Although there is no specific set of genes to define the subpathotypes [15, 16], APEC, UPEC and NMEC generally form genetically distinct groups.", [["APEC", "GENE_OR_GENE_PRODUCT", 81, 85], ["UPEC", "GENE_OR_GENE_PRODUCT", 87, 91], ["NMEC", "GENE_OR_GENE_PRODUCT", 96, 100], ["the subpathotypes", "TEST", 53, 70], ["APEC", "TEST", 81, 85], ["UPEC", "TEST", 87, 91], ["no", "UNCERTAINTY", 18, 20]]], ["There is, however, a substantial overlap especially within the B2 phylogenetic group, which comprises strains isolated from both humans and chickens, showing high virulence in the chicken infection model and in the neonatal rat meningitis model with low or no host specifity [16\u201318].", [["infection", "DISEASE", 188, 197], ["meningitis", "DISEASE", 228, 238], ["humans", "ORGANISM", 129, 135], ["chickens", "ORGANISM", 140, 148], ["chicken", "ORGANISM", 180, 187], ["rat", "ORGANISM", 224, 227], ["humans", "SPECIES", 129, 135], ["chickens", "SPECIES", 140, 148], ["chicken", "SPECIES", 180, 187], ["rat", "SPECIES", 224, 227], ["humans", "SPECIES", 129, 135], ["chickens", "SPECIES", 140, 148], ["chicken", "SPECIES", 180, 187], ["rat", "SPECIES", 224, 227], ["a substantial overlap", "PROBLEM", 19, 40], ["strains", "PROBLEM", 102, 109], ["high virulence", "PROBLEM", 158, 172], ["the chicken infection model", "PROBLEM", 176, 203], ["the neonatal rat meningitis model", "PROBLEM", 211, 244], ["host specifity", "TEST", 260, 274], ["substantial", "OBSERVATION_MODIFIER", 21, 32], ["overlap", "OBSERVATION", 33, 40], ["B2 phylogenetic", "OBSERVATION_MODIFIER", 63, 78], ["high", "OBSERVATION_MODIFIER", 158, 162], ["virulence", "OBSERVATION_MODIFIER", 163, 172], ["infection", "OBSERVATION", 188, 197], ["neonatal rat", "ANATOMY", 215, 227], ["meningitis", "OBSERVATION", 228, 238]]], ["Moreover, an isolate showing high virulence in the rat meningitis model has been found in faeces of a healthy chicken [5], another finding that suggests an association between poultry and poultry products as a potential source of human pathogens.BackgroundRecently, several highly virulent and resistant ExPEC lineages with worldwide distribution have emerged (e.g. ST131, ST95 etc.) [19].", [["faeces", "ANATOMY", 90, 96], ["meningitis", "DISEASE", 55, 65], ["rat", "ORGANISM", 51, 54], ["faeces", "ORGANISM_SUBDIVISION", 90, 96], ["chicken", "ORGANISM", 110, 117], ["human", "ORGANISM", 230, 235], ["rat", "SPECIES", 51, 54], ["chicken", "SPECIES", 110, 117], ["human", "SPECIES", 230, 235], ["rat", "SPECIES", 51, 54], ["chicken", "SPECIES", 110, 117], ["poultry", "SPECIES", 176, 183], ["poultry", "SPECIES", 188, 195], ["human", "SPECIES", 230, 235], ["an isolate", "TEST", 10, 20], ["high virulence in the rat meningitis model", "PROBLEM", 29, 71], ["human pathogens", "PROBLEM", 230, 245], ["high virulence", "OBSERVATION", 29, 43], ["pathogens", "OBSERVATION", 236, 245], ["highly", "OBSERVATION_MODIFIER", 274, 280], ["virulent", "OBSERVATION_MODIFIER", 281, 289], ["resistant", "OBSERVATION_MODIFIER", 294, 303], ["ExPEC lineages", "OBSERVATION", 304, 318]]], ["Whereas some of them are associated exclusively with human infections, others are frequently isolated from diseased poultry or poultry products [20\u201325].", [["infections", "DISEASE", 59, 69], ["human", "ORGANISM", 53, 58], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["human infections", "PROBLEM", 53, 69], ["infections", "OBSERVATION", 59, 69]]], ["It is however difficult to assess the real importance of poultry as a source of human infections.", [["infections", "DISEASE", 86, 96], ["human", "ORGANISM", 80, 85], ["human", "SPECIES", 80, 85], ["poultry", "SPECIES", 57, 64], ["human", "SPECIES", 80, 85], ["human infections", "PROBLEM", 80, 96], ["infections", "OBSERVATION", 86, 96]]], ["Mechanisms of transmission of pathogenic clones through the production chain to humans are very complex and not quite elucidated, as well as the relationships between genetic \u201earsenal \u201cof virulence and resistance-associated genes and pathogenesis of the disease.", [["clones", "CELL", 41, 47], ["humans", "ORGANISM", 80, 86], ["humans", "SPECIES", 80, 86], ["humans", "SPECIES", 80, 86], ["pathogenic clones", "PROBLEM", 30, 47], ["virulence", "PROBLEM", 188, 197], ["the disease", "PROBLEM", 250, 261], ["pathogenic clones", "OBSERVATION", 30, 47], ["disease", "OBSERVATION", 254, 261]]], ["Moreover, an immense variability of APEC pathotype and differences in geographic distribution of specific clones underlines the importance of mapping the local situation.", [["APEC", "GENE_OR_GENE_PRODUCT", 36, 40], ["clones", "CELL", 106, 112], ["APEC pathotype", "PROBLEM", 36, 50], ["APEC pathotype", "OBSERVATION", 36, 50], ["geographic", "OBSERVATION_MODIFIER", 70, 80], ["distribution", "OBSERVATION_MODIFIER", 81, 93]]], ["While several papers have reported occurrence of highly pathogenic APEC clones in different counries, the information for the Central Europe have been sporadic or is lacking [27].Samples collection and preliminary characterization ::: ResultsA total of 95 isolates were subjected to preliminary characterization including serogrouping, antimicrobial resistance (AMR) testing and PCR detection of virulence and antibiotic resistance genes.", [["Samples", "ANATOMY", 179, 186], ["APEC clones", "CELL", 67, 78], ["APEC clones", "CELL_LINE", 67, 78], ["virulence and antibiotic resistance genes", "DNA", 396, 437], ["highly pathogenic APEC clones", "PROBLEM", 49, 78], ["Samples collection", "TEST", 179, 197], ["preliminary characterization", "TEST", 202, 230], ["preliminary characterization", "TEST", 283, 311], ["serogrouping", "PROBLEM", 322, 334], ["antimicrobial resistance", "TEST", 336, 360], ["AMR) testing", "TEST", 362, 374], ["PCR detection", "TEST", 379, 392], ["virulence", "PROBLEM", 396, 405], ["antibiotic resistance genes", "TREATMENT", 410, 437], ["highly", "OBSERVATION_MODIFIER", 49, 55], ["pathogenic", "OBSERVATION_MODIFIER", 56, 66], ["APEC clones", "OBSERVATION", 67, 78], ["antibiotic resistance", "OBSERVATION", 410, 431]]], ["The disc diffusion test showed that 69.5% were resistant to three or more groups of antimicrobials, which we considered as a criterion of multiresistance.", [["The disc diffusion test", "TEST", 0, 23], ["antimicrobials", "TREATMENT", 84, 98], ["multiresistance", "PROBLEM", 138, 153], ["disc", "ANATOMY", 4, 8]]], ["Resistance to ampicillin was recorded in 78 isolates (82.0%), followed by resistance to nalidixic acid (62 isolates; 65.3%), sulphonamides (45; 47.4%) and sulphonamides-trimethoprim (28; 29.5%).", [["ampicillin", "CHEMICAL", 14, 24], ["nalidixic acid", "CHEMICAL", 88, 102], ["sulphonamides", "CHEMICAL", 125, 138], ["sulphonamides", "CHEMICAL", 155, 168], ["trimethoprim", "CHEMICAL", 169, 181], ["ampicillin", "CHEMICAL", 14, 24], ["nalidixic acid", "CHEMICAL", 88, 102], ["sulphonamides", "CHEMICAL", 125, 138], ["sulphonamides", "CHEMICAL", 155, 168], ["trimethoprim", "CHEMICAL", 169, 181], ["ampicillin", "SIMPLE_CHEMICAL", 14, 24], ["nalidixic acid", "SIMPLE_CHEMICAL", 88, 102], ["sulphonamides", "SIMPLE_CHEMICAL", 125, 138], ["sulphonamides-trimethoprim", "SIMPLE_CHEMICAL", 155, 181], ["ampicillin", "TREATMENT", 14, 24], ["nalidixic acid", "TEST", 88, 102], ["sulphonamides", "TREATMENT", 125, 138], ["sulphonamides", "TREATMENT", 155, 168], ["trimethoprim", "TREATMENT", 169, 181]]], ["Nineteen isolates (20.0%) showed reduced susceptibility to ciprofloxacin (additional file 1 \u2013 Figure 1).", [["ciprofloxacin", "CHEMICAL", 59, 72], ["ciprofloxacin", "CHEMICAL", 59, 72], ["ciprofloxacin", "SIMPLE_CHEMICAL", 59, 72], ["Nineteen isolates", "TEST", 0, 17], ["reduced susceptibility", "PROBLEM", 33, 55], ["ciprofloxacin", "TREATMENT", 59, 72]]], ["Using four antisera (O1, O8, O18 and O78), 49 isolates (52%) were typeable, with predominant serogroups O1 (30; 32%) and O8 (13; 14%).", [["O78", "PROTEIN", 37, 40], ["predominant serogroups O1", "PROBLEM", 81, 106], ["O8", "TREATMENT", 121, 123]]], ["Four isolates reacted to O78 and two against O18 antisera.Samples collection and preliminary characterization ::: ResultsThe blaTEM gene was detected in 45 isolates (47.4%).", [["Samples", "ANATOMY", 58, 65], ["O78", "CHEMICAL", 25, 28], ["O78", "SIMPLE_CHEMICAL", 25, 28], ["O18 antisera", "GENE_OR_GENE_PRODUCT", 45, 57], ["blaTEM", "GENE_OR_GENE_PRODUCT", 125, 131], ["O18 antisera", "PROTEIN", 45, 57], ["blaTEM gene", "DNA", 125, 136], ["O18", "SPECIES", 45, 48], ["Four isolates", "TEST", 0, 13], ["Samples collection", "TEST", 58, 76], ["The blaTEM gene", "TEST", 121, 136]]], ["Other prevalent genes detected by PCR included tet(A) (26 isolates; 27.4%) and sul2 (28.4%).", [["tet(A)", "GENE_OR_GENE_PRODUCT", 47, 53], ["sul2", "GENE_OR_GENE_PRODUCT", 79, 83], ["isolates", "TEST", 58, 66], ["sul2", "TEST", 79, 83]]], ["As for virulence genes, most isolates carried typical APEC plasmid-associated genes iss (75; 78.9%), iroN (73; 76.8%), iut(A) (68; 71.6%), whereas others, plasmid- or chromosome-associated genes, e.g. cvaC (49; 51.6%), frzorf4 (44; 46.3%), tsh (32; 33.7%) and felA (7; 7.4%) were less prevalent.In silico serotyping, MLST and phylogenetic analysis of 32 selected isolates ::: ResultsWe found a diversity of serogroups in the collection of 32 isolates subjected to whole genome sequencing.", [["chromosome", "ANATOMY", 167, 177], ["APEC", "GENE_OR_GENE_PRODUCT", 54, 58], ["iroN", "GENE_OR_GENE_PRODUCT", 101, 105], ["iut(A)", "GENE_OR_GENE_PRODUCT", 119, 125], ["chromosome", "CELLULAR_COMPONENT", 167, 177], ["cvaC", "GENE_OR_GENE_PRODUCT", 201, 205], ["frzorf4", "GENE_OR_GENE_PRODUCT", 219, 226], ["tsh", "GENE_OR_GENE_PRODUCT", 240, 243], ["virulence genes", "DNA", 7, 22], ["APEC plasmid", "DNA", 54, 66], ["plasmid", "DNA", 155, 162], ["chromosome-associated genes", "DNA", 167, 194], ["cvaC", "DNA", 201, 205], ["frzorf4", "DNA", 219, 226], ["tsh", "DNA", 240, 243], ["felA", "DNA", 260, 264], ["virulence genes", "PROBLEM", 7, 22], ["APEC plasmid", "TEST", 54, 66], ["genes iss", "TEST", 78, 87], ["iroN", "TEST", 101, 105], ["iut", "TEST", 119, 122], ["plasmid", "TEST", 155, 162], ["chromosome-associated genes", "PROBLEM", 167, 194], ["cvaC", "TEST", 201, 205], ["frzorf4", "TEST", 219, 226], ["tsh", "TEST", 240, 243], ["felA", "TEST", 260, 264], ["silico serotyping", "TEST", 298, 315], ["phylogenetic analysis", "TEST", 326, 347], ["a diversity of serogroups", "PROBLEM", 392, 417], ["diversity", "OBSERVATION_MODIFIER", 394, 403], ["serogroups", "OBSERVATION_MODIFIER", 407, 417]]], ["Overall 14 different O types and 16 H types were identified and 10 isolates failed to be typed by WGS (the results are summarized in Table 1, additional file 1).", [["14 different", "OBSERVATION_MODIFIER", 8, 20]]], ["Except for serogroup O8 (7 isolates), the remaining serogroups were only represented by one or two isolates.", [["serogroup O8", "TREATMENT", 11, 23], ["the remaining serogroups", "PROBLEM", 38, 62]]], ["The predominance of O8 serogroup appeared as a selection bias since only Czech isolates were selected for sequencing.", [["O8", "CHEMICAL", 20, 22], ["O8", "GENE_OR_GENE_PRODUCT", 20, 22], ["O8 serogroup", "PROBLEM", 20, 32], ["a selection bias", "TEST", 45, 61], ["Czech isolates", "TREATMENT", 73, 87], ["predominance", "OBSERVATION_MODIFIER", 4, 16], ["O8 serogroup", "OBSERVATION", 20, 32]]], ["Of the O8 serogroup, six isolates belonged to the O8:H9 serotype, most of them to ST23 type.In silico serotyping, MLST and phylogenetic analysis of 32 selected isolates ::: ResultsThe isolates were derived from all phylogroups according to the Clermont scheme [28] except for the group E: group F (3 isolates), B2 (9 isolates), D (2 isolates), clade I (1 isolate), A (4 isolates), C (6 isolates), B1 (7 isolates).In silico serotyping, MLST and phylogenetic analysis of 32 selected isolates ::: ResultsThe MLST analysis identified 22 distinct sequence types (please see Table 1 in the supplementary material and Fig. 1), most of them represented only by a single isolate (ST352, ST95, ST140, ST354, ST93, ST4110, ST1249, ST1914, ST770, ST2223, ST746, ST1249, ST162, ST1157, ST602, ST1841, ST533, ST7104).", [["O8:H9 serotype", "ORGANISM", 50, 64], ["the O8 serogroup", "TREATMENT", 3, 19], ["H9 serotype", "TREATMENT", 53, 64], ["silico serotyping", "TEST", 95, 112], ["phylogenetic analysis", "TEST", 123, 144], ["The isolates", "TEST", 180, 192], ["the Clermont scheme", "TEST", 240, 259], ["B2", "TEST", 311, 313], ["D (2 isolates", "TEST", 328, 341], ["C", "TEST", 381, 382], ["B1", "TEST", 397, 399], ["silico serotyping", "TEST", 416, 433], ["phylogenetic analysis", "TEST", 444, 465], ["The MLST analysis", "TEST", 501, 518], ["22 distinct sequence types", "PROBLEM", 530, 556], ["ST95", "TEST", 678, 682], ["ST140", "TEST", 684, 689], ["ST354", "TEST", 691, 696], ["ST93", "TEST", 698, 702], ["ST4110", "TEST", 704, 710], ["ST1249", "TEST", 712, 718], ["ST2223", "TEST", 735, 741], ["ST746", "TEST", 743, 748], ["ST162", "TEST", 758, 763], ["ST602", "TEST", 773, 778]]], ["Two isolates were typed as ST117 belonging to the phylogenetic group F; ST429 of the B2 group and ST23 of the C group were detected in 4 and 6 isolates, respectively.", [["ST23", "CANCER", 98, 102], ["C", "CANCER", 110, 111], ["Two isolates", "TEST", 0, 12]]]]}